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ABSTRACT 
 
This research assesses the impact of user charges in the context of consumer choice to 
ascertain how user charges in healthcare impact on patient behaviour in Ireland. 
Quantitative data is collected from a subset of the population in walk-in Urgent Care 
Clinics and General Practitioner surgeries to assess their responses to user charges and 
whether user charges are a viable source of part-funding healthcare in Ireland.  
 
Examining the economic theories of Becker (1965) and Grossman (1972), the research 
has assessed the impact of user charges on patient choice in terms of affordability and 
accessibility in healthcare. The research examined a number of private, public and 
part-publicly funded healthcare services in Ireland for which varying levels of user 
charges exist depending on patients’ healthcare cover.  
 
Firstly, the study identifies the factors affecting patient choice of privately funded 
walk-in Urgent Care Clinics in Ireland given user charges. Secondly, the study assesses 
patient response to user charges for a mainly public or part-publicly provided service; 
prescription drugs. Finally, the study examines patients’ attitudes towards the potential 
application of user charges for both public and private healthcare services when patient 
choice is part of a time-money trade-off, convenience choice or preference choice. 
These services are valued in the context of user charges becoming more prevalent in 
healthcare systems over time. 
 
The results indicate that the impact of user charges on healthcare services vary 
according to socio-economic status. The study shows that user charges can 
disproportionately affect lower income groups and consequently lead to affordability 
and accessibility issues. However, when valuing the potential application of user 
charges for three healthcare services (MRI scans, blood tests and a branded over a 
generic prescription drug), this research indicates that lower income individuals are 
willing to pay for healthcare services, albeit at a lower user charge than higher income 
earners.  
 
xviii 
 
Consequently, this study suggests that user charges may be a feasible source of part-
financing Irish healthcare, once the user charge is determined from the patients’ 
perspective, taking into account their ability to pay.
xix 
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1 INTRODUCTION 
 
1.1 User Charges in Health Care 
 
User charges are a common policy adopted in most EU healthcare systems such as 
Ireland, Portugal, Denmark, Spain, Belgium, Poland, Austria and France that result in 
the sharing of healthcare costs between the patient and provider.  User charges are 
defined as payments made in an out-of-pocket (OOP) manner by users of healthcare 
services as a contribution towards their costs (Morris et al., 2007).  
 
These patient-targeted user charge policies are grounded in the economic theory of 
consumer choice and how price can be used as a tool to change consumer behaviour. 
Transferring a proportion of the cost to the patient, it is theorised that user charges 
encourage consumers to become more cost-conscious (Hurley and Johnson, 1991). 
This is based on the assumption that consumers reduce unnecessary demand (Hurley 
and Johnson, 1991). This unnecessary demand is referred to as ‘moral hazard’; defined 
as “the intangible loss-producing propensities of the individual assured” (Dickerson, 
1959, p. 67) (Dickerson, 1959) (Dickerson, 1959) (Dickerson, 1959) (Dickerson, 
1959) (Dickerson, 1959) (Dickerson, 1959) (Dickerson, 1959). In other words, moral 
hazard is the excess use of services when the patient is insured against all of the cost 
or a proportion of the cost (Morris et al., 2007). This reduction in moral hazard, reduces 
unnecessary spending in healthcare (Hurley and Johnson, 1991, Skinner, 2002). This 
research acknowledges that user charges may not always raise revenue and whether 
they do or not depends on the revenue they are replacing. If the money generated from 
the user charge is used to reduce overall healthcare spending, then the user charge does 
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not raise revenue. However, if the money it replaces continues to be spent in health 
then the user charge does raise revenue for the healthcare system. 
 
There is the counter-argument that the absence of user charges in healthcare systems 
can continue to increase healthcare expenditure as there is the risk of patients 
excessively using some healthcare services due to lower healthcare costs (Xu et al., 
2006). Lack of healthcare funding, such as user charges, may negatively impact the 
provision of healthcare thereby impacting on availability of healthcare for patients. 
Economic theory states that when a patient must pay the full cost of healthcare, he/she 
will consume healthcare based on preferences and budgetary constraints (Becker, 
1965, Grossman, 1972). If a third party pays all the cost, it is expected that patients 
will have a higher utilization rate. 
 
In healthcare, some patients have full financial protection (full third party payment) 
against user charges while other patients must pay the full user charge for a healthcare 
service (full cost borne OOP by the patient). When the user charge lies between full 
third-party payment and the full user charge, the patient is subject to some form of 
payment for the healthcare service.  
 
Throughout this research, unless otherwise stated, the term “user charge” is generally 
applied when referring to any OOP payment made by patients for healthcare services. 
More specifically, the term “cost-sharing” is used to indicate that only a proportion of 
the total cost of the healthcare service is paid OOP by the patient. Consequently, this 
research defines cost-sharing as a subset of user charges.  
3 
 
Cost-sharing can involve either direct or indirect payment for a healthcare service by 
the patient (Tamblyn et al., 2001). Direct cost-sharing includes co-payments (flat fee 
for service), deductibles (payment which covers a specific proportion of the healthcare 
cost before insurer/government begins to pay), co-insurance (percentage of total cost) 
and balance billing (difference between the doctor’s fee and health insurance 
reimbursement). Indirect cost-sharing is still paid OOP by the patient but is not directly 
imposed (Robinson, 2002). Indirect cost-sharing includes coverage exclusions 
(services not covered by insurance) and pharmaceutical mechanisms such as generic 
substitution (switching a branded drug for a generic drug), reference pricing (patient 
pays difference between reference price and actual cost of the drug) and formularies 
(positive, negative and selected lists) (Robinson, 2002). The current study addresses 
the impact of full OOP user charges, direct cost-sharing (co-payments and deductibles) 
and indirect cost-sharing (generic substitution and reference pricing) on patient choice 
of healthcare services in Ireland.  
 
The different types of user charges have varying impacts on patient behaviour (Hurley 
and Johnson, 1991). For example, a co-insurance rate for which the patient pays a 
percentage of the total cost encourages the patient to become cost-conscious and 
incentivises them to use the service sparingly as their OOP payment will depend on 
the amount or level of the service they use. Unless the co-payment is applied per 
service/item, a patient who pays a flat rate co-payment (e.g. per prescription) has no 
incentive to be cost-conscious as the OOP payment will be the same regardless of 
whether the patient uses the service sparingly or not.  
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User charges commonly exist in EU healthcare systems for most healthcare services 
such as; prescription drugs, GP (General Practitioner) services, out-patient services, 
in-patient care and dental care  (Robinson, 2002, Tambor et al., 2011, Barros and 
Siciliani, 2012). A mixture of direct and indirect cost-sharing is applied in terms of co-
payments, co-insurance, deductibles, reference pricing and balance billing throughout 
EU member states for prescription drugs (Thomson et al., 2009, Barros and Siciliani, 
2012). With regard to GP and out-patient care, in 2011, Tambor et al (2011) conducted 
a review of cost-sharing in the 27 European Union (EU) countries at the time. They 
found that more than half of these EU countries had some form of cost-sharing for GP 
services and out-patient care with co-payments and co-insurance being the most 
commonly applied forms of cost-sharing for these services. Tambor et al (2011) also 
report that EU countries apply user charges for in-patient care with daily co-payments 
forming the most common type of cost-sharing for this service.  
 
1.2 Research Objective  
 
This research assesses the impact of user charges in the context of consumer choice to 
ascertain how user charges in healthcare impact on patient behaviour in Ireland. Using 
two specifically designed questionnaires, primary data is collected from patients in the 
Irish healthcare system. The research examines three different topics in Irish 
healthcare; the first topic examines the factors that affect patient choice for a private 
health service for which a user charge is already in place. It assesses the impact of a 
full user charge that is paid OOP by the patient.1  Primary data is collected from 
                                                          
1 Patients with private health insurance (PHI) may be subject to ex-post reimbursement for part of this 
user charge depending on the health insurance plan they have. 
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patients attending three walk-in urgent care clinics (UCCs) in Ireland. 2  These UCCs 
offer an alternative choice of care to patients for the treatment of a minor injury or 
illness. Comparable to walk-in UCCs in the UK, US and Canada (Weinick et al., 
2009), UCCs in Ireland fill the gap between the traditional GP services and Accident 
and Emergency (A&E) departments.  
 
The second topic examines how consumer choice changes as a result of a recently 
introduced or increased user charge for a mainly public or part-publicly provided 
service. Collecting primary data from patients in selected GP surgeries in Cork, the 
research investigates if prescription drug user charges cause patients to change their 
behaviour in order to afford and access prescription medication. This topic investigates 
the impact of co-payments, deductibles and full user charges on patient behaviour for 
prescription drugs.  
 
The third and final topic presents patients with three different healthcare services and 
determines how much they are willing to pay OOP for each service. This topic also 
collects primary data from patients as they wait in selected GP surgeries in Cork. The 
topic examines patients’ attitudes towards the potential of user charges for both public 
and private healthcare services when it is part of a time-money choice (MRI scan), a 
convenience choice (blood tests) or a preference choice (branded drug). These services 
are valued in the context of user charges becoming more prevalent in healthcare 
systems over time. 
                                                          
2 It is important to note in this research that the walk-in UCCs where this data is collected are 
privately funded clinics. There are also publicly funded walk-in UCCs in Ireland and in other 
countries such as the US, UK and Canada but this research only collects data from three privately 
funded clinics in Ireland. When referring to the data collected for this research, it is in the context of 
a privately funded walk-in clinic unless otherwise stated. The literature review in Section 3.2 deals 
with public as well as private UCCs.  
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The results of the research will reveal patients’ responses to user charges in the 
different situations and how these responses vary by socio-economic status. Assessing 
patients’ response to price is essential in the healthcare system and is particularly 
important in a system where user charges are gaining popularity as a method of 
healthcare financing. Understanding patients’ response to user charges is important, as 
this response will indicate whether user charges are a viable source for part-funding 
healthcare in Ireland. 
 
1.3 Research Questions 
 
The three research questions addressed are: 
1.  What factors influence patient choice of Walk-in Urgent Care Clinics in 
Ireland in the face of user charges? 
2. What impact have prescription drug user charges had on patient behaviour 
in Ireland? 
3.  What are Irish healthcare consumers willing to pay for three selected 
healthcare services (Blood tests, MRI scans and branded versus a generic 
prescription drug)?  
 
From these questions stem more specific objectives that include: 
 
 Characterize the type of patient who chooses a walk-in UCC in Ireland. 
 Identify using a zero-truncated negative binomial model the factors that 
determine why a patient pays a higher user charge to receive urgent care at an 
UCC. 
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 Identify using a probit regression what factors affect the likelihood of a patient 
being a first-time user of an UCC in Ireland. 
 Identify the impact that different types of user charges have on patient 
behaviour for prescription drugs. 
 Using a multinomial logit model, measure the association between patient 
behaviour regarding prescription drugs and individual characteristics. 
 Reveal patients’ willingness-to-pay (WTP) values for three healthcare services. 
 Identify discrepancies between patients’ reported WTP and the current market 
price.  
 Using a two-part model, identify the factors that are associated with patients’ 
WTP values for the three selected healthcare services.  
 
1.4 Motivation 
 
User charges increase patient OOP expenditure, which contributes towards the 
healthcare system but can lead to a welfare loss for patients who cannot afford the 
necessary healthcare services (Srivastava and McGuire, 2015). Consequently, user 
charges can restrict patient access and may make some services unaffordable for 
patients (Robinson, 2002). User charges may be “regressive” with larger effects on 
patients who spend a larger proportion of their income on a particular healthcare 
service (Adams et al., 2001, Contoyannis et al., 2005, Gibson et al., 2005a, Lexchin 
and Grootendorst, 2004, Smith and Kirking, 1992). Conversely, lack of healthcare 
funding, such as user charges, may negatively impact the provision of healthcare 
thereby impacting on availability of healthcare for patients. While user charges can 
contribute towards healthcare financing, accessible and affordable healthcare for all 
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patients must be at the centre of healthcare delivery. This research assesses the impact 
of user charges in the context of consumer choice to establish how they affect patient 
behaviour in Ireland. 
 
In Ireland, OOP payments as a percentage of total healthcare financing has increased 
from 15% to 18.1% between 2007 and 2011 (OECD, 2013). It is suggested this 
increase in OOP is due to corresponding increases in the hospital and out-patient costs 
and fees for healthcare professionals (OECD, 2013) in addition to increases in user 
charges for prescription drugs (Mladovsky et al., 2012). Government spending also 
fell during this period, which would have contributed to the increased share of health 
expenditure accounted for by OOP payments. With an extra €510 million in additional 
healthcare funding required by the end of 2014 and €600 million supplementary 
funding required for public services at the end of 2015, it is evident that the Irish health 
sector is under increasing pecuniary pressure and user charges will need to remain to 
help contribute towards healthcare financing (Hurley and Johnson, 1991, Robinson, 
2002, Usher et al., 2012, Xu et al., 2006). This research examines the impact of user 
charges on patient choice of healthcare services in Ireland in the context of whether 
user charges are a viable method of part-funding healthcare. 
 
Similar to other countries in the EU, user charges exist in the Irish healthcare system 
for most healthcare services; GP services, ambulatory care, specialist care and 
prescription drugs. User charges are imposed on these services for patients with or 
without private health insurance (PHI). For most healthcare services in Ireland, the 
user charge depends on the level of healthcare cover the patient has. Consequently, the 
first topic in this research assesses patients who have already made a choice to pay a 
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full user charge for a private health service in order to identify what drives patient 
choice. The second topic assesses the impact of co-payments, deductible and full user 
charges for a mainly public or part-publicly provided service to reveal patient 
response. The third and final topic examines patients’ attitudes towards the potential 
application of user charges in the form of OOP payments for both public and private 
healthcare services when it is part of a time-money (MRI scans) choice, a convenience 
choice (blood tests) or a preference (branded drug) choice. 
 
1.5 Methodology  
 
The research methodology is of a quantitative nature, revolving around three research 
questions as identified above. Two specifically constructed questionnaires are used to 
collect primary data from Irish healthcare consumers. 
 
Using a self-completion questionnaire, the first topic (see Chapter 3) collects primary 
data from patients attending three walk-in UCCs in Ireland. This methodology is 
consistent with international empirical research studies conducted in walk-in UCCs 
across the US, UK and Canada (Bell and Szafran, 1992, Hunter et al., 2009, Rizos et 
al., 1990, Salisbury et al., 2002, Scott et al., 2009). A zero-truncated negative binomial 
model is used to estimate the factors that influence patient choice of walk-in UCCs in 
Ireland. A probit regression is also applied to identify the factors that affect the 
likelihood of the patient being a first-time user of the service. 
 
The second study, (see Chapter 4) develops a questionnaire based on a previous study 
conducted by Reed et al (2008) to examine the impact that prescription drug user 
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charges have on patient behaviour in Ireland. The questionnaire measures three types 
of patient behaviour that can result from an increase or introduction in user charges for 
prescription drugs; decreased adherence, financial constraints and cost-coping 
strategies (Reed et al., 2008). Behavioural responses are assessed by measuring the 
percentage of patients who report any behaviour change (decreased adherence, 
financial burden or cost-coping behaviours). A multinomial logit model measures the 
association between behaviour and individual characteristics. 
 
The final topic, (see Chapter 5) is a contingent valuation method (CVM) using a 
questionnaire designed stated preference approach to identify what Irish healthcare 
consumers are willing to pay for healthcare (blood tests, MRI scans and prescription 
drugs). This study examines the potential application of user charges when it is part of 
a time-money choice (MRI scan), a convenience choice (blood tests) or a preference 
choice (branded drug). The econometric analysis of the WTP studies is shaped on how 
the WTP question is asked and any underlying theoretical implications (Donaldson et 
al., 1998). Percentages and frequencies are examined to generate a response profile for 
WTP for the three identified healthcare services (Liu et al., 2013, Marvasti, 2006). A 
two-part model (probit and OLS regression) is used to identify the factors associated 
with patients’ WTP for the three services.  
 
1.6 Contributions  
 
User charges are gaining popularity as a commonly used financing method in 
healthcare. User charges transfer a proportion of the cost to the patient, which 
consequently contributes towards their healthcare costs.  In Ireland, very little research 
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has examined the impact of user charges on consumer choice from the patient 
perspective, predominantly due to a lack of data. This needs to be done before one can 
determine if user charges can be used to part-fund healthcare. If user charges do not 
exist and patients excessively utilize healthcare services, this may negatively impact 
on the provision of healthcare, thereby impacting on availability of healthcare for 
patients. 
 
Collecting primary data from a subset of the population in walk-in UCCs and GP 
surgeries, the research contributes to the literature by examining user charges in the 
context of consumer choice to determine how they impact on patient behaviour in 
Ireland. This research will provide a direct insight into patients’ responses to user 
charges in Ireland. This contribution is important at a time of increasing financial 
pressure in the Irish healthcare system in which user charges are becoming a more 
common method of healthcare financing. The results will indicate whether user 
charges may be a viable source of part-funding Irish healthcare and the results will 
serve as an evidence base for development of user charge policies and pricing 
decisions for healthcare services in Ireland. The results also have potential for 
international applicability for other healthcare systems which may be considering an 
introduction/increase in user charges. 
 
1.7 Thesis Structure 
 
Chapter 2 of this research provides a background to the current Irish healthcare system, 
a description of healthcare financing in Ireland and identifies the health economic 
theories that support this study. Section 2.2 describes the current Irish healthcare 
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system while Sections 2.2.1 to 2.2.3 in particular describe patient eligibility for 
healthcare services in Ireland with a primary focus on full eligibility, limited eligibility 
and Long-Term Illness (LTI). Section 2.2.4 describes PHI in Ireland.  Section 2.3 
describes healthcare funding in Ireland and Section 2.4 presents the health economic 
theories that support this research. Consumer choice is presented in Section 2.4.1 and 
the impact of user charges on affordability and accessibility is described in Section 
2.4.2. Section 2.5 concludes Chapter 2.  
 
Chapter 3 addresses the first research topic, What factors influence patient choice of 
Walk-in Urgent Care Clinics in Ireland in the face of user charges? Section 3.1 
provides the introduction to this topic while Section 3.1.1 to 3.1.3 describe the research 
objective, research motivation and chapter structure for Chapter 3. Section 3.2 
provides the literature review for this topic while Section 3.3 provides the 
methodology used in this chapter. Section 3.4 presents the econometric model, results 
and a discussion of the findings in this chapter while Section 3.5 concludes this topic.  
 
Chapter 4 examines the second research question, What impact have prescription drug 
user charges had on patient behaviour in Ireland? Section 4.1 provides the 
introduction to this topic while Sections 4.1.1 and 4.1.2 describe prescription drug user 
charges in Ireland and the impact of prescription drug user charges on affordability 
and accessibility in healthcare. Sections 4.1.3 to 4.1.5 discuss the research question 
and aim, research motivation and chapter structure. Section 4.2 presents the literature 
review on this topic and Section 4.3 describes the methodology used to answer the 
research question in Chapter 4. Section 4.4 presents the econometric model, results 
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and a discussion of the results in this chapter. Finally, Section 4.5 concludes Chapter 
4.  
 
Chapter 5 addresses the final topic in this thesis, What are Irish healthcare consumers 
willing to pay for three selected healthcare services? (Blood tests, MRI scans and 
prescription drugs)? Section 5.1 introduces this topic, Section 5.1.1 discusses the 
impact of accessibility and affordability in the context of this topic and Sections 5.1.2 
to 5.1.3 present the research question, objective and research motivation. Section 5.1.4 
describes the structure of Chapter 5. Section 5.2 presents the literature review on this 
topic and Section 5.3 describes the methodology used in Chapter 5. Section 5.4 
presents the results of Chapter 5 which focuses on the econometric model, research 
findings and a discussion on the findings. Section 5.5 concludes Chapter 5. 
 
Finally, Chapter 6 provides an overall conclusion to this thesis. Section 6.1 provides 
an overview of the research. Section 6.2 discusses the research findings, Section 6.3 
presents the research contributions, Section 6.4 describes recommendations for future 
studies and Section 6.5 concludes this thesis. 
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2 IRISH HEALTHCARE SYSTEM AND HEALTH ECONOMIC 
THEORIES.  
 
2.1 Introduction  
 
The initial focus of this chapter is to provide a description of the Irish healthcare system 
in terms of healthcare financing and patient eligibility to healthcare services. The 
second function of the chapter is to identify the health economic theories that support 
this research. Sections 2.2.1 to 2.2.3 describe patient eligibility to healthcare services 
with a particular emphasis on full eligibility, limited eligibility and LTI while Section 
2.2.4 describes PHI in Ireland. Section 2.3 examines the current situation of healthcare 
financing in Ireland. Finally, Section 2.4 identifies the health economic theories that 
support the research; consumer choice (Section 2.4.1) and affordability and 
accessibility in healthcare (Section 2.4.2).  
 
2.2 Irish Healthcare System 
 
The Irish healthcare system is a primarily government financed public healthcare 
system with general taxation forming 67% of the funding. OOP payments (17%) and 
PHI (13%) also contribute towards healthcare funding (OECD, 2015).3,4. Public 
healthcare is available to every resident yet some people choose to purchase PHI. 
Patients purchase PHI in order to receive faster access to hospital services or as a result 
of preference for care in a private hospital rather than a public hospital (HIA, 2014c).   
                                                          
3 The remainder of healthcare funding comes from private corporations.  
4 The research acknowledges that Wren et al (2015) also report statistics on healthcare funding in 
Ireland  (Wren et al., 2015) However, for consistency purposes, this research will include the most 
up-to-date OECD figures when possible.  
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Entitlement to public health services in Ireland is based on residency rather than 
individuals’ contribution of tax or pay-related social insurance (PRSI). There are two 
forms of eligibility for healthcare in Ireland. The first is full eligibility and the second 
is limited eligibility.  
 
The following sections; 2.2.1 to 2.2.4 describe the different types of healthcare cover 
which exist in Ireland.   
 
2.2.1 Full Eligibility 
 
Full eligibility is granted to patients primarily on an income basis under the General 
Medical Services (GMS) Scheme.5 There is separate eligibility criteria for the GMS 
scheme depending on the patients age (under 65 years, between 66 and 70 years and 
patients over 70 years) and living situation (single living alone, living with a family, 
married couple or a single parent with dependent children) (HSE, 2015b). For 
example, to be eligible for the GMS scheme, the gross weekly rate income threshold 
for a person under 65 years living alone is €184, the threshold for a person between 66 
and 70 years is €201.50 while the gross weekly rate income threshold for a patient over 
70 years of age is <€500 (HSE, 2015b). Patients who are granted full eligibility are 
given a GMS card which entitles them to free GP services, prescription drugs (subject 
to a recently introduced user charge on each item), public hospital services, dental, 
optical and aural services, maternity and infant care services and community care and 
social services (HSE, 2013f).  
                                                          
5  Some medical cards are issued on a discretionary basis if the individual cannot access healthcare 
service without undue hardship (HSE, 2014) 
16 
 
Previous to 2010, all of these services were provided free of charge to all GMS 
patients. However, in 2010 a 50c fixed fee per prescription item was introduced on all 
prescription drugs dispensed by pharmacies to GMS patients. This user charge was 
subject to a maximum ceiling of €10 per family per calendar month. In October 2013, 
this co-payment was further increased to €1.50 per item with a monthly limit of €19.50. 
Currently, since October 2014, this co-payment is set at €2.50 per item with a monthly 
maximum of €25 per family per calendar month (DOH, 2013). The GMS co-payment 
saved €43 million in 2015 (IMO, 2016).  
 
The latest available figures show that in 2013, 40.31% of the population (1,849,340) 
were eligible for GMS status (PCRS, 2013)6. This costs the HSE an average payment 
to pharmacies of €973.26 per person for prescription drugs (PCRS, 2013). The number 
of individuals under the GMS scheme increased by approximately 34% between 2009 
and 2013 (PCRS, 2013). One reason for this increase in eligibility is due to the onset 
of the recession in Ireland in 2008. Increasing levels of unemployment led to lower 
incomes which resulted in a higher number of patients becoming eligible for GMS 
status. While GMS numbers have increased, the HSE cost per GMS patient decreased 
from €1,245.79 in 2009 to €973.26 per patient in 2013. One of the possible reasons for 
this reduction in cost per person is due to the increase that occurred in the prescription 
charge between 2010 and 2013. Patients were contributing towards a higher share of 
their prescription medication, therefore, reducing the HSE cost per claimant. 
                                                          
6 The HSE Annual Report (2014), reports that 39% (1.77m) of the population were eligible for the 
GMS scheme in 2014. However, the HSE does not provide detailed statistics for the other publicly 
funded categories addressed in this thesis (Drugs Payment Scheme (DPS) and LTI).  The PCRS 
provides the most up-to-date statistics for all community drug schemes in Ireland so for consistency 
purposes, the PCRS statistics are used when possible.  
17 
 
2.2.2 Limited Eligibility 
 
Patients with limited eligibility (non-GMS) are entitled to public hospital services but 
may be subject to in-patient and out-patient hospital charges in Ireland.7 Non-GMS 
holders are entitled to subsidised maternity and infant care services. Patients who do 
not qualify for the GMS scheme can apply for a General Practitioner Visit Card 
(GPVC). This is a primarily means-tested card which entitles the patient to attend a 
participating GP for free. The same eligibility criteria exist for GPVC as GMS cards 
except the income thresholds for a GPVC are higher than the income thresholds for a 
GMS card. For example, the gross weekly rate income threshold for a person under 65 
years living alone is €276, the threshold for a person between 66 and 70 years is €302 
while the gross weekly rate income threshold for a patient over 70 years of age is over 
€500 but less than €700 (HSE, 2015b). In 2013, 3% of the population (125,426) had a 
GPVC (PCRS, 2013).8 Unless you have a GMS card or a GPVC in Ireland, the cost of 
the visit to the GP must be paid for OOP. The national average GP visit cost in Ireland 
is €51 (Nolan et al., 2014). Approximately 60% of the population must pay this charge 
(Nolan et al., 2014).  
 
Patients without a GMS card may apply for a Drugs Payment Scheme (DPS) card to 
receive financial protection for prescription drugs. With a DPS card, a patient pays a 
monthly deductible for their prescription drugs after which the cost is covered by the 
HSE. In comparison to the recent introduction of the GMS user charge, the DPS user 
                                                          
7 A non-GMS in-patient must pay €75 per night in hospital subject to a maximum of €750 per year. A 
non-GMS out-patient who does not have a referral from their GP must pay €100 for their out-patient 
or A&E treatment (HSE, 2013d). 
8 Since 2015, automatic entitlement to a GPVC is granted to children under 6 years and adults over 70 
years irrespective of patient income (HSE, 2015a; HSE 2015d).  
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charge has been in existence in Ireland since 1999 (DOH, 1999). In 1999, the DPS set 
a monthly deductible of £42 (€56) per family per month (DOH, 1999). This meant that 
once a patients’ drug cost exceeded £42 (€56) per month, the remainder of their drug 
costs were covered by the State. This deductible has increased considerably; in 2008 
it increased to €90 (DOH, 2008) and in 2010 it rose to €120 (DOH, 2010). In 2012 it 
was further increased to €132 (DOH, 2011) and since the 1st of January 2013 an 
individual with a DPS card can pay up to €144 for prescription drugs per calendar 
month (DOH, 2012b). Any prescription drug costs in excess of this are covered by the 
State.  
 
The latest available figures show that in 2013, 30.5% (1,399,208) of the population 
were registered under the DPS scheme. This costs the HSE an average payment of 
€272.56 per claim9 (PCRS, 2013). The number of individuals under the DPS scheme 
decreased by approximately 12% between 2009 and 2013 (PCRS, 2013). One reason 
for this reduction is due to the onset of the recession in Ireland in 2008. Increasing 
levels of unemployment led to lower incomes which resulted in a higher number of 
patients becoming eligible for GMS status. This reasoning is supported as the number 
of GMS patients increased by almost 34% during the same time-frame (2009 to 2013) 
(PCRS, 2013). 
 
 
                                                          
9 Figures are based on number of eligible persons who availed of services under the scheme. The PCRS 
only has data on the DPS patients who exceed the monthly deductible as it is only after a patient 
reaches €144 per calendar month that the HSE covers the cost of the patient’s prescription drugs. 
Until this point, the patient pays OOP. Consequently, the €272.56 per claim refers only to patients 
who exceed the €144 per month.  
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2.2.3 Long-Term Illness (LTI) 
 
The LTI scheme is also available which provides drugs and treatment for a long-term 
illness free of charge. There is a list of 16 long-term illnesses for which this scheme is 
available. In 2012, 1.57% of the population were covered by the LTI scheme with an 
average net cost of €1,480,83 to the HSE (PCRS, 2013).10 Unlike the GMS and DPS, 
the LTI scheme is granted irrespective of patient income. 
 
2.2.4 Private Health Insurance (PHI) in Ireland 
 
Despite public healthcare being available to all of the population, just under half the 
population, 44%11 (2.03m) purchase PHI12 (HIA, 2014a). The number of individuals 
taking out PHI policies decreased by approximately 11.8% between 2008 and 2014. 
This decrease in coverage has occurred across all age groups up to 60 years with the 
sharpest decrease among lower age groups (HIA, 2014b). While entitlement under PHI 
plans vary, quicker access to hospital care is seen as the main benefit as well as 
preference for care in a private hospital rather than a public hospital (HIA, 2014a). 
Therefore, privately insured patients often access hospital services faster based on their 
ability to purchase PHI.  
 
                                                          
10 These figures are based on the number of eligible persons who availed of services under the LTI 
scheme.  
11 This figure corresponds to the end of 2014.  
12 Some people who have a medical card will also have PHI. According to the latest available figures, 
6% of the population have both types of cover QNHS 2010. Health Status and Health Service 
Utilisation. Dublin.  
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Sections 2.2.1 to 2.2.3 described the GMS, DPS and LTI schemes in Ireland. These 
are three of the largest publicly funded health schemes in Ireland.13 Section 2.2.4 
described the PHI market in Ireland. As mentioned in Section 1 .4, user charges for 
healthcare services in Ireland vary depending on the level of cover a patient has. This 
research distinguishes between the public and private schemes in order to understand 
the impact of the different user charges on patient choice.  
 
2.3 Healthcare Funding in Ireland 
 
Ireland entered a recession in 2008 and subsequently entered an international bailout 
in 2010 worth €85 billion (Burke, 2008). The bailout resulted in a number of severe 
austerity budgets leading to a 27% cut in the health budget between 2008 and 2014 
(IMO, 2015). Since 2008, approximately €4 billion has been cut from the Irish health 
system (IMO, 2015). The HSE budget is consistently overrun requiring €510 million 
in supplementary healthcare funding by the end of 2014 and €600 million additional 
funding required at the end of 2015 (IMO, 2015). In Ireland, total health expenditure 
is 8.9% of GDP which is similar to the OECD average of 9% (OECD, 2015). Due to 
the imbalance between profits repatriated by foreign multinationals and overseas 
profits of Irish companies, it is also appropriate to acknowledge that total health 
expenditure in Ireland is 12.4% of GNI where GNI excludes the profits of foreign-
owned companies in the country (Publicpolicy, 2016).  
 
                                                          
13 There are 15 community schemes in Ireland; the GMS, DPS and LTI scheme, Dental Treatment 
Services Scheme (DTSS), European Economic Area (EEA), High Tech Drugs (HTD), Primary 
Childhood Immunisation, Health(Amendment) Act 1996, the methadone treatment and the HSE 
Community Ophthalmic Services Scheme, Immunisations for GMS eligible persons, GPVC, 
Discretionary Hardship Arrangements, Centralised reimbursement of selected high cost drugs 
administered or dispensed to patients in hospitals, Centralised reimbursement of Outpatient 
Parenteral Antimicrobial Therapy (OPTAT) (PCRS, 2013).   
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While healthcare spending in Ireland has decreased, demand on the public health 
system has increased. As mentioned, the number of individuals with PHI decreased by 
11.8% between 2008 and 2014. In December 2008, almost 2.3 million individuals had 
PHI. This fell by 272,000 to just over 2 million in December 2014. Furthermore, the 
number of individuals eligible for GMS status increased by nearly half a million 
between 2009 and 2013 (HSE, 2015a, PCRS, 2013). This is due predominantly to an 
increase in the unemployment rate which increased by approximately almost 7 
percentage points from 5.1% in 2008 to 12.2% in 2014 (QNHS, 2014b, QNHS, 2014a). 
This resulted in lower incomes and subsequently a greater number of individuals 
eligible for GMS status.  
 
In addition to the decrease in PHI coverage and the increase in GMS numbers, demand 
on the public health system is stretched even further due to the ageing population in 
Ireland. The number of people over 70 years has increased by 20% since 2006 (IMO, 
2016). The increasing demand on the healthcare system coupled with the need to keep 
within the healthcare budget has led to theatre closures and cancellation of elective 
procedures (IMO, 2015). This has a negative impact on the country’s A&E 
departments, hospital wards, outpatient appointments and elective procedure waiting 
lists. A&E departments in Ireland are facing a daily struggle. Overcrowding in A&E 
departments reached an all-time high on the 6th January 2015 when there were 601 
patients waiting on trollies in A&E departments and hospital wards across the country 
(Doran, 2015). In 2015, the HSE set a target of treating all A&E attendances within 6 
hours of registration (HSE, 2015a). Extensive waiting periods are also experienced in 
the out-patient departments around the country. In May 2015, 85,130 patients had been 
waiting over 1 year for an out-patient appointment while 11,609 patients were waiting 
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for over 2 years (IMO, 2016). This is despite the HSE setting a target of treating all 
outpatients within 52 weeks of first access to the outpatient department (HSE, 2015a). 
In addition, over 9,180 adults and children were waiting over 12 months for an elective 
procedure.  
 
It is apparent that changes need to be introduced in the Irish healthcare system in order 
to cope with the restricted budget and the increasing demand. Not only do user charges 
contribute towards patients’ healthcare costs, they also impact on patient choice by 
making consumers more aware of the costs of healthcare and deter patients from using 
unnecessary healthcare services. A combination of these objectives could be one of 
many methods of alleviating the financial strain on the Irish healthcare system. This 
thesis aims to examine the impact of user charges in the context of consumer choice 
to ascertain whether user charges are a viable source of part-funding healthcare in 
Ireland.   
 
2.4 Health Economic Theories 
 
Healthcare is an economic service for which patients must choose, in the onset of an 
illness, how much healthcare to consume. User charges in healthcare alter the price of 
healthcare services which has a knock-on effect on patient choice in terms of 
affordability and accessibility (Adams et al., 2001, Contoyannis et al., 2005, Gibson 
et al., 2005a, Lexchin and Grootendorst, 2004, Smith and Kirking, 1992). 
Affordability and accessibility are two fundamental considerations in equity in 
healthcare. Equity is one of many key objectives in healthcare policies and is a 
complex process for which there is no universal definition (Morris et al., 2007). 
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Generally, equity refers to equal access to healthcare for all patients regardless of their 
ability to pay (Andersen, 1975, Bergmo and Wangberg, 2007, LeGrand, 1978, 
Rosenzweig and Schultz, 1991). While this research focuses primarily on affordability 
and accessibility, the research recognizes that they are two dominant considerations in 
the complex process of equity in healthcare.  
 
This research acknowledges that user charges may also impact on allocative efficiency 
in healthcare. Allocative efficiency is achieved when resources are allocated based on 
the preferences of the individual (Arrow, 1963, Morris et al., 2007). This type of 
efficiency ensures that the health service is provided to patients who need it most 
(Dupas, 2012). However, as this research focuses on the impact of user charges from 
the patients’ perspective, the research measures the impact of user charges on patient 
choice in terms of affordability and accessibility in healthcare. The impact of user 
charges is examined using the theoretical foundations of Becker’s household 
production function (1965) and Grossman’s household production function (1972). 
 
2.4.1 Consumer Choice 
 
When consumers demand healthcare, they do not demand the service itself, but they 
demand good health. Therefore, the demand for healthcare is a derived demand. 
(Grossman, 1972, Lancaster, 1966).  Healthcare demand is based on consumer 
preference; that is, what consumers want along with their ability to pay for the service 
(Morris et al., 2007).  
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Consumers’ choice is driven by the objective of utility maximisation (Lancaster, 
1966). Lancaster’s approach to economic theory presents the idea that consumers 
demand a good or service for the characteristics it possesses. It is these characteristics 
that are the object of a consumer’s utility (Lancaster, 1966). The characteristics of each 
good or service are objective, but the utility derived from the characteristics are 
subjective and based on the consumer’s preferences. This theory was progressed by 
Grossman (1972) as he applied this concept to the demand for healthcare. It is the 
characteristics of the healthcare services which result in good health that are the source 
of utility maximisation for healthcare consumers. Utility maximisation for healthcare 
consumers is limited due to their income and the price the consumer must pay to use 
the service. Consequently, the price of healthcare goods and patient’s income influence 
patient choice.  
 
Consumer choice theory states that as price increases, the demand will decrease 
(Lancaster, 1966). This law of demand is relevant for most goods and services but for 
healthcare services, this theory needs to be applied with caution. In healthcare, user 
charges do not have a discriminating effect between necessary and unnecessary health 
services (EXPH, 2014).  In other words, user charges not only discourage unnecessary 
consumption for discretionary health services (services that do not affect morbidity) 
but also reduce consumption of essential health services (services that do affect 
morbidity) (Robinson, 2002). Reducing the consumption of essential health services 
can have a long-term financial impact on the healthcare system as patients may become 
sicker without sufficient access to essential healthcare and consequently require more 
care in the long-run.   
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Good health requires patients to invest in healthcare now and reap the benefits in the 
future. This is known as an investment in health capital. The concept originally 
stemmed from the concept of human capital theory which was contributed to by Gary 
Becker (1965). Human capital theory promotes the idea that present costs, which 
enhance future productivity, are seen as an investment in capital. The implications of 
such a theory have implications for the economic analysis of health expenditure.   
 
This theory was developed further by Grossman (1972) and is a foundation block in 
health economics. Grossman developed a household production model where 
individuals were producers and consumers of health. He proposed that a consumer 
spent time and resources on investments in their health to improve overall health, 
particularly future health (Grossman, 1972). The model views health as both a 
consumption good, as it allows people to feel well, and an investment good, as it 
promotes productivity, fewer sick days and higher wages (Grossman, 1972). In the 
model, health is treated as a stock which depreciates over time if there are no 
“investments” in health. Consequently, health is viewed as a form of capital. Investing 
in health increases the stock of health which provides benefits in the future 
(consumption of health) in terms of increased time available for other activities such 
as work and leisure (Grossman, 1972). Investing in health now reduces the risk of 
future illness or disease which consequently reduces healthcare costs in the long-term.  
 
As identified by Becker (1954) and Grossman (1972), individuals consume healthcare 
subject to a budget constraint. As user charges increase the proportion of the cost borne 
directly by the patient, the amount of healthcare the patient can afford will be reduced, 
therefore reducing the patient’s access to healthcare. Research has shown that an 
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increase in the cost of healthcare has a regressive impact; patients with lower incomes 
are affected more so than patients with higher incomes (Wagstaff et al., 1999). If the 
user charge is set below the average cost but continues to reduce healthcare utilization 
more for the poor than the rich, this user charge is regressive as it disproportionately 
affects the poor.  
 
The user charge for a healthcare service signals the cost to the patient of using the 
service (Mwabu, 1997). User charges provide information to the patient on what they 
must pay to utilize the service efficiently (Mwabu, 1997). Patients who pay a higher 
OOP cost for a healthcare service are more likely to be more cost-conscious and 
therefore, use the service sparingly. As highlighted by Grossman (1972), individuals 
are subject to a budget constraint when investing in their health. If the expected benefit 
from consuming a particular healthcare service is lower than the cost of the service, 
the patient is unlikely to invest.  It is this budget constraint that allows patients to 
realise that spending a proportion of their budget on unnecessary healthcare reduces 
their ability to consume other goods or services (Mwabu, 1997). This response to user 
charges can reduce unnecessary demand of healthcare.  
 
This unnecessary demand is referred to as ‘moral hazard’. As in Section 1.1, moral 
hazard is defined as “the intangible loss-producing propensities of the individual 
assured” (Dickerson, 1959, p. 67). Economic theory states that when a patient must 
pay the full cost of healthcare, he/she will consume healthcare based on preferences 
and budgetary constraints (Becker, 1965, Grossman, 1972). If a third party pays all the 
cost, it is expected that patients will have a higher utilization rate. Lower user charges 
cause the patient to consume more healthcare because the price to the patient is less 
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than the full price. Reducing unnecessary demand for a particular healthcare service 
reduces healthcare expenditure on this service and allows for efficient allocation of the 
service to patients who require it most. 
2.4.2 Impact of User Charges on Accessibility and Affordability 
 
High healthcare costs may influence a patient’s decision to seek healthcare and 
particularly impact on patients who cannot afford healthcare. As previously 
mentioned, this research examines affordability and accessibility as two key 
considerations in equity. A useful method to examine equity is to distinguish between 
horizontal and vertical equity. Both forms of equity can be assessed in terms of 
affording and accessing healthcare (Black and Gruen, 2005).    
 
Horizontal equity in relation to affordability in healthcare refers to the equal payment 
by those who have equal ability to pay. For example, setting the same user charge for 
a prescription drug for individuals within the same income group or the same insurance 
premium for individuals in the same income category. Horizontal equity in terms of 
accessibility refers to equal access for patients with equal need. For example, equal 
waiting time for patients with similar health conditions.  
 
Vertical equity regarding affordability implies payment for care is related to patients’ 
ability to pay, for example; progressive income tax rates. If the proportion of income 
used to pay for healthcare rises as income rises, then a healthcare system is identified 
as progressive. Vertical equity relating to accessibility in healthcare refers to the 
unequal treatment of unequal needs. For example, unequal treatment for patients with 
minor versus serious illnesses or injuries (Black and Gruen, 2005). 
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Inequity in healthcare can also arise in both forms of equity as discussed above. 
Horizontal inequity in affordability arises when patients with the same income pay 
different amounts towards healthcare (Morris et al., 2007). With regard to user charge 
payments, horizontal inequity arises due to the uncertain nature of the onset of illness 
and preferences for use of the healthcare service among individuals with the same 
income. Direct OOP payments have higher levels of horizontal inequity than social 
health insurance and tax-based systems. Horizontal inequity in terms of accessibility 
results when patients with similar needs do not have the same access to healthcare 
(Starfield, 2006).  
 
Vertical inequity relating to affordability arises if the proportion of income used to pay 
for healthcare increases as income decreases. If this is the case then the healthcare 
financing system is identified as regressive (Wagstaff et al., 1999). Empirical work has 
found that user charges disproportionately affect the vulnerable in society such as the 
elderly and patients with low incomes (Bishop et al., 2009, Lexchin and Grootendorst, 
2004, Thomson et al., 2009, Xu et al., 2006). Transferring a proportion of the cost to 
the patient, user charges contribute towards patients’ healthcare costs which may help 
alleviate financial strain on healthcare systems. Vertical inequity in terms of 
accessibility exists when patients with higher healthcare needs do not have as much 
access to these services as patients who have the ability to pay for the service. Once 
inequity is identified, governments can intervene to create a more affordable and 
accessible healthcare system by providing financial protection to low-income patients 
and/or high risk patients (Tambor et al., 2011). 
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2.5 Conclusion 
 
Examining the health economic theories of consumer choice and equity in terms of 
affordability and accessibility, this research assesses the impact of user charges on 
patient choice in Ireland. As proposed by Grossman (1972), price and income 
influence patient choice in healthcare. This research aims to reveal patients’ responses 
to user charges in the different situations and how these responses vary with socio-
economic status. For most healthcare services in Ireland, the user charge varies 
depending on the level of healthcare cover the patient has. To assess the impact of user 
charges on accessibility and affordability, this research deals with three different topics 
in the Irish healthcare system. The first topic assesses patients who have already made 
a choice to pay a user charge for a private healthcare service in order to identify what 
drives patient choice. The second topic looks at patients for whom a user charge has 
been recently introduced or increased, for a mainly public or part-publicly provided 
service, to reveal patient response. The third and final topic examines patients’ 
attitudes towards the potential application of user charges for both public and private 
healthcare services when it is part of a time-money (MRI) choice, a convenience 
choice (blood test) or a preference (branded drug) choice.  
 
The following chapter, Chapter 3, presents the first topic, What factors influence 
patient choice of urgent care clinics in the face of user charges in Ireland?  
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3 WHAT FACTORS INFLUENCE PATIENT CHOICE OF URGENT 
CARE CLINICS IN THE FACE OF USER CHARGES IN IRELAND? 
 
3.1 Introduction  
 
Patient choice of urgent care services in Ireland has expanded due to the development 
of public and private walk-in urgent care clinics. These UCCs offer an alternative 
choice of care to patients for the treatment of a minor injury or illness. Prior to the 
establishment of walk-in UCCs in Ireland, a patient had the choice of two traditional 
providers of urgent care; a GP or an A&E department.14 The establishment of 
alternative providers of urgent care has increased accessibility for patients when 
seeking treatment for a minor injury or illness.   
 
Comparable to walk-in UCCs in the UK, US and Canada (Weinick et al., 2009), UCCs 
in Ireland fill the gap between the traditional GP services and A&E departments. Walk-
in UCCs do not replace the services of a GP but act as a provider for specific needs 
such as x-rays or a service that is unavailable in a GP surgery. Patients also attend 
UCCs when they perceive their injury to require urgent care rather than the full 
facilities of an A&E department (Dolan and Dale, 1997, Weinick et al., 2009). While 
the treatment list in UCCs may not be as extensive as A&E Departments15, a re-
direction of injuries/illnesses by A&E departments to UCCs within the community can 
                                                          
14 Throughout this thesis, the term” traditional provider of urgent care” is used when referring to GP 
and A&E departments while “alternative providers of urgent care” is used when referring to walk-in 
UCCs. 
15 Urgent care clinics do not treat cardiac/chest pain, loss of consciousness, severe head/neck injuries, 
severe stomach pain, severe burns, infants under 12 months, pregnancy related conditions (VHI. n.d. 
VHI SwiftCare Clinics [Online]. Available: https://www.vhi.ie/swiftcare [Accessed 28 December 
2015]..  
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be a possibility in Ireland. This structural change is possible as the injuries treated in 
UCCs could previously only be treated in an A&E department (CentricHealth, n.d.). 
The emergence of UCCs could therefore be one solution to relieving pressure on 
traditional providers of urgent care in Ireland. Understanding the factors that affect 
patient choice when attending an UCC is important while delivering affordable and 
accessible urgent care within an appropriate time-frame (Shearer et al., 2015). 
 
Differences in the user charge and waiting times are the two main comparisons 
between the traditional and alternative providers of urgent care in Ireland. With regards 
to the user charge for traditional providers; the national average user charge for a GP 
consultation is €51 (Nolan et al., 2014) while a patient seeking care at a traditional 
public A&E department in Ireland pays €100 if they do not possess a medical card or 
a GP referral letter (HSE, 2013d). If they have either of these, treatment is provided to 
the patient free of charge. Similarly, the user charge to attend a public walk-in UCC in 
Ireland is €100 if the patient does not possess a medical card or a GP referral letter and 
if they have either of these, care is provided free of charge. In contrast, a patient 
attending a private walk-in UCC in Ireland may face an initial user charge between a 
range of €125 and €15016 plus additional charges depending on the services required.17  
 
In addition to disparities in the user charge, treatment waiting times also vary between 
the traditional and alternative providers of urgent care in Ireland. Traditional models 
of urgent care are associated with considerable waiting times; for example, a patient 
                                                          
16 This range of user charges is based on the cost of receiving urgent care at a number of private walk-
in UCCs that exist in Ireland; the Vhi SwiftCare Clinics (€125), the Blackrock Clinic (€140), the 
Mater Private (€150) and the Beacon Clinic (€150)  (BLACKROCKCLINIC. 2016. 
MATERCLINIC.2016,  BEACONHOSPITAL. 2016)...  
17 For example, X-rays and stitches, casts, splints and crutches (VHI. n.d.].. 
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may wait on average 6 hours or more for treatment of a minor injury/illness in an A&E 
department (HSE, 2013a). Similarly, GP surgeries in Ireland are experiencing excess 
utilisation which also leads to potentially lengthy waiting times for patients (NAGP, 
2015). Parallel to UCCs in the UK, US and Canada, UCCs in Ireland are based on a 
model of care which promote shorter waiting times (Dolan and Dale, 1997). For 
example, most private UCC groups in Ireland promote a waiting time of 60 minutes 
or less (VHI, n.d., Blackrockclinic, 2016).  
 
While private walk-in UCCs in Ireland improve patient access to urgent care, patients 
attending these clinics must pay the full user charge OOP at the point of use.18 As 
discussed in Section 2.4.1, subject to a budget constraint, healthcare is demanded based 
on consumer preferences; what a patient wants and what they are willing to pay for it 
(Grossman, 1972, Lancaster, 1966).  Attending an alternative UCC in Ireland requires 
a higher user charge and consequently, a larger proportion of the patient’s budget is 
used. This research examines the impact of this full user charge on patient choice and 
what factors influence patient choice of this privately funded service given the 
potentially higher user charge.  
 
This research notes that while there are differences in the services provided by 
traditional and alternative urgent care providers in terms of the waiting time and user 
charge, there is no empirical evidence to date to suggest that the quality of care differs 
in each location (Hutchison et al., 2003). There is growing evidence to suggest that the 
quality of care in alternative locations is equal to that of traditional urgent care 
                                                          
18 Patients with PHI may be subject to reimbursement for part of this user charge depending on the 
health insurance plan they have. 
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providers, for a number of acute minor conditions (Chang et al., 2015, Jacoby et al., 
2011, Mehrotra et al., 2008, Shrank et al., 2014). 
 
3.1.1 Research Question and Aim 
 
This chapter aims to answer the following research question:  
 
What Factors Influence Patient Choice of Urgent Care Clinics in Ireland in the face 
of User Charges? 
 
This question led to two more specific objectives that include:  
 
 Characterize the type of patient who chooses a walk-in UCC in Ireland. 
 Identify using a zero-truncated negative binomial model the factors that 
determine why a patient pays a higher user charge to receive urgent care at an 
UCC. 
 Identify using a probit regression what factors affect the likelihood of a patient 
being a first-time user of an UCC in Ireland. 
 
Through the construction of a unique questionnaire, this research collects primary data 
from patients attending three walk-in UCCs in Ireland in order to answer the objectives 
listed above.19 Collecting primary data, the research investigates the impact of user 
                                                          
19 As described in Section 1.2, the primary data collected in this chapter is collected from patients 
attending a privately funded walk-in UCC in Ireland. Therefore, from this point on, any 
acknowledgement to walk-in UCC in an Irish context are referring to privately funded walk-in 
UCCs.  
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charges on patient for this service and also identifies the other factors that affect patient 
choice of this service given the potentially higher user charges such as; patient 
demographics (age, gender), socio-economic characteristics (income, healthcare 
cover) and clinic characteristics (waiting time, non- appointment service, GP referral, 
extended opening times, travel, clinic location, injury type and parking) affect patient 
choice when deciding to use UCCs. 
 
3.1.2 Motivation 
 
As previously stated, walk-in UCCs have increased accessibility for some patients 
when seeking treatment for a minor injury or illness. If walk-in UCCs were not 
established in Ireland, it is assumed the patients attending the alternative providers 
would continue to present at the traditional providers of urgent care as found by Rizos 
et al (1990) in Canada. Therefore, understanding why patients choose to use this 
alternative healthcare provider is important. Understanding these factors may enable a 
re-direction of patients with minor injuries and illnesses away from A&E departments 
and towards an alternative urgent care provider. This would encourage a healthcare 
system which promotes affordable and accessible urgent care within an appropriate 
time-frame (Shearer et al., 2015).   
 
In an attempt to improve Irish healthcare, the “Strategic Framework for Reform of the 
Health Service” proposes the delivery of a major reshaping of the Irish healthcare 
system in an attempt to improve the governance, accountability and organization 
systems in the primary, community and hospital sectors in Ireland (DOH, 2012a). The 
results from this study may indicate the possible reshaping of care between GP and 
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A&E departments with walk-in UCCs by successfully treating patients at the walk-in 
UCCs. This would promote a more efficient use of urgent care services in Ireland. 
 
3.1.3 Chapter Structure 
 
Section 3.2 presents the empirical literature that has been conducted on alternative 
providers of urgent care. Section 3.3 presents the methodology that was employed to 
identify the factors which influence patient choice of UCCs in the face of user charges; 
Section 3.4 describes the econometric methods and subsequent results while Section 
3.5 concludes this chapter.  
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3.2 Literature Review 
 
3.2.1 Introduction  
 
Section 3.2 provides a critical review of existing literature on various aspects of 
alternative urgent care providers. Section 3.2.2 provides a description of traditional 
urgent care providers. Section 3.2.3 identifies three types of alternative urgent care 
providers and identifies similarities and differences between each provider. Section 
3.2.4 compares alternative urgent care providers with traditional urgent care providers. 
Sections 3.2.5 to 3.2.10 focus on the various attributes of the alternative healthcare 
providers such as; patient demographics of the users of these clinics, factors 
influencing patient choice, patient satisfaction and the impact of UCCs on traditional 
healthcare providers. Section 3.2.11 describes the previous methodology used 
throughout previous literature and Section 3.2.12 concludes this section.  
 
While this research collects data from three private walk-in UCCs, this chapter 
acknowledges that the alternative urgent care providers that are addressed in this 
review can be publicly or privately financed.  
 
3.2.2 Overview of Traditional Urgent Care Providers 
 
Emergency health services in Ireland are traditionally delivered by GPs and A&E 
departments. A GP can be the first point of contact within the healthcare system. A GP 
will deal with all health problems regardless of patient age, gender or any 
characteristics of the patient. As stated in Section 2.2.2, the national average adult 
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consultation to attend a GP is €51 if the patient does not have a GMS or GPVC (Nolan 
et al., 2014). Should the patient require further treatment and/or care, the GP will refer 
the patient to the necessary provider. Previous to the establishment of UCCs in Ireland, 
should a patient require further urgent care, a GP would commonly refer the patient to 
an A&E department. Most A&E departments are open 24 hours and 7 days a week in 
Ireland. Non-GMS patients without a letter of referral from their GP must pay €100 to 
attend an A&E department. Patients can also self-refer to an A&E when they perceive 
an injury/illness as urgent or due to an inability to access other medical care (Schneider 
et al., 1998).  Based on triage categories, patients with life-threatening injuries and 
illnesses are given priority treatment.20 Consequently, patients with non-life-
threatening injuries and illnesses can face an extensive waiting time for treatment.  
 
Overcrowding and increasing costs in A&E departments are a worldwide problem 
(Khangura et al., 2012). Consequently, patients do not receive urgent care in a timely 
manner. The use of A&E departments for non-urgent cases is the primary cause of this 
overcrowding (Lee et al., 2000). This type of A&E use is often referred to as 
“inappropriate use” (Liggins, 1993). Inappropriate A&E use leads to increasing costs, 
overcrowding and compromised care for true urgent cases (Derlet and Richards, 2000, 
Jepson, 2001, Siddiqui and Ogbeide, 2002). Over 50% of A&E cases are considered 
non-urgent giving rise to the “inappropriate use” of an A&E department (IAEM, 
2007). These patients are categorized as being ambulant ill or injured i.e. patients with 
a recent condition that results in their discharge instead of hospital admission (IAEM, 
                                                          
20 Triage Categories: Category 1 – Patient needs immediate treatment; Category 2 – Patient needs 
treatment within 15 minutes; Category 3 – Patient needs treatment within 1 hour; Category 4 – 
Patient needs treatment within 2 hours; Category 5 – more appropriate to send patient to GP (HSE, 
2013a) 
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2007), and their injuries/illness are more appropriate for treatment at an alternative 
urgent care provider such as an UCC.  
  
In comparison to traditional providers, the alternative providers are not a substitute for 
A&E departments. They improve accessibility for patients with conditions requiring 
urgent care but without the requirement for the full services offered in A&E 
departments.  
 
3.2.3 Overview of Alternative Urgent Care Providers  
 
A review of international literature has revealed various alternative providers of urgent 
care such as: Walk-in Clinics (WICs) (Hutchison et al., 2003, Salisbury and Munro, 
2003, Weinkauf and Kralj, 1998), UCCs (Merritt et al., 2000, Sibbald, 2000, Weinick 
et al., 2009) and Retail Clinics (RCs) (Mehrotra et al., 2008, Wang et al., 2010). Similar 
to UCCs in Ireland, each location provides urgent care for non-life threatening minor 
injuries and illnesses. The extent of services offered and the provider of care differ in 
each location yet all three locations provide increased accessibility for patients in terms 
of extended opening hours and shorter waiting times. With regard to cost, the user 
charge between each location varies yet all three alternative locations aim to provide 
affordable care.  The user charge between each location fluctuates due to the different 
payment protection policies that are in place in different health systems. UCCs in 
Ireland possess similar characteristics to WICs, UCCs and RCs. Consequently, it is 
relevant that all three healthcare settings are examined in this review.  
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WICs emerged in the United States (US) in the early 1970s (Jones, 2007) followed by 
Canada in the late 1970s (Hutchison et al., 2003) and more recently in the United 
Kingdom (UK) in 2000 (Salisbury and Munro, 2003). In addition to improving access 
to healthcare, WICs aim to reduce pressure on traditional healthcare providers such as 
GPs and Emergency Departments (EDs)21 (Jackson et al., 2005, Salisbury and Munro, 
2003). WICs provide treatment for minor injuries and illnesses22 (Desborough et al., 
2012). In the US and Canada the clinics are doctor-led (Jones, 2007, Salisbury and 
Munro, 2003) while in the UK the clinics are nurse-led (Salisbury and Munro, 2003). 
The provider of care is acknowledged as it has been proven that patients place different 
preferences on healthcare providers (Ahmed and Fincham, 2010). This may be an 
influential factor for service utilization. Despite variations in healthcare providers, 
WICs aim to provide rapid and convenient access to primary healthcare on a non-
appointment basis. 
 
UCCs emerged in the US in the early 1980s (Weinick et al., 2009) and are also 
established in Canada and Australia and more recently in Ireland. The care in UCCs is 
delivered by physicians, physician assistants and nurse practitioners (Weinick et al., 
2009). UCCs deliver acute episodic care for minor injuries such as fever, earaches, eye 
injuries, cuts, sprains and broken bones. UCCs fill the gap between hospital A&E 
departments and a primary physician’s office (Weinick et al., 2009). Patients use 
UCCs for services that are unavailable in a physician’s surgery such as; x-rays. Patients 
                                                          
21 In this thesis, the terms A&E departments and EDs both represent the same provider of urgent care. 
These terms are used interchangeably throughout this research and previous literature when 
referring to a department which provides urgent care for patients who present with or without a 
prior appointment. 
22 Infections and rashes, blood pressure checks, fractures and lacerations, emergency contraception 
and advice, stomach aches, vomiting and diarrhoea, hay fever, insect and animal bites, stitches 
(sutures), dressing care, minor cuts and bruises, minor burns and strains, stop smoking support  
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also attend UCCs when they perceive their injury to require urgent care rather than the 
full facilities of an A&E department (Dolan and Dale, 1997, Weinick et al., 2009). 
UCCs in the US encompass the distinguishing characteristics of walk-in urgent care 
clinics in Ireland such as; non-appointment service, short waiting times (Yee et al., 
2013) and patients do not need to be registered with UCCs (Qin and Prybutok, 2013). 
The average user charge in UCCs in the US is $155. This is less than a primary care 
visit cost at $165 and an ED visit which can reach $583. This comparison is reversed 
in the Irish Healthcare system where attending an UCC can result in a higher user 
charge than a traditional urgent care provider (see Section 3.2.2). The higher user 
charge may act as a deterrent for patients choosing UCCs in Ireland. This is similar in 
Australia where the user charge for attending an UCC can be more expensive than a 
GP yet less expensive than an A&E department (UrgentCareAustralia.ie). This 
research examines the effect of the potentially higher user charge on patient choice of 
UCCs.  
 
RCs appeared in the US in 2000 (Mehrotra et al., 2008) and more recently in Canada. 
In contrast to WICs and UCCs, RCs are based in stores such as Target, CVS, Walgreen 
and Walmart. Throughout the literature, RCs are also called “convenient care clinics” 
and “in-store medical clinics.” The scope of treatment offered by RCs differs 
considerably in comparison to WICs and UCCs. Rather than treating urgent 
conditions, RCs provide treatment for common medical conditions such as respiratory 
infections, allergic reactions, sinusitis, bronchitis, strep throat, influenza, insect bites, 
urinary tract infections and conjunctivitis (Hunter et al., 2009). Routine 
immunizations, physical examinations and routine preventative health screening are 
also available for diabetes, tuberculosis and hypertension (Hunter et al., 2009). 
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Healthcare is provided by nurse practitioners or physician assistants (Mehrotra et al., 
2008) and there is an average user charge of $50. The lower user charge in RCs 
compared to UCC could be due to the differences in staffing. Also, the cheaper user 
charge in RCs compared to the traditional providers and other alternative care 
providers could be due to the variation in injuries/illnesses that are treated.  Despite 
the difference in services, the models of care on which RCs are established are similar 
to that of Irish UCCs. The accessible and affordable healthcare provided by RCs 
responds to consumer-driven healthcare which the American health industry has failed 
to recognise due to political, social and economic pressures (Hunter et al., 2009). 
Privatized market-driven companies are the driving force behind RCs. This is also the 
case for a number of walk-in UCCs in Ireland which are privately funded such as; Vhi 
SwiftCare Clinics, Blackrock Clinic, Mater Private and the Beacon. 
 
In addition to varying attributes amongst the alternative providers themselves, notable 
differences exist between the alternative providers and the traditional providers of 
urgent care.  
 
3.2.4 Differences between Traditional and Alternative Urgent Care Providers 
 
The central difference between alternative and traditional providers of urgent care is 
the time-money trade-off faced by users of the services. With regards to time and 
accessibility, alternative urgent care providers offer a non-appointment service and 
promote shorter waiting times than traditional providers. One must acknowledge that 
EDs do provide unscheduled care but at the risk of longer waiting times for patients. 
For example, in the US in 2009, ED waiting times were in excess of 4 hours (Horwitz 
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et al., 2010) while 80% of UCC visits in alternative providers were 60 minutes or less 
(Yee et al., 2013). Similarly, in Ireland, HSE targets for 2015 aimed to have 95% of 
patients admitted or discharged within 6 hours of arrival at the A&E department (HSE, 
2015a). However, in the HSE Performance Report (2015) only 68.6% of patients were 
discharged or admitted within 6 hours in 2015 (HSE, 2015a). Comparable to the US, 
UCCs in Ireland work on a similar time-frame offering treatment for minor injuries 
and illnesses in less than 60 minutes.  The spectrum of treatment available at 
alternative providers of urgent care may contribute to the shorter waiting times for 
patients. For example, alternative providers of urgent care do not provide treatment for 
all services offered in a traditional physician’s office or in particular a hospital A&E 
department. The nature of injuries and illnesses they treat may be generally less severe 
(particularly in comparison to emergency departments) and as a result can be treated 
efficiently in a shorter time frame.  
 
While access to urgent care is improved due to alternative urgent care providers  the 
increase in accessibility may  result in a higher user charge for patients in comparison 
to the traditional urgent care providers.  In Ireland, patients who attend a walk-in UCC 
pay the full user charge OOP between €125 to €150 at the point of use23 plus additional 
fees for additional services.24  This is a higher user charge than the traditional A&E 
department user charge which is €10025, irrespective of the intensity of the treatment, 
and considerably more expensive than a GP for which the national average user charge 
is €51.  
                                                          
23 See footnote 1. 
24 See footnote 17. 
25 As previously mentioned, a patient without a medical card or a letter of referral from a GP must pay 
the relevant user charge of €100 for treatment received in the A&E irrespective of the amount or 
intensity of treatment received, while those with a medical card or a GP referral do not have to pay 
anything.  
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The differences in accessibility and cost between the traditional and alternative urgent 
care providers presents the patient with a time-money trade-off.   
 
3.2.5 Literature Review of Alternative Urgent Care Providers 
 
In an effort to identify the factors affecting patient choice of UCCs in Ireland, 
international literature on alternative urgent care providers is assessed with the 
intention of guiding the construction of the empirical model used in the methodology 
section for this research topic. An extensive literature review of alternative urgent care 
providers has identified patient demographics, socio-economic characteristics of the 
clinic users, factors influencing patient choice of the service, patient satisfaction and 
their impact on traditional urgent care providers (Ahmed and Fincham, 2010, 
Desborough et al., 2012, Hunter et al., 2009, Jackson et al., 2005, Mehrotra et al., 2008, 
Salisbury et al., 2002, Weinick et al., 2009). These studies identify patient 
characteristics which help understand the drivers of choice for these alternative urgent 
care providers.  With this information, alternative providers can generate an 
understanding of their customers’ needs and alter their services to better suit the needs 
of the patient as consumer choice in healthcare is based on the patients’ preferences 
(Grossman, 1972, Lancaster, 1966). Understanding why patients choose to use an 
alternative urgent care provider in Ireland informs policy makers about what 
consumers want from urgent care providers. This will help to shape the delivery of an 
accessible and affordable urgent care system (Shearer et al., 2015). 
 
The literature review was guided using a combination of the following search words 
in Academic Search Complete (urgent care, convenient care, alternative care, 
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emergency care, primary care, factors, cost and user charge). A citation approach was 
adopted where citations were recorded and from there reference lists were scanned 
until such a time it was thought that all key paper/authors were retrieved. The criteria 
extracted from each study was as follows; data source, study design, outcome 
measurement and study results.  
 
Table 3.1 shows a breakdown of the literature conducted in this area of research 
throughout the UK, US and Canada on alternative urgent care providers.
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Table 3.1  Synopsis of Literature Examining Alternative Providers of Urgent Care 
 
Authors         Date      Study Population                  Design                    Outcomes                     Results 
             (Date Source) 
 
Ahmed and 
Fincham 
2010 Adult residents in Georgia (N=493) Patients interviewed using a 
DCE. 
4 attributes with 2 levels each: 
cost ($59; $75) (€44.61; €56.71)26 
, appointment wait time (same 
day;1 day longer), care setting 
(nurse in RC and physician in 
private office), acute illness (UTI; 
flu).  
Reduced waiting time 
and reduced cost in RC 
is attractive to patients. 
Appointment wait time 
is most important 
factor when seeking 
healthcare.  
Bell and Szafran 1992 Patients attending a WIC over a 6-
month period (N=531) 
Cross-sectional questionnaire Patients use of WICs (visited a 
WIC in past 6 months), reasons 
for choosing this location, 
attempted to make an 
appointment with traditional 
provider, attended traditional 
provider after attending the WIC 
and patient demographics. 
Convenient location of 
WIC, minor medical 
problem and increased 
accessibility were top 
three influential 
factors.  
Hsu et al 2003 12 GPs. 6 in Loughborough with a 
WIC (N=69 and N=70) and 3 in 
Market Harborough; control town 
(N=39 and N=40) 
Observational study Mean daily rate of emergency GP 
consultations, mean number of 
half days to sixth bookable 
appointment, attendance at out of 
hours’ services, minor injury units 
and A&E departments. 
WIC did not greatly 
impact on the workload 
of the GP. Attendance 
at minor injury unit 
increased. Authors 
suggest this is because 
the unit was in the 
same building as the 
WIC.  
                                                          
26 The prices included in this table have been converted into the Euro equivalent value corresponding to the year each study was conducted. 
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Hunter, Weber and 
Wall 
2009 Patients in two RCs in Arizona 
between May 2006 and July 2007 
(N=684) 
Descriptive design using an 
anonymous voluntary self-
report questionnaire. 
Patient characteristic and factors 
influencing patient choice. 
Patients with various 
income and different 
ethnicities value the 
same attributes of RC.  
Jackson et al 2005 Patients using a WIC (N = 23)  Semi-structured interviews Seeking care (execution and 
professional advice), resources 
and access 
Patients experience of 
WICs suggest the 
clinics improve access 
to healthcare and serve 
as an alternative 
method of seeking 
healthcare.  
Maheswaren et al 2007 2,509 GPs in 56 primary care trusts 
in England and 32 walk-in centres 
within 3km of each GP practice 
Ecological Study Impact of WICs in primary care 
access times: ecological study 
WICs do not impact on 
waiting times to access 
primary care facilities. 
Results do not support 
this purpose. 
Plauth and Pearson 1998 Patients 18+ years in an urgent care 
department in US (N=551). 
Cross-sectional questionnaire Patient demographics, health 
status, why patient chose the 
location, barriers in accessing 
care in traditional healthcare 
provider.  
Barriers reported when 
accessing traditional 
provider of care. 
Factors influencing 
patient choice; quick 
access to care, 
traditional provider 
closed, unable to get 
appointment with 
physician and 
constrained by work or 
childcare.  
Rizos et al 1990 Patients attending a WIC in 
Toronto over a 16-day period 
(N=321). 
Cross-sectional questionnaire Reason for attending, perception 
of urgency, satisfaction with care 
received and concerns regarding 
care received.  
Three most influential 
factors were location, 
inability to get 
appointment with 
traditional provider and 
the non-appointment 
service of the WIC. 
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Salisbury et al 2006 8 hospitals with co-located EDs and 
WICs compared with EDs without 
WICs 
Routine data on attendances and 
resources used. Random sample 
of patients attending before and 
after the opening of the WIC. 
Postal questionnaire sent to 
patients who had not been 
admitted.  
Impact of co-located WICs on 
EDs: Effect on patient 
throughput, visit duration, process 
of care, resource use and costs, 
patient outcome and re-
consultation 
No evidence of an 
effect on the outcome 
measures. 
Salisbury et al 2002 38 WICs and 34 neighbouring GPs 
(N=6229) 
Observational study using 
questionnaires 
Socio-demographic 
characteristics, reasons for 
consulting, attitudes to continuity, 
satisfaction, enablement, further 
referrals and intentions. 
Main influential 
factors: speedier access 
and convenient care, 
less importance on 
continuity of care. WIC 
improve access to 
health but not 
necessarily for patients 
with the greatest needs.  
Scott et al 2009 Patients attending an UCC 
(N=1,006) 
Cross-sectional questionnaire Demographic characteristics, 
socio-economic characteristics, 
reasons for choosing UCC, 
previous primary care use, 
reasons for delaying care and 
preventative care needs. 
Patients use UCC 
largely because of the 
convenient and timely 
care. Not for economic 
reasons.  
Source: Authors Own 
 
48 
 
From this table, the following sections discuss patient demographics, socio-economic 
characteristics, factors influencing patient choice of alternative urgent care providers, 
patient satisfaction, and the impact of alternative providers on traditional providers.  
 
3.2.6 Patient Demographics 
 
In Canada, using a prospective questionnaire, Bell and Szafran (1992) assessed family 
practice patients’ use of WICs. Females and young adults (aged 20-29) are 
predominant users of WICs while patients over 40 prefer to use a regular family 
physician. In the UK, using a self-administered questionnaire, Salisbury et al (2002) 
support existing findings that younger adults constitute a high proportion of NHS WIC 
visits. In Boston, Plauth and Pearson (1998) implemented a cross-sectional study using 
a primary care comparison group to identify patient demographics in an UCC. Patients 
attending UCCs were younger than those attending primary care centres. In addition 
to comparing alternative providers of urgent care to primary care services, Mehrotra 
et al (2008) used a cross-sectional comparison of RCs with physician offices and EDs. 
Once more, age was deemed as a significant variable with a younger age cohort 
attending RCs compared to physician office and EDs.  
 
The nature of the injuries and illnesses treated at alternative urgent care providers 
could be an influential factor for the younger age groups that choose these healthcare 
locations. For example; bone fractures, sprains and sports injuries are more likely to 
occur among young adults due to active lifestyles. Older age groups are more 
susceptible to serious illness/injuries consequently requiring longer healthcare visits 
and long-term care rather than the episodic care offered by the alternative providers of 
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urgent care (WHO, 2016). This influences patient behaviour in older adults as they 
prefer traditional providers of care for the treatment of minor injuries and illnesses. 
Older patients prefer to go to their “regular” doctor as they always have done before 
UCCs were established. Older patients will be less likely to change their (Beache and 
Guell, 2015). Mehrotra et al (2008) strengthens this rationalization as a low percentage 
of users at an alternative urgent care provider in the US reported registration with a 
regular family physician. In conclusion, patients who choose to use an alternative 
urgent care provider tend to be a younger age group and are less likely to be registered 
with a regular doctor.  
 
The results of these studies generate concerns that alternative providers of urgent care 
only meet the needs of a younger healthier age group and as a result do not provide a 
healthcare service which satisfies the needs of the older and possibly unhealthier 
section of the population (Salisbury et al., 2002).   
 
3.2.7 Socio-Economic Characteristics 
 
With regard to socio-economic characteristics, the literature reveals diverse findings 
amongst patients using alternative urgent care providers. Jackson et al (2005) found 
patients attending a WIC in the US are of a high socio-economic status reporting high 
levels of education and a high social demographic.27 (Jackson et al., 2005). Similarly, 
Rylko-Bauer (1988) found an insignificant presence of medical aid beneficiaries using 
WICs in the US. This is a logical finding as the majority of medical aid is granted on 
                                                          
27 Social demographic in this case is based on employment type: Professional, Blue-collar worker, 
civil servant, business owners or unemployed. 
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an income basis. If the individuals using these healthcare providers are of a high socio-
economic background, they are not likely to receive government aid for access to 
healthcare services.  
 
Conversely, Scott et al (2009) found patients in an UCC in Denver to be of a low socio-
economic background; 24.8% reported low levels of education, 17.9% reported 
literacy issues and 12% were homeless.  
 
Diverse payment methods between the traditional and alternative urgent care providers 
offer justification for these conflicting findings. For example, in the US, traditional 
and alternative urgent care providers provide care to all income groups. They provide 
treatment to patients with PHI and also to those who receive government medical aid.28 
Consequently, different income groups have no reason to place a higher preference on 
one urgent care provider over another compared to Ireland where patients face varying 
user charges at traditional and alternative providers of urgent care depending on their 
healthcare cover. Using a Primary Care Comparison group, Plauth and Pearson (1998) 
support this justification as they found no difference in socio-economic status between 
traditional and alternative providers of urgent care. Their study could be strengthened 
by identifying and comparing the number of patients who pay OOP for treatment, those 
who are covered by medical aid and patients who are covered by PHI for treatment 
received in physician offices and UCCs. This would determine if patients of various 
socio-economic backgrounds reveal similar utilization patterns for physicians and 
UCC services. Consequently, this research measures patient healthcare cover to test if 
                                                          
28 A survey conducted by the Urgent Care Association of America (UCAOA), found 51% of 
respondents had their treatment paid for through PHI, 17% paid OOP while 32% of respondents 
reported that payment to the clinic was made by Medicare, Medicaid or workers’ compensation on 
their behalf. 
51 
 
the full OOP user charge required to attend an alternative provider of urgent care is 
significant in an Irish context29.  
 
3.2.8 Factors Influencing Patient Choice of Alternative Urgent Care Providers 
 
A number of studies have addressed the issue as to why patients choose alternative 
urgent care providers over the traditional services. Findings are consistent among the 
studies. Increased accessibility in terms of the non-appointment service, extended 
opening hours, clinic location, difficulty in accessing traditional providers of urgent 
care and patients’ perception of need are the main characteristics influencing patient 
choice of alternative urgent care providers (Bell and Szafran, 1992, Dolan and Dale, 
1997, Hunter et al., 2009, Plauth and Pearson, 1998, Salisbury et al., 2002). The user 
charge associated with the alternative providers is revealed to be less significant in 
comparison to the factors measuring accessibility.  
 
The non-appointment service and extended opening hours are the most common 
influential factors for patients deciding to use an alternative provider of urgent care 
(Bell and Szafran, 1992, Dolan and Dale, 1997, Plauth and Pearson, 1998, Rizos et al., 
1990). These attributes allow patients to seek healthcare at a time which is most 
suitable to them. Due to the uncertain onset of an urgent injury/illness, the non-
appointment service offered by alternative urgent care providers offers peace of mind 
                                                          
29 It is important to note that depending on the nature of the urgent care provider in Ireland (public or 
private), the level of cover varies. Private UCCs in Ireland such as Vhi SwiftCare Clinics and the 
Medical Assessment Unit in the Bon Secours hospitals do not accept government aid as payment for 
their services. The clinics will only treat patients who are willing to pay for the service. Some PHI 
plans reimburse a proportion of the cost.. Public healthcare providers in Ireland such as the Mercy 
Urgent Care Clinic in Cork do accept government aid as a method of payment for their services.  
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that urgent care is accessible outside the traditional scheduled service offered by 
traditional healthcare providers.30   
 
Location of the alternative clinics is another factor which influences patient choice of 
alternative providers of urgent care. Previous literature has found these services to be 
locally used services (Dolan and Dale, 1997, Grafstein et al., 2013, Rizos et al., 1990, 
Shearer et al., 2015). Distributing a pre-consultation questionnaire to self-referred 
patients in a minor injury unit in South Kent, Dolan and Dale (1997) reveal that 
patients in their sample travelled 10 minutes or less to attend the minor injury unit. 
Distributing a cross-sectional questionnaire to patients at 6 Canadian EDs31, Grafstein 
et al (2013) investigated the factors that influence patient choice in attending an ED 
for urgent care. Assessing the importance of distance to the ED on a five-point Likert 
scale, they found 44%32 of their sample reported distance to the ED as one of the 
primary reasons for choosing to visit that particular location. Similarly, Shearer et al 
(2015) found that patients chose a private Australian ED33 due to close proximity to 
their home.  
  
Several studies also found that patients chose an alternative provider of urgent care 
due to difficulty in accessing traditional providers of urgent care (Dolan and Dale, 
1997, Paxton and Heaney, 1997, Jackson et al., 2005). As noted, traditional providers 
generally work on a scheduled basis and can involve longer waiting times than the 
                                                          
30 While GPs in Ireland do operate on a scheduled basis, this research acknowledges that A&E 
departments in Ireland are open 24/7 and do operate on a non-appointment basis but with the risk of 
extensive waiting times for treatment.   
31 It is acknowledged that an ED is a traditional provider of urgent care and not an alternative provider 
of urgent care. Yet this study is included in this review as the study investigated factors affecting 
patient choice of urgent care.  
32 Total sample size was 634 (83.8% response rate). 
33 See footnote 21. 
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alternative providers. For example, in 2009 there was an average wait time of 4 hours 
in EDs in the US. In comparison, some alternative providers of urgent care treat 
patients within 60 minutes (Qin and Prybutok, 2013, Yee et al., 2013). It appears 
people choose an alternative urgent care provider due to increased accessibility and 
not as a result of dissatisfaction with the care provided by the traditional providers of 
urgent care (Rizos et al., 1990).  
 
Jackson et al (2005) found patients in the NHS were concerned the nature of their 
injury/illness would not be deemed appropriate for treatment in a GP surgery. Some 
patients viewed GPs as a “precious service” with limited appointment times and were 
concerned with the increasing demand on the NHS. Despite the limitation of a small 
sample size, this study emphasises that alternative urgent care providers can function 
as a medium between the traditional primary care offices and hospital A&E 
departments. Some alternative urgent care providers  erve as a complement to 
traditional services for convenience purposes while others use this alternative provider 
as a substitute to their preferred provider may not be  accessible at that time (Jackson 
et al., 2005). Salisbury et al (2002) show similar findings to Jackson et al (2005). 
Patients in their study chose to use the alternative service as they did not want to 
needlessly bother their “regular” doctor. These results indicate that patients are aware 
of the overcrowding issues in the traditional urgent care providers. Patient awareness 
of the correct treatment location is crucial in the organization of an efficient healthcare 
system. Currently, patients present at hospital EDs with illnesses/injuries that are not 
deemed serious enough but do require immediate care outside that of the family 
physician. The objective of alternative urgent care providers is to meet the demand for 
patients whose needs lie between that of the traditional family doctor and hospital ED.  
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Three studies directly acknowledge the importance of the user charges on patient 
behaviour (Ahmed and Fincham, 2010, Hunter et al., 2009, Qin and Prybutok, 2013). 
Two reasons may explain this scarcity in literature; the patient payment mechanisms 
in different healthcare systems and the consequent pricing strategies that exist amongst 
alternative urgent care providers.  
 
Disparity in payment mechanisms are as a direct result of healthcare financing across 
international healthcare systems.  For example, the NHS in the UK is a publicly 
provided and financed system where user charges mainly exist in dental and optical 
care (Black and Gruen, 2005). Similar to the UK, healthcare in Canada is also publicly 
financed with most funding generated through taxation (Chua, 2005) and for the most 
part healthcare is free at the point of use. With healthcare free at the point of use in 
alternative urgent care providers, it can be assumed that the cost of the visit would not 
be an influential factor for choice and consequently does not feature heavily in the UK 
or Canadian literature. In the US, healthcare is largely financed through PHI (Black 
and Gruen, 2005) and payment is expected at the point of use for treatment received 
by alternative urgent care providers.  Patients with PHI cover can apply for 
reimbursement for the treatment received in WICs (Wieczner, 1998). Collecting 
financial data from UCCs, Weinick, Bristol and DesRoches (2009) found 50% of UCC 
visits were paid for by a private health insurer in the US between September and 
November 2007.  
 
As mentioned, Hunter et al (2009), Ahmed and Fincham (2010) and Qin and Prybutok 
(2013) did directly acknowledge the importance of cost on patient behaviour for 
alternative urgent care providers. Hunter et al (2009) examined the impact of user 
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charges in RCs in two survey sites. An examination of the demographic data revealed 
distinct socio-economic variation between the two locations.  Income per capita in 
region one was $59,355 and $18,068 in region two. Examining the influence of the 
user charge on patient choice between the two socio-economic groups revealed very 
little variation (27% Vs 38% respectively).  Only 34% of this sample reported cost as 
an influential factor when deciding to use a RC. As previously stated, patients 
attending a RC in the US can pay for treatment OOP34 and/or obtain reimbursement 
for a portion of the cost from their health insurance provider (Mehrotra et al., 2008). 
More recently, Medicare and Medicaid are paying for RC visits (Bohmer, 2007). 
Consequently, the user charge is not reported as being influential amongst a host of 
accessibility factors.  
 
This indicates that patients who do not pay the full price for attending an alternative 
provider of urgent care, such as RCs, place less importance on cost. These findings are 
supported by economic theory. If a third party pays a proportion of the cost, it is 
assumed utilization of a service will be higher as patients are not paying the full cost 
of healthcare; the user charge does not influence utilization. Economic theory states 
that a when a patient must pay the full cost of healthcare, he/she will consume an 
amount of healthcare based on preferences and budgetary constraints (Becker, 1965, 
Grossman, 1972). 
 
Ahmed and Fincham (2010) examined the impact of cost on treatment-seeking 
behaviour in RCs and physicians’ offices. Using a Discrete Choice Experiment (DCE), 
they created 16 choice scenarios from which the respondents could choose. The 
                                                          
34 A patient without health insurance would face a cost of $50 per visit 
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scenarios involved two types of care setting and clinician combination (nurse in a RC 
and physician at a private office), two symptoms (urinary tract infection or influenza), 
two price levels35 ($59 or $75)36  and two levels of appointment wait time (same day, 
1 day or more). To calculate the preferences for care at RCs or a physician’s office, a 
random-effects logistic regression was used. Ahmed and Fincham (2010) found that 
cost was important to patients, with cost-saving in RCs more likely to encourage 
treatment in this location rather than a physicians’ office. It is not explicit in their study 
if the patients had PHI cover yet total annual household income levels are reported 
with 13.7% of the sample earning less than $25,000 and 40% earning $75,000 or more. 
If PHI status was recorded, exclusive results could be obtained determining the 
magnitude of the impact of user charges on RC utilization. Do patients who pay OOP 
place a higher preference on cheaper care and are patients who are covered by PHI less 
cost-conscious? This research will control for PHI status and income level when 
identifying the impact of user charges on patient behaviour when choosing UCCs in 
Ireland. While PHI does not cover the cost of attending a walk-in UCC, some PHI 
plans offer a reimbursement for part of the initial consultation fee. 
 
 
To date, previous literature   reveals patients place a higher preference on the increased 
accessibility offered by the clinics. This finding is supported by Shearer et al (2015) 
who assessed why patients chose to use a private ED37 in Australia. In this study, cost 
was not deemed an influential factor in patient decision making amongst a host of 
                                                          
35 Captured respondents’ WTP. 
36 $59 represents the cost of treatment in RC based on the prevailing fee at a large RC in Georgia. $75 
represents physician fees and the figure is taken from the 2004 Medical Expenditure Panel Survey. 
37 It is acknowledged that an ED is a traditional provider of urgent care and not an alternative provider 
of urgent care. Yet this study is included in this review as the study investigated factors affecting 
patient choice of urgent care. 
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convenience characteristics. The study assessed patients attending the ED, therefore 
the patient has already made the decision to utilize this service.  Shearer et al (2015) 
suggest that as the patients decided to use the private ED they are not truly deterred by 
the OOP cost. This finding is relevant to UCCs in Ireland as this study also focuses on 
users of the service. Similar to Shearer et al (2015), the patients have already made the 
decision to pay the full user charge for attending this alternative provider of urgent 
care. Despite already being users of the clinics, price of the visit is still controlled for 
by asking patients to indicate how influential the cost of the service was in their 
decision to seek care at this location.  
 
In a time where the urgent care industry is expanding, Qin and Prybutok (2013) wanted 
to understand how urgent care providers are perceived by patients and what influences 
patient satisfaction and patient behaviour. To develop and validate an urgent care 
service quality instrument, Qin and Prybutok (2013) considered the concept of 
perceived value. In terms of healthcare, perceived value is the trade-off between the 
service cost and the received value (Eggert and Ulaga, 2002). The inclusion of this 
concept is based on the impact patient perceptions have on service providers’ long-
term success. Patient perceptions influence behavioural decisions (Qin and Prybutok, 
2013).  This is important in particular in the urgent care industry where a number of 
options exists; hospital EDs, WICs, UCCs, RCs and family doctors etc. Urgent care is 
provided in terms of working hours, convenience and service scope. Differences in 
waiting time and costs vary among providers. Qin and Prybutok (2013) use the 
following example to highlight this disparity “...prices in hospital emergency 
departments are generally higher. The waiting times in primary care physicians’ 
offices are longer. Therefore, we view perceived value as an important factor when 
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influencing the patient’s provider selection for urgent care services”. Patient 
perception can have positive effects on behaviour (Sirohi et al., 1998, Sweeney et al., 
1999) but the relationship can be mediated by patient satisfaction (Bolton and Drew, 
1991, Cronin et al., 2000, Patrick and Park, 2004). This theory is supported by Qin and 
Prybutok (2013). Despite not assessing the importance of treatment cost in alternative 
urgent care providers, the study highlights the importance that perceived value can 
play in behavioural decisions guided by patient satisfaction. While cost is not explicitly 
identified in the studies included in this paragraph, the studies highlight how the 
perceived value of healthcare is important to patients.  
 
Less significant factors influencing patient choice of alternative urgent care providers 
are also revealed; absence of regular physician, free parking (Bell and Szafran, 1992); 
preference for nurse rather than doctor, more confidence in advice, not registered with 
GP, better range of services offered, didn’t think about going anywhere else (Salisbury 
et al., 2002); previous experience and word of mouth (Jackson et al., 2005). Even 
though these factors were reported as less significant than the convenient and timely 
care offered by the clinic, they will be included amongst the variables for this research 
to test their significance in an Irish context.   
 
3.2.9 Patient Satisfaction 
 
Patient satisfaction in alternative urgent care providers has also been examined 
throughout the literature (Chesteen et al., 1986, Feldman and Cullum, 1984, Garnett 
and Elton, 1991, Hunter et al., 2009, Jackson et al., 2005, Paxton and Heaney, 1997). 
In Canada using structured questionnaires at a hospital-based WIC, Feldman and 
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Cullum (1984) found high levels of patient satisfaction during patients’ experience at 
the clinic. In the US, Chesteen, Warren & Woolley (1986) used a cross-sectional study 
and found that patients attending a free-standing emergency care clinic reported higher 
levels of satisfaction than patients attending a family physician. Similarly, in the UK, 
analysing the first six months within opening of a nurse-led minor injury clinic, Garnett 
and Elton (1991) also determined high levels of patient satisfaction. Heaney and 
Paxton (1997) performed an evaluation38 of a minor injury unit in the UK, where 
98%39 of cases reported satisfactory treatment. More recently in the UK, Jackson et al 
(2005) conducted semi-structured interviews to study patients’ experiences in an NHS 
WIC. This study also reported higher levels of patient satisfaction in WICs than 
traditional providers such as family physician offices.  
As suggested by Jackson et al (2005), high levels of patient satisfaction in WICs may 
be due to the fact that patients do not have to discuss access with a receptionist or 
justify reasons for seeking care at a WIC (Jackson et al., 2005). Patients attending this 
WIC reported feeling a burden when attending a family practitioner as they are not 
sure whether their illness requires a visit to the GP.  Despite GP healthcare being free 
at the point of use in the UK, patients remain conscious of unnecessarily utilizing a 
GP’s valuable time. In a WIC, patients do not face the prospect that they are utilizing 
scarce appointment resources from someone more “deserving” (Jackson et al., 2005). 
While the sample size in Jackon et al’s (2005) study is quite small (23 patients) the 
study offers another perspective as to why patients may choose to visit a WIC. 
 
                                                          
38 Distributed a self-completed questionnaire to patients in the clinics with a follow-up questionnaire 
posted to the patient, 10 to 14 days after their clinic visit (Paxton and Heaney, 1997). 
39 Questionnaire 1 yielded 749 respondents while the follow-up questionnaire retrieved 456 
respondents. 
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The importance of assessing patient satisfaction for a healthcare service is highlighted 
in previous studies. Considering patients using a private ED in Australia, Shearer et al 
(2015) identified patient satisfaction of a service as an influencing factor in patient 
behaviour. A patient who reports high satisfaction with a service is more likely to 
return to the service again while low levels of satisfaction reduce this likelihood. It is 
argued that patient satisfaction mediates patients’ perceived value and patient 
behaviour (Qin and Prybutok, 2013). Therefore, patient satisfaction with a particular 
service can influence their behaviour towards this service should they demand the 
service in the future. Consequently, this research will measure patient satisfaction in 
Irish urgent care clinics to test its significance in an Irish context.  
 
3.2.10 Impact of Alternative Urgent Care Providers on Traditional Urgent Care 
Providers 
 
As a consequence of their establishment, alternative urgent care providers may relieve 
demand on traditional healthcare providers and subsequently improve access to urgent 
care for patients. A number of studies have investigated this effect (Hsu et al., 2003, 
Maheswaran et al., 2007, Rizos et al., 1990, Salisbury and Munro, 2003).  
 
Conducting an observational study, Hsu et al (2003) assessed the impact on demand 
of an NHS WIC on a traditional primary healthcare provider. They compared primary 
and emergency services in two different locations, one with a WIC and one without a 
WIC. Hsu et al (2003) retrieved data on daily phone calls, data collection forms, 
emergency GP consultations40, number of out-of-hours attendances/visits, routine 
                                                          
40 Defined as an appointment requested on the same day of consultation. 
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computerised data, number of A&E visits and number of calls to NHS Direct41. In the 
intervention town, Hsu et al (2003) conclude that primary and emergency service 
utilization did not experience a significant decrease in demand due to the existence of 
the WIC. This study did however, observe an increase in the use of a minor injuries 
unit that was co-located with the WIC. The authors propose that the publicity the minor 
injury unit received from the co-located WIC increased the attendance at the minor 
injury unit.  
 
With similar  results, Salisbury et al (2006) assessed the impact of NHS WICs on ED 
statistics. They examined the attendance rates, treatment duration, costs and outcomes 
of care in co-located emergency departments. Comparing 8 hospitals with co-located 
EDs and WICs, with 8 matched EDs without WICs, the researchers conclude that NHS 
WICs have little effect on the attendance rates, treatment duration, costs and outcomes 
of care in co-located emergency departments. Likewise, in the NHS, Maheswaren et 
al (2007) used data from a national primary care service to investigate the impact of 
WICs on waiting times for a doctors’ appointment. They also found NHS WICs to 
have little impact on traditional healthcare providers.  
  
While the findings of these studies are similar, the results are conflicting with the 
objectives of alternative urgent care providers. There are two possible reasons for this; 
patient demographics within the different healthcare systems and/or poor study design. 
The countries in which these studies are conducted may have an ageing population 
who continue to use traditional providers.  As previously mentioned, the elderly 
                                                          
41 Digital health and advice service for health matters which are not urgent enough for dialling traditional 
emergency services such as 999. 
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population are more likely to visit their regular doctor for treatment of an urgent injury 
or illness. These older patients are less likely to change their behaviour to attend an 
alternative provider (Beache and Guell, 2015). If so, the studies fail to pick up on the 
magnitude of the impact of alternative urgent care providers. With regard to the study 
design, studies which aim to identify the impact of alternative urgent care providers 
are of limited value as they generally only include users of the services (Hunter et al., 
2009, Jackson et al., 2005, Salisbury et al., 2002, Salisbury and Munro, 2003, Scott et 
al., 2009). A number of these studies fail to assess why patients do not decide to use 
these alternative services. Understanding why patients chose to avoid alternative 
urgent care providers would provide further insight into patient behaviour regarding 
alternative urgent care providers. This is discussed in the context of this research in 
Section 6.4. 
 
In addition to incorporating non-users, to successfully identify the impact of alternative 
urgent care providers, studies need to address 3 key considerations (Salisbury and 
Munro, 2003). Firstly, the correct function of the alternative urgent care provider(s) 
needs to be identified; does the alternative provider successfully treat and discharge 
patients rather than encourage duplicate care? Secondly, the user charge to attend the 
alternative provider needs to be recognised; is the user charge less than that of the 
traditional provider? Finally, it needs to be established if the alternative provider of 
urgent care was unavailable, whether the patient would attend a traditional provider of 
urgent care rather than self-manage the injury or illness (Salisbury and Munro, 2003). 
Rizos et al (1990) investigated the 3rd consideration listed here and of the 416 
respondents in their study, 89 patients reported a regular physician as their alternative 
choice while 77 respondents stated they would have attended an emergency 
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department had the WIC been closed. This finding proves that the existence of 
alternative urgent care providers could prevent GP waiting rooms and A&E 
departments from becoming overcrowded with non-urgent cases. These three 
considerations are acknowledged in the Irish research, either in the data collection tool 
itself or in the discussion of the results.  
 
3.2.11 Previous Methodology 
 
Studies assessing factors which influence patient choice of alternative urgent care 
providers used self-completion questionnaires to collect primary data from users of the 
service (Bell and Szafran, 1992, Hunter et al., 2009, Rizos et al., 1990, Salisbury et al., 
2002, Scott et al., 2009) . Using self-completion questionnaires, recurring variables are 
measured such as; patient demographics (age, gender, nationality), socio-economic 
factors (education and healthcare cover), clinic characteristics (waiting time, non- 
appointment service, GP referral, extended opening times, travel, clinic location, 
injury type and parking), patient satisfaction and in some cases the questionnaires 
assessed the importance of the user charge for alternative urgent care providers. 
Subsequently, similar target samples, data location and collection methods are 
implemented in this research to identify the factors affecting patient choice of walk-in 
UCCs in Ireland.  
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Table 3.2 Previous Methodology 
Author Methods  Sample Size  Data Analysis  
Rizos et al (1990)  Two-part questionnaire 
provided to all patients in 
a WIC in Toronto during a 
16-day period in February 
1988  
N= 321 patients  Descriptive statistics  
Bell and Szafran 
(1992) 
Canada  
Prospective 
questionnaire completed 
in physician waiting room 
over a 1-week period  
N=531  Z test 
Chi Squared  
Salisbury et al 
(2002) 
UK  
Self-administered 
questionnaire divided in 
2 sections “before” and 
“after” treatment b/w Oct 
2000 and April (2001) 
N= 6,229  Descriptive stats 
Linear Models  
Hunter, Weber and 
Wall (2009)  
Anonymous, voluntary, 
self-report questionnaire 
completed during RC visit 
b/w May 2006 – June 
2007  
N= 684 Descriptive Statistics  
Scott et al (2009)  Cross-sectional 
questionnaire of patients 
in UCCs over a six-week 
period  
N= 1,006   Multiple logistic 
regressions  
Source: Authors Own 
 
3.2.12 Conclusion 
 
A review of international literature has revealed various alternative providers of urgent 
healthcare such as; WICs (Hutchison et al., 2003, Salisbury and Munro, 2003, 
Weinkauf and Kralj, 1998), UCCs (Merritt et al., 2000, Sibbald, 2000, Weinick et al., 
2009) and RCs (Mehrotra et al., 2008, Wang et al., 2010). Studies conducted in these 
various locations have identified patient demographics, socio-economic 
characteristics, factors influencing patient choice, patient satisfaction and the impact 
of alternative urgent care providers on the traditional urgent care providers.  Literature 
conducted in the area of alternative providers of urgent care does not find the user 
charge to influence patient choice of this service.  
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Using the theoretical foundations in Section 2.4, (Becker, 1965, Grossman, 1972, 
Lancaster, 1966) and including the characteristics identified throughout the literature, 
this research investigates the impact of the user charge on patient choice of UCCs in 
Ireland and identifies the factors which influence patient choice of this service. This 
literature review guides the methodology utilised in the following section of this 
chapter. 
 
Section 3.3 presents the methodology employed to identify the factors which influence 
patient choice of walk-in UCCs in Ireland given user charges. 
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3.3 Methodology 
 
3.3.1 Introduction 
 
Section 3.3 presents the methodology used to answer the research question in this 
chapter; 
 
What Factors Influence Patient Choice of Urgent Care Clinics in Ireland in the Face 
of User Charges? 
 
A cross-sectional questionnaire was specifically designed to collect primary data from 
patients in three UCCs in Ireland to investigate the factors influencing patient choice 
of these clinics given user charges. Section 3.3.2 describes the location of the data 
collection. Section 3.3.3 describes the data source. Section 3.3.4 explains the 
questionnaire construction. Section 3.3.5 describes the data collection procedure. 
Finally, Section 3.3.6 will present some descriptive statistics on the population sample. 
 
3.3.2 Location of Data Collection 
 
As the principal aim of this research is to assess the impact of the user charge and to 
identify the factors influencing patient choice when deciding to use walk-in UCCs in 
Ireland, patients using these clinics form the sample. Patient choice of urgent care 
services in Ireland has expanded due to the development of walk-in UCCs. This type 
of walk-in UCC was first established in Ireland in 2005 by Vhi Healthcare in 
conjunction with Centric Health (CentricHealth, n.d.). These privately financed clinics 
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are called Vhi SwiftCare Clinics. Vhi SwiftCare Clinics operate as walk-in urgent 
clinics and as outlined in this paper, provide a non-appointment service, extended 
opening hours and decreased waiting times. To attend a Vhi SwiftCare Clinic a patient 
faces a user charge of €125 for the initial consultation42 plus additional charges 
depending on the services required.43 All patients in Ireland are eligible to attend Vhi 
SwiftCare Clinics once they are willing to pay the relevant user charges.44 Vhi 
SwiftCare Clinics do not acknowledge medical cards or GP visit cards.  There are 
currently three Vhi SwiftCare Clinics in Ireland; one in Mahon in Cork, one in Swords, 
Dublin and one in Dundrum, also in Dublin.  
 
This research acknowledges that since 2005, a number of public walk-in UCCs have 
been opened in Ireland. Unlike Vhi SwiftCare Clinics, these walk-in UCCs are 
publicly financed and are generally co-located with public hospitals and under the 
governance of that hospital.45 Patient access routes to both the Vhi SwiftCare Clinics 
and the publicly financed urgent care clinics are similar46, however, there is variation 
in the waiting times and the user charge in each location. Publicly funded walk-in 
UCCs are not included in this research. As shown in Table 3.3, 2 out of the 3 categories 
of patients do not have to pay for attending a public walk-in UCC. Therefore, if 
publicly funded walk-in UCCs were included, the overall research question would not 
be addressed as a large proportion of the sample may not have to pay to use the service. 
This would not capture the effect of the user charge on patient choice.  
                                                          
42 See footnote 1. 
43 See footnote 17. 
44 The clinics are not solely for patients who have PHI. 
45 Examples of such clinics are the Mercy Urgent Care Clinic in Cork and the Mater Rapid Injury Unit 
in Dublin. 
46 Self-refer or GP referral.  
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In addition to publicly financed walk-in UCCs, private medical assessment units 
(MAUs) are also emerging in Ireland. These MAUs are established as part of the Bon 
Secours private hospital group. While these MAUs improve accessibility to urgent 
care, these units do not operate on a walk-in basis and were therefore not considered 
as a possible data source for this research. As Vhi SwiftCare Clinics were the first 
walk-in UCCs to be established in Ireland, this research focuses solely on patients 
attending the three Vhi SwiftCare Clinics in Ireland.  
 
Table 3.3 User Charge Comparison between Walk-in Urgent Care Clinics in 
Ireland 
 
Patient type Vhi SwiftCare Clinics Public Walk-in Urgent 
Care Clinics 
GMS patients Initial consultation charge €125 plus 
additional charges 
Free 
Non-GMS patients with a 
GP referral letter 
Initial consultation charge €125 plus 
additional charges 
Free 
Non-GMS patients without 
a GP referral letter 
Initial consultation charge €125 plus 
additional charges 
€100 
Source: Authors Own 
 
Collecting primary data, the research investigates if user charges, amongst other 
factors such as patient demographics, socio-economic characteristics and clinic 
characteristics affect patient behaviour when deciding to use Vhi SwiftCare Clinics. 
As identified in Section 3.1.2, understanding why patients decide to use an alternative 
urgent care provider informs policy makers on the delivery of an efficient urgent care 
system (Shearer et al., 2015).  
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3.3.3 Data Source 
 
There are only three Vhi SwiftCare Clinics in Ireland and all three were surveyed. The 
need to survey all three was due to location considerations which were identified in 
the literature and also as it would provide a more representative sample. Patients 
presenting at the three Vhi SwiftCare Clinics in Ireland on a non-appointment basis, 
between the 12th to the 26th February 2014, were eligible for inclusion in the sample. 
This data collection time-frame was recommended by the clinic managers in the clinics 
as this is a busy period in the clinic. This would contribute to a representative sample 
size. Vhi SwiftCare Clinics accept patients between 8am until 10pm, seven days a 
week. Patients are treated in the SwiftCare Clinic when they present directly for care 
or are referred by their GP.  
 
 Access to the Vhi SwiftCare Clinics was an on-going process (Gummesson, 1991, 
Marshall and Rossman, 2010, Robson, 2011). Allowing sufficient time, direct contact 
was made with the Medical Director of the Vhi SwiftCare Clinics and also the clinic 
managers in each of the three clinics in Ireland to present the research and the overall 
requirements needed to answer the research question. Following best practice, this 
access approach was adopted as recommended by Saunder, Lewis and Thornhill, 2009.  
 
A non-probability convenience sampling technique is used. All three Vhi SwiftCare 
Clinics were surveyed but only patients in attendance at the clinic were included. This 
was due to a lack of time, cost and lack of access to non-users of UCCs. It is 
acknowledged this technique may lead to sampling bias as members of the general 
population that do not use the Vhi SwiftCare Clinics are not represented.  An ideal 
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sample would include both users and non-users of the walk-in UCC. However, as the 
main research objective is to identify the factors influencing patient choice of clinic, 
the research solely focussed on users of all three Vhi SwiftCare Clinic in Ireland.  
 
The Social Research Ethical Committee (SREC) in University College Cork approved 
the research protocol and questionnaire (see Appendix A.1).  
 
3.3.4 Questionnaire Construction 
 
This section describes the construction of the questionnaire that was specifically 
designed to collect the primary data for this research.  
 
Comparable to previous literature, a self-completion questionnaire was purposely 
designed and utilized to collect primary data from Vhi SwiftCare Clinic patients (see 
Appendix A.2) (Hunter et al., 2009, Rizos et al., 1990, Scott et al., 2009). A self-
completion questionnaire was chosen as the most appropriate measure due to the high 
response rate found in previous studies conducted in similar healthcare locations 
across the US, UK and Canada (Bell and Szafran, 1992, Salisbury et al., 2002). When 
deciding on the data collection instrument, it was also important to identify the sample 
source in order to ensure a reliable sample and ensure minimum disruption to the 
services in the SwiftCare clinics. Due to the nature of this research, the main focus was 
on the patients’ current visit to the clinic and the factors that played a role in choosing 
the clinic for the treatment of this particular injury/illness. Therefore, a self-completion 
questionnaire at the time of clinic use was most appropriate in order to answer the 
research question accurately. This methodology allowed for efficient data collection 
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from a large number of respondents. As the same information was required from all 
patients in the three clinics, a standardized self-completion questionnaire was suitable.  
The self-completion questionnaire also ensured anonymity for the patient as possible 
reactive effects of direct contact between the researcher and respondent were 
eliminated (Sim and Wright, 2000). However, this eliminated the possibility to explore 
questions in depth or seek clarification from the respondent (Sim and Wright, 2000). 
Due to the factual nature of the answers required this concern was overcome due to a 
well-constructed standardized questionnaire including pre-determined responses 
generated from the literature review and discussions with the clinic managers and Vhi 
SwiftCare Clinic Medical Director (Sim and Wright, 2000). Further clarification from 
the respondent was not necessary. Another disadvantage associated with this 
methodology is that there is no guarantee the respondent will answer the questionnaire 
as anticipated by the researcher i.e. at the correct time or in the correct order (Sim and 
Wright, 2000). This was controlled using clearly labelled instructions and questions 
throughout the questionnaire.   
 
To achieve reliable and valid results, the questionnaire was easy-to-follow and used 
clear direction and instructions. This was accomplished using factual questions for the 
majority of the questionnaire. The reliability of the questionnaire was tested by 
conducting a pilot study (January 2014). Assessing validity of the questionnaire 
proved to be more difficult as validity is usually established after the event 
(Oppenheim, 1992). Cross-checking may have been a possibility using information 
collected from the Vhi SwiftCare Clinics email survey47 but this data was not made 
                                                          
47 The Vhi SwiftCare Clinics collect the email addresses of their patients and send an annual survey to 
measure patient characteristics and satisfaction associated with the clinics. Vhi SwiftCare Clinic 
surveys collect similar information to this research but do so from a marketing perspective in order to 
improve their service. 
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available.  Therefore, the pilot study tested the reliability and validity of the 
questionnaire instrument.  
 
Each questionnaire was printed in black and white and printed back-to-back. This 
resulted in two pages in total. It was acknowledged that shorter questionnaires with 
concise completion time encourage a higher response and this was taken into 
consideration in the questionnaire design process (Dillman, 2000).  This was 
important, as respondents would be eager to leave the clinic once treatment was 
received and it was necessary that the completion of the questionnaire would not 
excessively delay the respondent.   
 
Each questionnaire included an introduction to inform potential respondents of the 
study’s aims and why this area of research was chosen. In addition, they were informed 
why they were chosen as suitable candidates. Once they agreed to take part, they were 
asked to indicate this on the attached consent form.  
 
The questionnaire required information regarding medical card status, PHI cover and 
income level. Due to the sensitive nature of this information it was assured that this 
information, i.e. information on individuals, would not be disclosed to anyone. To 
ensure anonymity, the respondents name was not required on the questionnaire.  
Respondents are more willing to provide information if they know the questionnaire 
is anonymous (Babbie, 2009). The potential respondent was advised that participation 
was voluntary and they could leave the questionnaire at any stage.  
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Due to the nature of the data collection instrument, a debriefing process was not 
necessary. However, if the respondent had questions regarding the questionnaire 
(before/after completion) they could consult a list of FAQs, which were available at 
the reception of the clinics (see Appendix A.3).  
 
In the questionnaire itself, there were five sections in total. The questionnaire adopted 
a funnel approach i.e. it began with broad demographic questions such as the 
respondent’s age and gender, socioeconomic variables such as education, nationality 
and health care cover were measured. The questions then narrowed down to measure 
the more specific variable categories such as Vhi SwiftCare Clinic characteristics, Vhi 
SwiftCare Clinic satisfaction and the dependent variables; patients’ use of Vhi 
SwiftCare Clinics. The first dependent variable measures if the patient is a first-user 
or a second/multiple user of the Vhi SwiftCare Clinics. The second and final dependent 
variable measures the number of times a patient has used a Vhi SwiftCare Clinic.  
 
The next paragraph will discuss each of the sections included in the questionnaire to 
identify and justify the nature of the variables included in each section.  
 
Section 1 of the questionnaire explored patient demographics and type of healthcare 
cover. This section included nominal, continuous and categorical variables in order to 
generate an understanding of Vhi SwiftCare Clinic users. Section 2 measured the 
dependent variable in the research. This was a count variable measuring patient’s 
previous use of Vhi SwiftCare Clinics. There were six levels in this variable ranging 
from; first-time user, second time user, third time user, fourth time user, fifth time user 
and more than five times. The dependent variable is explained further in Section 
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3.3.6.6. Section 3 assessed the current Vhi SwiftCare Clinic visit. This section included 
matrices presenting the characteristics of walk-in urgent care clinics. Using a Likert 
Scale, respondents indicated how important each characteristic was when deciding to 
visit the SwiftCare Clinic. Section 4 measured the gross annual income level of the 
person responsible for payment to the SwiftCare Clinic. To minimise non-response for 
this variable, respondents were presented with an interval scale including 6 ranges. 
Finally, Section 5 gathered information regarding further possible referrals as a result 
of this visit, total treatment cost and patient satisfaction with their visit at the SwiftCare 
Clinics.  
 
The majority of the questions that appeared in the questionnaire are closed-ended. This 
research is of a quantitative nature, therefore, valid and reliable results were required. 
Close-ended questions were chosen as they are less time consuming and concise given 
the time restraints placed on the respondents (Oppenheim, 1992) and consequently are 
associated with a high response rate (Dillman, 2000). This permitted easier 
interpretation and coding of the data. The codebook can be found in Appendix A.4. 
 
3.3.5 Data Collection Procedure 
 
To ensure reliability of the questionnaire and the data collection procedure, a pilot 
study was conducted in the Vhi SwiftCare Clinic in Cork for 5 days in January 2014. 
A total of 30 surveys were collected during the pilot study. The administration process 
of the questionnaire was modified subsequent to the pilot study to ensure a high 
response and minimum disruption to the daily services in the clinics. The initial 
protocol required the receptionist to distribute the questionnaires to patients as they 
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registered upon arrival at the clinic. Patients were then to complete the questionnaire 
throughout the visit (before and after treatment) and return the questionnaire to an 
allocated area within the reception area upon leaving the clinics48 (see Appendix A.5). 
Following the pilot study and subsequent communication with the administrators in 
the clinics, this protocol was deemed unsatisfactory due to the risk of patients 
mislaying the questionnaire during their visit and consequently reducing the response 
rate. To overcome this, the survey process was adjusted. The new and final protocol 
required the receptionists to administer the questionnaires to the patients as they were 
signing out of the clinic after treatment was received. The patient was then invited to 
return the completed questionnaire to a clearly labelled box provided at reception. Due 
to the injuries/illnesses treated at Vhi SwiftCare clinics, it was recognised that the 
patient themselves may be unable to complete the questionnaire. To overcome this 
issue, the patient’s parent, guardian, relative or friend, could fill in the patients’ 
information on behalf of the patient.  It is acknowledged this may increase the risk of 
recall bias if an individual other than the patient was completing the questionnaire. 
Instructions were provided on the questionnaire to ensure accuracy. It was important 
to include patients in the research with all levels of injuries.  
 
In all three clinics during the given timeframe, all patients were asked to complete the 
questionnaire as they signed out of the clinic. Receptionists were given a brief to 
deliver to the potential participants. In this brief, potential respondents were informed 
that this questionnaire was part of a research project in University College Cork, they 
were assured of anonymity, patients were then invited to complete the questionnaire 
                                                          
48 This questionnaire had sections that were to be completed before treatment was received and after 
treatment was received. These directions were clearly labelled. (See Appendix A.5) 
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and if they agreed to take part they were provided with a questionnaire attached to a 
clip board for ease of completion (see Appendix A.6).  
 
It is important to note that face-to-face interviews were another consideration but this 
method was not conducive to generating a large sample size and proved to be more 
time-consuming in the pilot study. With the nature of injuries/illnesses presenting at 
these clinics and the one-hour treatment policy, it was important not to keep patients 
in the clinic longer than necessary.  
 
Due to the nature of the data collection method, the study acknowledges the risk of 
sample selection bias and recall bias. However, due to the research question, it was 
necessary to use the specially constructed questionnaire to collect the data directly 
from patients who are using these clinics. While all attempts have been made during 
the construction of the questionnaire and its distribution to reduce sample selection 
and recall bias, the research acknowledges this risk in the interpretation of the research 
results. 
 
3.3.6 Descriptive Statistics 
  
Initially, 321 questionnaires were collected. Twenty-six questionnaires were excluded 
from analysis; twenty-two participants returned incomplete questionnaire49 and four 
participants were not eligible for inclusion as they were not using the clinic on a non-
                                                          
49 Left pages blank. 
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appointment basis.50 In addition to the non-appointment services offered by the 
SwiftCare Clinics, services such as physiotherapy, minor surgeries, and orthopaedic 
services are also offered. As this research focuses on the non-appointment service 
provided by the Vhi SwiftCare Clinics, patients with pre-booked appointments were 
excluded from the study. This resulted in a total of 295 participants eligible for this 
research. The collected data was analysed using STATA 11.0.  
 
The following sections present the descriptive statistics. Patient demographics are 
presented with the purpose of providing an overview of the patients that use Vhi 
SwiftCare Clinics in Ireland. Socio-economic characteristics are presented to 
understand the type of patients who use Vhi SwiftCare Clinics. Descriptive statistics 
on the patients’ current visit to the Vhi SwifCare Clinic are also provided. Patients’ 
satisfaction with the current visit is presented. Factors influencing the patients’ 
decision to use the clinics are described. Finally, descriptive statistics on the dependent 
variable are presented.  
 
3.3.6.1 Patient Demographics 
 
In Table 3.4, the most common age categories presenting at the clinics are 25-44 year 
olds (38%) and 45-64 year olds (24%). Similar to previous literature in the UK, US 
and Canada it appears that age groups below the age of 65 years constitute a higher 
proportion of Vhi SwiftCare Clinic visits than older age groups (65+) (Bell and 
Szafran, 1992, Mehrotra et al., 2008, Plauth and Pearson, 1998). The nature of the 
                                                          
50 These four questionnaires were excluded as participants indicated on their questionnaire that they 
were attending the clinic to receive a service which required a pre-booked appointment such as; stitch 
removal, verruca treatment or to receive an injection.  
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injuries/illnesses treated at Vhi SwiftCare Clinics could be an influential factor for the 
age groups that use the clinics.51 Bone fractures and sprains are more likely to occur 
among young adults and children due to perhaps more active lifestyles. While this also 
happens in an older age group, older patients are more susceptible to serious illnesses 
requiring longer visits and long-term care rather than the episodic care offered by Vhi 
SwiftCare Clinics (WHO, 2016). This influences patient behaviour in older adults as 
they prefer traditional providers of care for the treatment of minor injuries and 
illnesses. A qualitative study conducted in the Caribbean found patient use of 
traditional urgent care to be habitual (Beache and Guell, 2015). Older patients prefer 
to go to their “regular” doctor as they always have done before UCCs were established.  
Literature has also shown that older people are more likely to be registered with a 
family doctor and therefore, are more likely to use this traditional urgent care provider 
(Mehrotra et al., 2008). This may be the case particularly in an Irish context where the 
older age groups are more likely to have a medical card and consequently attend a 
traditional provider of urgent care where they will receive urgent care for free. Should 
a GMS patient attend an alternative provider, they must pay the relevant user charge.  
In Table 3.4, there is a broadly equal prevalence of males and females in the sample, 
52% and 48% respectively. The average patient travel time to the clinics is 21 minutes. 
Proximity to alternative urgent care providers is deemed important in previous 
research (Dolan and Dale, 1997, Grafstein et al., 2013, Shearer et al., 2015). This 
statistic indicates that similar to alternative urgent providers described earlier in the 
literature review, Vhi SwiftCare Clinics are also locally used services.  
 
                                                          
51 Fractures, sprains or possible breaks, lacerations or cuts requiring stitches, sports injuries, burns and 
scalds, fever, infections rashes, eye and ear injuries, insect and animal bites and joint, muscular back 
pain (VHI. n.d).. 
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Table 3.4 Patient Demographics 
       Surveyed patients 
       N=295      % 
Age (Years) 1-14     66   (22.37) 
  15-24      35   (11.86) 
  25-44      111   (37.63) 
  45-64     70   (23.73) 
  65+     8   (2.72) 
  Missing     5   (1.69) 
           Total     295   (100) 
Nationality Irish     270   (91.53) 
  Other Eu    15      (5.08) 
  UK     7         (2.37) 
  Non-EU     3   (1.02) 
            Total     295   (100) 
Gender  Male     153    (51.86) 
  Female      142   (48.14) 
            Total     295   (100) 
Travel time Mean   21.2 Minutes 
  Range  (0 – 90) 
Note: Age categories begin with 1 year olds. Vhi SwiftCare Clinics do not cater for infants 
less than 12 months.  
 
3.3.6.2 Socio-Economic Characteristics 
 
The patients surveyed reflect a high socio-economic status with 52% of the sample 
reporting a third level qualification and at least 57% reporting a gross income level 
above the national average.52  In Table 3.5, there is a high presence of PHI coverage 
within the sample (85%) and of those, 63% are Vhi members. Similar to the literature 
in the US (Rylko-Bauer, 1988), there is a low presence of medical aid in this sample 
with only 7% reporting the possession of a GMS card. These are justifiable findings 
as GMS status in Ireland is granted primarily on an income basis. With such high levels 
of income reported by this sample, it is logical that there would be a low level of GMS 
patients within the sample. Also, GMS patients may be less likely to choose a Vhi 
SwiftCare Clinic as these clinics do not accept medical cards as a form of payment. It 
is necessary to reiterate that everyone is entitled to attend Vhi SwiftCare Clinics once 
                                                          
52 National annual earnings in Ireland in Q2 2015: €36,271 (CSO. 2015.). 
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they are willing to pay the relevant user charges. These clinics are not solely directed 
towards patients with PHI and in particular, not just Vhi members. 
 
 Table 3.5 Socio-Economic Characteristics 
 
       Surveyed patients 
       N=295      % 
Education No Education    17      (5.76) 
  Primary Education   43     (14.58) 
  Secondary Education   77     (26.10) 
  Third Level    152    (51.53) 
  Other     5    (1.69) 
  Missing      1    (0.34) 
   Total     295   (100) 
Income  <€25,000    34    (11.53) 
  €25,000 - €39,000   64    (21.69) 
  €40,000 - €54,000   56    (18.98) 
  €55,000 - €69,000   39    (13.22) 
  €70,000 - € 84,000   28    (9.49) 
  €85,000+     46    (15.59) 
  Missing     28    (9.49) 
            Total     295   (100) 
PHI  Yes     250    (84.75) 
  No     45    (15.25) 
            Total     295   (100) 
PHI CompanyAllianz     1    (0.34)53 
  Aviva     22    (7.46) 
  ESB     1    (0.34)54 
  GloHealth    2    (0.68) 
  Laya     31    (10.51) 
  Vhi      187    (63.39) 
  No PHI     45   (15.25) 
  Missing     6   (2.03) 
            Total     295   (100) 
Medical Card Yes     22   (7.46) 
  No     273   (92.54) 
            Total     295   (100) 
 
 
 
 
 
                                                          
53 Vhi offer Pupil Accident Insurance cover with Allianz (ALLIANZ. n.d).. 
54 There is restricted membership undertaking of this form of medical insurance in Ireland.  
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3.3.6.3 Current Vhi SwiftCare Clinic Visit  
 
In addition to measuring demographics and socio-economic characteristics, the study 
investigates different features of the patients’ current visit to the SwiftCare Clinic; 
current injury/illness, possible further referral and treatment cost. In Table 3.6 the most 
commonly presented minor injuries/illnesses to the Vhi SwiftCare Clinics throughout 
the data collection period were sprains/strains (23%) and fractures/breaks (19%).  
The second attribute measures the possibility of the patient being referred further into 
the healthcare system.55 Previous literature (Rizos et al., 1990) indicated the 
importance of this variable as a proxy to measure the success of the Vhi SwiftCare 
Clinics. In Table 3.6, 66% of the sample were successfully treated at the Vhi SwiftCare 
Clinic and did not require further treatment elsewhere in the healthcare system. Only 
16% of the sample received further referral advice for the treatment of the minor 
injury/illness. This may occur if the injury/illness is beyond the scope of the Vhi 
SwiftCare Clinic requiring more intensive treatment. Alternatively, these patients may 
have presented with an injury/illness that Vhi SwiftCare Clinics do not treat; chest 
pain, pregnancy related illness etc.56  
 
The high treatment rate indicates that Vhi SwiftCare Clinics are successfully treating 
patients who would otherwise present at a GP practice or A&E department. This 
assumption is supported by Rizos et al 1990, who investigated patients preferred 
choice of healthcare location in Canada should the alternative provider be unavailable. 
                                                          
55 Referral to GP, A&E department, Consultant etc. 
56 18.6% of the sample did not answer this question (55 respondents). It is assumed these patients were 
successfully treated at the Vhi SwiftCare Clinic. The question on the questionnaire included the word 
“referred” and perhaps these respondents presumed this question was not applicable to them as they 
received no further referral. This is acknowledged as a possible leading question if the patient was 
successfully treated and subsequently deemed this question as inapplicable to them (Edwards et al., 
1997). 
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Patients indicated they would attend a family doctor or emergency department if the 
WIC was closed.  The successful treatment rate in this study indicates the success of 
Vhi SwiftCare Clinics which may potentially reduce the pressure on traditional 
healthcare providers in Ireland.  
 
The final variable estimates the patients’ user charge for the current visit to the Vhi 
SwiftCare Clinic. In Table 3.6, the reported median user charge is €125.57 This figure 
is representative of the actual user charge for initial consultation in Vhi SwiftCare 
Clinics which is also €125 (VHI, n.d.). The range of the user charge in this sample is 
€0-€400.58  While the median user charge is similar to an A&E department59 and nearly 
twice that of a GP60, the range in Table 3.6 is considerable. This range captures the 
potential expense for patients of Vhi SwiftCare Clinics.  
 
 
 
 
 
 
 
 
 
 
                                                          
57 The median is presented rather than the mean user charge as the mean response is subject to bias due 
to outliers (Buckland et al., 1999). 
58 €0 if patient was not treated in Vhi SwiftCare Clinic and referred elsewhere. As mentioned, in Vhi 
SwiftCare Clinics, there are additional charges for additional services such as x-rays, stitches, crutches 
etc.  
59 €100 for a patient without a medical card of GP referral. 
60 The National Average Cost for a GP visit in Ireland for a non-GMS patient is €51.   
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Table 3.6 Vhi SwiftCare Clinic Characteristics 
      Surveyed patients  % 
      (N=295) 
 
Injury/Illness treated 
Sprain/Strain    67    (22.71) 
Minor ear/eye condition   22    (7.46) 
Fracture/Break    57    (19.32) 
Sport     35    (11.86) 
Minor Burn    2    (0.68) 
Cut requiring stitches   5    (1.69) 
Minor Illness    48    (16.27) 
Other     51    (17.29) 
Missing     8    (2.71) 
Total     295    (100) 
Patient Referral    
GP     12    (4.07) 
A&E department    9    (3.05) 
Non-referral    194    (65.76) 
Other     25    (8.47) 
Missing     55    (18.64) 
Total     295    (100) 
User Charge (In Euro) 
Median (range)   €125 (€0-€400) 
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3.3.6.4 Patient Satisfaction 
 
This research estimates patients’ satisfaction with the current visit at the Vhi SwiftCare 
Clinic. In this research, using a 5 point Likert Ranking scale, patients indicated how 
satisfied they were with a number of Vhi SwiftCare Clinic characteristics.61,62 The 
attributes included in the matrix are based on clinic characteristics and characteristics 
emphasised in previous literature. Table 3.7 depicts how satisfied the patients were 
with Vhi SwiftCare Clinics characteristics such as, staff approach, quality of treatment 
received, waiting time, privacy from others, parking and cleanliness in the clinic. High 
levels of satisfaction are reported for each of the clinic characteristics.  Within the 
sample, 98% were satisfied or very satisfied with the staff in the clinic, 97% were 
satisfied or very satisfied with the cleanliness of the clinic, 97% were satisfied or very 
satisfied with the length of waiting time before treatment, 94% were satisfied or very 
satisfied with the privacy they had from other patients/individuals, 81% were satisfied 
or very satisfied with the parking and 78% were satisfied or very satisfied with the 
quality of the treatment received in the clinic.  
                                                          
61 A 5 point Likert scale was incorporated into the matrix ranging from “Very Satisfied” to “Very 
Dissatisfied”. A 3 point or 7-point scale could also have been used. However, when examining the 
difference between 5 point and 7 point scales, research shows that adding the 2 extra rankings to 
form a 7-point scale has no clear advantage (Goodwin, 2010). A 5-point scale usually provides a 
sufficient discrimination among the levels of satisfaction (Nunnally, 1978). Yet, it may become a de 
facto 3-point scale as some people have a tendency to avoid making choice at the end of the scale. 
On the other hand, a 7 pointer may prove to be a 5 pointer if this is the case but this makes the scale 
too long to read and will only increase questionnaire completion time (Goodwin, 2010). So as a 
result, a 5-point scale was chosen for this Likert ranking scale.  
62 For ease of interpretation when analysing the questionnaire responses, the matrix was re-coded into 
3 categories. The first two categories (Very Satisfied and Satisfied) were combined into “Satisfied”. 
The final two categories in this scale (Dissatisfied and Very Dissatisfied) were combined into one 
category, “Dissatisfied”. The third category in this scale (Neither satisfied nor dissatisfied) was re-
coded to “No Opinion”. Therefore, the analysis of this matrix was based on three categories 
“Satisfied”, “Dissatisfied” and “No Opinion” 
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Table 3.7 Patient Satisfaction 
 
 
 
 
 
 
 
Ranking Staff satisfaction 
N (%) 
Treatment satisfaction 
N (%) 
Waiting time 
satisfaction 
N (%) 
Privacy satisfaction 
N (%) 
Parking satisfaction 
N (%) 
Cleanliness 
satisfaction 
N (%) 
Very Satisfied 
Satisfied 
Neither 
Dissatisfied 
Very dissatisfied 
Missing 
248 (84.07) 0 (0) 234 (79.32) 212 (71.86) 174 (58.98) 248 (84.07) 
42 (14.24) 229 (77.63) 51 (17.29) 65 (22.03) 66 (22.37) 38 (12.88) 
1 (0.34) 48 (16.27) 3 (1.02) 10 (3.39) 27 (9.15) 4 (1.36) 
0 (0) 4 (1.36) 1 (0.34) 2 (0.68) 15 (5.08) 0 (0) 
0 (0) 0 (0) 0 (0) 0 (0) 7 (2.37) 0 (0) 
4 (1.36) 14 (4.75) 6 (2.03) 6 (2.03) 6 (2.03) 5 (1.69) 
Total 295 (100) 295 (100) 295 (100) 295 (100) 295 (100) 295 (100) 
86 
 
As suggested by previous literature, patients’ satisfaction with a healthcare service can 
be an indication of their perceived value of that service (Qin and Prybutok, 2013). 
Satisfaction levels can influence patient behaviour towards a service should they 
demand the service in the future (Shearer et al., 2015). Consequently, the high levels 
of satisfaction reported by users of the Vhi SwiftCare Clinic indicate that these patients 
have a high probability of using a Vhi SwiftCare Clinic in the future should they be 
faced with another minor injury or illness.  
 
3.3.6.5 Factors Influencing Patient Choice of Vhi SwiftCare Clinics 
 
Factors which influence patient choice of Vhi SwiftCare Clinics are examined. Also, 
using a matrix with a 5 point Likert Ranking Scale, patients indicated how important 
a number of Vhi SwiftCare Clinic characteristics were in their decision making 
process.63  The attributes included in the matrix are based on the characteristics of the 
clinics themselves and from characteristics highlighted in previous literature (Hunter 
et al., 2009, Plauth and Pearson, 1998, Salisbury et al., 2002).  
 
In Figure 3.2, the top 5 most important factors influencing patient choice of Vhi 
SwiftCare Clinic are reported; The 1-hour treatment policy (98%), accessibility (96%), 
nature of injury (95%), cleanliness (94%) and the non-appointment service (93%) were 
ranked the highest.  These findings are supported by previous literature which revealed 
similar influential factors for patients deciding to use alternative healthcare providers 
                                                          
63 For ease of interpretation, the matrix was re-coded into 3 categories. The first two categories (Very 
Important and Important) were combined into “Important”. The final two categories in this scale 
(Unimportant and Very Unimportant) were combined into one category, “Unimportant”. The third 
category in this scale (Neither important nor unimportant) was re-coded to “No Opinion”. Therefore, 
the analysis of this matrix was based on three categories “Important”, “Unimportant” and “No 
Opinion”.  
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in the UK, US and Canada (Bell and Szafran, 1992, Hunter et al., 2009, Scott et al., 
2009). 
 
The effect of a user charge on patient choice is proxied by measuring the patient’s 
knowledge of the cost and whether the cost is reimbursed. Patients were asked to rank 
the importance of cost64 and cost reimbursement65.  It can be seen in Figure 3.2 that 
patients do not rank cost and cost reimbursement as important amongst a plethora of 
factors measuring accessibility to the clinics.  At this point in the research, the user 
charge associated with Vhi SwiftCare Clinics does not appear to influence patient 
choice as much as other factors. Factors related to improved accessibility are those 
valued by patients using the clinics. The significance of the user charge is examined 
in more detail in Section 3.4.4.   
 
In addition to the walk-in service of Vhi SwiftCare Clinics, patients may also be 
referred to the clinics by their regular GP. Consequently, the matrix measured whether 
GP referral was an influential factor for patients using the clinics. Only 32% of the 
sample reported GP referral as an important factor when deciding to use the Vhi 
SwiftCare Clinic. This indicates that the patients in this sample chose to use this urgent 
care provider as a direct result of their decision-making and not as a result of a referral 
from a GP. Therefore, the majority of patients in this sample (68%) were self-referred 
and patient behaviour was not influenced by other healthcare providers.  
 
                                                          
64 Knowledge of possible cost for treatment. 
65 Reimbursement of part of the Vhi SwiftCare Clinic cost. 
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Finally, in Figure 3.1, 57% of the sample report a previous experience in an A&E 
department as an influential factor when choosing to visit a Vhi SwiftCare Clinic. As 
mentioned, waiting times in A&E departments in Ireland can be quite extensive 
depending on the nature of the injury or illness. Therefore, these patients may have 
had a negative previous experience in an A&E department and consequently chose a 
Vhi SwiftCare Clinic due to the reduced waiting times. Further research should 
investigate why a patient may not choose to seek urgent care at an A&E department 
and consequently prefer to seek treatment at a SwiftCare Clinic.   
 
At this point in the research it seems that despite potentially higher user charges in 
comparison to traditional healthcare providers, the main factors affecting patient 
choice when deciding to use Vhi SwiftCare Clinics are mainly factors associated with 
increased accessibility; one-hour treatment policy, extensive opening hours, injury 
type, non-appointment service. These findings will be examined further in Section 
3.4.4.  
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Figure 3.1 Factors Influencing Patient Choice of Vhi SwiftCare Clinics 
 
 
3.3.6.6 Patients’ Use of Vhi SwiftCare Clinics 
 
Patients’ use of Vhi SwiftCare Clinics formed the dependent variable for this research. 
The dependent variable is a count variable with 6 levels and measures the number of 
times the patient has used a Vhi SwiftCare Clinic. The descriptive statistics for the 
dependent variable are presented in Figure 3.3. Just over half of the sample, 54%, have 
used a Vhi SwiftCare Clinic at least once while 46% are first-time users. In the sample, 
20% are second time users, 12% were third time users, 8% were fourth time users, 5% 
were fifth time users and 8% had used the Vhi SwiftCare Clinics more than 5 times.  
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Figure 3.2 Patients’ VHI SwiftCare Clinic Use 
 
 
 
 
 
 
 
 
 
 
 
Source: Authors Own 
  
The dependent variable is a retrospective question; 
 
Has the patient ever attended a Vhi SwiftCare Clinics before?  
 
Yes                 No 
 
If yes, how many times previously? (Please State) 
______________________ 
 
As the dependent variable is retrospective, this study acknowledges the risk of recall 
bias. However, this risk is reduced as the patient is already in the clinic, therefore this 
should encourage them to correctly recall any previous occasion on which they may 
have used the clinic.  
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The importance of measuring patients’ use of a service was highlighted by Shearer et 
al (2015) who revealed patients’ experience of an alternative urgent care provider as 
an influential factor in the decision making process. Figure 3.3 indicates that 54% of 
this sample are repeat users of this service. It has been found that patients are loyal to 
services they have used previously (Philips et al., 2010). Therefore, patient choice of 
Vhi SwiftCare Clinics may be influenced by a previous positive experience at the 
clinics. Multiple use of a service can be associated with positive previous experience. 
If this is the case, high levels of patient satisfaction can be expected from patients in 
Vhi SwiftCare Clinics. Section 3.4.4 will examine if the same factors influence choice 
for first time users versus second or repeat users of the clinics.  
 
3.3.7 Conclusion 
 
Using a specifically designed self-completion questionnaire, the descriptive statistics 
in Chapter 3 reveals the demographics of the patients using walk-in UCCs in Ireland 
and it identifies the impact of the user charge and other characteristics on patient choice 
when choosing walk-in UCCs. The descriptive statistics also identify patients’ use of 
the Vhi SwiftCare Clinics.  
 
The descriptive statistics reveal that patients who use these clinics are between 25 to 
64 years of age with a high socio-economic status as indicated by a high prevalence of 
third level education and over half of the sample reporting an income level above the 
national average.66 It is mainly privately insured individuals who use the clinics and 
as expected, there are very few GMS patients who use these clinics.  
                                                          
66 See footnote 52. 
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Within this sample, 54% are repeat users of Vhi SwiftCare Clinics. This is consistent 
with research which shows patients’ experience of the alternative provider is an 
influential factor in the decision making process (Shearer et al., 2015). 
 
The descriptive statistics report it is mainly factors which measure accessibility are the 
most influential in patient choice when deciding to seek care at these clinics; reduced 
waiting time, increased accessibility, treatable injury, and the non-appointment 
service. These findings are consistent with previous research which also found the 
convenient care offered by alternative urgent care providers to influence patient choice 
(Bell and Szafran, 1992, Dolan and Dale, 1997, Hunter et al., 2009, Plauth and 
Pearson, 1998, Salisbury et al., 2002). Due to the uncertain onset of an urgent 
injury/illness, the convenient care provided in terms of the non-appointment service, 
reduced waiting time and increased accessibility provided by alternative urgent care 
providers offers peace of mind that urgent care is accessible outside the traditional 
scheduled service offered by traditional healthcare providers.   
 
The factors measuring the impact of the user charge; knowledge of possible cost and 
possible cost reimbursement were not reported as influential amongst the factors 
measuring accessibility. As the patients in this sample are users of the clinic, they have 
already decided to use the alternative provider of urgent care. Previous literature 
suggests these patients are not truly deterred by the OOP cost (Shearer et al., 2015). 
 
Despite patients in the sample reporting the influence of accessibility factors, the high 
socio-economic status reported by the descriptive statistics indicate that affordability 
does influence patient choice when choosing a walk-in UCC for the treatment of a 
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minor injury or illnesses. The influence of affordability on patient choice is also 
highlighted by the low presence of GMS patients in the sample. These walk-in UCCs 
do not acknowledge GMS cards. Therefore, the potentially higher user charge may act 
as a deterrent for GMS patients who have a lower income. These findings are examined 
further in Section 3.4.4.   
 
Section 3.4 presents the econometric methods for Chapter 3.  
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3.4 Results 
 
3.4.1 Introduction 
 
This section presents the econometric methodologies that were employed to 
investigate the factors influencing consumer choice of walk-in UCCs in Ireland. 
Section 3.4.2 discusses the rationale as to why the particular method was chosen. 
Section 3.4.3 presents the econometric model and focuses on model specification and 
model tests. The results are presented in Section 3.4.4 and Section 3.4.5 discusses these 
results. Chapter 3.5 concludes this research.  
 
3.4.2 Econometric Rationale 
 
The factors affecting patient choice of walk-in UCCs are tested using data collected 
from patients attending Vhi SwiftCare Clinics in Ireland. In modelling the factors 
affecting patient choice of walk-in UCCs, the nature of the data for the dependent 
variable determined the econometric methodology to be used. As identified in Section 
3.3.6.6, the dependent variable is a count variable which measures patients’ use of Vhi 
SwiftCare Clinics. There are six levels in this count variable; first time users, second 
time users, third time users, fourth time users, fifth time users and patients who have 
used the clinics more than five times. The count nature of the variable and the fact that 
the number of clinic visits is a variable that can only take on non-negative integer 
values, means that a count modelling data technique is appropriate (Mihaylova et al., 
2011).  
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Linear regressions may also be used for count variables but the results from these 
regressions can be inconsistent, inefficient and biased estimators (Long and Freese, 
2001 ). For example, an OLS regression would assume normal distribution of the error 
term and predict negative values for the dependent variable (Cameron and Trivedi, 
2005). As an alternative to the classical linear regression models, a count model is 
implemented in this research. A count model assumes a skewed, discrete distribution 
and restricts values to non-negative integers (Nolan et al., 2014).  There are a number 
of count models that could be used; Poisson Regression Model (PRM), Negative 
Binomial Regression Model (NBRM), Zero-Inflated Poisson (ZIP) regression, Zero-
Inflated Negative Binomial (ZINB) regression, Zero-Truncated Poisson Regression 
(ZTP) and Zero-Truncated Negative Binomial (ZTNB) (Long and Freese, 2001 ).  
 
3.4.3 Econometric Model  
 
In general, empirical research using count data would begin with the PRM (Hilbe, 
2011). This model lies on the assumption that the expected number of counts (mean) 
is equal to the variance. This is known as equi-dispersion, an assumption which is 
rarely satisfied in datasets (Long and Freese, 2001 ). In general, the conditional 
variance will exceed the conditional mean and the PRM does not account for this. 
When this is the case, the NBRM is used to model the over-dispersed data. The NBRM 
has the same mean structure as the PRM but it has an extra parameter for over-
dispersion and corrects for the under-representation of zeros in the PRM.  This is done 
in the NBRM by increasing the conditional variance without altering the conditional 
mean. The zero-inflated poisson and negative binomial models go one step further by 
changing the conditional mean to account for dispersion and excess zeros. The zero-
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inflated model uses two distinct processes to fit two models simultaneously. In general, 
one is a probit or logit which estimates the probability of having a count greater than 
zero or not. The second model estimates the parameters that affect the count. While 
the zero-inflated models and the NBRM correct for over-dispersion, the NBRM is a 
better fit based on Bayesian Information Criteria (BIC) and Akaike Information 
Criteria (AIC) statistics67.  However, PRM, NBRM, ZIP and ZINB require a zero-
count value for the dependent variable. Should a count variable begin at a count of 1, 
then the PRM, NBRM, ZIP and ZINB will not be appropriate count models. Zero-
truncated models; zero-truncated poisson (ZTP) and zero-truncated negative binomial 
regression (ZTNB) are used when the dependent count variable cannot have a value of 
0 (Zuur 2009).  
 
As the patients included in this research are all users of the Vhi SwiftCare Clinics, 
every patient has at least one clinic visit. Therefore, the dependent count variable 
begins at a count of 1.  
 
The following section compares the ZTP regression and the ZTNB regression 
implemented in this research and identifies why the ZTNB is the most appropriate 
count model for this data.  
 
 
                                                          
67 AIC and BIC are two model selection criteria. The two criteria are formed on different model 
selection methods. AIC focuses on finding the best approximating model and BIC finds the true 
model. AIC does not depend on sample size and consequently lacks properties of asymptotic 
consistency (Bozdogan, 1987). Conversely, BIC does reflect sample size and therefore, BIC does 
have properties of asymptotic consistency. Studies have identified BIC is consistent while in 
contrast AIC is not (Bickel and Zhang, 1992; Zhang, 1993). 
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3.4.3.1 Model Selection 
 
As mentioned, the PRM enables the probability of a count, such as the number of visits 
to a walk-in UCC, and is determined by the following Poisson distribution (Nolan and 
Nolan, 2003): 
 
Pr(Y=yi) = 
exp⁡(−λ1)λ1
yi
yi!
,    (yi = 0,1,2,…..)     (3.1) 
 
Where yi are the observed frequencies of the dependent variable and λ1 is a function of 
the set of independent variables. As stated, the PRM assumes equality of the 
conditional mean and variance (equi-dispersion). This assumption is not satisfied by 
the dependent variable in this research where the variance (2.63) is larger than the 
mean (2.32). This is known as over-dispersion which may be caused by unobserved 
heterogeneity. Even though the values are almost identical, the possible presence of 
over-dispersion in the data needs to be controlled for as using the classical Poisson 
model may lead to biased results. The negative binomial model is used to deal with 
over-dispersion (Long and Freese, 2001 ). The NBRM has an extra variable which 
allows the variance of y to exceed the conditional mean. The NBRM has the same 
mean structure as the PRM but it has an extra parameter for over-dispersion; the 
gamma-distributed error term. Therefore, the probability distribution of the NBRM is: 
 
Prob(Y=yj / u) = 
e−𝜆𝑗𝑒(𝑢𝑗)𝜆𝑗
⁡⁡⁡𝑢𝑗
y𝑗!
      (3.2) 
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where y is the probability of choosing a Vhi SwiftCare Clinic and j equals first time 
user, second time user, third time user, fourth time user, fifth time user and more than 
five visits.  euj has a gamma distribution with the mean and variance equal to 1 and α, 
respectively. The NBRM increases the conditional variance without altering the 
conditional mean (Long and Freese, 2001). 
 
The following paragraphs explain how the ZTP is not an appropriate fit for this data 
due to over-dispersion and how the ZTNB appears appropriate according to the 
goodness-of-fit and over-dispersion tests. The likelihood ratio (LR) test and the 
Bayesian Information Criteria (BIC) are used to examine the goodness-of-fit of both 
models and to identify that the ZTNB is a more appropriate fit than the ZTP.    
 
As mentioned, over-dispersion is evident in the dependent variable in this research. 
The ZTNB controls for over-dispersion as this count model is defined in terms of the 
over-dispersion parameter, 𝛼. The model estimates the ln(𝛼) with the estimate given 
in the Stata results table by /lnalpha. Estimating ln(𝛼) forces 𝛼 to be positive (Long 
and Freese, 2001 ). In this case, the ln(𝛼) is -0.69 and the value for 𝛼 is 0.50 (see Table 
3.9). As the ZTNB reduces to the ZTP when α = 0, overdispersion can be tested with 
the hypothesis: Ho: α= 0. Stata provides a likelihood ration (LR) test at the end of the 
ZTNB output table to test if Ho: α= 0 (Long and Freese, 2001 ). When the over-
dispersion parameter α = ⁡0⁡the ZTNB is equal to the Poisson distribution. In this 
model, 𝛼 is significantly different from zero (p<0.05) indicating that the Poisson 
distribution is not sufficient to explain the data.  To further investigate the model fit, 
both the ZTP and ZTNB were compared using the BIC model selection criteria (see 
Appendix A.7). The BIC value for the ZTP model was 944.05 while the BIC value for 
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the ZTNB is lower at 926.44. According to Rafferty (1996), if the difference in the 
BIC between the first (ZTP) and second model (ZTNB) is greater than 0, then the 
second model is preferred. Therefore, the ZTNB is identified as the most appropriate 
model for this research. 
 
3.4.3.2 Model Specification 
 
The explanatory variables included in the model are based on economic theory and 
previous literature. If economic theory could not defend the inclusion of an 
explanatory variable it was not included in the model (Kennedy, 2003). Patients’ age, 
healthcare cover, gross monthly income level and factors affecting patient choice of 
choosing a Vhi SwiftCare Clinic are included. The explanatory variables included  a 
combination of binary variables (male GMS, PHI, waiting time, no appointment 
necessary, GP referral, extended opening housr, location, injury type , parking and 
costs), categorical variables (age and income) and continuous variables (travel time to 
the clinic).68 The model investigates the impact of patient demographics (age and 
gender), socio-economic characteristics (health care cover and income), clinic 
characteristics which may influence patient choice (reduced waiting time, non-
appointment service, GP referral, extended opening hours, travel time, location, injury 
type and parking access), and cost (importance of cost69) on the number of times the 
clinic has been used. Table 3.8 provides more information on the variables included in 
the model.  
 
                                                          
68 Travel time to the clinics is measured in minutes. 
69 In the questionnaire, patients were asked to indicate the importance of knowing the possible 
treatment cost of choosing this urgent care provider.  
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Table 3.8 Variable Description 
Variable Coding Description 
Age (in years) 1 = 1-14  
2 = 15-24  
3 = 25-44  
4 = 45-64  
5 = 65+  
Gender 0 = female 
1 = male 
GMS 0 = no 
1 = yes 
PHI 0 = no  
1 = yes 
Income 1 = <€25,000 
2 = €25,000 - €39,000 
3 = €40,000 - €54,000 
4 = €55,000 - €69,000 
5 = €70,000 - €84,000 
6 = €85,000+ 
1 hour waiting time 0 = 1-hour treatment was not important in patient decision 
1 = 1-hour treatment was important in patient decision 
No appointment 
necessary 
0 = Non-appointment service was not important in patient decision 
1 = Non-appointment service was important in patient decision 
GP referral 0 = Referral by GP was not influential in decision 
1 = Referral by GP was influential in decision 
Extended opening 
hours 
0 = Longer opening hours were not influential in patient decision 
1 =Longer opening hours were influential in patient decision 
Travel time Continuous variable – measured in minutes 
Location 0 = Location of clinic was not influential in patient decision 
1 = Location of clinic was influential in patient decision 
Knowledge of 
treatable injury 
0 = Knowing injury was treatable at clinic was not influential 
1 = Knowing injury was treatable at clinic was influential 
Parking 0 = Parking access at the clinic was not influential in patient decision 
1 = Parking access at the clinic was influential in patient decision 
User charge 0 = Knowledge of possible treatment cost was not influential 
1 = Knowledge of possible treatment cost was influential 
 
 
Patient satisfaction is not included in the econometric model. In this research, 
satisfaction is measured based on the current visit so therefore could not be included 
as an influential factor for choosing the SwiftCare Clinic on this particular occasion.  
However, as discussed in Section 3.3.6.4, measuring patient satisfaction is important 
in gauging possible future use as patients who report high levels of patient satisfaction 
are more likely to use the clinic again in the event of a minor injury or illness. Yet, due 
to the nature of the research question, patient satisfaction is not included in the 
econometric model. 
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As the objective of the research is to investigate the impact of the independent 
variables on the dependent variable, multi-collinearity can be a problem (Paul, 2006 ). 
Detection of multi-collinearity was carried out using a correlation matrix (Kennedy, 
2003). Due to the nature of the independent variables, it was expected the relationships 
between some variables may be correlated as they measured similar aspects of the 
clinic. As expected, high correlations were found amongst variables measuring similar 
clinic characteristics (parking and cleanliness of the clinic). (see Appendix A.8). 
According to Kennedy, there are a number of methods of dealing with multi-
collinearity; obtain additional information on the data, drop the highly correlated 
variable or do nothing and acknowledge the possibility of multi-collinearity (Kennedy, 
2003). In this case, obtaining additional information was not possible. The “do 
nothing” approach was an option yet due to the small sample size it was important not 
to include variables that were not adding to the regression as these variables would 
affect the degrees of freedom. As these two variables both measure clinic 
characteristics and are highly correlated, including both in the regression was not 
adding to the regression so the variable measuring clinic cleanliness was not included 
in the regression. 
 
In Ireland, access to urgent care is constrained by healthcare cover and income. 
Furthermore, income can affect access to healthcare cover (Nolan and Nolan, 2004). 
Consequently, it was suspected there may be an interaction effect between patient 
income and healthcare cover (GMS and PHI). Generally, patients with an income level 
below a certain income threshold in Ireland are entitled to a medical card. Patients who 
can afford to, purchase PHI to access healthcare.  In this study, a chi square test of 
independence was used to test the relationships between income level, PHI and 
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medical card possession. A significant positive relationship was found between PHI 
and an annual income level in excess of €85,000 (see Appendix A.9) and a significant 
positive relationship was found between medical card possession and an income level 
less than €25,000 (see Appendix A.9). While a significant relationship is found 
between medical eligbility and an annual income level less than €25,000, the income 
category (€25,000) forms the base category for the income variable in the model. 
Consequently, no interaction variable is created for GMS and this income level as the 
main effect variable (€25,000) is not included in the regression.  
 
An interaction variable was created for PHI and income over €85,000 (phiy17) and the 
variable was included in the model to assess its significance. No significance was 
found for this interaction variable (see Appendix A.10). As the interaction variable 
was only included to check its significance and no hypotheses was made about the 
variable, the insignificant finding meant the variable was excluded from the final 
model as it did not add anything to the model (Kleinbaum and Klein, 2002).  
 
For ease of interpretation of the results, the marginal effects for the significant 
variables are discussed. The third column in Table 3.9 shows the marginal effects at 
the mean (MEM) for both the categorical and continuous variable.70 The marginal 
effects are computed differently for categorical and continuous variables. For binary 
explanatory variables, the marginal effects measure the discrete change; how the 
predicted probabilities change as the explanatory variables change from 0 to 1 
(Cameron and Trivedi, 2005): 
 
                                                          
70 Only one continuous variable; time travelled to the clinic which is measured in minutes.  
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Marginal Effect Xk = Pr(Y = 1|X, Xk = 1) – Pr(y=1|X, Xk = 0)  (3.3) 
 
For continuous independent variables, the marginal effects measure the instantaneous 
rate of change; estimate the change in the dependent variable produced by a 1-unit 
change in an independent variable (Cameron and Trivedi, 2005): 
 
Marginal Effect of Xk = limit[Pr(Y = 1|X, Xk+Δ) – Pr(y=1|X, Xk)] / Δ]  
as Δ gets closer and closer to 0.      (3.4) 
 
The marginal effects at the mean for continuous variables indicate that if Xk increases 
by a very small amount (e.g. 0.001), then P(Y=1) would increase by that amount. 
 
3.4.4 Results 
 
To examine the factors influencing patient choice of walk-in UCCs given user charges, 
a ZTNB was estimated (see Appendix A.11). The ZTNB coefficients and the MEM 
are presented in Table 3.9.  
 
In Table 3.9, holding all other variables at their mean, GMS patients visit the clinics 
1.56 times less than a non-GMS patient. In other words, GMS patients visit the clinics 
less frequently than non-GMS patients. Patients with PHI cover visit the clinics 0.92 
times more than patients without PHI cover and patients who have an annual income 
level of €70,000-€84,000 visit the clinics 0.68 times more than a patient with an annual 
income less than €25,000. Therefore, patients with PHI and an annual income level in 
excess of €70,000-€84,000 visit the clinics more frequently than patients without PHI 
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and patients on an annual income level less than €25,000. Table 3.9 shows that patient 
who have a longer travel time to the clinic visit the clinics 0.02 times less than patients 
with a shorter travel time to the clinic. This indicates that patients who have further to 
travel to attend the clinic visit the clinics less frequently. Finally, holding all other 
parameters at their means, patients who report parking as an influential factor for 
choosing the clinics, visit the clinics 0.61 times more than patient who do not report 
this characteristic as important. Therefore, patients who value the parking access at 
these clinics are higher users of the clinics. 
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Table 3.9 Zero-Truncated Negative Binomial Estimates 
Independent Variable Coefficient dy/dx 
Patient Demographics 
1-14 Years 
0.36 
(0.71) 
0.51 
(1.02) 
15-24 Years 
0.53 
(0.73) 
0.75 
(1.04) 
25-44 Years 
0.57 
(0.70) 
0.81 
(0.10) 
45-64 Years 
0.34 
(0.71) 
0.48 
(1.01) 
65+ Years  base category 
Male 
-0.11 
(0.15) 
-0.16 
(0.22) 
Socio-Economic Characteristics 
GMS  
-1.10** 
(0.48) 
-1.56** 
(0.67) 
Private health insurance 
0.65*** 
(0.25) 
0.92*** 
(0.35) 
<€25,000 base category 
€25,000-€39,000 
0.01 
(0.25) 
0.01 
(0.36) 
€40,000-€54,000 
-0.04 
(0.26) 
-0.06 
(0.37) 
€55,000-€69,000 
-0.29 
(0.30) 
-0.42 
(0.43) 
€70,000-€84,000 
0.48* 
(0.29) 
0.68* 
(0.42) 
€85,000+ 
0.20 
(0.27) 
0.29 
(0.39) 
Clinic Characteristics 
Waiting time 
-0.06 
(0.59) 
-0.08 
(0.94) 
No appointment necessary 
0.16 
(0.32) 
0.23 
(0.45) 
GP referral 
0.11 
(0.17) 
0.16 
(0.24) 
Extended opening hours 
0.14 
(0.45) 
0.19 
(0.65) 
Travel time 
-0.01* 
(0.01) 
-0.02* 
(0.01) 
Location 
-0.18 
(0.22) 
-0.26 
(0.32) 
Injury type 
0.03 
(0.55) 
0.05 
(0.78) 
Parking 
0.43** 
(0.18) 
0.61** 
(0.27) 
Affordability 
User charge 
-0.30 
(0.18) 
-0.43 
(0.26) 
Zero Truncated Negative Binomial 
No. of obs. = 263                       Pseudo R2 = 0.0442 
LR chi2 (21) = 36.88                 ln(α) = -0.69 
α = 0.500                                   Prob > chi2 = 0.0174 
chibar2(01) = 23.17 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
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The results in Table 3.9 show GMS cover, PHI cover, income level, travel time to the 
clinic and parking access are the factors which influence patient choice of Vhi 
SwiftCare Clinics. While the user charge associated with the clinic is not directly 
identified as a significant factor, most of the significant variables (GMS, PHI and 
income (€70,000-€84,000)) act as a proxy for affordability. These results indicate that 
affordability is significant for patients who choose to attend a private walk-in UCC. 
Patients with higher incomes and higher healthcare cover may find the full OOP user 
charge more affordable than a patient on a lower income with lower healthcare cover.  
 
This insignificant finding associated with the user charge is supported by Shearer et al 
(2015). Since the patients in the sample are users of the clinic, they have already made 
the choice to utilize the service. Therefore, the potentially higher user charge in 
comparison to traditional providers of urgent care does not act as a deterrent. At this 
point, it seems the user charge does not significantly influence patient behaviour for 
alternative urgent care clinics in Ireland. However, while knowledge of the user charge 
is not significant for patients, significant socio-economic variables measuring 
healthcare cover and patient income can be related to affordability and are perhaps 
indirectly measuring the impact of the user charge associated with these clinics. As 
patients have already decided to use this service, they must be willing and able to pay 
the relevant user charge.  
 
The research proceeds to investigate the factors which affect the likelihood of the 
patient being a first-time user of the walk-in UCC. This is conducted using the 
application of a standard probit regression. The results of the probit model will indicate 
107 
 
the type of patient who is more likely to be a first-time user and less likely to be a 
repeat or multiple user of the clinic.  
 
The dependent variable is modified and transformed into a binary dependent variable 
coded 1 for first time users (n= 135) and 0 for repeat or multiple users (n = 160). The 
explanatory variables included in the probit regression are identical to those included 
in the ZTNB (See Table 3.8 for description). As the probit model is nonlinear, it is 
difficult to describe the relationship between a variable and its outcome probability. 
For ease of interpretation of the results from the probit, the MEM are also presented 
for this regression.  
 
Table 3.10 shows that, holding all parameters at their mean, GMS cover increases the 
probability of the patient being a first-time user by 0.43. In other words, GMS patients 
are more likely to be a first-time user and consequently, this research assumes GMS 
patients are less likely to be repeat or multiple users of these walk-in UCCs.  Holding 
all parameters at their mean, PHI and an annual income level of €70,000-€84,000 
decrease the probability of the patient being a first-time user by 0.26 and 0.34, 
respectively. Subsequent to this finding, it is assumed that patients with PHI and a high 
income level (€70,000-€84,000) are more likely to be repeat or multiple users of these 
clinics in comparison to patients without PHI and an annual income level less than 
€25,000. Reporting the importance of extended opening hours decreases the 
probability of a patient being a first-time user by 0.40. This highlights that patients 
who do value the extended opening hours of walk-in UCCs are more likely to be repeat 
or multiple users of the clinics. Longer travel time the clinic increases the probability 
of the patient being a first-time user by 0.01. This indicates that patients who have a 
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longer travel time to the clinic are less likely to be repeat or multiple users of these 
clinics. Finally, reporting the importance of parking access decreases the probability 
of the patient being a first-time user by 0.20. Similar to extended opening hours, 
patients who value the parking access at these clinics are more likely to be repeat or 
multiple users of the clinics. 
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Table 3.10 Probit Regression: First-time Users Vs Multiple Users 
Independent Variable Coefficient dy/dx  
Patient Demographics 
1-14 Years 
0.32 
(0.58) 
0.13 
(0.23) 
15-24 Years 
0.37 
(0.61) 
0.15 
(0.24) 
25-44 Years 
0.33 
(0.56) 
0.13 
(0.22) 
45-64 Years 
0.43 
(0.56) 
0.17 
(0.22) 
65+ Years  base category 
Male 
0.00 
(0.17) 
0.00 
(0.69) 
Socio-Economic Characteristics 
GMS  
1.07** 
(0.44) 
0.43** 
(0.17) 
Private health insurance 
-0.66*** 
(0.25) 
-0.26*** 
(0.10) 
<€25,000 base category 
€25,000-€39,000 
-0.09 
(0.27) 
-0.04 
(0.11) 
€40,000-€54,000 
-0.00 
(0.29) 
-0.00 
(0.11) 
€55,000-€69,000 
0.14 
(0.32) 
0.05 
(0.12) 
€70,000-€84,000 
-0.85** 
(0.37) 
-0.34** 
(0.15) 
€85,000+ 
-0.02 
(0.31) 
-0.01 
(0.12) 
Clinic Characteristics 
Waiting time 
0.28 
(0.70) 
-0.11 
(0.28) 
No appointment necessary 
-0.23 
(0.37) 
-0.09 
(0.15) 
GP referral 
0.10 
(0.19) 
0.04 
(0.07) 
Extended opening hours 
-0.10* 
(0.58) 
-0.40* 
(0.23) 
Travel time 
0.02*** 
(0.01) 
0.01*** 
(0.00) 
Location 
0.19 
(0.27) 
0.07 
(0.11) 
Injury type 
0.20 
(0.69) 
0.08 
(0.11) 
Parking 
-0.51** 
(0.21) 
-0.20**  
(0.08) 
Affordability 
User charge 
0.13 
(0.21) 
0.05 
(0.08) 
Probit Regression 
No. of obs. = 263 
LR chi2 (21) = 46.06 
Prob > chi2 = 0.0019 
Pseudo R2 = 0.1270 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
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Similar to the findings of the ZTNB, the socio-economic characteristics (PHI and 
income €70,000-€84,000) reported by the probit which significantly decrease the 
likelihood of the patient being a first-time user can be related to a patients’ ability to 
pay the potentially higher user charge for these clinics. The results of the probit 
indicate that first-time users are more likely to be without PHI and from a lower income 
background. Therefore, patients with PHI and a high income level (€70,000-€84,000) 
are more likely to be repeat or multiple users of the walk-in UCCs. Similarly, GMS 
cover increases the probability of a patient being a first-time user. This finding in 
conjunction with the descriptive statistics, presented in this chapter, which report 7% 
of the patients in this sample are GMS patients, highlights that GMS patients do attend 
these clinics but they are more likely to be first-time users and consequently, less likely 
to be repeat or multiple users.  
 
The clinic characteristics reported by the probit (extended opening hours and parking) 
which decrease the likelihood of the patient being a first-time user are variables that 
could only be influential if the patient had previously used the clinics. If the patient is 
a first-time user, then they may be not aware of the extended opening hours or the 
access to parking that is provided.  This supports the assumption that patients who 
value the extended opening hours and the parking access at these clinics are more 
likely to be repeat or multiple users of the clinics. 
 
3.4.5 Discussion  
 
Table 3.9 presented the results of the ZTNB which assessed the factors influencing 
patient choice of walk-in UCCS in the face of user charges. Table 3.10 presented the 
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results of the probit regression which investigated the factors that affect the likelihood 
of the patient being a first-time user of the walk-in UCC. 
 
The ZTNB found patient socio-economic characteristics (GMS, PHI and income 
(€70,000-€84,000)) and clinic characteristics (travel time to the clinic and parking 
access) significantly influence the number of times the walk-in UCCs are used.  
 
PHI, income level and parking access are positively related to the number of times the 
clinic is used. Patients who purchase PHI generally have the income to do so and 
consequently, affordability to attend these clinics is less of an issue for high income 
earners in comparison to lower-income patients. In addition to a greater ability to pay, 
PHI patients may be subject to cost-reimbursement for the initial consultation charge 
at these clinics. For example, depending on their PHI plan, patients who are covered 
by Vhi, are entitled to a reimbursement of €75 off the initial consultation fee (€125). 
Reimbursement is also available with other Irish PHI providers, depending on the level 
of their health insurance plan. In addition to higher income levels, knowledge of this 
possible cost-reimbursement may further increase the affordability gap between PHI 
and lower income earners.  
 
In addition to healthcare cover and income, parking also increases the number of times 
the clinics are used. This finding is supported by literature which also found parking 
to influence patient choice of an alternative provider of urgent care (Bell and Szafran, 
1992, Jackson et al., 2005, Salisbury and Munro, 2003). Supply of parking and in 
particular, the supply of free parking provided by these Irish walk-in UCCs, enhances 
the convenient nature of these clinics. This is in contrast to A&E departments in 
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Ireland which can be co-located with hospitals and therefore result in a limited number 
of parking spaces for patients of the A&E. In addition to a limited number of parking 
spaces, patients parking in A&E departments may also incur parking charges.  
 
The ZTNB found GMS cover and travel time to be negatively associated with the 
number of times the clinic is used.  As mentioned, all patients attending the Vhi 
SwiftCare Clinics must pay the relevant user charge. The clinics do not accept medical 
cards as a method of payment. As GMS patients can receive free urgent care from 
traditional urgent care providers, this significant finding indicates that the user charge 
may be a deterrent for GMS patients. This is supported by previous literature which 
found lower income groups place higher value on cost-saving associated with urgent 
care providers (Ahmed and Fincham, 2010).  Also, the impact of diverse payment 
methods has been found to influence the type of patients using alternative providers of 
urgent care (Jackson et al., 2005, Plauth and Pearson, 1998, Rylko-Bauer, 1988, Scott 
et al., 2009). It appears that patients with medical aid in Ireland are less likely to choose 
alternative urgent care providers as these providers do not accept medical aid as a 
method of payment.  
 
 The negative relationship between clinic use and travel time to the clinic is also 
supported by previous literature which found proximity to the home as an influential 
factor affecting patients’ decisions for alternative providers of urgent care (Grafstein 
et al., 2013, Shearer et al., 2015). Similarly, as found in this study, alternative providers 
of urgent care in Ireland are locally used services.  
.  
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The probit regression found similar socio-economic characteristics (GMS, PHI and 
income (€70,000-€84,000)) and clinic characteristics (extended opening hours, travel 
time to the clinic and parking access) to significantly affect the probability of a patient 
being a first-time user at these clinics. The results of the probit regression suggest that 
GMS patients and patients with longer travel time to the clinic are more likely to be 
first-time users and consequently, less likely to be repeat or multiple users of the 
clinics. This is in comparison to patients who have PHI, a higher income level and a 
preference for the extended opening hours and parking access offered by these clinics. 
These patients are less likely to be first-time users of the clinics and are subsequently 
assumed to be repeat or multiple users of the clinics. Similar to the results of the ZTNB, 
the significant variables found in the probit model also highlight the affordability and 
accessibility issues that exist for lower incomes patients attending these clinics. The 
results further emphasise, that higher income earners and patients with PHI have 
increased accessibility to convenient urgent care due to their ability to pay. 
 
The following section, Section 3.5, concludes this chapter. 
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3.5 Conclusion 
 
This chapter identified the factors which influence patient choice of UCCs in Ireland 
in the face of user charges. Due to the nature of the question, the research collected 
primary data from patients attending three private UCCs in Ireland where all patients 
are subject to an OOP user charge to use the service. Vhi SwiftCare Clinics were the 
first type of walk-in UCCs to be established in Ireland. The clinics were founded by 
Vhi Healthcare in conjunction with Centric Health (CentricHealth, n.d.). These are 
privately financed clinics. Vhi SwiftCare Clinics operate as walk-in urgent clinics and 
provide a non-appointment service, extended opening hours and decreased waiting 
times. To attend a Vhi SwiftCare Clinic a patient faces a user charge of €125 for the 
initial consultation71 plus additional charges depending on the services required.72 All 
patients in Ireland are eligible to attend Vhi SwiftCare Clinics once they are willing to 
pay the relevant user charges.73 Vhi SwiftCare Clinics do not accept medical cards or 
GPVCs as a method of payment. There are currently three Vhi SwiftCare Clinics in 
Ireland; one in Mahon in Cork, one in Swords, Dublin and one in Dundrum, also in 
Dublin.  
 
Using a cross sectional study, this research collected primary data from patients 
attending all three Vhi SwiftCare Clinics in Ireland. A ZTNB is used to estimate the 
factors which influence patient choice of walk-in Vhi SwiftCare Clinics in Ireland. A 
probit regression was then used to identify the factors which increase the likelihood of 
the patient being a first-time user. 
                                                          
71 See footnote 1.  
72 See footnote 17. 
73 The clinics are not solely for patients who have PHI. 
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Chapter 3 has acknowledged the objectives as set out in Section 3.1.1. This Chapter 
has revealed the type of patient that uses Vhi SwiftCare Clinics as mainly young 
patients with a high income level and PHI cover. Overall the findings show that PHI, 
GMS cover, income (€70,000-€84,000), parking and travel time to the clinic influence 
patient choice when deciding to use a Vhi SwiftCare Clinic. Despite an unexpected 
insignificant relationship found between the user charge and Vhi SwiftCare Clinics 
use, the significant variables measuring patient socio-economic characteristics (PHI, 
GMS and income) are related to patients’ ability to pay and act as a proxy for 
affordability. Therefore, this section concludes that patient affordability is important 
when choosing a Vhi SwiftCare Clinic. 
 
An insignificant relationship was found between the user charge and Vhi SwiftCare 
clinic use. In an Irish healthcare context, this can be identified as an unexpected finding 
as the cost of this urgent care provider is potentially more expensive than traditional 
providers. However, the significant variables measuring patient socio-economic 
characteristics (PHI, GMS and income) are related to patients’ ability to pay and act 
as a proxy for affordability. The influence of affordability for this service raises 
accessibility concerns for lower income patients. Patients with lower incomes may not 
be able to afford this service and consequently, may not have the same access to this 
healthcare service as a patient with a higher income level. Therefore, this chapter 
concludes that patient affordability is important when choosing these clinics.  
 
Another reason for the insignificant relationship between the user charge and use of 
these clinics may be due to the exclusion of non-users of the clinics in this study. As 
the patients included in this study have already made the decision to use the clinic, the 
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potentially higher user charge may not act as a deterrent for these patients. The 
exclusion of non-users has been identified as an implication in this study in terms of 
sample bias. However, as the main research objective is to identify the factors 
influencing patient choice of the clinic, it was appropriate to include only users of the 
clinics to successfully answer the research objective. See Section 6.4 for further 
discussion. This research acknowledges the potential sample bias and interprets the 
results in terms of users of the clinic.  
 
 This section finds that 66% of the sample were successfully treated in the clinics and 
were not referred for further treatment. This indicates that without services such as the 
Vhi SwiftCare Clinics in Ireland, these patients would have had no choice but to attend 
a GP or A&E department with their injury or illness. The research concludes that 
patients of Vhi SwiftCare Clinics are influenced by clinic characteristics such as 
extended opening hours, parking and travel time to the clinics rather than be deterred 
by the potentially higher user charge in comparison to the traditional urgent care 
providers. While alternative urgent care providers have extended opening hours in 
comparison to GP services in Ireland, these clinics are not open 24 hours like an A&E 
department in Ireland. Further research should be conducted to confirm whether; if 
UCCs in Ireland were open 24 hours a day, patients would utilize the service despite 
the potentially higher user charge. If so, this would in turn reduce the increasing 
pressure occurring in A&E departments in Ireland.  
 
Chapter 3 has shown that while patients in this sample have already made the choice 
to pay the higher user charge for this private service, the significant factors which are 
driving choice for alternative urgent care providers are also associated with 
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affordability; GMS, PHI and income. These results indicate that when patients must 
pay the full user charge OOP for a healthcare service, it is predominantly patients with 
higher income and PHI that do so. The following chapter, Chapter 4, examines the 
impact of three different types of user charges on patient behaviour for a mainly public 
or part-publicly provided service in Ireland. The three different types of user charges 
result in varying OOP payments for the patients and varying OOP costs relative to the 
overall cost of the service. Rather than focussing on just one type of user charge as 
done in Chapter 3, Chapter 4 examines the impact of a co-payment, a deductible and 
also a full user charge for a mainly public or part-publicly provided service; 
prescription drugs.  
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4 WHAT IMPACT HAVE PRESCRIPTION DRUG USER CHARGES 
HAD ON PATIENT BEHAVIOUR IN IRELAND? 
 
4.1 Introduction  
 
In 2012, the total pharmaceutical bill across the EU was €200 billion (OECD, 2014). 
Pharmaceutical expenditure accounted for nearly one fifth of health expenditure in the 
EU in 2012 and accounted on average for 1.2% of GDP in the EU with two thirds of 
expenditure publicly financed and the remainder privately financed. There are wide 
variations in the pharmaceutical expenditure per capita amongst EU countries. For 
example, Belgium had the highest pharmaceutical expenditure per capita in 2012 at 
€550, followed by Germany at €501 per capita and Ireland at €500 per capita. Ireland 
spent 40% more on pharmaceutical expenditure per capita than the OECD average 
(€350) (OECD 2014). High pharmaceutical expenditure urges governments and policy 
makers to introduce policies such as user charges. User charges result in the sharing of 
healthcare costs between the patient and provider and result in the patient contributing 
towards the cost of their prescription drugs. User charges are an example of one of the 
strategies that are introduced by governments in the EU in an attempt to alleviate the 
financial strain on pharmaceutical expenditure (Gemmill et al., 2008).    
 
User charges for prescription drugs are defined as payments made by the patient when 
a prescription is dispensed (Gibson et al., 2005b). This payment is a contribution 
towards their prescription costs (Morris et al., 2007). These user charge policies are 
grounded in economic theory of consumer choice and how price can be used as a tool 
to change consumer behaviour. Transferring a proportion of the prescription cost to 
the patient, it is theorised that user charges encourage consumers to become more cost-
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conscious (Hurley and Johnson, 1991). This is based on the assumption that consumers 
reduce unnecessary demand which is referred to as “moral hazard”. As defined in 
Chapter 1 of this thesis, moral hazard is the excess use of a healthcare service and in 
the context of this chapter, moral hazard refers to the excess use of prescription drugs.  
 
In healthcare, some patients have full financial protection (full third party payment) 
against user charges for prescription drugs while other patients must pay the full user 
charge (full cost borne OOP by the patient). When the user charge is set between full 
third-party payment and the full user charge, the patient is subject to some form of 
cost-sharing for prescription drugs. Throughout this chapter, unless otherwise stated, 
the term “user charge” is generally applied when referring to any OOP payment made 
by patients towards the cost of their prescription drugs. More specifically, the term 
“cost-sharing” is used to indicate that only a proportion of the total cost of the 
prescription drug is paid OOP by the patient. Consequently, this chapter defines cost-
sharing as a subset of user charges. Cost-sharing for prescription drugs can include 
direct or indirect payments (Tamblyn et al., 2001). Direct cost-sharing includes co-
payments, deductibles and co-insurance. Indirect cost-sharing includes coverage 
exclusions, generic substitutions and reference pricing (Grootendorst et al., 2001, 
Motheral and Fairman, 2001). In Ireland, the main types of user charges that exist for 
prescription drugs are co-payments, monthly deductible, zero-cost-sharing and the full 
user charge. The type of user charge imposed on patients for prescription drugs is 
dependent on the type of prescription drug cover they have.   
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4.1.1 Prescription Drug User Charges in Ireland 
 
Under the GMS Scheme, the user charge for prescription drugs was first introduced in 
2010 and has increased substantially over the last 5 years. In 2010, a 50c fixed fee per 
prescription item was introduced on all prescription drugs dispensed by pharmacies to 
GMS patients.  This user charge was subject to a maximum ceiling of €10 per family 
per calendar month. In October 2013, this co-payment was further increased to €1.50 
per item with a monthly limit of €19.50. Currently, since October 2014, this co-
payment is set at €2.50 per item with a monthly maximum of €25 per family per 
calendar month (DOH, 2013). The GMS co-payment saved €43 million in 2015 (IMO, 
2016).  
 
The latest available figures show that in 2013, 40.31% of the population (1,849,340) 
were eligible for GMS status (PCRS, 2013)74. This costs the HSE an average payment 
to pharmacies of €973.26 per person for prescription drugs (PCRS, 2013). The number 
of individuals under the GMS scheme increased by approximately 34% between 2009 
and 2013 (PCRS, 2013). One reason for this increase in eligibility is due to the onset 
of the recession in Ireland in 2008. Increasing levels of unemployment led to lower 
incomes which resulted in a higher number of patients becoming eligible for GMS 
status. While GMS numbers have increased, the HSE cost per GMS patient decreased 
from €1,245.79 in 2009 to €973.26 per patient in 2013 (PCRS, 2013). One of the 
possible reasons for this reduction in cost per person is due to the increase that occurred 
                                                          
74 The HSE Annual Report (2014), reports that 39% (1.77m) of the population were eligible for the 
GMS scheme in 2014. However, the HSE does not provide detailed statistics for the othe publicly 
funded categories addressed in this thesis (Drugs Payment Scheme (DPS) and LTI).  The PCRS 
provides the most up-to-date statistics for all community drug schemes in Ireland so for consistency 
purposes, the PCRS statistics are used when possible.  
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in the prescription charge between 2010 and 2013. Patients were contributing towards 
a higher share of their prescription medication, therefore, reducing the HSE cost per 
claimant. 
 
Patients without a GMS card may apply for a DPS card to receive financial protection 
for prescription drugs. With a DPS card, a patient pays a monthly deductible for their 
prescription drugs after which the cost is covered by the HSE. In comparison to the 
recent introduction of the GMS user charge, the DPS user charge has been in existence 
in Ireland since 1999 (DOH, 1999). In 1999, the DPS set a monthly deductible of £42 
(€56) per family per month (DOH, 1999). This meant that once a patients’ drug cost 
exceeded £42 (€56) per month, the remainder of their drug costs were covered by the 
State. This deductible has increased considerably; in 2008 it increased to €90 (DOH, 
2008) and in 2010 it rose to €120 (DOH, 2010). In 2012 it was further increased to 
€132 (DOH, 2011) and since 1st January 2013 an individual with a DPS card can pay 
up to €144 for prescription drugs per calendar month (DOH, 2012b). Any prescription 
drug costs in excess of this are covered by the state.  
 
The latest available figures show that in 2013, 30.50% (1,399,208) of the population 
were registered under the DPS scheme. This costs the HSE an average payment of 
€272.56 per claim75 (PCRS, 2013). The number of individuals under the DPS scheme 
decreased by approximately 12% between 2009 and 2013 (PCRS, 2013). One reason 
for this reduction is due to the onset of the recession in Ireland in 2008. Increasing 
                                                          
75 Figures are based on number of eligible persons who availed of services under the scheme. The PCRS 
only has data on the DPS patients who exceed the monthly deductible as it is only after a patient 
reaches €144 per calendar month that the HSE covers the cost of the patient’s prescription drugs. 
Until this point, the patient pays OOP. Consequently, the €272.56 per claim refers only to patients 
who exceed the €144 per month.  
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levels of unemployment led to lower incomes which resulted in a higher number of 
patients becoming eligible for GMS status. This reasoning is supported as the number 
of GMS patients increased by almost 34% during the same time-frame (2009 to 2013) 
(PCRS, 2013). 
 
Patients in Ireland who are entitled to the LTI scheme do not pay any cost towards 
prescription drugs that are dispensed to them under the LTI scheme for the treatment 
of their LTI. In some cases, LTI patients may be prescribed prescription drugs that are 
unrelated to their long-term condition and consequently, be subject to some form of 
user charges. A patient with LTI entitlement can also apply to the GMS or DPS scheme 
depending on their eligibility.  
 
Patients who are not eligible for the GMS scheme or LTI scheme, and patients who 
have not applied to the DPS scheme are subject to the full cost of their prescription 
drugs which must be paid OOP at the point of use.  
 
As a result of the three community drug schemes (GMS, DPS and LTI) and patients 
without any form of prescription drug cover, a number of user charge policies exist in 
Ireland for prescription drugs; a fixed co-payment per prescription item (GMS 
Scheme) and a deductible (DPS), zero cost-sharing (LTI) and the full user charge. 
Patients face different types of user charges depending on their eligibility for 
prescription drug cover. This research aims to assess the impact of the various types 
of user charges which exist for prescription drugs in Ireland. This is done in the context 
of consumer choice to ascertain how the user charges impact on patient behaviour in 
Ireland 
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4.1.2 Impact of Prescription Drug User Charges on Affordability and 
Accessibility 
 
One of the major concerns associated with user charges on prescription drugs is the 
impact on patient affordability and accessibility.  
 
Affordability suggests that patients with a higher income level pay a higher cost as a 
proportion of their income (Gemmill et al., 2008). As user charges transfer a proportion 
of the cost to the patient, there are concerns that user charges may cause patients to 
reduce their medication adherence, may create a financial burden for patients or may 
encourage individuals to engage in cost-coping strategies in order to afford and access 
prescription medication (Reed et al., 2008). User charges can be “regressive” with 
larger effects on patients who spend a larger proportion of their budget on prescription 
drugs, namely, the sick and the poor (Wagstaff et al., 1999). As patient user charges 
contribute towards pharmaceutical financing in EU countries, the impact of user 
charges needs to focus on all individuals and not just homogenous groups such as 
vulnerable patients76 (Tele and Groot, 2009). 
 
There are also concerns regarding user charges and their impact on accessibility to 
prescription drugs. As stated, one of the objectives of user charge policies is to reduce 
moral hazard. While research may find user charges encourage patients to reduce their 
consumption of prescription drugs, user charges do not have a discriminating effect 
between necessary and unnecessary prescription drugs (EXPH, 2014).  User charges 
                                                          
76 This thesis defines vulnerable populations as those covered by GMS, low-income individuals who 
have an income level below the national average’, patients with 3 or more chronic illnesses and those 
who report a self-reported health status as poor or very poor. This definition is similar to that used in 
a previous study by Lexchin and Grootendorst (2004).   
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not only discourage unnecessary consumption of discretionary prescription drugs77 but 
user charges can also reduce consumption of essential prescription medication78 
(Robinson, 2002). If user charges are set at a price which does reduce the utilization 
of essential prescription drugs, then the user charge can lead to long-term financial 
impact on the healthcare system. Reducing the consumption of essential prescription 
drugs can have a long-term financial impact on the healthcare system as patients may 
become sicker without sufficient access to these drugs and consequently require more 
healthcare in the long-run (Kephart et al., 2007).   
 
4.1.3 Research Question and Aim 
 
This chapter aims to answer the following research question:  
 
What Impact have Prescription Drug User Charges had on Patient Behaviour in 
Ireland? 
 
This question led to two more specific objectives that include:  
 
 Identify the effect that different forms of prescription drug user charges have 
on patient behaviour in Ireland.  
 Using a multinomial logit model, measure the association between patient 
behaviour and individual characteristics. 
 
                                                          
77 Prescription drugs that do not affect morbidity. 
78 Prescription drugs that do affect morbidity. 
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Through the construction of a novel questionnaire, this research collects primary data 
from patients in selected GP surgeries in Cork to investigate patient response to user 
charges for prescription drugs. Collecting primary data, the research investigates if 
prescription drug user charges cause patients to change their behaviour in order to 
afford and access prescription medication. The research assesses three types of 
behaviour in response to prescription drug user charges in Ireland; decreased 
adherence, financial burden and/or if the patient engaged in cost-coping strategies in 
order to afford and access prescription medication (without reducing adherence or 
creating a serious financial burden). The research will also control for patient 
characteristics such as age, GMS cover, DPS cover, patients without any prescription 
drug cover, prescription cost, gross monthly income level and the number of self-
reported chronic illnesses.  
 
4.1.4 Motivation 
 
As Ireland spends 40% more than the OECD average on pharmaceuticals per capita, 
understanding patient response is crucial in order to identify whether or not user charge 
policies can be an effective method of contributing towards pharmaceutical costs in 
Ireland.  If user charges for prescription drugs do not exist, patients have no incentive 
to be cost-conscious regarding this healthcare service and it is inevitable that 
pharmaceutical expenditure will continue to increase.  This will negatively impact on 
the public provision of prescription drugs, thereby impacting on availability of 
prescription drugs for patients.  
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In Ireland very little research has examined the direct impact of prescription drug user 
charges on consumer choice from the patient perspective predominantly due to a lack 
of data. Some Irish studies have analysed prescription claims data to examine 
prescription drug utilization as a result of introduced/increased co-payments and 
deductibles (Sinnott et al., 2013, Usher et al., 2012, Walshe and Kenneally, 2013). 
However, these studies do not capture the direct impact user charges have on patient 
behaviour from the patients’ perspective. This needs to be done before one can 
determine if user charges can be used to part-fund healthcare services such as 
prescription drugs.  With this in mind, it is important to conduct this research in an 
Irish context from the patients’ perspective to assess if user charge policies influence 
patient behaviour while providing affordable and accessible care to prescription drugs.  
 
4.1.5 Chapter Structure 
 
4.2 presents the previous literature that has been reviewed on the impact of prescription 
drug user charges. Section 4.3 presents the methodology that was employed to 
investigate patient response to prescription drug user charges in Ireland. Section 4.4 
describes the econometric method that was utilized and Section 4.5 concludes this 
chapter.
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4.2 Literature Review 
 
4.2.1 Introduction 
 
This chapter provides a critical review of existing literature on user charges for 
prescription drugs and their impact on patient behaviour. Similar to a literature review 
conducted by Lexchin and Grootendorst (2004), the following search words in EconLit 
guided this review: (drug OR pharma) AND (cost-sharing OR co-payment OR fee OR 
deductible OR coinsurance OR elasticity). A citation approach was adopted where 
citations were recorded and from there reference lists were scanned until such a time 
it was thought that all key paper/authors were retrieved. The criteria extracted from 
each study was as follows; data source, outcome measurement, price variation, study 
design and study results. Table 4.1 summarises the studies on which this review is 
based.  
 
The studies included in this review come from the US, UK, Canada, Ireland, France, 
Spain and Italy (see Table 4.1). Due to diverse healthcare systems in these countries 
in terms of funding mechanisms and healthcare entitlements, user charge policies in 
these healthcare systems are also varied, resulting in different forms of cost-sharing 
such as co-payments, deductibles, co-insurance and benefit caps existing among the 
studies. Despite price variation, all studies aim to assess the impact of prescription 
drug user charges on patient behaviour such as medication adherence, financial burden 
or cost-coping strategies. Some studies also assess the impact of cost-sharing on health 
outcomes (Mojtabai and Olfson, 2003, Piette et al., 2004a, Rahimi et al., 2007). 
However, as the objective of this research focuses solely on patient behaviour in 
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response to cost-sharing, health outcomes are beyond the scope of this research (see 
Section 6.4). The review will focus on three types of patient behaviour in response to 
user charges; medication adherence, financial burden and cost-coping strategies (Dor 
and Encinosa, 2010, Gilman and Kautter, 2008, Mojtabai and Olfson, 2003, Piette et 
al., 2004a, Piette et al., 2004b, Reed et al., 2008, Schafheutle et al., 2002).  
 
Section 4.2.2 presents the impact of prescription drug user charges on medication 
adherence. Section 4.2.3 focuses on the financial burden of prescription drug user 
charges while Section 4.2.4 discusses cost-coping strategies adopted by patients in 
order to access and afford prescription drugs (without reducing adherence or creating 
a serious financial burden).  
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Table 4.1 Synopsis of Literature Examining User Charges and Prescription Drugs 
 
Authors  Date      Study Population           Outcomes  Price Variation79                  Design            Results 
        (Date Source) 
 
Atella et al 2005 Patients with dyspepsia or 
mild hypertension presenting 
at 51 physician offices in 
Italy and at 21 pharmacies in 
the UK during a set time 
period in 2000 (N = 519) 
Self-reporting of cost-
reducing strategies such as 
those initiated by the 
patient, those involving 
self-medication. Self-rated 
affordability measure. 
UK – Fixed flat rate co-
payment £6(€8.93) 
Italy – 3 reimbursement 
groups; Class A – Drugs 
for severe and chronic 
illness (fixed charge 
£5.90 (€8.68) Class B – 
Non-essential but useful 
(50% of the retail price) 
Class C – Other drugs 
(Fully paid for by 
patient) 
Cross-sectional 
study; probit 
regression, ordered 
probit regression and 
poisson regression  
Prevalence of 
cost-reducing 
strategies are 
higher in the UK 
where the co-
payment is higher 
than Italy.  
Carlson, 
DeVoe and 
Wright  
2006 Adults (<19 Years) enrolled 
in the Oregon Health Plan 
(OHP) (N=2,783) 
Coverage pattern, access 
to care, healthcare 
utilization, financial 
impact. 
OHP premiums doubled 
for couples; Certain 
benefits eliminated and 
6-month lockout for 
enrolees who miss a 
payment. 
Prospective cohort 
study, bivariate and 
multivariate analyses 
to examine the effect 
of disrupted and lost 
insurance coverage 
on unmet needs, 
utilization and 
medical debt.  
Lost or disrupted 
coverage resulted 
in unmet 
medication needs 
when compared to 
those continuously 
insured.  
Kambia-
Chopin and 
Perronnin 
2013 Participants from the French 
Health, Health Care and 
Insurance Survey of 2013 
(N=4985) 
Drug consumption prior to 
2008 and drug 
consumption after 2008. 
Introduction of a €0.50 
deductible levied on 
every prescription drug 
packet. 
Cross-sectional 
study, logistic 
regression. 
Deductibles on 
prescription drugs 
create a financial 
burden and 
accessibility 
concerns for low-
income 
                                                          
79 The prices included in this table have been converted into the Euro equivalent value corresponding to the year each study was conducted. 
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individuals in poor 
health.  
Dor and 
Encinosa 
2010 Claims data from eight large 
firms. Largest database of 
insured individuals in the 
US, Market Scan. Adults 
<18 with type II diabetes 
(N=28,031)  
“Non-compliers”, 
“Partially Compliant”, 
“Fully Complaint” 
individuals. Adherence - 
to reﬁlling of prescriptions 
of preventive care drugs 
without interruption 
Fixed co-payments or 
coinsurance  
Cross-sectional, 
ordered logit 
regression 
When coinsurance 
and co-payments 
have the same 
OOP payment ($9) 
(€6.86) , at least 
34%of patients 
under co-payment 
refill meds 
compared to only 
24% under co-
insurance. 
Gilman and 
Kautter 
2008 Largest database of insured 
individuals in the US, 
Marketscan 2002 
(N=352,760) 
Number of co-payment 
tiers on total and enrollee 
drug payments, number of 
prescriptions filled and 
generic substitution.  
Multi-tiered formularies 
applying fixed enrolee 
co-payment amounts to 
different types of 
prescription medications 
depending on payer 
preferences. 
Cross-sectional 
variation in co-
payment structures 
among firms, 
Multivariate 
regression 
Medicare 
beneficiaries on 
three-tiered plans 
had 14.3% lower 
drug expenditure, 
14.6% fewer 
prescriptions 
filled, 57.6% 
higher OOP costs 
than those on 
lower-tier plans.  
Kephart et al 2007 Prescription drugs claims for 
beneficiaries <65 years in 
Canada between 1989 and 
1992 (N = 2,407,758) 
Monthly drug use (Vs 
non-use) and the mean 
quantity of medication 
used per month by 
medication users. 
Prior to 1990 – 
Prescription drugs free of 
charge; 1990 - $3 (€2.03) 
co-pay per prescription 
(max. annual co-pay 
$150 (€101.62); 1991 – 
20% coinsurance of the 
total cost (max. annual 
co-pay $150). 
Logistic regression 
models 
Co-payments $3 
(€2.03) and 20% 
co-payments) 
decreased quantity 
of meds. used 
ranging from 5% 
to 15%. Only 
when the 
maximum was 
unlikely to be 
reached. 20% 
coinsurance rate 
increased the % 
who reached the 
maximum, 
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decreasing 
proportion of 
patients who 
reduced drug use.  
Mojtabi and 
Olfson 
2003 Medicare Beneficiaries from 
the Health and Retirement 
Study (HRS), 2000 wave 
(N=10,413) 
Office visits, preventative 
services, Drug cover and 
cost related poor 
medication adherence, 
health ratings, OOP 
spending and income 
Decline in Medicare 
supplemental coverage. 
More than two million 
Medicare beneficiaries 
have no prescription 
drug cover.  
Self-reported, cross-
sectional study. 
Binary and ordinal 
logistic regression, 
Descriptive Statistics, 
Frequency weights, 
strata and primary 
sampling to adjust 
parameter estimates 
and their variances. 
No or partial 
medication 
coverage results in 
poor medication 
adherence, poor 
health and higher 
rates of 
hospitalization.  
Piette et al  2004 Detailed telephone 
interviews with patients and 
linkage to insurance 
information and 
haemoglobin test results 
(N=766). 
Self-reported medication 
underuse as a result of 
cost, haemoglobin levels, 
symptom burden, Medical 
Outcomes Study 12-Item 
scores 
No insurance – full cost 
(avg. $100 
(€75.22)/month); 
Medicare – FFS; 
Medicaid - $1-$3 (0.75c-
€2.26) per refill (max. 6 
drugs/month); VA- 
100% covered, $7 
(€5.27) co-pay for non-
service illness/injury 
(<$840 (€631.86), costs 
waived); Privately 
insured $10-$30 (€7.52-
€22.57) co-pay per script 
subject to annual cap.  
Cross-sectional, 
bivariate correlations, 
follow-up pairwise 
tests, multivariate 
logistic regression, 
OLS regression 
Fewer VA patients 
(9%) reported 
reduced 
medication use 
than those 
privately insured 
(18%), Medicare 
patients (25%), 
Medicaid (31%) 
and those with no 
insurance (40%).  
Piette, 
Heisler and 
Wagner 
2004 Survey of nationwide panel 
of adults in the US, (N=875) 
Decreased medication 
adherence among older 
adults with diabetes, 
financial burden of 
medication costs, extents 
of discussion between 
patients and clinicians.  
Insured Vs no form of 
insurance (See above 
price variation for Piette 
et al 2004) 
Cross-sectional, 
Bivariate analysis, 
Pearsons chi square, 
multivariate logistic 
regression, post-
stratification to adjust 
for distribution of 
respondents to match 
US population 
19% decreased 
adherence due to 
cost, 28% gave up 
food and other 
essentials, 14% 
increased credit 
card debt, 10% 
borrowed from 
family/friend to 
pay for meds.  
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Puig-Junoy, 
Rodriguez-
Feijoo, 
Lopes-
Valcarel 
2014 NHS data on dispensed 
prescription from Jan. 2003 – 
July 2013.  
Number of prescriptions 
dispensed. 
2012 - “Three-payment 
reform”. National co-
insurance rate of 10% 
with monthly, income-
related ceiling, 
Cataluña/Madrid - €1 co-
pay per prescription, 
delisting of some meds. 
for minor symptoms 
(100% coinsurance) 
Time-series, 
Univariate ARIMA 
model,  
First 14 months 
after the co-pay 
reform, total 
number of 
prescriptions 
decreased 
dramatically.  
 Rahimi et al  2007 Patients enrolled in US 
study, Prospective Registry 
Evaluating Myocardial 
Infarction: Event and 
Recovery (PREMIER) 
between January 2003 and 
June 2004 (N= 2498) 
Health status symptoms 
(Seattle Angina 
Questionnaire – SAQ), 
overall health status 
(Short-Form 12), 
rehospitalisation.   
Privately-insured, 
Medicare, Medicaid, 
Uninsured (Various co-
pays) 
Observational, self-
reported financial 
burden. 
12.9% reported 
financial burden, 
of these, 68.5% 
were insured. 1-
year follow-up, 
more likely to 
have angina, lower 
SAQ score and 
increased 
hospitalization.  
Reed et al 2008 Adults in a large prepaid, 
integrated delivery system 
(IDS) (N= 932). 
Knowledge of cost 
sharing structures, 
knowledge of cost-sharing 
amounts, decreased 
adherence, financial 
burden and other cost-
coping behaviours.  
Members have either one 
co-pay for all covered 
drugs (one-tier), different 
co-pays for brand and 
generic drugs (two-tier), 
some had a pharmacy 
benefit cap; patients had 
to pay the cost of any 
drugs over this threshold.  
Cross-sectional study 
using telephone 
interviews, 
descriptive statistics 
and frequencies, 
multivariate logistic 
regression. 
27% knew their 
cost-sharing 
amount, additional 
tiers and caps and 
higher co-pays 
were associated 
with decreased 
adherence, 
financial burden 
and cost-coping 
methods.  
Schafeulte et 
al 
2002 Sufferers of dyspepsia, hay 
fever, hypertension or people 
taking hormone replacement 
treatment, recruited from 3 
community pharmacies in 
North-West England. (N=31) 
Medication costs and 
strategies to reduce 
medication costs.  
£5.90 (€9.23) per 
prescription item (April 
2001) Prepayment 
certificates (PPC) also 
available as a protection 
mechanism. 
6 focus groups  Patient behaviour 
is influenced by 
medication cost, 
encouraged cost-
reduction 
strategies,  
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Schafeulte  2008 Patients approached in 6 GP 
surgeries in Northwest 
England (N=61) 
Views on prescription 
charge, principle of 
paying for medication, 
current level of the 
charge, level of 
exemption, ideas on 
potential changes. 
£6.85 (€9.59) (April 
2007) 
Qualitative, semi-
structured interviews 
Cost creates a 
financial burden 
for paying for 
prescription drugs.  
Sinnott et al 2013 All GMS patients attending a 
community pharmacy in 
Munster in Ireland, (N=23) 
Knowledge on purpose of 
the levy, opinion on the 
levy, levy as a financial 
barrier, suggestions for 
policy 
50c per prescription item 
subject to a monthly 
ceiling of €10 per family.  
Qualitative, semi-
structured interviews 
Patients mostly 
accepting of the 
levy, concern 
about how the 
money would be 
used by the 
government, 
acknowledged 
moral hazard but 
questioned 
efficiency of the 
50c levy. Felt it 
was affordable but 
may cause a 
financial impact 
for others.  
Steinman et 
al 
2001 Patients <70 years, Survey of 
Asset and Health Dynamics 
Among the Oldest Old 
(1995-1996) (N=4,935) 
Medication restriction due 
to cost. 
No prescription 
coverage, partial 
prescription coverage or 
full prescription 
coverage. 
Cross-sectional, 
Bivariate and 
Multivariate analysis. 
Medication 
restriction 
reported by 8% of 
those with no 
prescription 
coverage, 3% with 
partial coverage, 
2% with full 
coverage. 
Tseng et al 2004 Medicare+Choice 
beneficiaries <65 years with 
high medication costs (N= 
665) (control N=643) 
Proportion of 
beneficiaries reporting 
strategies to decrease 
medication costs, meds. 
affected, difficulty paying 
for prescription meds.  
Annual beneficiary caps 
of $750 (€564.14) to 
$1504 (€1830.40). Co-
pays ranging from $7-
$30 (€5.27-€22.57) per 
prescription.  
Multivariate analysis 
adjusting for 
demographic and 
health characteristics 
Patients who 
exceed the cap 
reported using less 
prescription meds 
(18%), stopping 
prescription drug 
use (8%), not 
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starting 
medications (6%), 
switched 
medications 
(15%), used 
samples (34%), 
difficulty 
affording 
prescriptions 
(62%).   
Source: Authors Own 
135 
 
4.2.2 Medication Adherence 
 
A number of studies have demonstrated a negative relationship between prescription 
drug user charges and medication adherence (Dor and Encinosa, 2010, Doran et al., 
2005, Gilman and Kautter, 2008, Kephart et al., 2007, Mojtabai and Olfson, 2003, 
Piette et al., 2004a, Piette et al., 2004b, Puig-Junoy et al., 2014, Reed et al., 2008, 
Schafheutle et al., 2002, Steinman et al., 2001, Tseng et al., 2004). The following 
paragraphs review the literature which assesses decreased adherence as a result of 
prescription drug cost-sharing. Patients are said to engage in this type of behaviour, as 
a result of the cost, if they reduce their medication without the advice of their doctor, 
do not refill an existing prescription or if the patient does not fill a new prescription. 
This section initially presents studies which assess the impact of various levels of 
prescription drug coverage on patient behaviour in terms of decreased adherence 
(Gilman and Kautter, 2008, Mojtabai and Olfson, 2003, Piette et al., 2004a, Steinman 
et al., 2001) and then compares the impact of different forms of cost-sharing such as; 
co-payments, co-insurance and/or benefit caps and their impact on patient behaviour 
(Kephart et al., 2007, Reed et al., 2008, Dor and Encinosa, 2010, Puig-Junoy et al., 
2014 ).  
 
In the US, Steinman et al (2001) assessed medical adherence for patients over 70 years 
of age with different levels of insurance. The study included uninsured patients, 
patients with partial drug coverage and patients who had full prescription drug 
coverage. Consequently, the level of the user charge would be different for each group; 
uninsured patients had an average monthly OOP drug expenditure of $60 in 
comparison to partially insured patient who paid a monthly average of $25. In this 
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cross-sectional study, 8% of uninsured patients reported taking less medication to 
avoid the cost in comparison to 3% of patients with partial drug coverage and 2% of 
patients with full prescription coverage. Using multivariate analysis, Steinman et al 
(2001) found medication restriction is common among vulnerable populations80, while 
in contrast, seniors with partial or full prescription drug coverage were less likely to 
reduce medication adherence due to the cost.  
 
Steinman et al (2001) acknowledge concerns regarding validity and bias issues that 
may be present in their study due to the self-reported nature of the data. To reduce 
these risks, the researchers ensured they developed a questionnaire that was a reliable 
measure of patients’ response to cost-sharing. As the current research also collects self-
reported data, all efforts are made to develop a well-constructed questionnaire in order 
to ensure reliable results.   
 
The previous findings are also supported by Mojtabi and Olfson (2003) who assessed 
decreased adherence among 10,413 Medicare Beneficiaries with full, partial or no 
prescription coverage. Using a binary logistic regression, Mojtabi and Olfson (2003) 
found that 7% of 8,704 Medicare beneficiaries reported decreased adherence due to 
cost.  Similar to Steinman (2001), the study also revealed higher OOP expenditure is 
associated with cost-related decreased adherence; over 20% of low-income 
beneficiaries in the study who spent over $1000 per month reported decreased 
adherence due to cost.  
 
                                                          
80 Classified as ethnic minorities, poor, sick, frail and high OOP costs (Steinman et al., 2001). 
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Mojtabi and Olfson (2003) focus solely on the impact of cost-sharing on patient 
behaviour. The researchers do not assess the impact of cost-sharing on healthcare 
outcomes as adverse selection would cause problems in the results (Federman et al., 
2001). As mentioned in Section 4.2.1, this research also only focuses on the impact of 
prescription drug user charges on patient behaviour and does not assess the impact of 
user charges on health outcomes as this is beyond the scope of this study.  The 
objective of this study is to assess patient response to prescription drug user charges to 
determine whether user charges are a viable source of part-funding prescription drugs 
in Ireland.  
 
Examining the effect of 5 different levels of co-payments, Piette et al (2004) also found 
patients with lower prescription drug cover were more likely to reduce medication 
adherence due to cost. Using self-reported data from telephone interviews, Piette et al 
(2004) included uninsured patients, privately insured patients, Medicare and Medicaid 
beneficiaries and patients under the Veterans Health Administration (VA). At the time, 
privately insured patients paid $10-30 per prescription, Medicare patients paid a fee-
for-service, Medicaid patients paid $1-3 per refill subject to a maximum of 6 drugs per 
month while VA patients were 100% covered for prescription drugs.81 Patients with 
the lowest level of cover for prescription drugs, uninsured patients, were most likely 
to report decreased adherence (40%), 31% of Medicaid beneficiaries reported reduced 
medication use, 25% of Medicare patients reported underuse, 18% of privately insured 
patients reported a reduction while only 9% of VA patients reported reduced 
medication use as a result of the cost. Similar to the previous studies, this study also 
                                                          
81 A $7 co-payment for a 30 day supply was paid by VA patients for prescription medication treating a 
non-service injury/illness (Piette et al., 2004b). 
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states that patients with lower prescription drug coverage are more likely to engage in 
cost-related medication adherence.  
 
Piette et al (2004) recommend the retrieval of further information on patients’ 
medication regimen. This would allow the authors to assess if the patients’ decreased 
adherence was only for high-cost drugs or whether patients equally reduced all of their 
medication. The current research does not identify the type of drug that the patient 
reduces as a result of cost. The research instead focuses on patients’ overall response 
to prescription drugs user charges. This research does however collect data on the 
patients’ medication regime by asking patients to report if they waited to fill an existing 
prescription, if they reduced their medication dose without the advice of the doctor or 
if they failed to fill a prescription for a new medication.  
 
Finally, Gilman and Kauter (2008) also examined the impact of various co-payment 
levels on medication adherence. Extracting data from the largest database of insured 
individuals in the US, this study focused on multi-tiered formularies that were 
implemented to encourage the use of generic or preferred brand name medications, to 
control the use of non-essential drugs and limit financial exposure (Gilman and 
Kautter, 2008). Using a multivariate regression, the study found Medicare 
beneficiaries on three-tiered plans had 14.3% lower drug expenditure, 14.6% less 
prescriptions filled and 57.6% higher OOP payments than patients on one-tier plans. 
The study indicates that higher-tier drug plans are associated with a reduction on 
prescription drug expenditure and use by Medicare beneficiaries. The study found 
Medicare beneficiaries are less responsive to user charges for drugs treating chronic 
conditions implying that multi-tiered plans encourage efficient use of prescription 
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drugs without creating an access barrier to essential medication (Gilman and Kautter, 
2008). While this study makes these claims, the study does not identify whether the 
reduction in drug use under the three-tier plan is as a result of access barriers or 
efficiency improvements.  If the reported decreased adherence is associated with less 
essential drugs that have no beneficial value, this signifies an improvement in 
efficiency. A reduction in all medications, including essential drugs indicates that the 
cost of prescription drugs decrease accessibility for patients.  
 
These four studies conclude that lower prescription drug coverage amongst patients 
results in higher OOP expenditure and consequently leads to cost-related decreased 
adherence. In studies of this kind, decreased adherence needs to be correctly defined 
by assessing whether the patient reduced medication doses or failed to refill 
prescriptions. This definition is used in the current Irish study to correctly assess the 
impact of prescription drug user charges on patients’ behaviour.  When assessing the 
impact of user charges on patient behaviour, Gilman and Kauter (2008) highlight the 
importance of acknowledging all drug plans within a healthcare system. As pointed 
out in the previous paragraphs, different drug plans and benefits influence patient 
behaviour in different ways.  In Ireland, depending on eligibility for community drug 
schemes, a patient pays a co-payment of €2.50 per item subject to a monthly maximum 
of €25 or a €144 monthly deductible. Some patients have no drug cover and must pay 
the total cost of the prescription drugs. Consequently, this Irish research includes 
patients covered by both community drug schemes and patients without this cover who 
must pay the total cost OOP.  
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The following four studies assess how different types of cost-sharing such as co-
payments, deductibles, co-insurance and benefit caps impact on patient behaviour.  
Kephart et al (2007) examined the impact of the introduction and subsequent increase 
in co-payments on the use (and non-use) of prescription drugs in Nova Scotia, Canada. 
Prior to 1990, prescription drugs in Nova Scotia were provided free of charge. In 1990 
a $3 co-payment per prescription was introduced subject to an annual maximum 
amount of $150. This was subsequently changed to a 20% co-insurance rate in 1992. 
The maximum amount remained unchanged ($150). The study found both forms of 
cost-sharing reduced medication consumption between 5% and 15%.  However, the 
reduction only occurred when the annual maximum amount was unlikely to be 
reached. The introduction of the co-insurance rate increased the number of patients 
who would reach the maximum amount. Therefore, this reduced the proportion of 
patients who decreased their medication use. This finding highlights the different 
impacts that co-payments cause. Ellis (1986) and Moffitt (1990) indicate that patients 
who expect to exceed their maximum amount, perceive the marginal OOP cost to be 
$0. Patients who do not expect to exceed their maximum amount view their marginal 
OOP cost as greater than $0. This indicates that patients respond differently to different 
forms of cost-sharing which influence their OOP expenditure. The study conducted by 
Kephart et al (2007) raises the questions regarding maximum amounts. If the 
maximum amount was also increased under the co-insurance regimen introduced in 
1992, would the user charge have encouraged the desired effect of reducing overall 
expenditures while maintaining equitable access to prescription drugs? 
 
Inconsistent with other studies, Kephart et al (2007) did not find user charges to have 
a stronger effect on decreased adherence for low-income patients. Kephart et al (2007) 
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suggest the proxy variable they used for income may be a cause for this inconsistency 
(Finkelstein, 2004, Geronimus and Bound, 1998).   
 
Using self-reported data from patients in a large prepaid integrated delivery system 
(IDS), Reed et al (2008) examined the effect of co-payments and a benefit cap on 
patient adherence to medication. Of the 932 participants, 9.2% of the sample reported 
not filling a new prescription, 8% stopped refilling an existing prescription while 5.6% 
reported reducing their medication dosage without the advice of their doctor. Patients 
over 65 years and patients who took fewer drugs were less likely to report decreased 
adherence.  Using adjusted multivariate analysis, a strong association was found 
between the benefit cap and decreased adherence. Patients will not want to exceed the 
benefit cap as they will want to avoid OOP payments for the medication (Reed et al., 
2008). At this point in the review, it would appear that benefit caps are associated with 
decreased adherence while co-payments such as deductibles or maximum amounts 
only decrease adherence when the maximum amount is unlikely to be reached.  
 
This theory is further supported by Dor and Encinosa (2010). Using data from the 
largest database of insured individuals in the US, Dor and Encinosa (2010) assessed 
patient adherence to prescription drugs by examining prescription refills during a 19-
month period (June 1st 1999 to December 31st 2000).  Depending on their insurance 
regimen, some patients paid co-payments while others paid co-insurance for 
prescription drugs. The study found that when the OOP payment for both coinsurance 
and co-payment patients remained at a constant level ($9), decreased adherence was 
higher under coinsurance than under co-payment. Thirty-four per cent of those under 
co-payment refilled their prescription medication while only 24% under coinsurance 
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refilled their medication. The higher rate of non-compliance under the coinsurance 
regimen than under the co-payment policy may be due to the uncertainty in OOP costs 
under coinsurance. Under a co-payment scheme, the OOP payment remains relatively 
constant for the patient while under the co-insurance scheme, the amount fluctuates 
due to changes in retail drug prices (Dor and Encinosa, 2010).  
 
In the current Irish study, the co-payment theory as suggested by Dor and Encinosa 
(2010) is applicable under the GMS Scheme. GMS patients can be confident that they 
will only pay €2.50 per prescription item subject to a monthly maximum of €25. Under 
the DPS, patients face an element of uncertainty regarding their OOP payments unless 
they have reached the €144 deductible. Including patients covered by both community 
drug schemes and patients without community drug cover, the current Irish study 
assesses if patients’ response to prescription drug user charges vary as a result of 
different types of user charges.   
 
Following a “Three Payment Reform” in 2012, Puig-Junoy et al (2014) analysed 
prescription claims from NHS data between January and July 2013 to estimate the 
impact of the co-payment change on the number of prescriptions dispensed in the 17 
regions in Spain. The first co-payment reform involved a national co-insurance rate of 
10% with a monthly income-related maximum (€8, €18 or €60 maximum). Secondly, 
two regions; Cataluña and Madrid introduced a €1 co-payment per prescription (€61 
annual maximum) and finally, the third national reform involved delisting of some 
prescriptions which treat minor symptoms (100% coinsurance) (Puig-Junoy et al., 
2014). One region (Pais Vasco) did not introduce the national co-insurance reform 
until 1 year later. According to descriptive statistics, there was an anticipation effect 
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(stockpiling) in all three regions prior to the reform.  Following time-series analysis82, 
there was a dramatic change in the number of prescriptions dispensed in July 2012 
immediately following the introduction of the reforms. The highest impact was found 
in Cataluña where the co-payment and co-insurance rate were applied simultaneously. 
There was a 23.7% reduction in the number of prescriptions dispensed after 14 months. 
By contrast, Pais-Vasco did not apply the co-payment until July 2013 and only saw a 
3.8% reduction in prescriptions dispensed in 2013. Examining the regional differences 
on co-payment policies it appears the first euro of cost-sharing largely impacts on 
medication use (Ellis, 2012, Puig-Junoy et al., 2014). The relatively low co-payment 
removes over-consumption associated with the free status. This co-payment was 
universal with an annual limit and was easy to manage (Puig-Junoy et al., 2014).  
 
The decreased adherence reported by Puig-Junoy et al (2014) may be as a result of 
reduced overprescribing on the supply  side or a result of stockpiling. If so, it signifies 
improvement in efficiencies in the health system. Conversely, the decreased adherence 
could also be a negative result as it may be due to some patients not being able to 
access prescription medications because of the cost. 
Despite this limitation, similar to Kephart et al 2007, Reed et al 2008 and Dor and 
Encinosa 2010, Puig-Junoy et al (2014) also report that different forms of cost-sharing 
and their subsequent OOP costs cause different effects on patient behaviour.  
 
The results of the studies included in the previous paragraphs highlight the different 
impacts that different forms of cost-sharing such as co-payments, co-insurance and 
                                                          
82 The authors focus on three areas that represent three “models” of cost-sharing; Cataluña (Regional 
fee of €1 per prescription and national co-insurance rate); Castilla-Leon (national co-insurance only) 
and Pais Vasco (no cost-sharing reform until 1 year later) (Puig-Junoy, 2010).  
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benefit caps have on patient behaviour. All of these regimens reduce prescription drug 
utilization at varying levels with some having a larger impact than others. These effects 
are driven further in conjunction with benefit caps and monthly and/or annual 
maximums. With regard to maximum amounts, a patient who is unlikely to reach this 
amount decreases prescription drug use while a patient who is likely to reach the 
ceiling demands more prescription drugs. As mentioned, patients’ perception of their 
marginal cost influences this behaviour. The result of Kephart et al’s study (2007), 
suggest that in conjunction with national co-payments, higher monthly/annual ceilings 
should be introduced under co-insurance regimens. While co-insurance regimens are 
associated with uncertainty and fluctuating prices, setting a monthly ceiling would put 
an upper limit on this uncertain cost. This cost-sharing combination would reduce 
inequity in user charge policies. It would reduce the inadvertent effects on the 
vulnerable population and patients requiring higher-cost medication.  However, the 
“moral hazard” concern associated with annual maximum co-payments may reduce or 
even increase use of non-essential prescription drugs (Pauly, 2004) so this would need 
to be monitored. Following a recommendation from Kephart et al (2007), this current 
Irish study examines how co-payments with monthly ceilings and monthly deductibles 
impact on patient behaviour for prescription drugs in Ireland.  
 
4.2.3 Financial Burden 
 
A number of studies assess the financial impact that prescription drug user charges 
may have on patient behaviour (Carlson et al., 2006, Kambia-Chopin and Perronnin, 
2013, Piette et al., 2004a, Rahimi et al., 2007, Reed et al., 2008, Schafheutle, 2008, 
Tseng et al., 2004). These studies conclude, that certain patients do find prescription 
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drug user chargers to be a financial burden. This is in particular for patients with lower 
income levels.  In this research, user charges are identified as a financial burden if 
patients report any of the following behaviours; borrowing money to pay for 
medication, going without a necessity to pay for medication and/or increasing credit 
card debt to afford medication (Reed et al., 2008, Tseng et al., 2004).  
 
In the US in 2004, Medicare beneficiaries faced gaps in their prescription drug 
coverage if their total drug costs exceeded $2250. The benefit paid 75% of the drug 
costs and if the beneficiary’s total drug costs exceeded $2250, the patient was left with 
no prescription drug coverage for the rest of the year (Tseng et al., 2004). Using a 
study83 and control group84, Tseng et al (2004) examined strategies adopted by 
beneficiaries due to prescription costs and the subsequent financial burden. The study 
group participants had an average OOP payment of $91 while the control group had 
an average of $72 in the month prior to exceeding the cap. Using a multivariate 
analysis adjusted for demographic and health characteristics, the study found that 62% 
of the Medicare+Choice beneficiaries who exceeded the maximum annual cap, report 
difficulty in affording their prescription medications. The cost of prescriptions 
impacted on both the study and control participants’ ability to undertake regular leisure 
activities (46% vs 34%) or borrowing money to pay for prescription drugs (12% vs 
10%), or both (Tseng et al., 2004). This study found prescription drug costs to act as a 
financial barrier for younger Medicare beneficiaries with lower incomes and poorer 
health.  
 
                                                          
83 Patients who did exceed the maximum amount ($750 or $1200 per year) (see Table 4.1). 
84 Patients who did not exceed the maximum amount ($2000 cap) (see Table 4.1). 
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The difficulty in designing the most efficient user charge policy while protecting 
vulnerable populations from the financial burden of prescription drug costs is 
highlighted by Tseng et al (2004). If benefit caps are lowered, more individuals are 
protected, yet exceeding the cap would then increase the OOP payments which results 
in decreased adherence and increasing the financial burden. Even if generous caps are 
introduced, patients with chronic illnesses who are high users of prescription drugs 
will still have high OOP as they are at a higher risk of exceeding the benefit cap (Tseng 
et al., 2004).  
 
As Medicare+Choice beneficiaries who exceeded their benefit cap were chosen as the 
population by Tseng et al (2004), sample selection may be an issue. It is also 
reasonable to assume that patients who do not exceed the cap may also find medication 
cost to be a financial strain. However, the sample is justified as Tseng et al (2004) note 
that patients with shorter gaps in drug cover will be less likely to reduce medication 
use as a result of cost while the effect on patients with longer gaps in coverage will be 
larger. To avoid this type of sample bias, the Irish study includes all patients subject 
to all types of prescription drug user charges in Ireland regardless of whether they 
exceed monthly ceilings or not. In order to assess their behaviour, the only eligibility 
criteria for the current Irish study is that patients must be over 18 years and must have 
purchased prescription drugs in the past 12 months.  
 
Carlson et al (2006) also investigated the effect of lost prescription drug coverage due 
to the doubling of insurance premiums for patients enrolled in the Oregon Health Plan 
(OHP). Using a uniquely constructed survey, Carlson et al (2006) assessed the impact 
of increased premium on coverage patterns, access to healthcare, utilization and the 
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financial impact. Of the patients who lost coverage, 67% reported that they 
experienced unmet medical need. The principal reason for unmet medical needs was 
cost; 74% of patients with lost or disrupted coverage reported cost as the reason in 
comparison to 52% of patients with stable coverage.  
 
As with previous studies, the self-reported nature of this data is subject to recall bias. 
Carlson et al (2006) acknowledge this and have reduced the risk of recall bias by 
including a 6-month recall period rather than a 12-month period. Despite this, this Irish 
study has a 12-month recall period but will acknowledge the risk of recall bias in the 
interpretation of the results.  
 
Non-response bias is also an issue for this study as the study excluded patients with no 
current address. Consequently, there is an under-reporting of patient behaviour for 
homeless or people in temporary housing (Carlson et al., 2006). In this current 
research, all patients attending the selected GP surgeries are eligible for inclusion. The 
GP surgeries are situated in various locations throughout Cork ensuring a 
representative sample that will capture patient demographic and socio-economic 
variation.  
Also using self-reported data, Reed et al (2008) conclude that cost-sharing can create 
a financial barrier for patients accessing prescription medication. Reed et al (2008) 
assessed the concept of a financial burden by asking patients if the cost of prescription 
drugs caused them to change their behaviour in the any of the following ways; borrow 
money to pay for prescription drugs or forego a necessity in order to pay for medication 
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(Reed et al., 2008). Using a multivariate analysis, it was found that 9.4%85 of patients 
who paid for prescription medication in the past 12 months reported borrowing money 
or going without a necessity in order to pay for their prescription drugs. Patients 
younger than 65 years and with a lower income level were more likely to report a 
financial barrier behaviour.  
 
The study design of this research is unique in that the researchers compared patients’ 
self-reported behaviour and actual drug cost-sharing. The importance of conducting 
this comparison is emphasised by the results. Patients have limited knowledge of their 
actual cost-sharing arrangement which indicates patients need to be made more aware 
and given possible alternative choices. This could be facilitated from the supply-side 
with healthcare providers advising their patients about making the correct choices 
should they financially struggle with the cost of their medications.  
 
Adapting a qualitative approach in the UK, Schafeulte (2008) reports similar findings 
regarding financial burdens. In the UK at the time, patients paid £6.85 (€9.28) per 
prescription item (April 2007).86 Patients with chronic conditions that required regular 
medication who currently pay for prescription medication were chosen as the data 
source for this study. Patients attending 6 GP surgeries in Northwest England were 
approached for inclusion in the study.87 Using semi-structured interviews, patients 
provided their views on the prescription charge in the UK. In general, patients 
                                                          
85 Overall sample size in the study wass 932 of which 848 patients paid for prescription drugs in last 
12 months. . 
86 Patients under 16 years and over 65 years are exempt from these charges, patients on the income 
support and low income scheme and patients with specified chronic conditions such as diabetes are 
also exempt from this charge (Schafheutle, 2008).  
87 Final sample size was 61 patients with chronic conditions; asthma, coronary heart disease and 
hypertension.  
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recognised the necessity for the NHS to charge per prescription medication. They 
acknowledged the concept of moral hazard and how patients place different values on 
their drugs depending on whether they paid for them or not (Schafheutle, 2008). 
However, the patients in the study thought the cost was too high and would act as a 
disincentive for vulnerable patients. They suggested a much lower charge of £1-£2 
would not have the same adverse effect. To reduce the potential financial burden to 
patients in the NHS, the study group suggested the construction of a “formulary” on 
which certain medicines would be exempt from the charge. They were of the opinion 
this would address the inequity that can exist as a result of the prescription charge.  
 
While providing useful insight into patients’ views on the prescription charge in the 
UK, the study is limited as it only includes patients with 1 of 3 chronic conditions and 
patients who had paid for prescription drugs. Patients with other illnesses and non-
users of prescriptions drugs were not included to assess if their views differ from the 
patients included in this study. As the current research aims to assess the impact of 
user charges on patient behaviour, to answer the question effectively it is necessary 
that only patients who actually pay for prescription drugs are the patients included in 
the analysis.  
 
The findings from the previous studies highlight that uninsured and low-income 
patients are more likely to report medication costs as a financial burden. Patients who 
exceed benefit caps or experience increases in cost sharing structures also report 
medication cost as a financial strain. While the user charges discussed in the previous 
paragraphs in the UK and in the US are relatively high, lower user charges do not seem 
to cause financial pressure as found by Chopin and Perronnin (2013) in France.   
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In France, following the introduction of a €0.50 deductible in 2008, Chopin and 
Perronnin (2013) assessed the financial impact of this user charge on patient 
behaviour. Only 12% of the sample88 reported changing their behaviour as a result of 
the user charge. The study found that the higher the income level, the lower the impact 
of the deductible; 14% of patients with an income level below €1,167 per month 
reported a change in consumption behaviour while only 8% of patients with an income 
level equal to or over €1997 per month reported a change in consumption behaviour. 
Using a logistic regression, the significant income effect indicates the introduction of 
the €0.50 deductible does have a negative effect on access to prescription medication. 
While there is a significant relationship, the number of patients who self-reported the 
cost as a financial burden was low, the impact may not be as detrimental as in the UK 
or US where the OOP user charges are higher.  
 
Similar to Carlson et al (2006) and Reed et al (2008), the dependent variable in this 
study is also self-reported providing a summary of the patients’ behaviour. Chopin and 
Perronnin (2013) recommend that the type of drug which is reduced needs to be 
identified. In addition to patients’ self-reporting data, a complementary study using 
prescription claims data should be conducted (Kambia-Chopin and Perronnin, 2013). 
This would capture the direct impact prescription drug user charges have on patient 
behaviour while controlling for actual prescription use. Reed et al (2008) conducted a 
study of this nature where patient behaviour and actual cost-sharing were compared. 
Despite this recommendation, Chopin and Perronnin (2013) recognise it may be 
difficult to find a sufficient control group as non-users of prescription drugs differ 
                                                          
88 Total sample size is 4985. 
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significantly in terms of age, health and prescription drug cover (Kambia-Chopin and 
Perronnin, 2013).  
 
The above studies are a combination of qualitative and quantitative studies revealing 
the financial burden that prescription drug user charges may cause for prescription 
drug users. While patients in the UK support the concept of user charges, they indicate 
that the OOP cost may be too high. These views are supported by patient behaviour in 
the US due to changes in cost-sharing structures which consequently increase the OOP 
cost for patients (Carlson et al., 2006, Reed et al., 2008, Tseng et al., 2004).  These 
findings are further supported in France by Chopin and Perronnin (2013) who reveal 
lower OOP costs have a lesser financial impact than the relatively higher OOP 
payments in the UK and US.  
 
All of the above studies report a strong association between income level and the 
financial burden of prescription drug user charges. As expected, patients with higher 
levels of cost-sharing (generic co-payments) or more complex cost-sharing structures 
such as benefit caps or multi-tiered co-payments, are more likely to report this type of 
behaviour (Reed et al., 2008). This signifies the importance of adopting user charge 
policies which protect vulnerable populations from the financial burden of prescription 
charges while simultaneously controlling pharmaceutical expenditure.  
 
4.2.4 Cost-Coping Strategies 
 
Previous research has identified cost-coping strategies that patients may adopt in order 
to afford and access prescription medication (without reducing adherence or creating 
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a serious financial burden) (Atella et al., 2005, Reed et al., 2008, Schafheutle et al., 
2002, Tseng et al., 2004). If a patient reports changing their behaviour in one or more 
of the following ways, they are said to adopt cost-coping strategies; substituting 
prescription medication for over-the-counter (OTC) remedies, substituting brand name 
to generic drugs, borrowing medication from others, requesting free samples from a 
doctor, purchasing prescription drugs from an on-line pharmacy and/or splitting tablets 
on the advice of the doctor (Reed et al., 2008). 
 
Tseng et al (2004) examined cost-coping strategies adopted by Medicare+Choice 
beneficiaries when they exceeded their annual benefit cap. Study participants were 
more likely than control participants to adopt at least one strategy that reduced 
medication use and consequently medication cost (24% vs 16% respectively). Study 
participants were more likely to switch medications (15% vs 9%), “shop around” in 
pharmacies for lower prices (46% vs 29%) and/or obtain free drug samples (34% vs 
27%) in order to decrease their medication costs. Cost-coping strategies were 
associated with independent risk factors such as younger age, low income and a higher 
number of health problems (Tseng et al., 2004). This research controls for cost-coping 
behaviours such as switching to cheaper generic drugs and requesting free drug 
samples as a result of the various types of prescription drug user charges that exits in 
Ireland.  
 
Tseng et al (2004), emphasise the importance of including a control group when 
assessing patient behaviour. While their study group participants report adopting at 
least one cost-coping strategy, control group participants also report adopting at least 
one cost-coping strategy, albeit at a lower rate (16%). This shows that patients with 
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lower prescription drug costs who consequently do not exceed their benefit caps are 
also likely to adopt cost-coping measures. In Section 4.2.3, Chopin and Perronnin 
(2013) acknowledge the difficulty in sourcing a control group with similar 
demographic and socio-economic characteristics to the study group. Despite this 
difficulty, Tseng et al (2004) succeeded in sourcing a comparable control group. 
However, it appears the importance of a control group depends on the objective of the 
study. For example, the study and control group used by Tseng et al (2004) included 
patients who exceeded their benefit cap and those who did not exceed the cap. Chopin 
and Perronnin (2013) were focused solely on users of prescription drugs and the impact 
of a €0.50 deductible had on patient behaviour. Therefore, including only patients who 
were subject to the deductible would correctly answer the question. Including a control 
group of non-users of prescription drugs would not contribute to the study as non-users 
will have zero drug costs and subsequently will not express a behavioural change as a 
result of cost-sharing.  As the objective of this research is to identify the impact that 
prescription drug user charges have on patient behaviour, the research does not include 
non-users of prescription drugs and only focuses on patients who have paid for 
prescription drugs in the last 12 months.  
 
Using a specifically constructed questionnaire, Atella et al (2005) assessed the impact 
of medication costs on patient behaviour in Italy and the UK. At the time of the study, 
the price variation for prescription drugs in the two countries were as follows; in the 
UK there was a fixed flat rate co-payment of £6 (€9.80) per prescription item while in 
Italy there were 3 reimbursement groups.  Class A provided drugs for severe and 
chronic illnesses at a fixed co-payment charge of €1.70, Class B provided non-essential 
but useful drugs for 50% of the retail price while Class C provided all other drugs 
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which were fully paid for by the patient. In this study, cost-reducing strategies were 
grouped into (i) patient-initiated and (ii) self-medication along with OTC products 
(Atella et al., 2005).  
 
Following econometric analysis, the study found strong tendencies in both countries 
for patients to adopt cost-coping strategies.  With regard to patient-initiated strategies, 
the influence of patient affordability is much stronger in the UK than in Italy. As 
suggested by Atella et al (2005), the reason for this discrepancy may be due to the 
difference in the level of prescription charges in the UK and Italy. As mentioned, the 
user charge for prescription drugs in the UK is much higher at £6 per prescription item 
than it is in Italy (€1.7089). Similar deductions can be made for the self-medication 
strategies. In Italy, because prescription drugs have a relatively low charge, €1.70, the 
most common patient strategy is to purchase prescription drugs because OTC drugs 
are more expensive. On the contrary, in the UK, patients consider OTC drugs first as 
they are cheaper than the relatively higher prescription charge (£6 per prescription 
item).  
 
The results of this study indicate the various cost-reducing measures adopted by 
patients and reveal patients to be cost-conscious regarding the employment of different 
strategies. Atella et al (2005) acknowledge the different strategies adopted by patients 
depend on the options available with the healthcare systems and their reimbursement 
methods. The study concludes that self-medication strategies involving the switch to 
OTC medications may be an affordable option in countries like the UK where the 
prescription charge is relatively high (Atella et al., 2005).  
                                                          
89 Class A drugs are the most commonly prescribed drugs and patients pay a €1.70 fixed co-payment. 
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In Ireland, self-medication strategies may differ between GMS and DPS patients due 
to the co-payment and deductible user charge policies they respectively face. As stated 
in Section 4.1.1, GMS patients pay €2.50 per prescription item while DPS patients 
must pay up to €144 in each calendar month before the State will cover any of their 
drug cost in that calendar month. In the case of self-medication, OTC substitution for 
GMS patients is likely be more expensive than the €2.50 co-payment they pay per 
prescription item. Conversely, OTC substitution for DPS patients may be a cheaper 
option depending on the patient’s drug consumption that month. As stated by Kephart 
et al (2007) the closer the patient is to reaching the maximum amount, the less likely 
they are to reduce medication use. If the patient is likely to reach the €144 in a calendar 
month, the patient is likely to purchase a prescription drug instead of an OTC 
medication in order to reach the maximum, after which, drugs are covered by the HSE.  
 
The final study assessing cost-reducing strategies was conducted by Reed et al (2008) 
in the US. They asked patients to report if they had engaged in at least one of eight 
different types of cost-reducing behaviours (listed in the introductory paragraph to this 
section). Using multivariate logistic analysis, 19.1% of patients90 who paid for 
prescription drugs in the last two months reported that the cost of their medication 
caused them to do at least one of the eight cost-coping behaviours. The generic co-
payment and the brand/generic co-payment difference were found to be significantly 
associated with the cost-coping behaviours.   
 
                                                          
90 Overall sample size in the study wass 932 of which 848 patients paid for prescription drugs in last 
12 months. . 
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Again, this finding highlights that different OOP payments resulting from user charge 
policies influence patient behaviour in different ways.  The results of this study may 
be underestimated due to the data source of the participants. Adults in a large prepaid 
integrated delivery system (IDS) form the sample for this research. In this system, 
there are high levels of care coordination and low levels of brand-name drug use (Reed 
et al., 2008). Consequently, the cost-sharing in this system may be less complex than 
other available plans such as benefit caps, deductibles and multi-tiered plans. If the 
level of cost-sharing was higher, patients may engage in other cost-coping behaviours 
than observed in this study.  
 
The data source for the current Irish study will not be restricted to a particular group 
as done by Reed et al (2008). Patients with different cost-sharing structures in Ireland 
are included in the study. This will allow for the assessment of cost-coping strategies 
for all user charge policies in Ireland.   
The studies included in this section imply that patients adopt cost-coping strategies in 
an attempt to access and afford prescription drugs. Patients undertake these strategies 
without reducing adherence or creating a serious financial burden (Atella et al., 2005, 
Reed et al., 2008, Schafheutle et al., 2002, Tseng et al., 2004). It is apparent that the 
various cost-coping behaviours adopted by prescription drug users are influenced by 
the alternatives that are available in healthcare systems (Atella et al., 2005).  
 
4.2.5 Conclusion 
 
The articles reviewed in Sections 4.2.2 to 4.2.4 reveal different user charge policies 
through the use of co-payments, coinsurance, deductibles and/or benefit caps result in 
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patients engaging in decreased adherence to medication, financial burden or cost-
coping strategies. The findings of these studies were relatively consistent with respect 
to the study design used; cross-sectional with regression-based analysis, qualitative 
studies using semi-structured interviews or time-series analysis (Atella et al., 2005, 
Dor and Encinosa, 2010, Gilman and Kautter, 2008, Kambia-Chopin and Perronnin, 
2013, Puig-Junoy et al., 2014, Schafheutle et al., 2002). While the types of cost-sharing 
and the data sources varied, the review reveals a strong relationship between user 
charges and patient behaviour. Overall, the study findings are consistent with the 
prediction of economic theory that the larger the proportion of income spent of 
prescription medication, the higher the degree of patient response.  
 
As noted from the sections in this review, the data sources for these studies are either 
secondary sources from claims databases (Dor and Encinosa, 2010, Gilman and 
Kautter, 2008, Kephart et al., 2007, Mojtabai and Olfson, 2003, Puig-Junoy et al., 
2014) or self-reported primary data which come directly from the patient (Piette et al., 
2004a, Piette et al., 2004b, Reed et al., 2008, Schafheutle et al., 2002, Steinman et al., 
2001, Tseng et al., 2004). The reliability of secondary data to examine the impact of 
prescription drug user charges on patient behaviour is questionable.  While claims 
databases provide reliable statistics on the number of prescriptions dispensed, this 
source does not effectively measure patients’ response to the user charge. To measure 
decreased adherence as a result of cost-sharing, patients subject to the user charge need 
to be asked if they have reduced medication as a result of the cost. It is acknowledged 
that this methodology may not be followed in studies utilizing claims data as the 
studies may be focused solely on the number of prescription items used. While a 
reduction in the number of prescription items that are dispensed might indicate patient 
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response, it is less clear than with self-reported information which can assess if the 
reduction is as a result of the cost. As this paper focuses on the impact of prescription 
drug user charges on patient behaviour, self-reported primary data will be collected 
directly from patients’ subject to some form of cost-sharing in the previous 12 months.  
The existence of user charge policies is dependent on the over consumption or under 
consumption of prescription drugs. If over consumption is the cause for intervention, 
cost-sharing could be used as a strategy to curb this over consumption. This will only 
be successful if healthcare professionals provide patients with sufficient information 
regarding the risks and benefits of medication. It is important to note that patient 
behaviour does not signify whether patients can successfully differentiate between 
over consumption, under consumption or appropriate consumption (Gibson et al., 
2005). This behaviour needs to be monitored to maintain patient accessibility to 
prescription drugs.  
 
The most obvious finding from this review is that user charges shift a proportion of 
the cost to the patient. As cost-sharing structures become more complex, concerns 
regarding affordability and accessibility emerge. Empirical research indicates that 
patients’ response to cost-sharing is not identical depending on the nature of the user 
charge. Patients respond differently to the various forms of user charges such as; fixed 
co-payments, co-insurance, deductibles and/or benefit caps (Dor and Encinosa, 2010, 
Hurley and Johnson, 1991). Therefore, this research assesses the impact of prescription 
drug user charges on patient behaviour by including patients subject to all types of user 
charge strategies in Ireland; GMS patients subject to a fixed co-payment per item, DPS 
patients subject to a monthly deductible and patients who have no form of community 
drug cover and must pay the full cost for prescription drugs.  
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Section 4.3 presents the methodology that was employed to investigate patient 
response to prescription drug user charges in Ireland. 
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4.3 Methodology 
 
4.3.1 Introduction  
 
This section presents the methodology used to answer the research question; 
 
What impact have prescription drug user charges had on patient behaviour in Ireland? 
 
A cross-sectional questionnaire was designed to collect primary data from patients 
attending selected GP surgeries in Cork to assess the impact that prescription drug user 
charges have on patient behaviour in Ireland. Section 4.3.2 describes the location of 
the data collection. Section 4.3.3 describes the data source. Section 4.3.4 explains data 
collection procedure. Section 4.3.5 describes the questionnaire construction.91. Finally, 
Section 4.3.6 will present the descriptive statistics on the population sample.  
 
4.3.2 Location of Data Collection  
 
As the principle aim of this chapter is to identify the impact of prescription drug user 
charges on patient behaviour in Ireland, patients subject to these user charges are the 
main focus of this sample. Patients attending six selected GP surgeries in Cork formed 
the data source (see Table 4.2).  
                                                          
91 The questionnaire instrument constructed for this chapter is modelled on a questionnaire used by 
Reed et al (2008) in the US to assess patients’ response to prescription drug cost-sharing.  
161 
 
Initially the questionnaires were to be distributed in pharmacies throughout Cork as 
patients waited for their prescriptions to be dispensed. However, the length of the 
questionnaire would be an issue as the patient may decide to leave the pharmacy while 
their prescription is prepared. GP waiting rooms were identified as an appropriate 
location as patients have no choice but to wait for their consultation, therefore, having 
more time to complete the questionnaire.92 GPs in Ireland treat all patients regardless 
of health cover therefore patient subject to all forms of prescription drug user charges; 
GMS patients, DPS patients, LTI patients and patients without any form of community 
drug cover would be included in the sample. As the research aims to identify the impact 
of prescription drug user charges on patients with all types of cover and consequently 
various types of user charges, the suitability of GP surgeries is further emphasised as 
the data collection location. In addition, previous research has found this healthcare 
location to be conducive to the generation of a high response rate using self-completion 
questionnaires (Bell and Szafran, 1992). 
 
4.3.3 Data Source 
 
Access to the GP clinics was an on-going process (Marshall and Rossman, 2010, 
Robson, 2011). Initial contact was made with a practising doctor in Ballincollig, Co. 
Cork, Dr. Eamonn O’Grady.93 Liaising with Dr. O’Grady, a list of ten GP surgeries in 
Cork was generated as possible locations for data collection. The ten surgeries are 
located in the HSE regions. There are currently 2,500 GPs in Ireland (HSE, 2013c) 
                                                          
92 The questionnaire also collected data for the next chapter in this thesis, “What are Irish patients willing 
to pay for health services in Ireland?” This added to the length of the questionnaire and it was 
important respondents would have sufficient time to complete the entire questionnaire.  
93 Dr. Eamonn O’Grady became the supporting GP for the data collection process.  
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and 394 practising in Cork (PCRS, 2013).94 Ten GP surgeries were chosen due to time 
and financial constraints. Consequently, a convenient, non-probability sample forms 
the sample for this research. While the fast and inexpensive nature of this method of 
sampling is an advantage there is the inherent bias that a convenience sample may not 
be representative of the study population (Gravetter and Forzano, 2012). This research 
attempts to reduce this bias by including at least one GP surgery from each of the four 
Local Health Offices (LHO) in the Cork HSE region; North Cork, West Cork, Cork 
South Lee and Cork North Lee (see Table 4.2). Table 4.2 shows three surgeries 
included in the sample are found in the Cork South Lee region while there is only one 
GP representation of Cork South Lee. However, Cork South Lee is the largest LHO in 
Cork with 156 GPs (PCRS, 2013), therefore, it was important for the sample to 
sufficiently represent this area. Representation bias was further reduced as GPs in 
Ireland treat all patients. Consequently, including patient from all four LHO regions in 
Cork controls for varying patient demographics and socio-economic characteristics.  
 
The contact process involved a phone call to each surgery to introduce the researcher 
and the research and request the questionnaire to be distributed in that surgery. 
Following a request for the surgery’s email address and with permission from the 
administration staff, a follow-up email was sent to each surgery with a cover letter 
from the supporting GP (see Appendix B.1) and a copy of the questionnaire (see 
Appendix B.2).  Of the ten surgeries contacted, six of the surgeries agreed to the 
distribution of the questionnaire to patients in their waiting rooms (see Table 4.2).95 
                                                          
94 This figure is a combination of the number of GPs in Cork South Lee (156 GPs), Cork North-Lee 
(130), North Cork (62) and West Cork (46) (PCRS, 2013).  
95 The overall excuse for refusal was concerns regarding patient confidentiality and fears that patients 
may feel uncomfortable disclosing information required in the questionnaire such as; income level.  
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Following best practice, this approach was adopted as recommended by Saunder, 
Lewis and Thornhill (2009).  
 
The Social Research Ethical Committee (SREC) in University College Cork approved 
the research protocol and questionnaire (see Appendix B.3).  
 
Table 4.2 General Practitioner List 
Surgery 
Number 
Contact Doctor Surgery 
Name 
Address Local Health Office 
1 Dr. Gerard 
O’Shaughnessy 
Skibbereen 
Medical 
Centre 
Market Street, 
Skibbereen, 
Cork. 
West Cork 
2 Dr. Denis 
Twomey 
Classes Lake 
Medical 
Centre 
Classes Lake, 
Ballincollig, 
Cork. 
Cork South Lee 
 
3 Dr. Tom English Broad lane 
Family 
Practice 
72 Great 
William 
O’Brien Street 
Cork North Lee 
4 Dr. Eamonn 
O’Grady 
The Clinic* Old Quarter 
Ballincollig, 
Cork 
Cork South Lee 
5 Dr Eamonn 
O’Grady  
Barnagore* Ovens, Co. 
Cork 
Cork South Lee 
6 Dr. Brendan 
Payne 
High Street 
Medical 
Centre 
High Street, 
Newmarket, 
Co. Cork  
North Cork 
*The data collected from The Clinic and Barnagore practices were merged together by 
the administration staff as the same contact doctor was located in both.  
Source: Authors Own 
 
4.3.4 Data Collection Procedure 
 
Questionnaire distribution began in December 2014 and finished at the end of January 
2015. Due to the convenient nature of the sample and based on previous literature, 300 
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patients were sampled. Questionnaires were randomly distributed by the 
administration staff to patients over 18 years of age as they entered each of the six 
surgeries. Administration staff were given a brief to deliver to the potential 
respondents (see Appendix B.4). In this brief, potential respondents were informed 
that this questionnaire was part of a research project in University College Cork and 
they were assured anonymity. The respondents were advised to complete the 
questionnaire as they waited for their consultation with the doctor. The patient was 
then invited to return the completed questionnaire to a clearly labelled box provided at 
reception. On average, questionnaires were distributed by the administration staff in 
each surgery for four weeks during this two-month period. These two months were 
chosen for data collection as December and January are two of the busiest months in 
a GP practice (according to expert opinion). These busy periods would allow for a 
larger sample size within this short timeframe.  
 
It is important to note that face-to-face interviews were another consideration for data 
collection but this method was not conducive to generating a large sample size and 
proved to be more time-consuming in the pilot study.  
 
Due to the nature of the data collection method, the study acknowledges the risk of 
sample selection bias and recall bias. However, due to the research question, it was 
necessary to use the specially constructed questionnaire to collect the data directly 
from patients who may be subject to prescription drug user charges. While all attempts 
have been made during the construction of the questionnaire and its distribution to 
reduce sample selection and recall bias, the research acknowledges this risk in the 
interpretation of the research results.  
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4.3.5 Questionnaire Construction 
 
This section describes the construction of the questionnaire that was designed to collect 
the primary data for this research.   
 
Comparable to previous research, self-reported data is collected from patients subject 
to prescription drug user charges (Atella et al., 2005, Costa-Font et al., 2007, Doran et 
al., 2005, Kambia-Chopin and Perronnin, 2013, Mojtabai and Olfson, 2003, Piette et 
al., 2004a, Piette et al., 2004b, Rahimi et al., 2007, Schafheutle, 2008, Schafheutle et 
al., 2002, Sinnott et al., 2013, Steinman et al., 2001, Tseng et al., 2004). While all of 
these studies collect self-reported data, the data collection method varies between self-
completion questionnaires, interviews and focus groups. As this research follows the 
methodology outlined by Reed et al (2008), a self-completion questionnaire is 
implemented to collect the primary data for the current Irish research (see Appendix 
B.2). 96 
 
When deciding on the data collection instrument, it was important to acknowledge the 
sample source in order to ensure a reliable sample and ensure minimum disruption to 
the services in the GP waiting room. Interviews with patients were not deemed 
appropriate due to the enclosed nature of GP waiting rooms. Patient confidentiality 
would be at risk in this situation. Therefore, a self-completion questionnaire was most 
appropriate to answer the research question accurately. This methodology allowed for 
efficient data collection from a large group of respondents.  
                                                          
96 As mentioned in section 4.3.1, this questionnaire was also used to collect the dataset for the next 
chapter in this thesis. Pages 1-3 in Appendix B.2 are the relevant pages for the questionnaire used to 
collect the dataset for this chapter.  
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As the same information was required from all patients in the six surgeries, a 
standardized self-completion questionnaire was suitable. The self-completion 
questionnaire also ensured anonymity for the patient as possible reactive effects of 
direct contact between the researcher and respondent were eliminated (Sim and 
Wright, 2000). However, this eliminated the possibility to explore questions in depth 
or seek clarification from the respondent (Sim and Wright, 2000). Due to the factual 
nature of the answers required this concern was overcome due to a well-constructed 
standardized questionnaire including pre-determined responses generated from the 
literature review, with a particular focus on Reed et al (2008), and discussions with 
the supporting GP. Further clarification from the respondent was not necessary. 
Another disadvantage associated with this methodology is that there is no guarantee 
the respondent will answer the questionnaire as anticipated by the researcher i.e. at the 
correct time or in the correct order (Sim and Wright, 2000). This was controlled using 
clearly labelled instructions and questions throughout the questionnaire.  
 
To achieve reliable results, the questionnaire was easy-to-follow and used clear 
direction and instructions. This was accomplished using factual questions for the 
majority of the questionnaire. The reliability of the questionnaire was tested by 
conducting a pilot study (1st and 2nd July 2014). The pilot study was conducted in two 
surgeries; The Clinic and Classes Lake Medical Centre where 10 surveys were 
distributed and collected in each surgery.  
Assessing the validity of the questionnaire proved to be more difficult as validity is 
usually established after the event (Oppenheim, 1992).  Cross-checking may have been 
a possibility using patients’ corresponding prescription drug claims or pharmacy 
dispensing data. The Primary Care Reimbursement Scheme (PCRS) collects 
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prescription drug claims for the community drug schemes in Ireland. However, the 
aim of the current Irish study is to collect primary data from the patients’ perspective 
and utilising a secondary source such as the PCRS would not capture this objective. 
Therefore, the pilot study tested the reliability and validity of the survey instrument.  
 
To maintain costs, each questionnaire was printed in black and white and printed back-
to-back. This resulted in three pages in total. It was acknowledged that shorter 
questionnaires with concise completion time encourage a higher response and this was 
taken into consideration in the questionnaire design process (Dillman, 2000). This was 
important as the patient was completing the questionnaire in the GP waiting room and 
it was the researcher’s aim that patients would complete and submit the questionnaire 
before their consultation. This reduced the risk of incomplete and/or mislaid 
questionnaires.  
 
Each questionnaire included an introduction to inform potential respondents of the 
questionnaire’s aims and why this area of research was chosen. In addition, they were 
informed why they were chosen as a suitable candidate. Once they agreed to take part, 
they were asked to indicate this on the attached consent form.  
 
The questionnaire required information regarding community drug cover, PHI cover 
and patients’ income level. Due to the confidential nature of this information, it was 
assured that this information would not be disclosed to anyone. To ensure anonymity, 
the respondents’ name was not required on the questionnaire. Respondents are more 
willing to provide information if they know the questionnaire is anonymous (Babbie, 
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2009). The potential respondent was advised that participation was voluntary and they 
could leave the questionnaire at any stage.  
 
Due to the nature of the data collection instrument, a debriefing process was not 
necessary. However, if the respondent had questions regarding the questionnaire 
(before/after completion) they could consult a list of FAQs, which were available at 
the reception of the surgery (see Appendix B.5).  
 
In the questionnaire itself, there are three sections in total. The questionnaire adopted 
a funnel approach i.e. it began with broad demographic questions such as the 
respondent’s age and gender, socio-economic variables such as education, nationality 
and healthcare cover. The questions then narrowed down to measure the variable 
categories assessing patient behaviour in response to prescription drug user charges.  
 
The next paragraphs discuss the three sections included in the questionnaire to identify 
and justify the nature of the variables included in each section.  
 
 Section 1 of the questionnaire explored patient demographics, community drug cover, 
PHI cover, health status and number of chronic illnesses. This section included 
nominal, continuous and categorical variables.  
 
Section 2 of the questionnaire measures the dependent variable which assesses 
patients’ behavioural response to prescription drug user charges. Following Reed et al 
(2008), the research categorises the different types of behavioural response. The 
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dependent variable measures decreased adherence by asking patients to indicate if they 
have engaged in any of the following behaviours; 
 
 Taking less of a prescription drug (skipping or decreasing dose) to make it last 
longer without the advice of their doctor. 
 Not filling a prescription for a new medication. 
 Not filling a prescription for existing medication. 
 
The dependent variable also measures three types of financial burden behaviours by 
asking patients if the cost of their prescription drugs caused them to engage in any of 
the following behaviours; 
 
 Borrowing money from friends or family to pay for medication. 
 Spending less on food/heat or other basic needs to pay for medication. 
 Increasing credit card debt to pay for medication. 
 
Finally, the dependent variables assessed strategies patients may use to obtain their 
prescriptions in response to the user charge (without necessarily reducing adherence 
or creating a serious financial burden). Participants were asked to report any of the 
following other cost-coping behaviours; 
 
 Using cheaper OTC drugs before purchasing prescription drugs. 
 Switching to cheaper drugs such as generic drugs. 
 Requesting free medication samples from the GP. 
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 Purchasing drugs from an on-line pharmacy.97 
 
Section 3 measured the gross monthly income level of the respondent. To minimise 
non-response for this variable, respondents were presented with an interval scale 
including six ranges. 
 
The majority of the questions that appeared in the questionnaire are closed-ended. This 
research is of a quantitative nature, therefore, valid and reliable results were required. 
Closed-ended questions were chosen as they are less time-consuming and concise 
given the time constraints placed on the patients (Oppenheim, 1992). Consequently, 
closed-ended questions are associated with a high response rate (Dillman, 2000). This 
permitted easier interpretation and coding of the data. The codebook can be found in 
Appendix B.6.  
 
4.3.6 Descriptive Statistics 
 
 Initially, 220 questionnaires were collected out of 300 questionnaires Seven 
questionnaires were excluded from the analysis as they were incomplete 
questionnaires. This resulted in a total of 213 respondents with a response rate of 71%. 
The collected data was analysed using STATA 14. The following sections present 
patient demographics, socio-economic characteristics and prescription drug cost 
sharing and patient response to prescription drug user charges.  
                                                          
97 The following section provides descriptive statistics for all of the behavioural responses listed above 
and provides a breakdown of the patient behaviour by community drug cover. However, it is important 
to note the dependent variable is recoded for econometric analysis to create a categorical variable with 
4 mutually exclusive categories. This is discussed further in Section 4.4.2.     
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4.3.6.1 Patient Demographics 
 
Table 4.3 shows the sample is predominantly female (68%) and Irish (95%).98 The 
average age of respondents is 46 years.99 Half of this sample (50%) report a health 
status between good, fair and poor health. As the patients in the sample are waiting to 
see their GP, it is presumed they are sick. This will influence their self-reported health 
status.  Corresponding to the self-reported health status statistics, just over half of the 
sample report having at least one chronic illness (52%). This is an important measure 
of demographics as it will test whether the findings of the current Irish research support 
that of previous research which suggest vulnerable patients are adversely affected by 
prescription drug user charges.   
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
98 The gender composition of this sample is slightly different from the national statistic where there is a 
broadly equal prevalence of males and females (CSO. 2014b).. The location of the data collection for 
this research may be the cause for the over-representation of females in this sample as females are 
higher users of GP services (Nolan and Smith, 2012). The nationality of this sample is representative 
of the national average where the majority of the population is Irish (87%) (CSO. 2014c). 
99 This is slightly higher than the national median age in Ireland (36.1 years) (CSO. 2014a)..  
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Table 4.3 Patient Demographics 
 
      Surveyed Patients 
      N = 213    % 
Gender 
Male     66    (30.99) 
Female     145    (68.08) 
Missing     2    (0.94) 
Total     213    (100) 
Age   
 Mean     45.77 
 Range     19-84 
 Nationality 
 Irish      203    (95.31) 
 UK     6    (2.82) 
 Other     3    (1.41) 
 Missing      1    (0.47) 
 Total     213    (100) 
Marital Status 
 Single      54    (25.35) 
 Married     138    (64.79) 
 Separated    3    (1.41) 
 Divorced    8    (3.76) 
 Widowed    10    (4.69) 
 Total     213    (100) 
  Health Status 
 Excellent    27    (12.68) 
 Very good    79    (37.09) 
 Good     76    (35.68) 
 Fair     24    (11.27) 
 Poor     7    (3.29) 
 Total     213    (100) 
Number of Chronic Illnesses 
 No chronic illness   102    (47.89) 
 1 chronic illness    62    (29.11)  
 2 chronic illnesses   31    (14.55) 
 3 or more chronic illnesses  18    (8.45) 
 Total     213    (100) 
 Reason for Visit  
 Minor illness    83    (38.97) 
 Repeat prescription   22    (10.33) 
 Routine check-up    27    (12.68) 
 Chronic illness follow-up   10    (4.69) 
 Doctors certificate   3    (1.41) 
 Accompanying child   27    (12.68) 
 Maternity check-up   8    (3.76) 
 Other      13    (6.10) 
 More than 1 reason   18    (8.45) 
 Missing     2    (0.94) 
_________________________________________________________________________________ 
 Total     213    (100) 
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4.3.6.2 Socio-Economic Characteristics 
 
In Table 4.4, at least 51% of the sample have an individual gross monthly income level 
below the national average100 while 59% of sample report a third level education and 
nearly two-thirds of the sample have PHI (64%).  
 
The following descriptive statistics will describe the prescription drug cover that exists 
within this sample. It is important to distinguish between the various drug schemes in 
the sample as each scheme imposes a different type of user charge for patients. Under 
the GMS scheme, as described in Section 4.1.1, the patient must pay a flat co-payment 
of €2.50 on each prescription item subject to a monthly ceiling of €25 per family per 
calendar month. Under the DPS, a family or individual pays a monthly deductible of 
€144 per calendar month. After they reach this ceiling, the cost of prescription drugs 
is covered by the HSE. Under the LTI, there is no form of cost-sharing for the patient 
for prescription drugs that treat the long-term illness. However, the patient may face 
an OOP cost should they be prescribed a prescription drug that is not related to their 
LTI. Finally, patients may have no form of community cover and must pay the full 
cost of their medication. To examine the impact of user charges, it is important to 
acknowledge the type of user charge the patient must pay (Hurley and Johnson, 1991).  
 
In Table 4.4, 35% of the sample possess a medical card. An identical proportion hold 
a DPS card (35%) while 14% of the sample have an LTI book. 101 In the sample, 33% 
                                                          
100 Average gross monthly income level in Ireland is €3,023 (CSO. 2015).  
101 With regard to GMS and DPS, these figures are representative of the national average where 40% 
of the population have a GMS card and 31% have a DPS card. The LTI coverage in the sample 
population is much higher than the national average where almost 2% of the population have an LTI 
card.  
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have no form of community drug cover. The mixture of prescription drug cover in this 
sample will accurately identify patient response to the different types of prescription 
drug user charges that exist in Ireland; fixed co-payments, deductibles and full OOP 
costs.   
 
Table 4.4 Socio-Economic Characteristics 
 
      Surveyed Patients  
      N = 213    % 
Education 
 Primary     13    (6.10) 
 Secondary    71    (33.33) 
 Third level    125    (58.69) 
 Other     3    (1.41) 
 Missing     1    (0.47) 
 Total     213    (100) 
Income (monthly) 
 <€1,000     46    (21.60) 
 €1,000 - €2,249    62    (29.11) 
 €2,250 - € 3,499    34    (15.96) 
 €3,500 - €4,749    22    (10.33) 
 €4,750 - €5,999    11    (5.16) 
 €6,000+     15    (7.04) 
 Other102     9    (4.23) 
 Missing      14    (6.57) 
 Total     213    (100) 
Private health insurance   
 Yes     137    (64.32) 
 No     76    (35.68) 
 Total     213    (100) 
Community Drug Cover 
 GMS     74    (34.74) 
 DPS     74    (34.74) 
 LTI     30    (14.08) 
No community cover    71    (33.33) 
_________________________________________________________________________________ 
 Total     249103 
                                                          
102 When reporting gross monthly income (Question 19), patients were given the opportunity to tick an 
“other” category if their monthly income level was not listed. Patients who chose this category were 
asked to state what their monthly income was. The responses from the 9 respondents included; student 
income, semi-retired, old age pension and unemployed.  
 
103 As seen in Table 4.4, the total figures (249) under community drug cover are higher than the 
sample size (213). This is due to patients in the sample having more than one form of community 
drug cover. A patient with an LTI book may apply for a DPS and/or a medical card should they be 
eligible. In this case, it most commonly occurs when a prescription drug unrelated to the long-term 
illness is prescribed to the patient. This drug will not be covered under the LTI scheme therefore the 
patient will need to pay the full cost of the medication. People should not have both GMS and DPS 
cover in Ireland but there are some exceptions. Due to the rare circumstances where patients have 
more than one form of cover, this is not accounted for in the analysis in this section but it is noted. 
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4.3.6.3 Prescription Drug Cost Sharing and Patient Response 
 
Of the 213 patients included in this sample, 160 patients (75%) paid for prescription 
drugs in the past 12 months. As the aim of the research question is to assess the impact 
prescription drug user charges have on patient behaviour in Ireland, the descriptive 
statistics for the following sections will only include patients who have paid for 
prescription drugs in the past 12 months.104 Consequently, the sample size is now 160 
(as shown in Table 4.5). Within the sample, 36 medical card patients, 66 DPS patients 
and 24 LTI patients paid for prescription drugs in the past 12 months while 58 patients 
without community drug cover paid for prescription drugs in the last 12 months. The 
following statistics provide a general overview of patient response to prescription drug 
user charges which include patient response to co-payments, deductibles and full OOP 
user charges.  
 
As described in Section 4.3.4 and shown in Table 4.5, patients were asked about three 
decreased adherence behaviours which assess if the patient did not take all of their 
medication as a result of the cost. Of the patients who reported paying for prescription 
drugs in the past 12 months, 12% reported taking less of a prescription drug (skipping 
or decreasing dose) to make it last longer without advice from the doctor, 6% reported 
not filling a prescription for new medication while 8% reported not filling a 
prescription for an existing medication. 
 
                                                          
 
104 This is except for Table 4.6 which presents patients’ prescription drug user charges. It was 
necessary to include the entire dataset in this table in order to present the particular descriptive 
statistics accurately.  
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Patients were also asked if the amount they paid for prescription drugs caused a 
financial burden. Of the 160 patients who paid for prescription drugs in the last 12 
months, 13% reported borrowing money from friends or family to pay for medication. 
14% spent less on food/heat or other basic needs to pay for their prescription while 7% 
increased credit card debt to pay for their prescription drugs.  
 
Patients were also asked to report if they engaged in any cost-coping behaviours 
(behaviours that didn’t necessarily involve reducing their adherence or creating a 
serious financial burden). Of the 160 patients who paid for prescription drugs in the 
last 12 months, 18% reported using cheaper OTC drugs before purchasing prescription 
drugs while 31% reported switching to cheaper generic drugs. Only 1% reported 
requesting free medication samples from their GP and only 1 patient reported 
purchasing drugs from an online pharmacy.  
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Table 4.5 Self-Reported Behavioural Responses to Cost-Sharing 
      Surveyed Patients 
      n = 160    % 
DECREASED ADHERENCE: 
Took less than prescribed 
              Yes     20    (12.50) 
              No     135    (84.38) 
              Missing      5    (3.13) 
 Total     160    (100) 
Stopped refilling a prescription 
 Yes     12    (7.50) 
              No     140    (87.50) 
              Missing      8    (5.00) 
 Total     160    (100) 
Did not fill a new prescription 
 Yes     10    (6.25) 
              No     142    (88.75) 
              Missing      8    (5.00) 
 Total     160    (100) 
FINANCIAL BURDEN: 
Spend less on other necessities 
  Yes     22    (13.75) 
              No     131    (81.88) 
              Missing      7    (4.38) 
 Total     160    (100) 
Borrow € to pay for meds 
 Yes     21    (13.13) 
              No     134    (83.75) 
              Missing      5    (3.13) 
 Total     160    (100) 
Increase credit card debt to pay for meds 
  Yes     11    (6.88) 
              No     143    (89.38) 
              Missing      6    (3.75) 
 Total     160    (100) 
COST-COPING BEHAVIOURS 
Switched to generic brand 
 Yes     50    (31.25) 
              No     106    (66.25) 
              Missing      4    (2.50) 
 Total     160    (100) 
  Used OTC medication first 
 Yes     28    (17.50) 
              No     126    (78.75) 
              Missing      6    (3.75) 
 Total     160    (100) 
Requested free GP samples    
Yes     2    (1.25) 
              No     151    (94.38) 
              Missing      7    (4.38) 
 Total     160    (100) 
Purchase meds from online pharmacy 
   Yes     1    (0.63) 
              No     152    (95.00) 
              Missing      7    (4.38) 
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_________________________________________________________________________________
Total     160    (100)  
 
The next section will initially present patient user charges and patient response to 
prescription drug user charges by community drug cover (GMS, DPS and LTI) and 
without community drug cover. This structure is followed as it allows for a precise 
assessment of patients’ response to the various levels of prescription drug user charges 
that exist in Ireland; co-payments, deductibles, and full OOP costs on patients’ 
behaviour for prescription drugs. Previous literature also highlights the importance of 
acknowledging the type of cost-share when examining its impact (Hurley and Johnson, 
1991).  
 
4.3.6.3.1 General Medical Services (GMS) Scheme 
 
As mentioned, GMS patients pay a flat co-payment of €2.50 per prescription item 
subject to a monthly ceiling of €25 per family. Before reaching the monthly maximum, 
a GMS patient can be certain that every prescription item they purchase will cost them 
€2.50. In this sample, the average monthly cost paid for prescription drugs under the 
GMS scheme was €3.76 (see Table 4.6). This indicates that GMS patients in this 
sample pay for between one to two prescription items per month on average.105 As 
GMS cards are granted primarily on an income basis and previous research has shown 
prescription drug user charges to be regressive (Adams et al., 2001, Contoyannis et al., 
2005, Gibson et al., 2005b, Lexchin and Grootendorst, 2004, Smith and Kirking, 1992) 
                                                          
105 The latest figures (2013) from the PCRS report 3.09 items as the average number of items per 
GMS form. While this research reports a lower number of items, the increase in the co-payment 
from €1.50 in 2012 to €2.50 in 2015 may be reason for the reduction in the number of GMS items 
(PCRS 2013).  
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it was important to analyse GMS patients’ response to prescription drug co-payments 
in Ireland.  
 
 With regard to decreased adherence, as shown in Table 4.7, 28% of medical card 
patients who paid for prescription drugs in the past 12 months reported decreasing their 
prescription dose without the advice of their GP, 8% reported not filling a new 
prescription while 11% reported not filling an old prescription. GMS patients also 
reported prescription costs causing a financial burden. Of the sample, 22% reported 
borrowing money to pay for prescription medications, 28% reported spending less on 
other basic necessities while 11% reported increasing credit card debt to pay for their 
prescription drugs. GMS patients also reported engaging in two cost coping behaviours 
as a result of their prescription drug costs; 19% reported substituting their prescription 
drugs with cheaper OTC drugs while 28% reported switching to cheaper generic 
versions. 
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Table 4.6 Prescription Drug User Charges 
 
      Surveyed Patients 
      N = 213   % 
 
Prescription payment in last 12 months 
 Yes     160   (75.12) 
 No     51   (23.94) 
 Missing     2   (0.94) 
 Total     213   (100) 
GMS Payment 
 Mean     €3.76 
 Range     €2.50 - €70106 
DPS Payment 
 Mean     €52.45 
 Range     €0 - €244107 
LTI Payment 
 Mean      €49.97 
 Range      €2.50 - €244 
No community drug cover 
 Mean     €24.45 
 Range     0-€250 
 
 4.3.6.3.2 Drugs Payment Scheme (DPS) 
 
As mentioned in Section 4.1.1, DPS patients pay for their prescription drugs until they 
reach the €144 monthly maximum. Any excess drug costs after this are covered by the 
State for the remainder of that calendar month. Unlike GMS patients, DPS patients are 
uncertain about their OOP payment for their prescription drugs until they reach the 
€144 monthly maximum. In this research, the average monthly cost paid under the 
DPS scheme was €52.45 (see Table 4.6). This cost is notably less than the €144 
deductible. According to research, when patients are unlikely to reach their maximum 
ceiling they reduce their use of prescription drugs (Kephart et al., 2007).  This €144 
deductible under the DPS may be incentivising DPS patients to reduce their 
                                                          
106 There were six patients who had a medical card and paid more than the €25 threshold. Perhaps 
these patients only received the medical card in the last 12 months and had to pay OOP costs for 
prescription drugs before this. Also, these patients may have DPS and/or LTI cover in addition to 
GMS cover. 
107 There was one patient who reported prescription drug costs in excess of the €144 deductible under 
the DPS. These patients may have only applied for their DPS card within the last 12 months and 
faced OOP costs before this.  
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prescription use as patients will pay the cost of their prescription drugs until they reach 
€144 per month.  
 
With regard to decreased adherence, of the DPS patients who paid for prescription 
drugs in the last 12 months, 5% reported taking less of a prescription drug to avoid 
cost, 5% reported not filling a new prescription while 6% reported not filling an old 
prescription due to the cost. Regarding financial burden behaviour, Table 4.7 also 
shows that 8% of DPS patients reported borrowing money to pay for prescription 
drugs, 8% reported spending less on other necessities to pay for prescription drugs 
while 3% reported increasing their credit card debt to pay for their prescription 
medication. DPS patients also report cost-coping behaviours; 12% report purchasing 
cheaper OTC medication before purchasing prescription drugs, 35% reported 
switching to the cheaper generic version while 3% reported requesting free medication. 
 
4.3.6.3.3 Long-term Illness (LTI) 
 
While LTI patients receive illness related prescriptions free of charge, they may also 
be prescribed medications that are not associated with their long-term illness and 
therefore must pay OOP for these medications.108 The average monthly OOP cost 
under the LTI scheme was €49.97 (see Table 4.6). It is assumed that these OOP costs 
are for medication unrelated to the patient’s long-term illness given that these are the 
medication they have to pay for.  
                                                          
108 As stated in footnote 103, an LTI patient can also apply for a DPS or GMS card should they be 
eligible. 
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As shown in Table 4.7, of the LTI patients in the sample, 21% report decreasing their 
prescription dose without the advice of their doctor, 8% report not filling a new 
prescription with the same percentage reporting avoiding the refill of an old 
prescription due to cost. LTI patients also find prescription drug user charges to cause 
a financial burden with 13% reporting borrowing money to pay for prescription 
medication, 17% of LTI patients spend less on other necessities while 13% report 
increasing their credit card debt to pay for prescription drugs. Finally, LTI patients 
also engage in cost-coping behaviours; 13% report purchasing cheaper OTC drugs 
before they purchase prescription drugs, while 25% report switching to a cheaper 
generic version.  
 
4.3.6.3.4 No community cover 
 
In Ireland there are patients who do not qualify for a medical card, an LTI book and 
by choice or perhaps lack of knowledge, may not apply for a DPS card. Consequently, 
they are left without any form of community drug cover. In this sample, patients 
without any form of community drug cover paid a monthly cost of €24.45. In 
comparison to DPS and LTI patients (who have to pay for unrelated prescription 
drugs), the average cost paid by patients with no community cover is markedly lower. 
This indicates that patients in this sample with no community drug cover use less 
prescription drugs than DPS and LTI patients. This indicates that these patients may 
be in better health than the other categories. As they use less drugs, it is reasonable to 
assume these patients may not consider or may not be aware of the benefit of having 
some form of community drug cover.  
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With regard to decreased adherence (see Table 4.7), 12% of patients with no form of 
community drug cover who paid for prescription drugs in the past 12 months reported 
taking less of their prescribed medication to reduce their prescription costs. 8% 
reported not filling a new or old prescription. Patients with no community drug cover 
reported that OOP costs created a financial burden for them as 15% reported spending 
less on other necessities while 17% reported increasing their credit card debt to pay 
for prescription drugs. . These patients also reported increasing their credit card debt 
to pay for prescription drugs (8%). Patients with no community drug cover reported 
substituting their prescription medications for OTC medication while similar to DPS 
patients, 32% reported switching to generic versions of their prescription medication. 
Only one patient with no community cover reported purchasing drugs from an online 
pharmacy.
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Table 4.7 Patients Response to User Charges by Community Drug Scheme Breakdown 
 
    GMS  DPS  LTI        No  community cover 
    n = 36  n = 66  n = 24  n = 60 
DECREASED ADHERENCE: 
Took less than prescribed 
              Yes   10 (27.78%) 3 (4.55%) 5 (20.83%) 7 (11.67%) 
              No   26 (72.22%) 59 (89.39%) 17 (70.83%) 52 (86.67%) 
              Missing    0  4 (6.06%) 2 (8.33%) 1 (1.67%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Stopped refilling a prescription  
Yes   4 (11.11%) 4 (6.06%) 2 (8.33%) 5 (8.33%) 
              No   30 (83.33%) 58 (87.88%) 17 (70.83%) 54 (90.00%) 
              Missing    2 (5.56%) 4 (6.06%) 5 (20.83%) 1 (1.67%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Did not fill a new prescription 
Yes   3 (8.33%) 3 (4.55%) 2 (8.33%) 5 (8.33%) 
              No   31 (86.11%) 58 (87.88%) 17 (70.83%) 55 (91.67%) 
              Missing    2 (5.56%) 5 (7.58%) 5 (20.83%) 0  
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
FINANCIAL BURDEN: 
Spend less on other necessities   
Yes   10 (27.78%) 5 (7.58%) 4 (16.67%) 9 (15.00%) 
              No   25 (69.44%) 58 (87.88%) 16 (66.67%) 49 (81.67%) 
Missing    1 (2.78%) 3 (4.55%) 4 (16.67%) 2 (3.33%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Borrow € to pay for meds 
Yes   8 (22.22%) 5 (7.58%) 3 (12.50%) 10 (16.67%) 
              No   28 (77.78%) 58 (87.88%) 18 (75.00%) 49 (81.67%) 
Missing    0  3 (4.55%) 3 (12.50%) 1 (1.67%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Increase credit card debt to pay for meds 
Yes   4 (11.11%) 2 (3.03%) 3 (12.50%) 5 (8.33%) 
              No   31 (86.11%) 61 (92.42%) 18 (75.00%) 53 (88.33%) 
              Missing    1 (2.78%) 3 (4.55%) 3 (12.50%) 2 (3.33%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
COST-COPING BEHAVIOURS 
Switched to generic brand 
Yes   10 (27.78%) 23 (34.85%) 6 (25.00%) 19 (31.67%) 
              No   25 (69.44%) 40 (60.61%) 15 (62.50%) 41 (68.33%) 
              Missing    1 (2.78%) 3 (4.55%) 3 (12.50%) 0 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
  Used OTC medication first 
Yes   7 (19.44%) 8 (12.12%) 3 (12.50%) 14 (23.33%) 
              No   28 (77.78%) 54 (81.82%) 19 (79.17%) 45 (75.00%) 
              Missing    1 (2.78%) 4 (6.06%) 2 (8.33%) 1 (1.67) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Requested free GP samples    
Yes   0  2 (3.03%) 0   0 
              No   35 (97.22%) 59 (89.39%) 22 (91.67%) 59 (98.33%) 
              Missing    1 (2.78%) 5 (7.58%) 2 (8.33%) 1 (1.67%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
Purchase meds from online pharmacy 
Yes   0  0  0  1 (1.67%) 
              No   35 (97.22%) 61 (92.42%) 22 (91.67%) 58 (96.67%) 
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              Missing    1 (2.78%) 5 (7.58%) 2 (8.33%) 1 (1.67%) 
 Total   36 (100)  66 (100)  24 (100)  60 (100) 
 
4.3.7 Conclusion 
 
The descriptive statistics presented in Table 4.7 reveal patient behaviours in an Irish 
context given prescription drug user charge policies. With regard to decreased 
adherence, Table 4.7 shows that GMS patients are the highest reporters of decreased 
adherence to prescription drugs due to cost. This finding is supported by previous 
literature that user charges have a higher impact on patients with lower incomes109 who 
spend a larger proportion of their income on prescription drugs (Carlson et al., 2006, 
Reed et al., 2008, Tseng et al., 2004). It is also noted that in comparison to DPS and 
LTI patients, GMS patients and patients without any form of community drug cover 
are more likely to report user charges as a financial burden. For GMS patients, this can 
be related to income while patients with no community drug cover face potentially 
high OOP costs as they are not protected by a monthly maximum ceiling.   
 
As expected, due to uncertainty regarding OOP costs, DPS patients are the highest 
reporters of cost-coping behaviours, with 35% of DPS patients, in comparison to 28% 
of GMS patients, reporting switching to generic versions of their prescription drugs in 
order to cope with the cost. This is important given the recent introduction of generic 
substitution in Ireland. It is now mandatory for pharmacists to dispense the generic 
version of a prescribed drug to all GMS patients. It is not surprising that a higher 
percentage of DPS patients compared to GMS patients report this type of behaviour. 
Switching to a cheaper generic version reduces the OOP payment for DPS patients.  
                                                          
109 As mentioned in Section 4.1.1, a GMS card is granted primarily on an income basis.  
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This type of cost-coping behaviour as reported by DPS patients’ needs to be examined 
further. When examining user charges, previous literature finds the closer a patient is 
to reaching the maximum amount they are required to pay, the less likely they are to 
engage in cost-coping strategies (Kephart et al., 2007). If a DPS patient is likely to 
reach the €144 deductible in a calendar month, the patient is less likely to switch to a 
generic or cheaper OTC version of the prescription drug. In this situation, the DPS 
patient has more of an incentive to reach the deductible after which, drugs are covered 
by the HSE.  
 
Unexpectedly, GMS patients report higher levels of switching to OTC versions of their 
prescription drugs than DPS patients (19% Vs. 12%). This is unexpected as OTC 
medications are more likely to be more expensive than the €2.50 co-payment paid by 
GMS patients for prescription drugs. Atella et al (2005) acknowledge the different 
strategies adopted by patients depend on the options available with the healthcare 
systems and their reimbursement methods. Switching to OTC medications may be an 
affordable option in countries where the prescription charge is relatively high in 
comparison to the OTC medications (Atella et al., 2005). However, this is not the case 
for GMS patients in Ireland where OTC drugs are generally more expensive than 
€2.50. 
 
In conclusion, the descriptive statistics in this section indicate that GMS patients, LTI 
patients and patients with no community drug cover are the highest reporters of 
decreased adherence as a results of the cost of their prescription drugs. These patient 
also report prescription drug costs as a financial burden. With regard to cost-coping 
strategies, GMS patient are more likely to report switching to OTC medications while 
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DPS patients are the highest reporters of switching to cheaper generic versions of 
prescription drugs. These descriptive statistics reveal that GMS patients and patients 
with lower income levels report a higher level of response to prescription drug user 
charges. Consequently, the statistics indicate that patients’ response to prescription 
drug user charges in Ireland vary with socio-economic status. Section 4 in this chapter 
tests the significance of these findings
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4.4 Results 
 
4.4.1 Introduction 
 
This section presents the econometric methodologies that were employed to assess the 
impact of prescription drug user charges on patient behaviour in Ireland. Section 4.4.2 
discusses the rationale as to why this econometric model was chosen. Section 4.4.3 
presents the econometric model and focuses on model specification and model tests. 
The results are presented in Section 4.4.4 and Section 4.4.5 discusses the research 
findings. 
 
4.4.2 Econometric Rationale 
 
The impact of prescription drug user charges on patient behaviour is tested using data 
collected from patients as they waited in GP waiting rooms in selected surgeries in 
Cork. The nature of the data for the dependent variable determined the econometric 
methodologies. As identified in Section 4.3.5, the dependent variable assesses patient 
response to prescription drug user charges in terms of decreased adherence, financial 
burden and cost-coping behaviours. The dependent variable was recoded into 4 
categories measuring the number of responses that were reported by patients. This re-
grouping was necessary due to a small number of observations in certain community 
drug schemes under the behavioural response categories (see Table 4.7). Due to the 
small sample size in a number of the behavioural response categories, it would not be 
appropriate to conduct econometric analysis focussing on a count of all nine responses.  
189 
 
Therefore, the 4 categories in the recoded dependent variable measure; no behavioural 
response to cost-sharing, one behavioural response to cost-sharing, two types of 
behavioural response and all three types of behavioural response (see Table 4.8). In 
other words, a patient who did not report any of the three types of behavioural 
responses; decreased adherence, financial burden or cost-coping strategies, was put 
into the first category “no behavioural response”. A patient who reported at least one 
of the three types of responses was put into the second category “one behavioural 
response”. A patient who reported at least two of the three types of responses was put 
into the third category “two types of behavioural responses”. Finally, a patient who 
reported all three types of behavioural response was put into the fourth and final 
category “all three types of behavioural response”. The categories of this dependent 
variable are now mutually exclusive.  
 
This type of dependent variable was chosen in order to estimate the actual level of 
patient response to prescription drug cost-sharing. In Section 4.3.6.3, the study 
presents descriptive statistics on patient response to prescription drug user charges by 
community care cover to identify what type of patients engage in behavioural change 
as a result of their prescription drug costs. The dependent variable was recoded into 
the four categories in order to identify what factors significantly affect the level of 
patient response. Due to the categorical nature of the dependent variable and its 
mutually exclusive categories, a multinomial logit model (MNLM) is appropriate 
(Jones, 2007). 
 
As the dependent variable measures the number of behavioural responses it may be 
argued that this is an ordinal variable and an ordered logit model may be the best 
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approach. However, this paragraph justifies why an ordered logit model is not 
appropriate for this study. The original coding of this variable does not enable it to be 
identified as an ordinal one. For example, a patient who reports only one type of 
decreased adherence behaviour110 and no other type of behavioural response (financial 
burden or cost-coping) will be coded as 1; one behavioural response, while a patient 
who reports all three types of decreased adherence behaviours111 (and no other type of 
response) will also be coded as having only one type of behavioural response. The new 
dependent variable does not capture the difference in the number of patient responses 
within each category. Therefore, the dependent variable is nominal, coded as 0 or 1 for 
the presence or absence of any type of behaviour in each category (decreased 
adherence, financial burden and cost-coping strategies). As the variable does not 
account for the number of patient responses within each category, to identify the 
dependent variable as ordinal would be inaccurate.  
 
Table 4.8 Dependent Variable 
 
 
Number of behavioural responses n = 158112  Percent 
   
No behavioural response   85  53.80  
One type of behavioural response  41  25.95   
Two types of behavioural response  19  12.03   
All three types of behavioural response 13  8.23  
_________________________________________________________________________________ 
Total     158  (100)  
 
 
 
 
                                                          
110 Stopped refilling an old prescription, did not fill a new prescription, or took less than prescribed. 
111 Stopped refilling an old prescription, did not fill a new prescription AND took less then prescribed. 
112 Sample size for the dependent variable is 158 as two missing observations for the dependent variable 
were dropped from the sample.  
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4.4.3 Econometric Model and Specification 
 
Under a number of assumptions, the MNLM is shown as follows (Greene, 2002): 
 
Pr (yj  = j) = 
exp(𝑋𝑖𝛽𝑗)
1+⁡∑ 𝑒𝑥𝑝
𝐽
𝑗=1 (𝑋𝑖𝛽𝑗)
      (4.1) 
 
Where yi is the observed outcome for the ith individual and Xi is a vector of the 
independent variables. The unknown parameters 𝛽j are estimated by using an extension 
of the maximum likelihood; maximum a posteriori (MAP) estimation.  
 
To identify the coefficients of the MNLM, one of the outcome categories of the 
dependent variable is nominated as a base category and set to zero (Greene, 2002): 
 
Pr (yi = 0) = 
1
1+⁡∑ 𝑒𝑥𝑝𝐽𝑗=1 (𝑋𝑖𝛽𝑗)
       (4.2) 
 
The log-odds for the other categories is then calculated relative to the base category 
(Jones, 2007). By default, Stata drops the category with the most observations (Jones, 
2007). In the current research the first category (y=0 no behavioural response) forms 
the base category as this category has the most observations (n=85). The log-odds for 
the last three categories is calculated relative to this base category. The qualitative 
interpretation of the coefficients depends on the sign of the coefficient (Jones, 2007).  
 
 
The MNLM does not assume normality, linearity or homoscedasticity (Long and 
Freese, 2001). However, the model does have some assumptions such as non-perfect 
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separation, independence of irrelevant alternatives (IIA) and an appropriate sample 
size; a minimum of 10 observations per independent variable is necessary (Schwab, 
2002). 
 
If the non-perfect separation assumption is not satisfied, the groups of the outcome 
variable are perfectly separated by the independent variables. This results in unrealistic 
coefficients (Starkweather and Kay, 2011). The assumption needs to be treated 
carefully in the MNLM as the model gives no warning that this assumption is violated 
(Long and Freese, 2001). An assessment of the variable coefficients reveals the 
violation of this assumption. Coefficients that have z=0 (and p > z = 1) should be 
excluded as these variables imply perfect prediction (Long and Freese, 2001). In this 
research, assessing the coefficients in earlier versions of the model reveal a number of 
coefficients do have z=0 (and p > z = 1) (see Appendix B.7). This implies perfect 
prediction which results in inaccurate coefficients. As recommended by Long and 
Freese (2001), the problem variables in this research were excluded from the model 
and the model was re-estimated in order to satisfy the assumption of non-perfect 
separation.  
 
The second assumption associated with the MNLM is the independence of irrelevant 
alternatives (IIA). This assumption states choice or membership in one category is not 
related to the choice or membership in another category (i.e. the dependent variable) 
(Starkweather and Kay, 2011).  
 
This assumption is described in terms of (Long and Freese, 2001):  
 
193 
 
Pr(𝑦=𝑚⁡|𝑥)
Pr(y=n⁡|𝑥)
 = exp (x [βm|b – β n|b])                     (4.3) 
 
where the odds are not dependent on other outcomes that are available. Thus, the 
alternative outcomes are “irrelevant” (Long and Freese, 2001). This means that 
increasing or decreasing the outcomes does not affect the odds among the remaining 
outcomes (Long and Freese, 2001). The nature of the dependent variable in this 
research cannot violate the assumption of IIA. A patient who reports engaging in one 
type of behaviour for example are classified in one category and each category is 
mutually exclusive. There are four categories; no behavioural response, one type of 
behavioural response, two types of behavioural response and all three types of 
behavioural response. Each individual is assigned into one behavioural category. 
Therefore, the odds of membership in one category are not dependent on the other 
outcome categories. The relative probabilities of the categories will not change if the 
number of categories are increased or reduced. The patient does not have the 
opportunity to select an alternative category as the categories in the dependent variable 
are not alternative choices (Kennedy 2003). An observation is assigned to an outcome 
category based on the number of responses to prescription drug user charges.  
 
After controlling for perfect prediction by removing the variables with z=0 (and p > z 
= 1) and acknowledging the IIA, the independent variables included in the model are 
a combination of binary variables (GMS, DPS, no community cover and 3+ chronic 
illnesses), categorical variables (age and income) and a continuous variable (monthly 
drug cost). The data contains 158 cases and 10 independent variables which satisfies 
the cases to variables assumption. 
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The nature of the independent variables generated concern that there may be an 
interaction effect between some of the independent variables. For example, in Ireland, 
medical card eligibility is primarily determined by income level. Consequently, it was 
suspected there may be an interaction effect between patient income and GMS status. 
In this study, a chi square test of independence was used to test the relationships 
between a gross monthly income level of <€1,000, €1,000-€2,249 and €2,250-€3,499 
and GMS status. A significant relationship was found between a gross monthly income 
level <€1,000 and €2,250-€3,449 and GMS cover (see Appendix B.9). Two interaction 
variables were created (inc1medc and inc3medc) and included in the model to test for 
significance. Due to the small sample size, the interaction variables were assessed 
separately. The model would not converge when the two variables were included in 
the MNLM simultaneously. The interaction variable measuring GMS and an income 
level <€1,000 was not found to be significant (see Appendix B.10). As the interaction 
variable was only included to check its significance and no hypotheses was made about 
the variable, the insignificant finding meant the variable was excluded from the final 
model as it did not add anything to the model overall (Kleinbaum and Klein, 2002). 
When the second interaction variable was assessed, the model would not converge and 
consequently, this interaction variable was not included in the MNLM either.  
 
4.4.4 Results 
 
Table 4.9 presents the results of the MNLM. The first category which measures no 
behavioural response is the base category. The other three categories; one type of 
behavioural response (decreased adherence, financial burden or cost-coping strategy), 
two types of behavioural response (decreased adherence, financial burden or cost-
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coping strategy), and all three types of behavioural responses (decreased adherence, 
financial burden and cost-coping strategy), are assessed relative to the base category. 
As the estimates are relative to the base group, the interpretation of the MNLM is that 
for a one-unit change in the independent variable, the logit of an outcome relative to 
the base group is expected to change by its parameter estimate (which is log-odds 
units) given the other variables in the model are held constant. The interpretation of 
the MNLM examines the significance and sign of the parameters under each type of 
behavioural response. 
 
Table 4.9 presents the MNLM coefficients for the last three categories of the dependent 
variable (one behavioural response, two behavioural responses and all three 
behavioural responses) relative to the base category (no behavioural response). Table 
4.9 shows significant variables occur when examining the last category (all three types 
of behavioural responses) relative to the base category (no behavioural response). No 
significant variables are found when assessing one type of behavioural response and 
two types of behavioural response relative to the base category.  
 
Table 4.9 shows GMS patients are more likely to engage in all three types of 
behavioural response compared to non-GMS patients. Patients without any form of 
community drug cover are more likely to engage in all three types of behavioural 
response when compared to the base category. As expected, patients with higher 
prescription drug costs are more likely to engage in all three types of behavioural 
response to prescription drugs compared to patient with lower prescription drug costs. 
Finally, patients with a gross monthly income level below the national average 
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(€1,000-€2,249) are more likely to engage in all three types of patient behaviour 
relative to patients with a higher income level (€4,750-€5,999).  
 
The results of the MNLM suggest that GMS patients, patient without community drug 
cover, higher prescription drug costs and an income level below the national average 
are more likely to decrease their adherence to prescription drugs without the advice of 
their GP. Furthermore, these patients are more likely to report their prescription drug 
costs as a financial burden and consequently borrow money or reduce spending on 
other necessities in order to afford their prescription drug costs. Finally, these patients 
are more likely to engage in cost-coping strategies to reduce the cost of their 
medication by switching to OTC or generic drugs, request free medication samples 
from their GP or purchase prescription drugs on-line.  
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Table 4.9 Multinomial Logit Results 
 
Base Category: No behavioural response 
Comparison groups: One behavioural response, two types of behavioural response and all three 
types of behavioural responses 
Variable One 
behavioural 
response 
Two types of 
behavioural 
response 
Three types of 
behavioural 
response 
19-29 years base category (age)  
30-44 years -0.13 
(0.51) 
1.07 
(0.77) 
0.96 
(0.93) 
45-59 years 0.18 
(0.54) 
0.15 
(0.98) 
0.41 
(1.23) 
GMS 0.30 
(1.34) 
0.38 
(1.93) 
5.44*** 
(1.97) 
DPS 0.59 
(1.27) 
-0.71 
(1.83) 
3.01 
(1.85) 
No prescription drug cover 0.77 
(1.31) 
-0.20 
(1.88) 
4.95** 
(2.06) 
Monthly prescription drug costs 0.01 
(0.01) 
0.00 
(0.01) 
0.03*** 
(0.01) 
<€1,000 0.20 
(0.68) 
1.25 
(0.97) 
2.03 
(2.26) 
€1,000-€2,249 -0.64 
(0.53) 
-0.13 
(0.90) 
4.11** 
(2.06) 
€2,250-€3,499 -0.51 
(0.57) 
1.03 
(0.82) 
1.13 
(2.25) 
€4,750 - €5,999 Base category (income) 
3 or more chronic illnesses -0.64 
(0.85) 
-0.11 
(1.27) 
0.43 
(1.09) 
_Cons -1.33 
(1.42) 
-2.47 
(2.15) 
-11.63*** 
(3.49) 
Multinomial Logit Model 
Multinomial Logit Model 
No. of obs. = 143113 
LR chi2 (30) = 43.58 
Prob > chi2 = 0.0520 
Pseudo R2 = 0.1343 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
 
4.4.5 Discussion 
 
Table 4.9 presented the results of the MNLM which assessed the impact of prescription 
drug user charges on patient behaviour in Ireland.  
 
                                                          
113 Number of observations dropped due to missing values in the data.  
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The MNLM found that patients with GMS cover, patients without any form of 
community drug cover, patients who report higher prescription drug costs and patients 
who have a low income (€1,000-€2,249) are more likely to engage in all three types 
of behavioural response. This indicates that the most vulnerable patients; the sick and 
the poor, report the highest response to prescription drug user charges in terms of 
decreased adherence, financial burden and cost-coping strategies as a result of 
prescription drug user charges in Ireland. The results are supported by previous 
literature which also suggests that the most vulnerable patients in the population are 
most likely to engage in behavioural changes as a result of prescription drug costs 
(Atella et al., 2005, Carlson et al., 2006, Dor and Encinosa, 2010, Kephart et al., 2007, 
Piette et al., 2004a, Rahimi et al., 2007, Reed et al., 2008, Schafheutle et al., 2002, 
Tseng et al., 2004) 
 
With regard to decreased adherence, the results of this study are supported by previous 
research which has shown that increased prescription drug user charges increase the 
likelihood of vulnerable patients reducing their adherence to prescription drugs 
(Sinnott et al., 2013). Studies have also shown that prescription drug users charges are 
associated with an increase in hospitalization and deteriorating health outcomes 
(Goldman et al., 2007). As this research proves that user charges cause patients to 
reduce their adherence to prescription drugs, user charge policies in Irish healthcare 
need to be re-assessed to prevent the associated adverse outcomes. If patients in Ireland 
cannot afford essential prescription drugs due to their cost, these patients are at risk of 
hospitalization and deteriorating health. This results in these patients requiring the 
need of more expensive secondary care services. Prescription drug user charges in 
Ireland need to be based on patients’ ability and willingness-to-pay to avoid the 
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adverse impact of user charges in Ireland. In this manner, patients would be able to 
access prescription drugs at a user charge that is affordable to them while still 
contributing to prescription drug financing.  
 
The MNLM shows that GMS patients, patients with no community drug cover, higher 
prescription drug costs and a lower income level are most likely to report prescription 
drug costs as a financial burden. This vulnerable population report the borrowing of 
money from others, reducing their spending on other necessities and increasing their 
credit card debt to pay for their prescription drugs. As identified by Becker (1954) and 
Grossman (1972), individuals consume healthcare subject to a budget constraint. As 
user charges increase the proportion of the prescription drug cost borne directly by the 
patient, the amount of prescription drugs the patient can afford will be reduced, 
therefore restricting the patient’s access to prescription drugs. These results indicate 
that prescription drug user charges in Ireland may have a regressive impact as patients 
with lower incomes appear to be most affected by the cost than patients with higher 
incomes (Adams et al., 2001, Contoyannis et al., 2005, Gibson et al., 2005b, Lexchin 
and Grootendorst, 2004, Smith and Kirking, 1992).  
 
Finally, the results indicate that GMS patients, patients with no community drug cover, 
higher prescription drug costs and patients with low incomes are more likely to engage 
in cost-coping strategies as a result of their prescription drug costs. These cost-coping 
strategies are as follows: using cheaper OTC and generic drugs, requesting free 
medication samples from the GP or purchasing prescription drugs from an online 
pharmacy. As the patients reporting this type of behaviour already reported financial 
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distress as a result of prescription drug user charges, it is expected that these patients 
would engage in strategies which may reduce the cost of their medication.  
 
While this research shows that GMS patients, patients with no prescription drug cover, 
higher prescription drug costs and lower income level are most likely to engage in 
decreased adherence, financial distress and cost-coping behaviours, the nature of the 
prescription drugs which are subject to this behavioural change need to be assessed. 
User charges for prescription drugs were introduced in Ireland as a method of 
contributing towards prescription drug financing. In order to assess if this objective is 
a success, the nature of the drugs that are subject to patients’ behavioural response ned 
to be evaluated. In other words, are these patients reducing their use of essential or 
non-essential drugs? This is discussed further in Section 6.4. 
 
The following section, Section 4.5, concludes this chapter.  
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4.5 Conclusion 
 
This chapter identified the impact prescription drug user charges have on patient 
behaviour in Ireland in terms of decreased adherence, financial burden and cost-coping 
behaviours.  Using a specifically designed self-completion questionnaire, the research 
collected primary data from patients attending six GP surgeries in Cork. This ensured 
patients subject to the various forms of prescription drug user charges in Ireland; co-
payments (GMS), deductibles (DPS) and full OOP costs (no form of cover), would be 
included in the sample. This enabled the research to assess the impact that various 
prescription drug user charges have on patient choice.  
 
This research finds the various types of prescription drug user charges in Ireland; co-
payments, deductibles and full OOP costs do cause patients to engage in decreased 
adherence, financial burden and cost-coping behaviours as a result of cost. Patients 
reported decreased adherence if they reduce their medication without the advice of 
their doctor, do not refill an existing prescription or if the patient does not fill a new 
prescription. Patients report the user charge as a financial burden if they borrow money 
to pay for medication, go without a necessity to pay for medication and/or increase 
credit card debt to afford medication. Finally, if patients report any of the following; 
substituting prescription medication for OTC remedies, substituting brand name to 
generic drugs, borrowing medication from others, requesting free samples from a 
doctor, purchasing prescription drugs from an on-line pharmacy and/or splitting tablets 
on the advice of the doctor, they are engaging in cost-coping strategies as a result of 
the prescription drug user charge.  
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The research finds GMS patients who face a flat co-payment per prescription item are 
the highest reporters of decreased adherence and financial burden as a result of 
prescription drug costs.  DPS patients are the highest reporters of cost-coping strategies 
as a result of prescription drug costs.  
 
Using a MNLM, this research finds that patients with GMS cover, patients without 
any form of prescription drug cover, patients with high prescription drug costs and 
patients with a low monthly income level (€1,000-€2,249) are more likely to engage 
in all three types of behavioural change as a result of prescription drug user charges.  
The results of this research are supported by previous literature and theory which also 
reveal vulnerable patients may struggle in terms of accessibility and affordability when 
attempting to purchase prescription drugs. As recommended by previous literature, the 
results of this research highlight that the drugs which are subject to the behavioural 
response need to be investigated further. This will indicate if the user charges for 
prescription drugs in Ireland are successfully reducing the over-consumption of 
unnecessary drugs or if the user charges are inadvertently reducing patients use of 
essential prescription drugs. While this research does indicate that prescription drug 
user charges reduce patients’ utilization of prescription drugs, future research would 
identify the extent of this reduction; if user charges are having the intended effect by 
successfully reducing patients’ use of prescription drugs or if the user charges are 
causing adverse effects as a result of the user charge being too high and creating 
affordability issues for the most vulnerable in society.  
 
Chapter 4 finds co-payments, deductibles and a full OOP user charge to impact patient 
behaviour for a healthcare service such as prescription drugs. Similar to Chapter 3, 
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Chapter 4 is also supported by economic theory that the higher the proportion of a 
patients’ income spent on a healthcare service, the higher the response.  Similar to the 
results in Chapter 3 of this thesis, Chapter 4 also finds that user charges can create 
accessibility and affordability issues for prescription drugs. However, before this can 
be definitively identified, the nature of the prescription drugs that are affected by users 
charges need to be examined to determine if the user charges are having the desired 
effect of reducing non-essential prescription drugs. 
 
Chapters 3 assessed the impact of user charges on patient choice for a private service 
for which a user charge exists while Chapter 4 assessed the impact of impact of user 
charges on patient choice for a mainly public or part-publicly financed service for 
which a user charge also exists. In contrast, Chapter 5 will assess the potential 
application of user charges for both public and private healthcare services. While 
Chapters 3 and 4 suggest that user charges in healthcare create accessibility and 
affordability issues for some patients, Chapter 5 will assess the hypothetical 
application of user charges for three healthcare services where choices are made as 
part of a time-money choice, a convenience choice and a preference choice. Chapter 5 
is conducted in the context of user charges becoming more prevalent in healthcare 
systems over time. 
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5  WHAT ARE IRISH PATIENTS WILLING TO PAY FOR 
HEALTHCARE SERVICES IN IRELAND (BLOOD TESTS, MRI 
SCANS AND BRANDED PRESCRIPTION DRUGS)? 
 
5.1 Introduction 
 
Understanding consumers’ value of a good or service is a crucial component of the 
pricing decision process (Breidert et al., 2006). Researchers agree that estimating 
consumers’ WTP for a good or service is key to developing a successful pricing 
strategy. WTP values can be used to predict consumers’ response to a price (Breidert 
et al., 2006). Assessing consumers’ response to price is essential in the healthcare 
system and is particularly important in a healthcare system where user charges are 
gaining popularity as a method of healthcare financing.  
 
As stated in Section 1.1 of this thesis, user charges are a common policy introduced in 
healthcare systems as a method of sharing the cost between the patient and provider. 
They are payments made in an OOP manner by users of healthcare services as a 
contribution towards their costs (Morris et al., 2007). These patient-targeted user 
charge policies are grounded in the economic theory of consumer choice and how price 
can be used as a tool to change consumer behaviour. While user charges are intended 
to help alleviate financial pressure on healthcare systems, it is crucial that healthcare 
services are provided at a price that patients are willing and able to pay to access the 
services. Therefore, understanding consumers’ WTP for healthcare services is 
important as consumers’ response to price will influence utilization of healthcare 
services (Uzochukwu et al., 2010).  
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To assess consumers’ WTP for a healthcare service, a Contingent Valuation Method 
(CVM) is commonly applied in health economics literature (Baji et al., 2012, Basu, 
2013, Carrere et al., 2008, Milligan et al., 2010, Olsen and Donaldson, 1998). This 
method uses a survey-based approach to estimate patients’ WTP for a healthcare 
service (Diener et al., 1998). This research adapts a survey-based methodology to 
estimate patients WTP to receive blood tests in GP surgeries, faster access to MRI 
scans and a branded over a generic prescription drug.  
 
5.1.1 Affordability and Accessibility 
 
As described in Section 2.4.1 and 2.4.2, the impact of user charges is examined in 
terms of affordability and accessibility. Healthcare costs influence patients’ decisions 
to seek healthcare and particularly impact on patients who cannot afford the applicable 
user charge for a healthcare service. User charges can be “regressive” with larger 
effects on patients who spend a larger proportion of their income on a particular 
healthcare service, namely, the sick and the poor (Adams et al., 2001, Contoyannis et 
al., 2005, Gibson et al., 2005b, Lexchin and Grootendorst, 2004, Smith and Kirking, 
1992). User charges increase patient OOP expenditure, which contribute to the 
financially constrained health sector but can lead to a welfare loss for patients who 
cannot afford the necessary healthcare services (Srivastava and McGuire, 2015). While 
user charges are gaining popularity as a method of funding healthcare expenditure, 
affordable and accessible care for all patients must be at the centre of healthcare 
delivery.  
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5.1.2 Research Question and Aim  
 
What are Irish Consumers Willing to Pay for Selected Healthcare Services in Ireland? 
 
This question led to three  more specific objectives that include: 
 
 Reveal patients’ willingness-to-pay (WTP) values for three healthcare services. 
 Identify discrepancies between patients reported WTP and the current market 
price.  
 Using a two-part model, identify the factors that are associated with patients 
WTP values for the three selected healthcare services.  
 
Through the construction of an original questionnaire, the objective of this study is to 
estimate what Irish patients are WTP for three selected healthcare services in Ireland. 
The three healthcare services measure a time-money choice (using MRI scans), a 
convenience choice (using blood tests) and a preference choice (choosing a branded 
or generic prescription drug). These services are valued in the context of user charges 
becoming more prevalent in healthcare systems over time. This research collects 
primary data from patients in the waiting rooms of selected GP surgeries in Cork. The 
research controls for age, GMS, PHI, education, self-reported health status and 
individual level gross monthly income level.  
 
There are numerous reasons for selecting these three particular healthcare services. 
The first service is blood tests. Blood tests are taken to assess a patient’s general state 
of health, for detection of a virus or bacteria and to test how well organs are functioning 
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(HSE, 2013b). Until 2013 in Ireland, GPs provided blood tests for GMS patients free 
of charge.  However, recent cut backs in general practice in Ireland have resulted in a 
number of GPs charging GMS patients to receive blood tests in their surgeries.  In 
general, GPs charge GMS patients on average a €5 user charge for blood tests. This €5 
charge is to cover transport costs to get the blood tests to and from the hospital lab.114 
Not all GPs enforce this cost as charging patients for blood tests depends on GP 
preferences and regular practice.115 Should a GMS patient wish to avoid this charge, 
they can attend a public hospital and receive a blood test free of charge. Despite 
receiving this service for free in a hospital, the access route to this service can in fact 
be costlier than the €5 user charge. The patient must make an appointment with the 
hospital, wait to receive an appointment and then attend the hospital for the blood test. 
Thus, in Ireland, a GMS patient can pay the user charge in the GP surgery to receive a 
blood test immediately or alternatively the patient can enter a public hospital and 
receive the test for free but with a potentially longer and costlier access route. In this 
case, the GMS patient faces a time-money trade-off. 
 
While GMS patients face an increase in the user charge for blood tests to cover 
transport costs, non-GMS patients may also face a similar increase in blood test 
charges. It is possible that GPs can increase the regular consultation charge for non-
GMS patients from the national average of €51 (Nolan et al., 2014) if a non-GMS 
patient requires a blood test. Similar to above, not all GPs enforce this cost as it can 
depend on GP preferences and regular practice.116 Similar to GMS patients, non-GMS 
                                                          
114 Expert opinion. This information was retrieved following a qualitative discussion with two GPs in 
Cork.  
115 See footnote 113. 
116 See footnote 113. 
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patients can also avoid the charge by attending a public hospital to receive the blood 
test for free.  
 
The second service included in the research is an MRI scan. Access to MRI scans in 
Ireland poses a similar time-money trade-off for patients. An MRI scan is used to 
diagnose health conditions affecting organs, tissue and bone (HSE, 2013b). In Ireland, 
all out-patients must be referred by their GP for an MRI scan. With a GP referral a 
patient faces two payment options to access this service; the patient can either receive 
an MRI for free by entering the public system but may face a possible waiting time of 
6 months to one and a half years (Ryan, 2016), or the patient can pay OOP and receive 
a scan within a much shorter time frame, such as 2 weeks.117 Patients with PHI may 
be covered for the cost of an MRI but patients who do not have PHI for this service 
must decide whether they want to wait to receive an MRI scan for free or whether they 
are willing to pay OOP to receive the scan within two weeks.  
 
The final service included in the research focuses on branded over generic prescription 
drugs. The active ingredient in generic medicine is identical to the brand medicine. 
The generic versions are as safe and effective as the branded versions. In Ireland 
previous to 2013, a pharmacist could only dispense what the GP prescribed on a 
patient’s prescription irrespective of whether a cheaper generic version was available. 
Since the implementation of the Health (Pricing and Supply of Medical Goods) Act in 
2013,118 pharmacists are now obliged to dispense the generic version of a prescription 
                                                          
117 Expert opinion. It is not possible to find actual statistics for MRI waiting times as the HSE 
proposes to start the publishing of this data in March 2016.  
118 The Health (Pricing and Supply of Medical Goods) Act 2013 commenced in Ireland in June of the 
same year and introduced generic substitution and reference pricing for prescription drugs. This Act 
was to provide value for money in the supply of prescription drugs. This in turn encourages 
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drug to all patients provided the drug has been identified as safely interchangeable by 
the Irish Medicines Board (IMB). Only in cases when the prescribers write “Do not 
Substitute” on a prescription, the pharmacist must dispense what is written on the 
prescription and cannot substitute the item for a cheaper generic version (HSE, 2013e). 
In addition to generic substitution, the HSE has set reference prices for each group of 
interchangeable medicines. The reference price is what is reimbursed to the pharmacist 
for all medicines in the group irrespective of the medicines’ cost. Patients covered by 
the GMS and DPS will not incur additional costs for medicines priced at or below the 
reference price. However, should a patient prefer to receive a particular brand that 
costs in excess of the reference price, the patient must cover the difference between 
the reference price and the cost of the branded version. In the case of a GMS patient, 
they must also pay the relevant user charges and DPS (non-GMS) patients still pay up 
to a €144 monthly threshold (HSE, 2013e).  
 
Since the introduction of the 2013 Act, patients face two options when purchasing their 
prescription medications. They either receive the generic version should there be one 
designated and pay the relevant user charge119 or request a preferred branded version 
and pay the difference between the reference price and the branded version.  
 
The reasons for choosing these three particular healthcare services are as follows; 
patients’ WTP for blood tests was chosen for inclusion due to GPs in Ireland starting 
                                                          
competition among suppliers and consequently lower prices for patients which saves money for the 
taxpayers and the patient (HSE, 2013e). 
119 This will depend on what community drug scheme the patient is covered under. As mentioned in 
Chapters one and two of this thesis, GMS patient pay a flat co-payment of €2.50 per prescription 
item while DPS patients pay the cost of their medication until they reach the monthly threshold of 
€144 after which the cost of the prescription drugs are covered by the State. Patients with an LTI 
book do not pay any user charge for illness related prescriptions and patient without any form of 
community drug cover must pay the full cost of their prescription medications.  
210 
 
to implement user charges for this service. WTP for MRI scans are included in this 
study for three reasons; firstly, they are revealed to be the most commonly referred 
scan made by GPs on behalf of their patients,120 secondly, due to the variation in 
waiting time and costs for MRI scans and thirdly, due to their presence in previous 
international research (van Helvoort-Postulart et al., 2009). WTP for prescription 
drugs are evaluated due to the introduction of generic substitution and reference 
pricing in Ireland in 2013. The three selected healthcare services currently exist in the 
Irish healthcare system. Consequently, the objective is not to estimate “a perfect” WTP 
as prices are already available but to provide evidence on the price that patients are 
WTP for these services. These services are valued in the context of user charges 
becoming more prevalent in healthcare systems over time to help fund the system. 
 
5.1.3 Motivation 
 
With €510 million in supplementary funding required by the HSE in 2014 and €600 
million additional funding required in 2015, it is reasonable to assume that user charges 
will continue to play a crucial role in the financing of healthcare in Ireland. With user 
charge policies in place in Irish healthcare, it is important to establish the level of user 
charges which contribute towards healthcare but also provides affordable and 
accessible care to patients. With this in mind, patients’ WTP for healthcare services 
must be measured.  
 
Understanding patients’ WTP helps to gauge the patients’ likely utilization of the 
healthcare services.  Estimating the price incentives from the patients’ perspective will 
                                                          
120 This was revealed through qualitative discussions with two GPs practicing in Co. Cork.  
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promote sufficient access and affordability to the selected healthcare services based on 
patients’ reported WTP values. Consequently, this reduces concerns associated with 
patient accessibility and affordability for the three healthcare services. With this in 
mind, this research aims to estimate what patients are WTP for the healthcare services 
to identify a user charge which promotes affordable and accessible care to these 
services.  
 
5.1.4 Chapter Structure 
 
Section 5.2 presents previous WTP literature in health economics. Section 5.3 presents 
the methodology that was employed to estimate what patients are willing to pay for 
the three selected healthcare services in Ireland. Section 5.4 describes the econometric 
methods that were utilized and Section 5.5 concludes this chapter with 
recommendations for future research. 
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5.2 Literature Review 
 
5.2.1 Introduction 
 
This section provides a critical review of existing literature on studies using the 
Contingent Valuation Method (CVM) with a particular focus on WTP research. The 
literature review was guided using the following search words in databases such as 
Academic Search Complete (willingness-to-pay, healthcare, contingent valuation, 
cost-benefit analysis, stated preference techniques and elicitation formats). A citation 
approach was adopted where citations were recorded and from there reference lists 
were scanned until such a time it was thought that all key paper/authors were retrieved. 
The criteria extracted from each study was as follows; data source, outcome 
measurements, elicitation methods, analysis and study results. Section 5.2.2 provides 
a general description of CVM and WTP methods. Section 5.2.3 provides a comparison 
of various elicitation formats. Section 5.2.4 describes methodological issues which 
arise in WTP studies such as; ordering effects, the embedding effect and protest zeros. 
Section 5.2.5 provides a review of WTP healthcare studies in order to provide an 
understanding of what has been conducted in studies of this kind and Section 5.2.6 
concludes this section. 
 
5.2.2 Overview of CVM and WTP  
 
As mentioned in Section 5.1 of this chapter, a WTP study is a Contingent Valuation 
Method (CVM) which is a survey-based hypothetical approach to elicit patients’ 
monetary value for a healthcare service (Diener et al., 1998). Generally, contingent 
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valuation (CV) techniques ask respondents to indicate the value they place on their 
health or the value they hold for a particular healthcare service (Bayoumi, 2004). The 
format of the question commonly asks respondents the maximum amount they are 
willing to pay to receive the service in question. The subjects of the CV study do not 
necessarily have to be users of the service and do not have to be at risk of the particular 
illness for which the service treats. CV studies can be targeted at both users of the 
service or potential users of the service (Bayoumi, 2004, Olsen and Donaldson, 1998).  
There are several benefits associated with CVM; 
 
CV is a form of cost-benefit analysis (CBA) which is firmly rooted in welfare 
economic theory (O'Brien and Gafni, 1996). Technical and allocative efficiency can 
be assessed using CBA.  
 
In comparison to cost-utility analysis (CUA) where no sufficient method exists for 
aggregating utility scores, the aggregation of benefits in a CVM is more 
straightforward (Bayoumi, 2004). 
 
1. A single unit of measurement for costs and consequences facilitates the estimation 
of uncertainty of the estimation results (Stinnett and Mullahy, 1998). 
 
2. CV allows for a prompt comparison and combination of health outcomes with 
externalities (non-health outcomes) (Bayoumi, 2004). 
 
3. As the outcomes in CV studies are measured in monetary terms, the translational 
use of the results for decision and policy makers is heightened (Bayoumi, 2004).  
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Despite numerous advantages associated with CVM, the main disadvantage associated 
with this technique is the difficulty in acquiring valid and reliable WTP estimates 
(Diener et al., 1998). It is argued that CVM estimates are only the stated intention of 
the respondent and actual observed behaviour may be different. This methodological 
issue is discussed further in Section 5.2.4.  
 
Focusing on survey-based techniques, WTP values can be elicited directly (stated 
preference) or indirectly (revealed preference technique) (Johannesson, 1996). Using 
the direct method, respondents state their maximum WTP for a service or their 
maximum WTP to be in good health. In this case, WTP is based on the expected 
behaviour of the respondent. Using an indirect method, respondents rate or rank their 
preferences for healthcare services and WTP is revealed from the observed behaviour 
of the respondent (Klose, 1999).   
 
As this research collects data directly from patients who may already use the services 
or may be potential users, the research adapts a direct, stated preference approach to 
estimate what Irish patients are willing to pay for blood tests, MRI scans and a branded 
over a generic prescription drug. Estimating the WTP values directly from patients in 
the Irish healthcare system should promote the translational effect of this research to 
encourage policy makers to design successful pricing strategies providing accessible 
services at an affordable price for patients.  
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 5.2.3 Comparison of the Elicitation Formats 
 
In healthcare literature there is debate surrounding the appropriate elicitation format 
for measuring WTP values. The elicitation format refers to the method in which the 
WTP question is asked. Five possible formats exist in the literature; 1) open-ended; 2) 
bidding game; 3) payment scale; 4) discrete-choice and 5) discrete-choice with follow-
up.  
 
An open-ended question asks the respondent to directly state his/her maximum amount 
they are willing to pay (Smith, 2000). For example, when estimating what women are 
willing to pay for a bone density scan, Donaldson et al (1997) asked the following 
open-ended question: “What is the most you would pay to have the scan?” 
Respondents were asked to write the maximum amount in the space provided. While 
open-ended questions are easy to administer and analyse and do not require a very 
large sample size the responses are unreliable and highly subject to strategic bias 
(Donaldson et al., 1997, Smith, 2000). Strategic bias is when the respondents’ WTP 
value is a representation of what they would like to pay for the good or service and not 
the maximum amount they would be willing to pay to receive the good or service 
(Bergmo and Wangberg, 2007). Open-ended questions do not have a reference point 
which results in the respondent estimating the cost of the good or service and stating 
this value rather than their WTP for the service. The open-ended method does not 
capture the consumer surplus (Donaldson et al., 1997).  
 
To overcome these challenges, the bidding game and payment scale techniques were 
developed. A bidding game presents respondents with an initial amount which they 
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either accept or reject. Subsequent to acceptance or rejection, they are bid up or down 
in increments until the WTP is reached (Smith, 2000).  Using the bidding technique, 
Schafie et al (2014) estimated WTP for a Quality-Adjusted Life Year (QALY) among 
the Malaysian population. They used the following bidding question:  
 
Imagine that you are stricken with a serious illness that immediately 
threatens your life. Now, please assume that Medication A has been 
developed to treat your illness and that if you take it, your life will 
be extended for one full year and you will be completely healthy 
(without being confined to bed) for one full year. Please assume, 
however, that Medication A will not be covered by health insurance 
or Government Hospital and you will have to pay the full amount to 
receive the product, which will cost MYR xxxx*. In this case, would 
you purchase the product? (*xxxx is bidding value) (Shafie et al., 
2014). 
 
If a positive WTP response was given, a bidding game approach with three different 
starting bids of 20,000 MYR (Malaysian Ringgit), 40,000 MYR and 100,000 MYR 
was used.   
 
The bidding game format requires face-to-face interviews with respondents. The 
nature of the data collection classifies questionnaires as an inappropriate data 
collection method for the bidding game format (Frew et al., 2004). Face-to-face 
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interviews are not conducive to a large sample size and are a time-consuming method 
of data collection.  In comparison to the open-ended format, the bidding game format 
does provide the respondent with a reference point to estimate their WTP value. 
Despite this improvement on the open-ended format, the technique is prone to bias as 
a result of the starting bid. Research has found respondents’ final WTP value estimated 
using the bidding game technique is influenced by the starting point which began the 
bidding process. In other words, higher starting bids lead to higher WTP values. In 
comparison to questionnaire formats, e.g. open-ended and payment scale (discussed in 
following paragraph), bidding game formats produce higher WTP values. Higher WTP 
values lead to unreliable results as an intervention valued using a bidding process will 
appear more valuable than an intervention valued using a questionnaire format (Frew 
et al., 2004).  
 
Payment scales present a range of values to respondents. Respondents indicate the 
maximum amount they are willing to pay. The scale begins at 0 and presents 
incremental values with a blank space at the end for respondents to fill in WTP if it is 
beyond the range presented (Smith, 2000). Donaldson et al (1997) used a combination 
of a payment scale and open-ended question. Once respondents answered the open-
ended question, they were presented with a range of values in a list ranging from £0 to 
£100 in £5 increments with a blank space at the end. Respondents were instructed to 
write their maximum amount they are willing to pay if it was in excess of £100. Next 
to this range of values respondents were given the following instruction: 
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“Put a √ next to the amounts that you are sure you would pay. Put 
an X next to the amounts that you are sure you would not pay. Put 
an O around the maximum amount that you are sure you would be 
prepared to pay.”(Donaldson et al., 1997) p. 83/4) 
 
In comparison to the open-ended and bidding game format, payment scales are more 
representative of real life situations. Payment scales allow respondents to “shop 
around” for the value which best represents their WTP for a good or service 
(Donaldson et al., 1997). Consequently, in contingent valuation studies in healthcare, 
the payment scale approach is the most popular format (Diener et al., 1998, Klose, 
1999, Smith, 2000). Payment scales reduce starting point bias as the payment scale 
begins with 0. Despite reducing starting-point bias, the payment scale is subject to 
range bias and mid-point bias. Range bias is when the values presented on the payment 
scale can influence the respondents’ WTP value (Ryan et al., 2004) while mid-point 
bias is when respondents state their WTP value as the middle of the card. Range bias 
can be reduced in the design of the payment scale by including a blank space at the 
end of the range so the respondent can state their WTP should it exceed the range that 
is presented (Smith, 2000). In comparison to open-ended questions, respondents are 
more likely to answer payment scale questions, payment scales generate consistent 
mean and median values and a stronger association between WTP and ability to pay is 
achieved using a payment scale (Donaldson et al., 1997).  
Discrete choice experiments (DCEs) are generally used in questionnaires and include 
numerous choice sets which include hypothetical options between which the 
respondents choose (Lancsar and Louviere, 2008). Each choice set is defined by a set 
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of attributes, and each attribute is set at one of several levels. The levels present 
different ranges of the attributes. For example, travel time may be a key attribute for 
patients when choosing a GP. In a DCE, this attribute can be set at different levels such 
as 5, 15 or 60 minutes (Lancsar and Louviere, 2008). Respondents make decisions 
based on the varying attributes of a service which may be based on quality or price 
difference. In this manner, DCEs encourage respondents to make trade-offs between 
attributes (Lancsar and Louviere, 2008). If cost is included as an attribute, it is possible 
to estimate the WTP for that good or service.  DCEs can include choices between 
multiple options, a pair of alternatives or binary choices (yes/no) (Lancsar and 
Louviere, 2008). Figure 5.1 provides an example of a DCE and the type of attributes 
that can be compared.  
Figure 5.1 Discrete Choice Experiment Example 
Scenario1 Clinic A Clinic B 
Attitudes of staff towards you Good Bad 
Chance of taking home a baby 25% 35% 
Continuity of contact with the same 
staff 
No Yes 
Time on waiting list for IVF attempt 18 months 18 months 
Cost to you of IVT attempt 
 
£1,500 £3,000 
Follow-up support No No 
Which Clinic would you prefer? (Please tick one box only) 
Prefer Clinic A Prefer Clinic B 
                                        
        (Ryan, 1999) 
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Similar to the payment scale, it is suggested that the DCE is a realistic representation 
of a real-life market as the respondent is faced with characteristics and price variations 
at which they must decide whether or not to purchase (Ryan et al., 2004). This provides 
the respondent with an understanding of the scenario which leads to reliable WTP 
estimates. DCEs also reduce strategic bias.  Strategic bias is reduced in the DCE as 
respondents are presented with only one bid, they cannot disproportionally influence 
the overall WTP estimate (Mitchell and Carson, 1989). This is in comparison to the 
open-ended and payment scale methods. Using the open-ended format, a respondent 
has no reference point and can state their maximum WTP pay. This format is highly 
vulnerable to strategic bias as the respondent can simply state the price they would like 
to pay as they are not guided by any reference price. While a range of values are 
presented to the respondent on a payment scale, the respondent can report a lower WTP 
value which represents what they would like to pay for the service rather than the true 
maximum value they are willing to pay. In a DCE, the respondents are presented with 
one bid, which is strategically selected to represent an acceptable market price for the 
service. This way, the respondent cannot strategically manipulate their WTP estimate. 
They either accept or reject the bid.  
 
However, this can lead to a disadvantage associated with the DCE that is referred to in 
the literature as “yea-saying”. This is when the respondents give a “Yes” answer to the 
offered bid as saying yes to the bid is deemed the socially desirable response (Yeung 
et al., 2006). “Yea-saying” can also occur when the respondent is presented with 
hypothetical pairs in a DCE. The respondent is forced to choose between the two pairs 
and in practice, the respondent may choose neither. While this can be minimised in the 
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design of the DCE by allowing respondents to opt-out or choose neither option, DCEs 
must acknowledge this risk when analysing results (Lancsar and Louviere, 2008). 
“Yea-saying” in DCEs can result in values which are biased in an upwards direction 
when compared to the open-ended format and payment scales (Ryan et al., 2004).  
Thus, the DCE generates higher WTP values in comparison to other elicitation 
formats. The final disadvantage associated with the discrete choice approach is the 
requirement for a large sample size. A large sample size is necessary due to the low 
level of information retrieved from respondents using the discrete choice approach 
(Kjaer, 2005).   
 
The information generated from the DCE can be enhanced by asking a follow-up 
question. This method is referred to as a discrete-choice with follow-up (Kjaer, 2005). 
Depending on the respondent’s first bid (accept or reject), the DCE with follow-up 
provides a second bid that is either increased (if initial bid is accepted) or decreased 
(if initial bid is rejected) from the first bid.  While this method does provide the 
researcher with more information, the format is subject to strategic bias as the 
respondent has more than one bid to choose from.  
 
There are conflicting views regarding the most appropriate elicitation format to choose 
when conducting a WTP study. A number of studies have been done which compare 
the various elicitation formats in healthcare studies (Frew et al., 2004, Ryan et al., 
2004). Frew et al (2004) compared the bidding game technique with the open-ended 
and payment scale formats. They found WTP values for colorectal cancer screening 
were higher when using the bidding game format than the WTP values estimated using 
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the open-ended or payment scale formats. The authors also found statistically 
significant differences in WTP values when respondents were presented with different 
starting bids.  They suggested that it showed the presence of starting-point bias in the 
bidding game. While the open-ended and payment scale formats are not subject to 
starting-point bias, neither is without criticism. As the open-ended format does not 
provide the respondent with any clues as to a reasonable valuation, the open-ended 
questions are difficult for respondents to answer and may result in hasty valuations. 
This raises concerns about the validity of open-ended questions as they do not reflect 
real-life situations for respondents. The payment scale alleviates this problem as the 
payment scale does reflect real-life situations due to the presentation of a range of 
values to the respondent with which they are familiar with.  
 
Conflicting with earlier concerns regarding the payment scale, Ryan, Scott and 
Donaldson (2004) found no evidence of range bias or starting-point bias associated 
with payment scale responses. The authors used an initial payment scale and an 
amended payment scale with a different range of values. They found no significant 
difference in the WTP values between both payment scales. This shows that starting 
point and mid-point bias was not an issue when using the payment scale. Guidelines 
for WTP studies indicate that the open-ended format should be avoided when 
conducting contingent valuation studies (Arrow et al., 1993, Donaldson et al., 1997, 
Johannesson et al., 1991). Consequently, payment scales and the discrete-choice 
formats are favoured in healthcare evaluations (Donaldson et al., 1997, Johannesson 
et al., 1991). 
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5.2.4 Methodological Issues 
 
There are a number of methodological issues which need to be addressed before 
implementing a WTP study to evaluate healthcare services. Ordering effects, 
embedding effects and protest zeros are three recurring methodological concerns that 
can arise when using any of the CVM elicitation methods (Fonta et al., 2010, Stewart 
et al., 2002).  
 
5.2.4.1 Ordering Effects 
 
The ordering effect is of concern when a study aims to estimate WTP values for more 
than one healthcare service. The ordering effect refers to the order in which the 
scenarios are presented to the respondent and whether this order impacts on their 
reported WTP estimates (Drummond et al., 2015, Stewart et al., 2002). When 
estimating WTP for three health care programmes (an increase in pain-relieving 
treatment for cancer patients, increase in number of heart operation and increase in 
community care services) Stewart et al (2002) tested for the existence of the ordering 
effect by examining if WTP values change when the services were presented to the 
respondents in a different sequence. Respondents in the study were told that each of 
the three services were competing for funding yet they were instructed to ignore the 
other two services when reporting their WTP value for each one (Stewart et al., 2002). 
The sample was divided in two and each sample was presented with the services in 
different arrangements. The order in sample 1 first presented the cancer service 
followed by the heart service and then the community care service. Sample 2 presented 
the community care service first followed the heart service and finally the cancer 
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service. Examining the mean WTP values for the three services, the researchers found 
the mean WTP values were different in both samples. If ordering effects were not 
evident, the mean WTP for the services would be consistent between the two samples.  
 
Stewart et al (2002) suggest that ordering effects may occur due to a concept known 
in the literature as fading glow. Fading glow is when respondents gain moral 
satisfaction or a warm glow from contributing to a publicly provided healthcare service 
(Stewart et al., 2002). The first good or service in a sequence usually receives the 
majority of this moral satisfaction. Stewart et al (2002) found that regardless of 
income, when valuing public goods respondents exaggerated their WTP for the first 
service in each sequence. The succeeding valuations are lower as contributing to the 
first presented programme generates the highest utility for the respondent. The authors 
suggest the respondents may have felt they met their social obligations once they 
contribute to the first programme (Stewart et al., 2002). 
 
In this current Irish research, more than one healthcare service is valued. Therefore, 
ordering effects may arise. However, the risk of ordering effects is reduced as the 
services are not competing with each other for funding as described in the study 
conducted by Stewart et al (2009). Also, the services are not publicly funded. 
Respondents are informed that access to the healthcare services rely on OOP payment 
made by the respondent to the health service provider. This reduces the risk of fading 
glow as the respondents have no incentive to generate moral satisfaction as they are 
not contributing to a publicly financed good.  The separate valuation of the healthcare 
services and the method of payment in this research negates the risk of ordering effects 
and warm glow.   
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5.2.4.2 Embedding Effect 
 
The embedding effect (also referred to as part-whole effect, symbolic effect or 
disaggregation effect) (Kahneman and Knetsch, 1992) is another methodological issue 
that needs to be controlled for when conducting a CV study. The embedding effect 
occurs when a respondents’ WTP for a good is not significantly different from the 
respondents’ WTP for the overall good from which the identified good is part of 
(Bateman et al., 1997, Beattie et al., 1998, Boyle et al., 1994, Morrison, 2000). In other 
words, a “respondent values a broader or narrower policy package than the one 
intended by the researcher” (Mitchell and Carson, 1989, p. 231). Respondents’ 
insensitivity to the characteristics of the good under valuation has significant 
implications for the reliability of WTP studies (Morrison, 2000).  
 
A detailed description of what the respondent is to value can potentially alleviate the 
embedding effect from a study (Mitchell and Carson, 1989). This is particularly useful 
for studies which aim to elicit a WTP value for a basket of goods. By identifying what 
is included in the package along with the various attributes of the service that are to be 
valued, the respondent can separate the embedded good from the overall good and 
provide an unbiased WTP value.  
 
Even though this research does not aim to elicit WTP values for a basket of goods, the 
scenarios included in the questionnaire provide detailed descriptions of the separate 
healthcare services so the respondents know exactly what attributes they are to value. 
Respondents provide WTP values for each individual service rather than a WTP value 
for a healthcare package. 
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5.2.4.3 Protest Zeros 
 
Protest zeros in WTP studies are a form of item non-response (Mitchell and Carson, 
1989). Protest zeros occur when respondents who object to the questionnaire simply 
do not respond and when respondents report a zero value for a good that they actually 
value (Carrere et al., 2008). Literature proposes reasons as to why respondents engage 
in this behaviour. When eliciting WTP values for a public good, some respondents 
consider placing a monetary value on public goods as unethical while others dispute 
that public goods should be provided “free of charge” (Halstead et al., 1992). 
Distinguishing protest zeros from respondents who report a genuine zero WTP is 
challenging. Debriefing questions are generally used by researchers to distinguish 
protest zeros from true zero values (Fonta et al., 2010). When eliciting WTP for a 
proposed community-based malaria control scheme, Fonta et al (2010) used the 
following debriefing questions to identify a protest zero; “do not have faith in 
community trust fund”, “wait for government” and “do not know”. To categorize a 
true zero value, the authors included the following two debriefing questions; “cannot 
pay due to lack of income” and “the scheme is not important to us”. Debriefing 
questions of this nature are typically used in face-to-face interviews (Hughes and 
DeMaio, 2002). It is difficult to include debriefing questions in a self-completion 
questionnaire as there is no opportunity for detailed probing questions.  
 
Protest zeros have no economic significance and do not reflect the patients’ preference 
for the service (Lindsey, 1994). In WTP studies, it is inevitable that protest zeros will 
occur and the correct approach needs to be adopted to effectively deal with this. One 
of the most commonly used strategies to deal with protest zeros is to remove the protest 
responses. This approach results in sample selection bias if the sample characteristics 
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of the protest respondents are different. Therefore, discarding protest zeros can result 
in biased estimates. The second solution to deal with protest zeros is to address them 
directly in the analysis. As there may be other reasons for zero responses other than a 
genuine zero WTP, it is possible that different factors influence WTP values and zero 
values (Donaldson et al., 1998). Positive WTP values are as a result of an economic 
decision-making process whereas zero responses are due to both economic responses 
and protest responses. Health economics literature proposes the double-hurdle 
approach as the best method for dealing with zero values and protest responses 
(Halstead et al., 1992). The econometric analysis in this study uses a two-part model 
to control for selection bias as a result of zero values. This is discussed in more detail 
in Section 5.4 of this chapter.  
 
5.2.5 Review of WTP Healthcare Studies 
 
There is large variation in healthcare WTP studies in terms of the study objectives, 
study population, the elicitation format and the consequent analysis of the study (Baker 
et al., 2008, Diener et al., 1998). While there is no standard method of designing and 
conducting a WTP study, reviewing the healthcare literature and acknowledging best 
practice guidelines is the most effective way to design a reliable study. This section 
reviews previous healthcare WTP literature in terms of the study objectives, the study 
population, the elicitation format, the econometric analysis and the results.  
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Table 5.1 Synopsis of WTP Healthcare Literature 
Author(s) Date Study Population Outcomes Elicitation Method Econometric Analysis Results 
Asgary et al 2004 Face-to-face interviews 
with the head of rural 
households in Iran (N = 
2139) 
Estimate the demand and 
WTP for health insurance. 
Iterative bidding game Regression analysis  Age, education level, 
health care facilities, 
access to medical 
care services, and 
households’ medical 
needs statistically 
significantly impacts 
on WTP for health 
insurance. Average 
WTP, $2.77 per 
month.   
Baji et al 2012 Data from two DCE 
experiments (used in a 
national survey) which 
focus on 2 healthcare 
services (N =1037) 
Elicit consumers’ 
preference about the choice 
of health care providers for 
out-patient service (visit to 
specialist) and in-patient 
service (planned surgery).  
Results from DCE Binary probit with random 
effects. Backward stepwise 
procedure was 
implemented for model 
specification.  
Young and elderly 
consumers with 
higher education and 
income are WTA a 
higher cost for the 
improvement of the 
quality of health care 
services. 
Basu 2013 Health and Retirement 
Survey (N = 678). 
Estimate WTP to prevent 
Alzheimer’s Disease 
Double-bounded technique Interval regression 
analysis  
Patients with higher 
perceived risk of 
Alzheimer’s   and 
greater household 
wealth report a higher 
WTP value.  
Bergmo and 
Wangberg 
2007 Patients were recruited 
via a questionnaire given 
to all adults (>18 years) 
in the waiting area of a 
primary clinic in Norway 
(N = 199) 
Patients’ WTP for electronic 
communication with their 
GP.  
Open-ended WTP question Summary statistics are 
produced for WTP 
amounts. Spearman's 
correlation coefficient. 
Mann-Whitney U test for 
between group differences. 
Logistic regression.  
52% were willing to 
pay for electronic GP 
contact. The group of 
patients with access 
(Intervention) 
revealed a 
significantly lower 
WTP than the group 
without such access 
(Control group).  
229 
 
Carrere et al 2011 Prospective, non-
randomized study. Face-
to-face interviews with 
patients in a 
Comprehensive Cancer 
centre, Lyon (N = 139).  
Estimate WTP for home 
blood transfusion and to 
analyse determinants of 
their choice 
Bidding process  Summary statistics for 
patients’ characteristics 
and WTP amounts. Type 
11 Tobit and a truncated 
regression model to check 
the robustness of the 
results.  
The median WTP 
was €26.50. Long 
home-hospital 
distance, poor quality 
of life and previous 
experience of home 
care were the 
determinants of 
patients’ WTP. 
Donfuet, 
Makaudze, 
Mahieu and 
Malin 
2011 A face-to-face 
questionnaire was 
administered to rural 
households in Bandjoun 
(West Province, 
Cameroon) during 
November 2009 (N = 
410) 
Identifying the factors that 
influence WTP for a 
community-based 
prepayment scheme. 
Double-bounded discrete 
choice 
Heckman two step. 
Participating equation for 
whether or not the 
respondent agrees to take 
part in the valuation. And 
a WTP equation.   
Age, religion, 
profession, 
knowledge of 
community-based 
health insurance, 
awareness of usual 
practice in rural areas, 
involvement in 
association and 
income are the key 
determinants of WTP. 
WTP 2.5US dollars 
/person/month. 
Golinowska 
and Tambor 
2012 Household budget 
surveys of the CSO in 
Poland and a 
representative 
questionnaire (N = 723) 
and (N = 156) 
Analyse the level and 
structure of OOP 
expenditure in Poland and 
factors influencing patients’ 
WTP.  
Not clear what elicitation 
format was used. 
Logistic Regression  Age, income, health 
status and place of 
residence influence 
patients’ WTP. 
Liu et al 2013 Non-institutionalised 
elderly residents in Hong 
Kong (60+) (N = 1164). 
What patients are WTP for 
private primary care 
services 
Payment Scale. All 
respondents shown the same 
card. 
Univariate analysis, cross-
tabs, ANOVA tests. 
Multivariate analysis. OLS 
for each type of service. 
Participation equation and 
consumption equation to 
address selection bias.  
Age negatively 
impacts WTP. 
Income and higher 
health status increase 
WTP. WTP for 
chronic conditions 
and preventative care 
fell below the market 
price.  
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Milligan, 
Bohara and 
Pagan 
2010 Survey data from the 
2002 Health and 
Retirement Study (N = 
463) 
Assessing WTP for cancer 
prevention 
Double-bounded elicitation 
technique 
Threshold modelling. Two 
equations; one measuring 
Ln(WTP) and the other 
measuring the probability 
of getting cancer. 
Age is negatively 
related to WTP. 
Income and the 
probability of 
developing cancer are 
positively related to 
WTP. 
Nosratnejad et 
al 
2014 Cross-sectional study 
using a structured 
telephone interview with 
household heads in Iran 
(N = 290)  
Estimated WTP for health 
insurance in Iran to suggest 
an affordable social health 
insurance. 
Double bounded discrete 
choice  
Interval Regression 
analysis 
Mean WTP is $5.5US 
per person. 
Education, family 
size, and the number 
of insured family 
members and income 
are significant 
variables of the WTP.  
Olsen and 
Donaldson 
1998 Residents in Troms in 
Norway (N =143) 
WTP in increased 
earmarked taxation for three 
different health care 
programmes: a helicopter 
ambulance service, more 
heart operations and more 
hip replacements. 
Payment Scale  OLS regressions Same 
regression analysis for 
each programme.  
For hips, women are 
willing to pay more, 
education and age 
have a sig. negative 
impact on WTP for 
helicopters.  
Source: Authors Own 
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5.2.5.1 Study Objectives and Study Population 
 
Previous studies have assessed WTP for healthcare services in general (Baji et al., 
2012, Golinowska and Tambor, 2012), WTP for health insurance (Asgary et al., 2004, 
Donfouet et al., 2011, Nosratnejad et al., 2014), WTP for primary care services; both 
public and private (Bergmo and Wangberg, 2007, Liu et al., 2013) and WTP for 
prevention services such as cancer and Alzheimer’s disease (Basu, 2013, Milligan et 
al., 2010). It is common for WTP studies to assess WTP values for more than one 
service (Olsen and Donaldson, 1998). Generally, WTP is elicited for programmes or 
services that exist in the market at the time of the study (Donaldson, 1990, Johannesson 
et al., 1991, Neumann and Johannesson, 1994) but studies can also elicit WTP for 
hypothetical programmes or services (O'Brien et al., 1995, Thompson, 1986). This 
research assesses patients’ WTP for three existing healthcare services in Ireland; two 
of which are primary care services (blood tests and prescription drugs) while the other 
is a secondary healthcare service (MRI scan). The nature of these services (public or 
private) is determined by the access route (as described in Section 5.1.2) the patient 
takes, or is directed to take to utilize these services.  
 
WTP for services may be elicited from current users and potential users of the service 
(O'Brien and Gafni, 1996). Best practice guidelines recommend that WTP values are 
estimated from all patients who are affected directly or indirectly by the service; not 
just current patients (O'Brien and Gafni, 1996). Focussing on current patients leads to 
biased WTP estimates as patients with previous experience of the service could yield 
very different WTP values than non-users (O'Brien and Gafni, 1996). This research 
controls for this bias by asking patients whether they have used each of the services 
before.   
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5.2.5.2 Elicitation Methods 
 
The elicitation formats used in the studies are either direct (open-ended, payment scale 
or bidding game) or discrete (discrete choice experiment) (Klose, 1999). A review 
including 66 articles conducted by Lin et al (2013) reveal DCEs (30.3%) to be the 
most widely used elicitation format in healthcare literature. The authors found payment 
scales (15.2%) to be the second most commonly occurring method followed by the 
bidding game format (13.6%) and finally open-ended questions (10.6%). The review 
found that a number of studies (21.2%) use more than one elicitation format (Olsen 
and Smith, 2001, Ryan and Watson, 2009, van Helvoort-Postulart et al., 2009, Whynes 
et al., 2003). Research shows the elicitation format is influenced by the mode of data 
collection and vice versa. Studies which use bidding techniques conduct face-to-face 
interviews with the study population (Asgary et al., 2004, Basu, 2013, Carrere et al., 
2008, Donfouet et al., 2011, Milligan et al., 2010, Nosratnejad et al., 2014). Elicitation 
formats requiring interviews or interactive communication with potential respondents 
are costly and time-consuming to implement. The most common mode of data 
collection is self-administered questionnaires (Lin et al., 2013). Self-administered 
questionnaires are easily produced and distributed to a large sample. While there is no 
opportunity to probe further information from the respondents, self-administered 
questionnaires allow for effective data collection thereby generating a large sample. 
Consequently, due to time and financial constraints, a self-administered questionnaire, 
containing a payment scale is chosen as the data collection method for this research. 
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5.2.5.3 Previous Method of Analysis 
 
Three features shape the method of analysis of WTP studies. Firstly, the type of WTP 
question asked influences the analysis, questions regarding respondents’ preferences 
about the alternatives being offered influence the type of analysis and finally, 
underlying theoretical implications influence the type of analysis and the nature of the 
variables that should be included (Donaldson et al., 1998).  
 
Analysis of WTP data generally begins with descriptive statistics of patient 
characteristics and the mean and median WTP values. Depending on data distribution, 
parametric t-tests or non-parametric Kruskal-Wallis and Mann Whitney tests are 
implemented to test for significant difference in WTP values between groups (Baji et 
al., 2012, Bergmo and Wangberg, 2007, Carrere et al., 2008, Liu et al., 2013, 
Nosratnejad et al., 2014, Olsen and Donaldson, 1998). Depending on the nature of the 
WTP question (elicitation format) and consequent dependent variable, the econometric 
analysis is determined. Studies using payment scales and bidding games generally 
have a continuous dependent WTP variable and consequently implement an OLS 
regression to identify the factors associated with patient WTP values (Asgary et al., 
2004, Liu et al., 2013, Olsen and Donaldson, 1998). The double-bounded technique 
can give way to various econometric analysis. For example, if the dependent variable 
has interval censoring, in other words, the researcher knows which ordered category 
the observation falls into, an interval regression can be used (Basu, 2013, Nosratnejad 
et al., 2014).  
 
WTP is viewed as a two-step decision making process. The patient initially decides 
whether or not they are willing to pay for the service and if they decide they are willing 
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to pay, the patient must decide on the maximum amount they are WTP. As the patient 
decides whether they are willing to pay or not, the decision to pay is a non-random 
selection process. The non-random selection process can lead to sample selection bias 
in WTP studies. Sample selection bias is defined as an “Error introduced when the 
study population does not represent the target population” (Delgado-Rodriguez and 
Llorca, 2004, p. 240). Depending on the goal of the analysis, a Heckman selection 
model or a two-part model can be implemented in WTP studies to control for sample 
selection bias. The Heckman selection model generally uses a probit model to begin 
with to estimate the probability of observing a positive WTP. The second step in the 
Heckman model uses an OLS regression on the observations that have a WTP value 
above zero. A two-part model follows the same two-step equation approach; the first 
equation is the participation equation and estimates whether or not a patient is willing 
to pay for the service. The second equation in the model is the consumption equation 
which estimates how much the patient is WTP for the service. A two-part model is 
appropriate if the second part of the model (the regression) is a result of taking the 
logarithm of zero values (Manning et al., 1987). This is generally the case in WTP 
studies where the second equation focuses on the amount patients are willing to pay, 
therefore only including respondents with a positive WTP value. If the objective of the 
analysis is to predict the value of the dependent variable observed in the absence of 
selection, the Heckman approach is most appropriate. When the objective is to predict 
an actual response, a two-part model is more sufficient (Manning et al., 1987). 
 
Literature reveals the type of models included in the two-part models are influenced 
by the WTP question and the nature of the dependent WTP variable. Using a bidding 
game process to elicit WTP values, Carrere et al (2011) used a Type 11 Tobit model 
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to measure French cancer patients’ WTP for home blood transfusion. This is a two-
part equation controlling for sample selection. When estimating elderly patients’ WTP 
values for primary care services in Hong Kong using a payment scale, Liu et al (2013) 
initially used an OLS regression of individuals’ WTP values on their characteristics. 
However, the large number of zero WTP values prompted the use of the Heckman 2-
step approach. Donfuet et al (2011) implemented a double-bounded discrete choice 
technique to elicit WTP values for a community-based prepayment scheme in 
Cameroon. The researchers also used a Heckman 2-step approach to analyse the 
results.  
 
Finally, when conducting the analysis of a WTP study, Mitchell and Carson (1989) 
recommend to test the construct validity of the method. Construct validity determines 
if the data is consistent with theoretical expectations that should be present if the WTP 
values are measuring the values as intended by the researcher (Drummond et al., 2015, 
Klose, 1999).  There are two concepts from economic theory that can be tested. First, 
a positive income elasticity of demand is expected, i.e. a higher income level should 
be associated with a higher willing to pay (Drummond et al., 2015). Second, the more 
of a positively valued good provided by a programme, the higher a respondents’ WTP 
(Drummond et al., 2015). Construct validity can be tested by regressing WTP values 
on individual characteristics.  
 
5.2.5.4 Factors Influencing WTP Values 
  
The association between WTP values and patient characteristics vary across studies. 
Some studies indicate that WTP values are positively influenced by age (Asgary et al., 
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2004, Bergmo and Wangberg, 2007) while other studies find younger patients are more 
willing to pay than older patients (Basu, 2013, Donfouet et al., 2011, Golinowska and 
Tambor, 2012, Liu et al., 2013, Milligan et al., 2010, Olsen and Donaldson, 1998). 
Most studies find a positive relationship between WTP values and patient income (Baji 
et al., 2012, Basu, 2013, Donfouet et al., 2011, Golinowska and Tambor, 2012, Liu et 
al., 2013, Milligan et al., 2010, Nosratnejad et al., 2014) and education (Asgary et al., 
2004, Baji et al., 2012, Nosratnejad et al., 2014). Patient health status is also found to 
influence WTP values. The better the health status of the patient, the higher the WTP 
value (Golinowska and Tambor, 2012, Liu et al., 2013). Conversely, patients with a 
lower health status are less willing to accept charges for healthcare services (Baji et 
al., 2012). When eliciting WTP values for preventative services, the patient’s 
perceived risk of the disease positively influences their WTP value (Basu, 2013, 
Milligan et al., 2010). A patient’s previous experience of the service is found to 
influence their WTP. A number of studies have found previous experience to 
positively impact on patients’ WTP (Carrere et al., 2008, Donfouet et al., 2011) while 
Bergmo and Wangberg (2007) found previous experience reduced patients’ WTP for 
electronic communication with their GP.  
 
Similarly, while estimating patients’ WTP for three selected healthcare services, this 
research controls for age, income, health status and previous use of the particular 
service. 
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5.2.6 Conclusion 
 
The articles reviewed in Sections 5.2.5.1 to 5.2.5.4 reveal age, income, education level, 
health status and previous experience of the service as significant factors influencing 
patients’ WTP value for healthcare services. Patients’ WTP for a healthcare service 
and the factors affecting this value need to be identified to provide evidence to promote 
sufficient access and affordability to healthcare services. The findings within these 
studies are varied with respect to the elicitation format such as: open-ended, bidding 
game format, payment scale, discrete-choice and discrete-choice with follow-up, and 
the consequent data collection method that was appropriate to facilitate the elicitation 
method such as: interviews, self-completion questionnaires, telephone interviews, 
face-to-face questionnaires and secondary sources such as the Health and Retirement 
Study in the US (Asgary et al., 2004, Basu, 2013, Bergmo and Wangberg, 2007, 
Donfouet et al., 2011, Milligan et al., 2010, Nosratnejad et al., 2014). Overall, the 
study findings are consistent with theoretical expectations that patients with a higher 
income level are willing to pay more for healthcare services and patients with a lower 
income level are willing to pay less for healthcare services.  
 
As noted from the studies in this review, the data sources for the studies are 
predominantly primary sources (Asgary et al., 2004, Baji et al., 2012, Basu, 2013, 
Bergmo and Wangberg, 2007, Carrere et al., 2008, Donfouet et al., 2011, Milligan et 
al., 2010, Nosratnejad et al., 2014, Olsen and Donaldson, 1998) while two studies used 
a secondary data source to estimate patients’ WTP (Basu, 2013, Milligan et al., 2010). 
As this research aims to estimate what patients are willing to pay for three specifically 
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selected healthcare services, primary data is necessary to answer the research question 
effectively.  
 
The originally designed questionnaire that is specifically constructed for this research 
was designed in a manner which controls for the methodological issues that arise in 
WTP studies as reviewed in this section; ordering effects, embedding effect and protest 
zeros. The WTP scenarios presented in the research are designed to minimise these 
effects as described in Section 5.2.4. 
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5.3.11 A Comparison of the Factors Affecting WTP Decisions and how much 
Individuals are WTP  
 
This section compares the results of the Chi2 and Fishers Exact test in Section 5.3.9 
with the results of the Mann Whitney and Kruskal-Wallis tests in Section 5.3.10. The 
purpose of this analysis is to identify whether similar patient characteristics influence 
both the patients’ decision to pay for the selected service and the amount they are 
willing to pay for the service.   
 
When analysing these sections, it is apparent that socio-economic characteristics such 
as; PHI cover, GMS cover, DPS cover, education level and income are the main drivers 
in the patients’ decision to pay and the amount patients’ are willing to pay for each 
service.  
 
While patients’ WTP for a brain  MRI scan was the only service to be significantly 
related to patients’ gross monthly income level, the other significant socio-economic 
characteristics serve as a proxy for income such as; PHI cover, GMS cover, DPS cover 
and education. In Ireland, patients with higher income levels are those who are more 
likely to purchase PHI (HIA, 2014c). The descriptive statistics shown throughout 
Tables 5.8 and 5.9 indicate that patients with PHI cover are willing to pay more; to 
receive blood tests in the GP surgery; for quicker access to MRI scans; for receiving a 
branded version of a prescription drug relative to patients who do not have PHI cover. 
These significant relationships are consistent with economic theoretical expectations 
that people earning a higher income are willing to pay more. As discussed in Section 
240 
 
5.2.5.3, O’Brien and Gafni (1996) refer to this concept as construct validity which is 
an indication of reliable WTP values.  
 
Construct validity is also confirmed when analysing the relationship between patients’ 
WTP and GMS status. In Ireland, GMS status is granted primarily on an income basis; 
individuals below a certain income threshold are granted a GMS card. Table 5.8 and 
5.9 show GMS patients are less willing to pay for blood tests, a brain MRI scan and a 
branded version of a prescription drug.  These significant relationships are expected as 
GMS patients have a lower income and as suggested by economic theory, these 
patients are willing to pay less. 
 
It is expected that patients with a higher education have a higher income level and 
subsequently, are willing to pay more for a service. Tables 5.8 and 5.10 confirm this 
expectation as patients with a third level education are willing to pay more for blood 
tests, a brain MRI and a shoulder MRI scan. More specifically in Table 5.10, patients 
with a third level education are found to be willing to pay more than patients with a 
lower education level.   
 
In addition to socio-economic factors, patients’ previous experience of the healthcare 
services also significantly influences patients’ WTP. Patients who have previously had 
a blood test and patients who have previously had an MRI scan are willing to pay more 
for these services than patients who have not used these services before.  
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5.3 Methodology 
 
5.3.1 Introduction  
 
Section 5.3 presents the methodology used to answer the research question in this 
chapter; 
 
What are Irish healthcare consumers willing to pay for three selected healthcare 
services (Blood tests, MRI scans and branded versus a generic prescription drug)?  
 
A cross-sectional questionnaire was purposely designed to collect primary data from 
patients attending selected GP surgeries in Cork. The structure of the methodology for 
this research follows the best practice guidelines developed by O’Brien and Gafni 
(1996). O’Brien and Gafni’s (1996) framework comprises nine considerations grouped 
into five general questions; 1) what question(s) does the research need to answer? 2) 
what type of measure is appropriate (WTP or Willingness-to-Accept (WTA))? 3) who 
forms the study sample, users or potential users of the healthcare services? 4) what 
characteristics of the healthcare services need to be defined in the scenarios? 5) what 
is the most appropriate elicitation format? (O'Brien and Gafni, 1996). Each of these 
questions is addressed in this section. 
 
Section 5.3.2 describes the location of the data collection. Section 5.3.3 describes the 
data source. Section 5.3.4 explains the data collection procedure. Section 5.3.5 
describes the questionnaire construction. Section 5.3.6 will present the descriptive 
statistics on the population sample. Section 5.3.7 presents the descriptive statistics on 
patients’ WTP for each of the selected healthcare services. Section 5.3.8 presents the 
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descriptive statistics on patients’ previous use of the healthcare services while Sections 
5.3.9 to 5.3.11 present the relationships between WTP and patient characteristics.  
Section 5.3.12 concludes the methodology section.  
 
5.3.2 Location of Data Collection 
 
Patients attending selected GP surgeries in Cork formed the data source. As suggested 
by the best practice guidelines, WTP values may be elicited from current users or 
potential users of the healthcare service that are the subject of evaluation (O'Brien and 
Gafni, 1996). As all GP surgeries provide and/or refer to the three selected healthcare 
services in this research, the waiting room of GP surgeries is an appropriate location 
for data collection as patients included in the sample are either current users or 
potential users of the healthcare services being valued.  
 
Initially the questionnaires were to be distributed in pharmacies throughout Cork as 
patients waited for their prescriptions to be dispensed. This was because this 
questionnaire was initially only designed for Chapter 4 which focuses on prescription 
drugs. The decision was then made to distribute the questionnaire in GP surgeries, and 
following this decision, the questions for this chapter were added in. GP waiting rooms 
were identified as an appropriate location as patients have no choice but to wait for 
their consultation, therefore, having more time to complete the questionnaire.121 
                                                          
121 As the questionnaire also collected data for the previous chapter in this thesis, “What impact have 
prescription drug user charges had on patient behaviour in Ireland?” this added to the length of the 
questionnaire and it was important respondents would have sufficient time to complete the entire 
questionnaire in order to provide data to answer both research questions.  
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5.3.3 Data Source 
 
Access to the GP clinics was a continuing process (Marshall and Rossman, 2010, 
Robson, 2011). Initial contact was made with a doctor practising in Ballincollig, Co. 
Cork, Dr. Eamonn O’Grady.122 Liaising with Dr. O’Grady, a list of 10 surgeries in 
Cork was generated as possible locations for data collection. There are currently 2,500 
GPs in Ireland (HSE, 2013c) and 394 GPs practicing in Cork (PCRS, 2013).123 A target 
of 10 GP surgeries was chosen due to time and financial constraints. Consequently, a 
convenient, non-probability sample forms the sample for this research. While the fast 
and inexpensive nature of this method of sampling is an advantage there is the inherent 
bias that a convenience sample may not be representative of the study population 
(Gravetter and Forzano, 2012). This research attempts to reduce this bias by including 
at least one GP surgery from each of the four Local Health Offices (LHO) in the Cork 
HSE region; North Cork, West Cork, Cork South Lee and Cork North Lee (see Table 
5.2). Table 5.2 shows three surgeries included in the sample are found in the Cork 
South Lee region while there is only one GP representative for each of the other LHOs. 
This generates concerns regarding over-representation of Cork South Lee. However, 
Cork South Lee is the largest LHO in Cork with 156 GPs (PCRS, 2013), therefore it 
was important for the sample to sufficiently represent this area. Representation bias 
was further reduced as GPs in Ireland treat all patients. Consequently, including 
patients from the four LHO regions in Cork controls for varying patient demographics 
and socio-economic characteristics.  
 
                                                          
122 Dr. Eamonn O’Grady became the supporting GP for the data collection process. 
123 This figure is a combination of the number of GPs in Cork South Lee (156 GPs), Cork North-Lee 
(130), North Cork (62) and West Cork (46) (PCRS, 2013). 
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The contact process involved a phone call to each surgery to introduce the researcher 
and the research and to request that the questionnaire be distributed in the surgery. 
Following a request for the surgery’s email address and with permission from the 
administration staff, a follow-up email was sent to each surgery with a cover letter 
from the supporting GP (see Appendix C.1) and a copy of the questionnaire (see 
Appendix C.2).  Of the 10 surgeries contacted in Cork, six of the surgeries agreed to 
the distribution of the questionnaire to patients in their waiting rooms (see Table 
5.2).124 Following best practice, this access approach was adopted as recommended by 
Saunder, Lewis and Thornhill (2009).  
 
The Social Research Ethical Committee (SREC) in University College Cork approved 
the research protocol and the questionnaire (see Appendix C.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
124 The overall excuse for refusal was concerns regarding patient confidentiality and fears that patients 
may feel uncomfortable disclosing information required in the questionnaire such as income level. 
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Table 5.2 General Practitioner List 
Surgery 
Number 
Contact Doctor Surgery 
Name 
Address Local Health Office 
1 Dr. Gerard 
O’Shaughnessy 
Skibbereen 
Medical 
Centre 
Market Street, 
Skibbereen, 
Cork. 
West Cork 
2 Dr. Denis 
Twomey 
Classes Lake 
Medical 
Centre 
Classes Lake, 
Ballincollig, 
Cork. 
Cork South Lee 
 
3 Dr. Tom English Broad lane 
Family 
Practice 
72 Great 
William 
O’Brien Street 
Cork North Lee 
4 Dr. Eamonn 
O’Grady 
The Clinic* Old Quarter 
Ballincollig, 
Cork 
Cork South Lee 
5 Dr Eamonn 
O’Grady  
Barnagore* Ovens, Co. 
Cork 
Cork South Lee 
6 Dr. Brendan 
Payne 
High Street 
Medical 
Centre 
High Street, 
Newmarket, 
Co. Cork  
North Cork 
Note: *The data collected from the Clinic and Barnagore practices were merged together by the 
administration staff as the same contact doctor was located in both.  
Source: Authors Own 
 
5.3.4 Data Collection Procedure 
 
Questionnaire distribution began in December 2014 and finished at the end of January 
2015. Due to the convenient nature of the sample and based on previous literature, 300 
patients were sampled. Questionnaires were randomly distributed by the 
administration staff to patients over 18 years of age as they entered the surgeries. 
Administration staff were given a brief to deliver to the potential respondents (see 
Appendix C.4). In this brief, potential respondents were informed that this 
questionnaire was part of a research project in University College Cork and they were 
assured anonymity. The respondents were advised to complete the questionnaire as 
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they waited for their consultation with the doctor. The patient was then invited to return 
the completed questionnaire to a clearly labelled box provided at reception. On 
average, questionnaires were distributed by the administration staff in each surgery for 
4 weeks during this two-month period. These two months were chosen for data 
collection as December and January are two of the busiest months in a GP practice 
(according to expert opinion). These busy periods would allow for a larger sample size 
within this short timeframe.   
 
It is important to note that face-to-face interviews were another consideration for data 
collection but this method was not conducive to generating a large sample size and 
proved to be more time-consuming in the pilot study. The nature of the data collected 
in the questionnaire was sensitive and therefore, it was not appropriate to conduct such 
interviews in this location. 
 
5.3.5 Questionnaire Construction 
 
When deciding on the data collection instrument, it was important to acknowledge the 
sample source in order to ensure a reliable sample and ensure minimum disruption to 
the services in the GP waiting room. Interviews with patients were not deemed 
appropriate due to the enclosed nature of GP waiting rooms. Patient confidentiality 
would be at risk in this situation. Therefore, a self-completion questionnaire was most 
appropriate to answer the research question accurately. This methodology allowed for 
efficient data collection from a large group of respondents.  
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As the same information was required from all patients in the six surgeries, a 
standardized self-completion questionnaire was suitable. The self-completion 
questionnaire also ensured anonymity for the patient as possible reactive effects of 
direct contact between the researcher and respondent were eliminated (Sim and 
Wright, 2000). However, this eliminated the possibility to explore questions in depth 
or seek clarification from the respondent (Sim and Wright, 2000). Due to the factual 
nature of the answers required this concern was overcome due to a well-constructed 
standardized questionnaire including pre-determined responses generated from the 
literature review and discussions with the supporting GP. Further clarification from 
the respondent was not necessary. Another disadvantage associated with this 
methodology is that there is no guarantee the respondent will answer the questionnaire 
as anticipated by the researcher i.e. at the correct time or in the correct order (Sim and 
Wright, 2000). This was controlled using clearly labelled instructions and questions 
throughout the questionnaire.  
 
To achieve reliable results, the questionnaire was easy-to-follow and used clear 
direction and instructions. This was accomplished using factual questions for the 
majority of the questionnaire. The reliability of the questionnaire was tested by 
conducting a pilot study (1st and 2nd July 2014). The pilot study was conducted in two 
GP surgeries in Cork; The Clinic and Classes Lake Medical Centre where 10 surveys 
were distributed and collected in each surgery. Consistent reliable results were found 
which indicated a reliable questionnaire had been constructed. Assessing the validity 
of the questionnaire proved to be more difficult as validity is usually established after 
the event (Oppenheim, 1992). Following the guidelines of O’ Brien and Gafni (1996), 
the validity of the questionnaire was conducted by examining the relationship between 
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the independent variables and the dependent variables to examine the conformity of 
the results with theoretical explanations (See Sections 5.3.9, 5.3.10 and 5.3.11). If the 
expected results were found, the validity of the measurement was confirmed (O'Brien 
and Gafni, 1996).  
 
To contain costs, the questionnaire was printed in black and white; except for page 5 
of the questionnaire. This was due to colour coded instructions that were necessary to 
include on this page. The questionnaire was printed back-to-back which resulted in 
two pages in total. It was acknowledged that shorter questionnaires with concise 
completion time encourage a higher response and this was taken into consideration in 
the questionnaire design process (Dillman, 2000). This was important as the patient 
was completing the questionnaire in the GP waiting room and it was the researcher’s 
aim that patients would complete and submit the questionnaire before their 
consultation. This reduced the risk of incomplete and/or mislaid questionnaires.  
Each questionnaire included an introduction to inform potential respondents of the 
questionnaire’s aims and why this area of research was chosen. In addition, 
respondents were informed why they were chosen as a suitable candidate. Once they 
agreed to take part, they were asked to indicate this on the attached consent form.  
 
The questionnaire required information regarding community drug cover, PHI cover 
and patients’ income level. Due to the confidential nature of this information, it was 
assured that this information would not be disclosed to anyone. To ensure anonymity, 
the respondents’ name was not required on the questionnaire. Respondents are more 
willing to provide information if they know the questionnaire is anonymous (Babbie, 
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2009). The potential respondent was advised that participation was voluntary and they 
could leave the questionnaire at any stage.  
 
Due to the nature of the questionnaire, a debriefing process was not necessary. 
However, if the respondent had questions regarding the questionnaire (before/after 
completion) they could consult a list of FAQs, which were available at the reception 
of the surgery (see Appendix C.5).  
 
In the questionnaire itself, there are three sections in total. The questionnaire adopted 
a funnel approach i.e. it began with broad demographic questions such as the 
respondent’s age and gender, socio-economic variables such as education, nationality 
and healthcare cover. The questions then narrowed down to measure the dependent 
variables; WTP for blood tests, WTP for MRI scans and WTP for a branded over a 
generic prescription drug.   
 
The following paragraphs will discuss the three sections included in the questionnaire 
to identify and justify the nature of the variables included in each section.  
 
Section 1 explored patient demographics, community drug cover, PHI cover, health 
status and number of chronic illnesses. This section included nominal, continuous and 
categorical variables in order to generate an understanding of the customer base in the 
GP surgeries. Section 2 measured patients’ income in terms of their monthly gross 
income level. To minimise non-response for this variable, respondents were presented 
with an interval scale including 6 ranges. Finally, Section 3 measured the dependent 
variables which estimate patients’ WTP for the identified healthcare services. The 
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dependent variables are continuous in nature as they measure the monetary value the 
patients place on each healthcare service.  
 
The majority of the questions that appeared in the questionnaire are closed-ended. This 
research is of a quantitative nature, therefore, valid and reliable results were required. 
Closed-ended questions were chosen as they are less time-consuming and more 
concise given the time constraints placed on the patients (Oppenheim, 1992). 
Consequently, closed-ended questions are associated with a high response rate 
(Dillman, 2000). This permitted easier interpretation and coding of the data. The 
codebook can be found in Appendix C.6. 
 
5.3.5.1 Development of Elicitation Format 
 
As described in Section 5.2.3 of this chapter, various questionnaire formats can be 
implemented in contingent valuation studies such as; open-ended, bidding, payment 
scale, discrete choice and discrete choice with follow-up questions (Smith 2000). Each 
format has its own strengths and weaknesses to be assessed before deciding on the 
most appropriate format. Immediately, the open-ended format was dismissed for the 
current research due to the strategic bias that arises when using this format (Smith, 
2000). The bidding game was also rejected due to the nature of the format which 
requires interview techniques to present the different bids to the respondents.  Before 
finalising the elicitation format, a number of issues had to be addressed; 1) The length 
of the format was of concern as the WTP estimates were collected on the same 
questionnaire that was used in chapter 4 of this PhD; “What impact do prescription 
drug user charges have on patient behaviour in Ireland?” 2) Selecting a feasible method 
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for measuring WTP was constrained. Time and monetary constraints determined the 
method of the elicitation format. The DCE was deemed inappropriate as a large sample 
size is necessary for this format to be efficient, therefore requiring a lengthy data 
collection time-frame. Similar to the bidding game format, a discrete choice with a 
follow-up question was also considered unsuitable for this research as interviewing 
patients for the follow-up questions was not possible. Due to these limitations and the 
identified mode of data collection (self-completion questionnaire), a payment scale 
was identified as the most appropriate method of elicitation.  
 
5.3.5.2 Payment Scale Construction 
 
The elicitation format was constructed in three phases. First, the CVM literature in 
healthcare was reviewed to identify the general structure of the elicitation format. 
Second, once the format was constructed, it was reviewed by a healthcare professional 
for content validity. Finally, the entire questionnaire including the elicitation format 
was pilot tested on 10 patients between the 1st and 2nd of July 2014.  
 
As explained in Section 5.2.3 of this chapter, the payment scale technique was 
developed by Mitchel and Carson (1981) and is one of the most widely used elicitation 
format in healthcare studies (Klose, 1999, O'Brien and Gafni, 1996, Smith, 2000). 
Payment scales present a range of values to respondents. Respondents indicate the 
maximum amount they are willing to pay. The scale begins at 0 and presents 
incremental values with a blank space at the end for respondents to fill in WTP if it is 
beyond the range presented (Smith, 2000). There are a number of advantages 
associated with this format; payment scales mimic real-life situations (Ryan et al., 
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2004). In comparison to the open-ended format and the bidding game, payment scales 
provide a context for the bids which reduces outliers, they encourage a high response 
rate when the scenarios are easily interpreted (Donaldson et al., 1995) and a strong 
association is found between WTP and ability to pay when using payment scales 
(Donaldson et al., 1997). This refers to the concept of construct validity as discussed 
in Section 5.2.5.3. WTP results elicited using payment scales are consistent with 
theoretical expectations such as; a higher WTP values associated with higher income 
levels (Drummond et al., 2015). Construct validity is tested in Sections 5.3.9 and 
5.3.10. The main disadvantage associated with the payment scale format is the risk of 
bias relating to the values used on the card. To overcome this, the best practice 
guidelines produced by O’Brien and Gafni (1996) were followed throughout the 
construction of the WTP scenarios to make the scenarios as realistic as possible. It was 
important for the WTP scenarios to fit in the context of the Irish healthcare system and 
to incorporate a method of payment which the respondents are familiar with (O'Brien 
and Gafni, 1996). 
 
The WTP scenarios present a detailed description of each healthcare service; the 
service as it currently exists in Ireland and the features of the service which were 
contingent on the patient making the payment. As this research estimates WTP for 
three healthcare services, three WTP scenarios were constructed. The scenarios are 
presented separately and independently on the questionnaire (see Appendix C.2). 
Presenting the scenarios independently ensures respondents will not perceive their 
WTP responses as cumulative and consequently reduce their WTP amount for the 
other healthcare services (Donaldson et al., 1997, Frew et al., 2004). This reduces the 
impact of the ordering effect as discussed in Section 5.2.4.1.  
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In each scenario on the questionnaire, respondents are presented with a payment scale 
consisting of a series of values listed from low to high (including zero) and increasing 
in defined increments. Each scenario presents the same payment scale to all 
respondents; payment scales are not varied. Respondents are instructed to indicate the 
maximum amount they were WTP OOP for each service. OOP payment was chosen 
as the payment vehicle as patients in Ireland are becoming more exposed to direct user 
charges as a form of payment for healthcare. Literature also deems this an appropriate 
method for payment when the patient is personally involved in the payment for the 
services (Carrere et al., 2008). Patients who were willing to pay a value that was not 
included on the payment scale were instructed to indicate their WTP value in the blank 
space provided at the end of the payment scale.  This technique reduced the risk of 
range bias (Liu et al., 2013).  
 
Patients are also asked to report if they have previously used each of the three 
healthcare services. CVM literature identifies patients’ previous experience of a 
service to impact their valuation of that service (Stewart et al., 2002). It is also argued 
that respondents who have previous experience with a particular programme have a 
better understanding of its value to them and consequently will not be inﬂuenced by 
the order of the WTP questions (Boyle et al., 1993, Kartman et al., 1996). 
Consequently, this research controls for patients’ previous experience.  
 
The first scenario measures patients’ WTP to receive blood tests in GP surgeries (See 
Figure 5.2).125 Following best practice guidelines by O’Brien and Gafni (1996), the 
                                                          
125 The quality of care when receiving blood tests is assumed to be equal in both the GP surgery and 
hospital setting. Regardless of the access route the patient follows; the blood tests are tested in a 
hospital lab. The €5 charge in the GP surgery is only to cover transport costs to transport the blood 
test to the hospital. The user charge in the GP surgery is not a reflection of the quality of care.  The 
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scenario provides the respondent with a description of the service, indicates that the 
service already exists in the Irish healthcare system and acknowledges the features of 
the service for which the patient will pay OOP. Receiving faster and more convenient 
access to blood tests is contingent on the patient paying a user charge. The payment 
scale presents a range of €0, €5, €10, €15, €20, €25, €30 and €35 with a blank space 
provided at the end should the patients’ WTP exceed these values. This is included to 
reduce range bias (Donaldson et al., 1997, Liu et al., 2013).  
 
The second scenario asks patients their WTP for an MRI test. As shown in Figure 5.3, 
there are two scenarios presented to respondents to estimate their WTP for MRI 
scans.126 The first MRI scenario estimates patients WTP for an MRI scan as a result of 
shoulder pain while the second scenario estimates patients WTP for an MRI due to 
persistent headaches. When estimating WTP for MRI scans, it is important to note that 
the associated diagnosis influences a patients WTP (Lin et al., 2013). Estimating WTP 
for a shoulder MRI and a brain MRI controls for patients’ perceived severity of the 
expected diagnosis. Similar to scenario 1, the second scenario defines an MRI scan, 
explains the current access route to this service in the Irish healthcare system, which 
consequently identifies the attributes which are contingent on the patient making an 
OOP payment. In this scenario, the attributes contingent on payment speed up access 
to MRI scans. The payment scale in both scenarios present values ranging from €0 to 
€400 in increments of €50. To reduce potential range bias, a blank space was provided 
at the end of the payment scale should patients’ WTP exceed the presented range of 
                                                          
quality of care in both locations is equal.  However, the quality of the service may differ as a result 
of the different access routes and subsequent waiting time as described in Figure 5.2.  
126 The quality of care when receiving an MRI scan in a hospital or scan centre is assumed to be equal 
as the same equipment (MRI scanner) is used in each location. However, depending on the patients’ 
WTP, the quality of the service will differ with regard to waiting time, as described in Figure 5.3.  
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values (Donaldson et al., 1997, Liu et al., 2013). The third scenario asks the 
participants their WTP value for a branded instead of a generic version of a cholesterol-
lowering drug (See Figure 5.4). Cholesterol-lowering medication was chosen for 
inclusion as it was amongst the top 10 most commonly prescribed drugs under the 
GMS and DPS community drug scheme in 2013 (PCRS 2013).127 At the time, there 
was a significant price discrepancy between the generic price (Rosuva) and branded 
price (Crestor) of the cholesterol lowering drug. A one-month supply (28 tablets) of 
Rosuva 10mg was €7.94 while a one-month supply of Crestor 10mg was €19.44. 
Despite this cost difference, GMS patients still pay €2.50 per item regardless of 
whether they receive the branded or generic version128 while non-GMS patients will 
pay the actual costs. On the basis of price variation between branded and generic 
versions, these cholesterol drugs were chosen for inclusion in this WTP scenario. As 
shown in Figure 5.4, the same scenario is presented to GMS and non-GMS patients 
while slightly different payment scales are presented in order to capture the cost 
difference for GMS and non-GMS patients. This enforces a more realistic scenario for 
patients.129  The scenario defines branded and generic drugs and refers to the concept 
of generic substitution on behalf of the pharmacist. Receiving a branded drug over a 
generic drug is contingent on the patient increasing their OOP cost.130 The intended 
payment scale for GMS payments runs from €0 to €30 in increments of €5. The 
payment scale for patients without a GMS card begins at €0, continues with €10 and 
                                                          
127 At the time there were two cholesterol-lowering ingredients in the top 10 most commonly dispensed 
drugs under the DPS and GMS schemes (PCRS, 2013). One of these ingredients was atorvastatin 
which is the ingredient in the branded version “Lipitor” while Rosuvastatin was also amongst the top 
10 most commonly dispensed prescription drugs which is the branded version “Crestor”. Atorvastatin 
was the most common amongst the two, however Lipitor came off patent in Ireland in late 2011 and 
consequently there was no price difference between the generic and branded version of this drug.  
128 This was the case until generic substitution and referencing pricing was introduced Ireland in 2013. 
129 The data collected in this scenario from both GMS and non-GMS patients are combined into one 
variable to estimate what patients are willing to pay for a branded version of cholesterol drug instead 
of a generic version of the same drug.  
130 This is the case unless the prescribing GP writes “Do not substitute” on a patients’ prescription.  
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increases in values of €5 up to €30. The payment scale for non-GMS patients does not 
include a €5 value as this value is lower than the existing market price. This is the only 
difference between the payment scales for GMS and non-GMS patients. To achieve 
reliable results for use by policy makers, it was desirable to include values based on 
actual market prices.  In both payment scales a blank space is provided should the 
respondents’ WTP exceed the values they are presented with. 
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 Figure 5.2 WTP Scenario for Blood Tests 
EXAMPLE 1: Blood tests help doctors check for certain diseases and conditions.  In Ireland, 
a GP can perform blood tests in the surgery but you may face a charge for this service. 
Alternatively, you can arrange an appointment in the outpatient department of a hospital 
where you can receive the blood tests for free but with a longer waiting time.   
 
Q20. What is the maximum price you are willing to pay to the GP for blood tests in the GPs 
surgery?  
                                                  
 
 
 
Q21. Have you had a blood test before? 
 
 
 
 
Figure 5.3 WTP Scenarios for MRI Scans 
EXAMPLE 2: An MRI (Magnetic Resonance Imaging) is a type of scan that is often used to 
diagnose health conditions that affect organs, tissue and bone. In Ireland, you can receive 
an MRI for free but with a possible waiting time of 6 months to one and a half years. 
Alternatively, you can pay to receive an MRI within a shorter time frame (e.g. 2 weeks) in a 
hospital or scan centre.  
 
Q22. Please assume situation A AND B in a healthcare system where private health 
insurance DOES NOT exist. 
 
 Situation A:                                                                                             
You have been suffering with 
shoulder pain for the last month. 
Your GP has referred you for an 
MRI scan.  
What is the maximum price you 
are willing to pay to the 
hospital/scan centre to receive 
this scan within 2 weeks from the 
time of the referral?
 
Situation B:
You have been suffering with headaches 
for the last month. Your GP has referred 
you for an MRI scan.  
What is the maximum price you are 
willing to pay to the hospital/scan centre 
to receive this scan within 2 weeks from 
the time of the referral?
  
 
€0, I would rather wait to receive the blood tests for free as an outpatient
 €5 €10           €15 €20 €25
€30 €35
OR please state the maximum amount you are willing to pay €____
Yes No
€0, I would rather wait to recieve the MRI for free
€50 €100 €150
€200 €250 €300
 €350 €400
OR please state the maximum amount you are 
willing to pay €_______
€0, I would rather wait to recieve the MRI for free
€50 €100 €150 €200
€250 €300 €350 €400
OR please state the maximum amount you are 
willing to pay €_______
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Figure 5.4 WTP Scenario for a Branded Over a Generic Cholesterol Lowering 
Drug. 
Q24.  Are you currently taking a prescribed drug to treat a high cholesterol level?  
              If yes, please name the drug 
________________________ (Please State) 
 
→ If you have a LONG-TERM ILLNESS (LTI) book, you may now submit the survey 
→ If you have a MEDICAL CARD please read example 3 and answer Q25 ONLY. 
→ If you have NO LTI OR MEDICAL CARD, please read example 3 and answer Q26 ONLY 
and then submit the survey. 
 
EXAMPLE 3: Your cholesterol is at a high level which could mean you are at risk of having a 
heart attack or a stroke. As a result, your GP has prescribed a cholesterol lowering drug. 
Your pharmacist, over the course of your treatment, may substitute a prescribed branded 
drug for a generic drug to treat a high level of cholesterol. The generic is as effective as the 
branded drug.  
 
 
Q25. MEDICAL CARD HOLDERS ONLY: PLEASE ASSUME THE FOLLOWING SITUATION: 
You currently pay €2.50 for the generic version of this drug (For example: Rosuva 
10mg, 28 tablets).  
What is the maximum price you are willing to pay to the pharmacy for the branded 
version of this drug (For example: Crestor 10mg, 28 tablets)?  
      
 
 
 
Q26. NON-MEDICAL CARD HOLDERS: PLEASE ASSUME THE FOLLOWING SITUATION: 
You currently pay €7.94 for the generic version of this drug (For example: Rosuva 
10mg, 28 tablets). 
What is the maximum price you are willing to pay to the pharmacy for the branded 
version of this drug (For example: Crestor 10mg, 28 tablets)? 
 
 
 
 
 
 
 
Yes No
Not willing to pay any extra €5 €10 15 €20 €25
€30
OR please state the maximum amount you are willing to pay €_____
Not willing to pay any extra €10 €15 €20 €25
€30
OR please state the maximum amount you are willing to pay €_____
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It was necessary to construct the scenarios in a manner which effectively defined the 
good and the features which were contingent on payment by the patient. As three 
scenarios are presented it was necessary not to “overload” the respondents with too 
much information. This would complicate the scenarios for respondents and obscure 
the results. Therefore, concise and comprehensible information was critical in the 
construction of each scenario.  
 
The payment vehicle is defined as a direct OOP payment made by the patient to the 
provider of the particular health service. As user charges are gaining popularity as a 
method of financing Irish healthcare, a direct OOP payment is an appropriate payment 
vehicle for this research. Including this payment method creates a sense of realism for 
the respondent as this method fits in the context of Irish healthcare (Carrere et al., 
2008). The research presumes that direct OOP payments capture WTP values better 
than a payment method that spreads the cost across other users also. 
 
 5.3.6 Descriptive Statistics 
 
Initially, 220 questionnaires were collected out of 300 questionnaires. Six 
questionnaires were excluded from the analysis as they were incomplete. This resulted 
in a total of 214 respondents with a response rate of 71%. The collected data was 
analysed using STATA 14. Descriptive statistics on patient characteristics 
(demographic and socio-economic) are presented. Percentage frequencies are 
examined to generate a response profile for WTP for the 3 selected healthcare services 
(Liu et al., 2013, Marvasti, 2006). Finally, relationships between patients’ WTP and 
socio-economic and demographic characteristics are examined. 
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5.3.6.1 Patient Demographics 
 
Table 5.3, shows the sample is predominantly female (68%) and Irish (95%).131 The 
average age is 46 years.132 Half of the sample, (50%) report a health status between 
good, fair and poor health. As the patients in the sample are waiting to see their GP, it 
is presumed they are sick. This will influence their self-reported health status.  
Corresponding to the self-reported health status statistics, just over half of the sample 
report having at least one chronic illness (52%).133  
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
131 The gender composition of this sample is slightly different from the national statistic where there is 
a broadly equal prevalence of males and females. The location of the data collection for this research 
may be the cause for the over-representation of females in this sample as females are higher users of 
GP services (Nolan & Smith 2012) . The nationality of this sample is representative of the national 
average where the majority of the population is Irish (88%) (CSO. 2014c). 
132 This is slightly higher than the national median age in Ireland (36.1 years) (CSO. 2014a). 
133 The number of chronic illnesses is controlled for in the questionnaire by asking respondents to report 
whether they have taken a prescription medication in the last 12 months to treat a chronic illness. In 
question 12 in the questionnaire, the patients are presented with a list of 17 chronic conditions from 
which they can choose from. The number of conditions they report represents the number of chronic 
illnesses a patient has.    
261 
 
Table 5.3 Patient Demographics 
 
     Surveyed Patients 
           N = 214    % 
Gender 
Male       67    (31.31) 
Female     145    (67.76) 
Missing         2    (0.93) 
Total     214    (100) 
Age   
 Mean             45.86 
 Range             19-84 
 Nationality 
 Irish      204    (95.33) 
 UK         6    (2.80) 
 Other         3    (1.40) 
 Missing          1    (0.47) 
Total     214    (100) 
Marital Status 
 Single        54    (25.23) 
 Married     139    (64.95) 
 Separated        3    (1.40) 
 Divorced        8    (3.74) 
 Widowed      10    (4.67) 
Total     214    (100) 
  Health Status 
 Excellent      27    (12.62) 
 Very good      79    (36.92) 
 Good       76    (35.51) 
 Fair       25    (11.68) 
 Poor         7    (3.27) 
Total     214    (100) 
Number of Chronic Illnesses 
 No chronic illness   102    (47.66) 
 1 chronic illness      63    (29.44)  
 2 chronic illnesses     31    (14.49) 
 3 or more chronic illnesses    18    (8.41)  
Total     214    (100)  
Reason for Visit  
 Minor illness      83    (38.79) 
 Repeat prescription     22    (10.28) 
 Routine check-up      28    (13.08) 
 Chronic illness follow-up     10    (4.67) 
 Doctors certificate       3    (1.40) 
 Accompanying child     27    (12.62) 
 Maternity check-up       8    (3.74) 
 Other        13    (6.07) 
 More than 1 reason     18    (8.41) 
 Missing         2    (0.93) 
Total     214    (100) 
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5.3.6.2 Socio-Economic Characteristics 
 
In Table 5.4, at least 50% of the sample have a gross monthly income level below the 
national average134 yet 58% of the sample report a third level education Within the 
sample, 35% of the sample are in possession of a GMS card. This is relatively 
representative of the 40% national average figure (PCRS, 2013). The presence of GMS 
patients in the sample is justifiable as GMS status in Ireland is primarily granted on an 
income basis.135 With regard to the other two main community drug schemes, 35% of 
the sample have a DPS card while 14% of the sample have LTI cover.136 Within this 
sample, 33% have no form of community drug cover. There is a high presence of PHI 
cover in the sample (64%) in comparison to the 44% national figure (HIA, 2014c).  
                                                          
134 The gross monthly average earnings in Ireland are €3,023 (CSO, 2015). 
135 For example, to be eligible for the GMS scheme, the gross weekly rate income threshold for a person 
under 65 years living alone is €184 (HSE, 2015c) 
136 With regard to GMS and DPS, these figures are representative of the national average where 40% 
of the population have a GMS card and 31% have a DPS card. The LTI coverage in the sample 
population is much higher than the national average where almost 2% of the population have an LTI 
card. 
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Table 5.4 Socio-Economics Characteristics 
 
     Surveyed Patients 
             N = 214    % 
Education 
 Primary       13    (6.07) 
 Secondary      72    (33.64) 
 Third level    125    (58.41) 
 Other         3    (1.40) 
 Missing             1    (0.47) 
Total     214    (100) 
Gross Monthly Income 
 <€1,000       47    (21.96) 
 €1,000 - €2,249      62    (28.97) 
 €2,250 - € 3,499      34    (15.89) 
 €3,500 - €4,749      22    (10.28) 
 €4,750 - €5,999      11    (5.14) 
 €6,000+       15    (7.01) 
 Other137         9    (4.21) 
 Missing        14    (6.54) 
Total     214    (100) 
Private health insurance   
 Yes     137    (64.02) 
 No       77    (35.98) 
Total     214    (100) 
Community Drug Cover 
 GMS       75    (35.05) 
 DPS       74    (34.58) 
 LTI       31    (14.49) 
No community cover      71    (33.18) 
Total     251138    
                                                          
137 When reporting gross monthly income (Question 19), patients were given the opportunity to tick an 
“other” category if their monthly income level was not listed. Patients who chose this category were 
asked to state what their monthly income was. The responses from the 9 respondents included; student 
income, semi-retired, old age pension and unemployed.  
138As seen in Table 5.4, the total figures (251) under community drug cover are higher than the sample 
size (214). This is due to patients in the sample having more than one form of community drug cover. 
A patient with an LTI book may apply for a DPS and/or a medical card should they be eligible. In 
this case, it most commonly occurs when a prescription drug unrelated to the long-term illness is 
prescribed to the patient. This drug will not be covered under the LTI scheme therefore the patient 
will need to pay the full cost of the medication. People should not have both GMS and DPS cover in 
Ireland but there are some exceptions. Due to the rare circumstances where patients have more than 
one form of cover, this is not accounted for in the analysis in this section but it is noted. 
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5.3.7 Patients’ WTP for the 3 Selected Healthcare Services 
 
Table 5.5 presents the WTP statistics for the selected healthcare services reported by 
patients in the sample. The number of patients who are willing to pay (WTP>0) and 
not willing to pay (WTP=0) for each service are presented in this table. Table 5.6 
presents the median WTP values for each healthcare service. The research presents the 
median WTP value rather than the mean WTP value as the mean response is subject 
to bias due to outliers in WTP values (Buckland et al., 1999). The median value reports 
the WTP value that the 50th percentile are willing to pay (Heiman, 2011). 
 
Table 5.5 Patients' WTP for the Selected Healthcare Services 
 
__________________________________________________________________________ 
Service     Surveyed patients    
      (n)    % 
WTP for blood tests 
 WTP = €0    27    12.62 
 WTP > €0     171    79.91 
 Missing     16    7.48 
 Total     214    (100) 
WTP for shoulder MRI 
 WTP = €0     30    14.02  
 WTP > €0     156    72.90 
Missing     28    13.08 
 Total      214    (100) 
WTP for brain MRI 
 WTP = €0     23    10.75 
 WTP > €0    163    76.17 
 Missing     28    13.08 
 Total     214    (100) 
WTP for a branded drug 
 WTP = €0     98    45.79  
 WTP > €0    79    36.92 
 Missing     37    17.29 
 Total     214    (100) 
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Table 5.6 Median WTP Values for the Selected Healthcare Services 
 
Service    Median WTP    Current Market Price 
Blood Test   €20139     
GMS    €12.50   €5 
Non-GMS   €20   €10 (depending on type of test) 
 
Shoulder MRI   €100   €200 (without PHI) 
Brain MRI   €150   €200 (without PHI) 
Branded drug    €10140    
GMS    €5   €2.50 
Non-GMS   €10   Drug cost (subject to deductible) 
 
 
  
The following sections will discuss the descriptive statistics for whether or not patients 
are WTP for the healthcare services and will also identify the amount they are WTP 
for each with a comparison to the existing market price.  
 
5.3.7.1 WTP for Blood Tests 
 
In Table 5.5, 80% of the sample are willing to pay (WTP > €0) to receive blood tests 
in their GP surgery while 13% are not willing to pay (WTP = €0) for this service. 
These statistics indicate that patients are willing to pay to receive blood tests in their 
GP surgery to avoid the time-consuming process of attending a public hospital to 
receive the service for free. These statistics suggest patients’ value convenient care. 
Figure 5.5 shows the percentage frequencies of the WTP values for blood tests within 
the sample.  Only observations with a positive WTP value (WTP>0) for blood tests 
are presented in Figure 5.5. Of the patients who are willing to pay for blood tests, 15% 
                                                          
139 This median value presents the combined median value reported by both GMS and non-GMS 
patients.  
140 See footnote 139.  
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are willing to pay €5 for this service, 16% are willing to pay €10, 5% are willing to 
pay €15, 29% are willing to pay €20, 13% are willing to pay €25, 15% are willing to 
pay €30, 5% are willing to pay €35141 and 2% are willing to pay €50.  
 
Figure 5.5 WTP for Blood Tests 
 
 
As shown in Table 5.6, the patients’ median WTP for blood tests is €20. It is necessary 
to examine this WTP value in terms of GMS patients and non-GMS patients and 
whether the reported WTP values are comparable to the existing market cost.  The 
median WTP for blood tests in GP surgeries reported by GMS patients is €12.50. As 
shown in Table 5.6, the current market cost for GMS patients to receive blood tests in 
GP surgeries is €5.142 These descriptive statistics show that 50% of GMS patients in 
                                                          
141 It is important to note that €35 was the highest value presented on this payment scale. Any values 
beyond this are WTP values that were stated by the respondent.  
142 As explained in Section 5.1.2, this recently introduced user charge is to cover hospital transport costs.  
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this sample are willing to pay over twice the amount than the market price. The median 
WTP value for blood tests reported by non-GMS patients is €20. As described in 
Section 5.1.2, it is at the discretion of the GP whether they charge non-GMS patients 
for blood tests. If so, GPs generally increase their consultation cost by €10 should a 
non-GMS patient require a blood test. The descriptive statistics in this research reveal 
non-GMS patients are willing to pay double the potential user charge.  
 
These statistics suggest that non-GMS patients are willing to pay more (€20 median) 
than GMS patients (€12.50 median) for blood tests in GP surgeries. As GMS cards are 
primarily granted on an income basis, the possession of a GMS card serves as a proxy 
for patient income levels. These statistics show that patients with higher incomes (non-
GMS patients) are willing to pay more than patients with a lower income level (GMS 
patient). This indicates that the data is consistent with theoretical expectations which 
strengthens the credibility of the WTP values elicited by the patients in the sample 
(Drummond et al., 2015, Klose, 1999).  
 
5.3.7.2 WTP for MRI Scans 
 
As mentioned in Section 5.3.5, two scenarios were constructed when estimating 
patients’ WTP for MRI scans; WTP for a shoulder MRI and WTP for a brain MRI. As 
acknowledged in previous literature, this was to control for the severity of the 
diagnosis. Therefore, descriptive statistics are presented in this section for both types 
of MRI scans.  
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In Table 5.5, just under three quarters of the sample (73%) are willing to pay (WTP > 
0) to receive a shoulder MRI scan within 2 weeks while 14% of the sample are not 
willing to pay (WTP = 0) to receive faster access to this service. These patients are 
willing to wait 6 months to one and a half years to receive the scan. Figure 5.6 presents 
the percentage frequencies of the WTP values for the patients who are willing to pay 
to receive quicker access to a shoulder MRI scan. Only observations with a positive 
WTP value (WTP>0) for shoulder MRI scans are presented in Figure 5.6. In Figure 
5.6, 23% of these patients are willing to pay €50, 37% are willing to pay €100, 17% 
are willing to pay €150, 12% are willing to pay €200, 5% are willing to pay €250, 3% 
are willing to pay €300 and 3% are willing to pay €400. No patient in the sample was 
willing to pay in excess of €400.  As shown in Table 5.6, the median WTP value in the 
sample for a shoulder MRI scan is €100. As the current market price to receive an MRI 
scan (without PHI) is €200, this statistic indicates that 50% of patients in this sample 
are only willing to pay half of this price to receive faster access to a shoulder MRI scan 
and over three quarters of people who are willing to pay are willing to pay less than 
€200.  
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Figure 5.6 WTP for a Shoulder MRI Scan 
 
 
With regard to WTP values for an MRI scan due to persistent headaches, Table 5.5 
shows 76% of patients are willing to pay (WTP>0) OOP to receive quicker access to 
this service while 11% of patients are not willing to pay (WTP=0) for this service. 
These patients are willing to wait six months to one and a half years to receive the 
scan. Figure 5.7 presents the percentage frequencies for patients’ WTP for a brain MRI 
Scan. Only observations with a positive WTP value (WTP>0) for brain MRI scans are 
presented. In Figure 5.7, 18% of these patients are willing to pay €50 for quicker 
access, 28% are willing to pay €100, 18% are willing to pay €150, 18% are willing to 
pay €200, 4% are willing to pay €250, 6% are willing to pay €300, 1% are willing to 
pay €350 and 7% are willing to pay €400. No patient in the sample was willing to pay 
in excess of €400. The median value that patients are willing to pay OOP to receive 
quicker access to a brain MRI is €150 (see Table 5.6). Figure 5.7 shows that over 60% 
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are not willing to pay the market price of €200 for an MRI scan on the brain (without 
PHI cover).  
 
Figure 5.7 WTP for Brain MRI Scan 
 
 
When comparing the median WTP values for an MRI scan of the brain (€150) and 
shoulder (€100), patients are willing to pay more for an MRI of the brain. This finding 
is consistent with previous research which suggests that WTP values are influenced by 
the associated diagnosis (Lin et al., 2013). It is reasonable to assume that patients 
would place a higher value on quicker access to a brain MRI due to a potentially more 
threatening diagnosis than a shoulder MRI scan. While a large proportion of the sample 
are willing to pay to receive quicker access to MRI scans, it is important to 
acknowledge that in both scenarios, patients are willing to pay less than the market 
price (€200 without PHI) to receive an MRI scan. 
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5.3.7.3 WTP for a Branded Over a Generic Cholesterol Lowering Drug. 
 
As shown in Figure 5.4, two scenarios were constructed when eliciting patients’ WTP 
for a branded over a generic cholesterol-lowering drug. Two scenarios were 
constructed due to the different user charges faced by GMS and non-GMS patients. 
The data collected from both GMS and non-GMS patients are combined to examine 
what patients are willing to pay for a branded cholesterol-lowering drug.  
 
Table 5.5 reports that 37% of the patients in the sample are willing to pay (WTP>0) to 
receive the branded version of a cholesterol drug while 46% are not willing to pay. 
Patients who are not willing to pay are prepared to accept the generic version of the 
drug. Figure 5.8 shows the percentage frequencies for patients who are willing to pay 
for a branded cholesterol-lowering drug. Only observations with a positive WTP value 
(WTP>0) for a branded drug are presented in Figure 5.8. In Figure 5.8, 19% of these 
patients are willing to pay €5, 48% are willing to pay €10, 13% are willing to pay €15, 
6% are willing to pay €20, 4% are willing to pay €25, 9% are willing to pay €30 while 
only 1 patient is willing to pay €40.  
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Figure 5.8 GMS Patients' WTP for a Branded Over a Generic Drug 
 
 
As shown in Table 5.6, patients’ median WTP for a branded version of a cholesterol-
lowering drug is €10. Due to the various user charges that exist under the community 
drug schemes in Ireland, it is necessary to examine this WTP value in terms of GMS 
patients and non-GMS patients. As discussed in Section 5.1.2, GMS patients pay a 
€2.50 flat co-payment per prescription item while non-GMS patients can apply for a 
DPS card. With a DPS card, a patient pays the cost of their prescription medication 
until they reach the monthly €144 deductible after which the cost of their prescription 
drugs are covered by the HSE.  
 
Within the sample, 34% of the GMS patients are willing to pay for a branded version 
of the drug. As shown in Table 5.6, the median value that GMS patients are willing to 
pay for a branded version of the prescription drug is €5. This indicates that GMS 
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patients in the sample are willing to pay double the €2.50 flat co-payment in order to 
receive a branded version of a prescription drug. The statistics show that these GMS 
patients are accepting of generic substitution that was introduced in 2013 as a large 
proportion of GMS patients (66%) are not willing to pay to receive a branded version 
of a prescription drug. The reverse side of this finding is that despite a large proportion 
of GMS patients not being willing to pay to receive a branded version of a prescription 
drug, 34% of the GMS patients are willing to pay. If a GMS patient wishes to receive 
a branded version of a prescription drug, the GMS patient must cover the difference 
between the reference price and the cost of the branded version (HSE, 2013e) unless 
their GP has deemed them exempt from substitution on a medicinal basis (see Section 
5.1.2). This generates revenue under the concept of reference pricing that was also 
introduced in the Health Act 2013.  
 
There are 139 non-GMS patients in the sample and 51% are willing to pay for the 
branded version of the drug while 49% are not. The non-GMS patients who are not 
willing to pay extra are prepared to accept the generic version of the drug and pay the 
relevant user charge. Table 5.6 shows the median value that non-GMS patients are 
willing to pay to receive a branded version of the drug is €10. As mentioned in Section 
5.3.5.2, non-GMS patients currently pay €7.94 for a month’s supply of the cholesterol-
lowering drug. When comparing the discrepancies in market value, non-GMS patients 
are only willing to pay 20% more than the market price while GMS patients are willing 
to pay 50% more than the current co-payment in order to receive a branded version of 
their prescription drug. As non-GMS patients already pay a higher OOP cost for 
prescription medication than GMS patients, it is reasonable to conclude that non-GMS 
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would be less willing to pay a higher proportion of the current market price than GMS 
patients. 
 
5.3.8 Patients’ Previous Use of the Healthcare Services 
 
Table 5.7 shows patients’ previous use of the healthcare services that are evaluated in 
this research. CVM literature identifies patients’ previous experience of a service to 
impact on their valuation of that service (Stewart et al., 2002). It is also argued that 
respondents who have previous experience with a particular programme have a better 
understanding of its value to them and consequently will not be inﬂuenced by the order 
of the WTP questions (Boyle et al., 1993, Kartman et al., 1996). As shown in Table 
5.7, 88% of the sample have previously received a blood test, 47% of the sample have 
had an MRI scan while 15% of the sample are currently taking a prescribed 
cholesterol-lowering drug. Since most patients have previous experience of at least 
one of the healthcare services evaluated in this research, the risk of ordering effects as 
discussed in Section 5.2.4.1 are reduced. 
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Table 5.7 Patients' Previous Use of the Healthcare Services 
 
Healthcare Service    Surveyed patients 
      n    % 
Blood test 
Yes     189    88.32  
No      5    2.34  
Missing     20    9.35 
 Total     214    (100) 
MRI Scan 
 Yes     100    46.73 
 No     58    27.10 
 Missing     56    26.17 
 Total     214    (100) 
Taking cholesterol-lowering drug  
 Yes     33    15.42 
 No     159    74.30 
 Missing     22    10.28  
 Total     214    (100) 
 
 
5.3.9 Investigating Relationships between the Decision to pay and Patient 
Characteristics.  
 
This section examines the relationships between the dependent variables measuring 
WTP for the three selected healthcare services (blood tests, MRI scans and a branded 
over a generic prescription drug) and patient characteristics. In previous literature, 
parametric and non-parametric tests are used to investigate relationships between the 
dependent and independent variables (Coolidge, 2013). The type of test depends on 
the nature of the variables, whether they are categorical, ordinal or interval and also 
relies on the distribution of the data i.e. normal distribution or non-normal distribution.  
 
In this section, the dependent variable measures the patient’s decision to pay or not to 
pay for each service. Thus, the dependent variables in this section are categorical in 
nature and are coded as 0 if the patient is not willing to pay (WTP=0) and coded as 1 
if the patient is willing to pay for the service (WTP>0). The independent variables 
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measuring patients’ demographic and socio-economic characteristics in this research 
are all categorical in nature with 2 or more categories. As this research aims to 
investigate the relationships between categorical dependent variables and categorical 
independent variables with two or more categories, the non-parametric chi square test 
is appropriate (Coolidge, 2013).  There are three assumptions of the chi square test 
which this data satisfies; individual observations are independent, there is a minimum 
of 5 frequencies in each cell and the dependent variable is a categorical variable 
(Coolidge, 2013). If the second assumption of minimum cell frequencies is violated, a 
chi square test can be substituted with a Fishers exact test (Everrit, 1992). The Fishers 
exact test provides a p-value but does not provide a test statistic.  
 
Table 5.8 presents the significant relationships that are found between patients’ WTP 
for the selected health services and patients’ demographic and socio-economic 
characteristics. The variables marked with asterisks are the variables that had cells 
containing less than five observations. Therefore, the Fishers exact test was performed 
on these variables. As shown in Table 5.8, only the p-value is presented for these 
variables as a test statistic is not produced by this test.  
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Table 5.8  Investigating the Relationship between WTP and Patient 
Characteristics 
 
Dependent    Independent  Chi2 Statistic  p-value 
variable                  variable 
    
 
 
 
WTP for Blood Tests 
     
     Age (75+ years)                         3.12                             0.078143 
      PHI cover               3.72        0.050 
      GMS cover                               4.82                     0.028 
      LTI cover               3.52        0.061 
      Nationality*                  -         0.005 
      Health status*               -         0.012 
 
 
WTP for Shoulder MRI 
Scan 
       
      PHI cover                                 8.92                             0.003 
      GMS cover                               9.88                             0.002 
      LTI cover                                 5.30                             0.021 
      Previous MRI                           5.01                             0.025 
 
 
 
 
WTP for Brain MRI 
Scan 
      
      PHI cover                               14.72                             0.000 
      GMS cover                             10.58                             0.001 
      DPS cover*                  -                                               0.054 
      LTI cover                                9.34                              0.002 
      Nationality*                 -                                               0.042 
      Education*                   -                                               0.055 
      Income*                       -                                               0.080 
      
WTP for a branded 
prescription drug 
      
      PHI cover                               6.74                               0.009 
      GMS cover                             5.02                               0.025 
      Nationality*                -                                                 0.055 
 
*These dependent variables violated the Chi square assumption which requires a minimum of 5 
observations in each cell. Consequently, a Fishers exact test was conducted on these variables.  
 
 
Using a chi square test, this research found PHI cover (χ2 = 3.72, p = 0.05), GMS cover 
(χ2 = 4.82, p = 0.03), LTI cover (χ2 = 3.52, p = 0.06) and age (75+ years) (χ2 = 3.12, p 
= 0.08) are significantly related to a patients’ decision of whether they are willing to 
pay or not willing to pay to receive blood tests in their GP surgery. A Fishers exact 
test reveals patient nationality (p = 0.01) and health status (p = 0.01) also significantly 
influence whether a patient is willing to pay or not willing to pay for a blood test.   
                                                          
143 Age was originally collected as a continuous variable but was recoded into 5 categories; 19-29, 30-
44, 45-59, 60-74 and >75 years.  
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Comparable relationships are also found for patients’ WTP for a shoulder MRI scan 
and health care cover. Significant relationships are found between PHI cover (χ2 = 
8.92, p = 0.00), GMS cover (χ2 = 9.88, p = 0.00) and LTI cover (χ2 = 5.30, p = 0.02), 
and patients’ WTP for a shoulder MRI scan. Patients’ previous experience of an MRI 
scan was also found to be significantly related to a patients’ WTP to receive quicker 
access to this service (χ2 = 5.01, p = 0.03) 
 
Patients’ health care cover such as PHI (χ2 = 14.72, p = 0.00), GMS (χ2 = 10.58, p = 
0.00) and LTI cover (χ2 = 9.34, p = 0.00) also have significant relationships with 
patients’ WTP for a brain MRI scan. A Fishers exact test also found DPS cover (p = 
0.05), patients’ nationality (p = 0.04), education level (p = 0.06) and patients’ income 
level (p = 0.08) to be significantly related to a patients WTP for a brain MRI.  
 
With regard to patients’ WTP for a branded prescription drug, a chi square test found 
PHI cover (χ2 = 6.74, p = 0.01) and GMS cover (χ2 =5.02, p = 0.03) are significantly 
related to patients’ WTP for a branded version of the drug over a generic version. A 
Fishers exact test also found nationality (p = 0.06) to be significantly related to a 
patients’ WTP for a branded prescription drug.  
 
The Chi square and Fishers Exact tests reveal that it is predominantly patient socio-
economic characteristics (health care cover, income and education) which have a 
significant relationship on patients’ decision to pay for the selected healthcare services. 
Patient demographics such as nationality and self-reported health status are also found 
to be significantly related to a number of the healthcare services.  
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5.3.10 Investigating the Relationships between Values and Patient 
Characteristics 
 
This section tests the relationships between patients’ WTP value for the healthcare 
services and patient demographic and socio-economic characteristics. Only patients 
who are willing to pay (WTP>0) are included in this section. In this section, the 
dependent variables are continuous in nature and measure patient’s maximum WTP 
for each service (WTP for blood tests, WTP for MRI scans and WTP for a branded 
over a generic prescription drug). The independent variables included in this section 
are the variables which were found to be significant in Section 5.3.9; PHI cover, GMS 
cover, LTI cover, income, education, age, nationality and self-reported health status 
and patients’ previous use of the service. In the literature, depending on the nature of 
the variables, parametric tests such as ANOVAS and t-tests are performed on the data 
to test for significant relationships. These parametric tests assume the variables are 
normally distributed. In this research, normality of the dependent variables is tested 
using the Shapiro-Wilk test in Stata (see Appendix C.7). The p values for the 
continuous dependent variables in the Shapiro-Wilk test are significant. Therefore, the 
research rejects the hypotheses that the continuous dependent variables are normally 
distributed. Consequently, non-parametric tests are appropriate in this section to test 
for significant relationships between patient characteristics and their WTP values for 
the three healthcare services.  
 
 A Mann Whitney test is used to compare the continuous dependent variables and the 
categorical independent variables which have two groups; PHI cover, GMS cover, 
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DPS cover, LTI cover, age144 and previous use of the service.  A Mann Whitney test 
is a non-parametric test and unlike its parametric version (t-test), this test makes no 
assumptions about normality and therefore is appropriate for this data.  This test 
measures whether there is a significant difference between two groups by comparing 
the median values. A Kruskal-Wallis test is used to assess the relationships between 
the continuous dependent variables and the categorical independent variables that have 
more than two groups; education level145, health status146, monthly gross annual income 
level147 and nationality148. The data satisfies the Kruskal-Wallis assumption that the 
observations are independent (Schlotzhauer, 2007).  
 
Table 5.9 shows the results of the Mann Whitney tests that were conducted on the 
continuous dependent variable and the categorical independent variables that are found 
to be significantly related to the amount patients are willing to pay for the three 
healthcare services. Table 5.9 presents the variable categories, the observations in 
each, the rank sum, the z test statistic and the p value.  
 
Table 5.10 presents the results from the Kruskal-Wallis tests that were conducted on 
the continuous dependent variable and the categorical independent variables (with 
more than 2 groups) that significantly affect the amount patients are willing to pay for 
the selected healthcare services. Table 5.10 presents the variable categories, the 
observations in each, the rank sum, the Kruskal-Wallis test statistic and the p value.  
                                                          
144 See footnote 143. 
145 The four categories in the education independent variable are primary education, secondary 
education, third level education and other education.  
146 The five categories in the health status variable are excellent health, very good health, good health, 
fair health and poor health. 
147 The seven categories in the income variable are <€1,000, €1,000-€2,249, €2,250 - €3,499, €3,500-
€4,749, €4,750-€5,999, €6,000+ and finally, the patient had the option to provide another income 
level on a blank space provided on the questionnaire. 
148 The three categories in the nationality variable are Irish, UK and other.  
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With regard to patients’ WTP for blood tests, Tables 5.9 and 5.10 show that PHI cover, 
education, previous experience and GMS cover significantly impact the amount 
patients are willing to pay to receive blood tests in their GPs surgery. A patient with 
PHI cover (U = 10582, z = -2.321, p = 0.02), a patient with a third level education (R 
= 9793.50, χ2 = 7.82, p = 0.05) and patients who have previous experience of a blood 
test (U = 13076.5, z = -2.92, p = 0.03) are willing to pay more to receive a blood test 
in the GP surgery. Patients with GMS cover are willing to pay less to receive this 
service (U =3427, z = 3.575, p = 0.00).  
 
Focussing on a shoulder MRI scan, PHI cover and patients’ previous experience of the 
service influence the amount patients’ are willing to pay to receive faster access to this 
service. Patients with PHI cover (U = 9343.5, z = -3.739, p = 0.00) and patients who 
have previously used an MRI scan before are willing to pay more for faster access to 
a shoulder scan (U =5963.5, z = -3.709, p = 0.00) than patients without PHI and who 
have no experience of an MRI scan.  
 
With regard to WTP for a brain MRI scan, Tables 5.9 and 5.10 show PHI, education 
level, income, previous experience of the service, GMS and DPS cover are 
significantly related to the amount patients are willing to pay to access this service.  
Patients with PHI (U = 9895.5, z = -3.164, p = 0.00), patients with a third level 
education (U = 9286.0, z = 9.242, p = 0.03), patients with a gross monthly income 
level of €1,000 to €2,249 (U = 3445.0, z = 15.853, p = 0.01) and patients with previous 
experience of the service (U = 5829, z = -2.491, p = 0.01) are willing to pay more for 
quicker access to a brain MRI scan.  Patients with GMS cover (U = 3564, z = 1.968, p 
= 0.05) and patients with DPS cover are willing to pay less for this service (U = 5132, 
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z = -1.925, p = 0.05) than patients who do not have these forms of community drug 
cover.  
 
Table 5.9 shows PHI GMS cover and age (75+ years) are significantly related to the 
amount a patient is willing to pay for a branded prescription drug. A patient with PHI 
cover (U = 2619, z = -3.955, p = 0.00) is willing to pay more for a branded version 
while patients with GMS cover (U = 682, z = 3.161, p = 0.00) are willing to pay less 
for a branded prescription drug. A patient over 75 years (U = 123, z = -1.737, p = 0.08) 
is willing to pay less for a branded prescription drug. 
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Table 5.9 Mann Whitney Test Results 
 
WTP FOR BLOOD TESTS (WTP>0) 
Variable Category Obs Rank sum Z statistic p value 
PHI No 
Yes 
Total 
56 
115 
171 
4124 
10582 
14706 
-2.321 0.02 
GMS No 
Yes 
Total 
119 
52 
171 
11279 
3427 
14706 
3.575 0.00 
Previous blood 
test 
No 
Yes 
Total 
4 
158 
162 
126.5 
13076.5 
13203 
-2.192 0.03 
 WTP FOR SHOULDER MRI SCAN (WTP>0 
Variable Category Obs Rank sum Z statistic p value 
PHI No 
Yes 
Total 
49 
107 
156 
2902.5 
9343.5 
12246 
-3.739 0.00 
Previous MRI 
Scan 
No 
Yes 
Total 
43 
83 
126 
2037.5 
5963.5 
8001 
-3.709 0.00 
 WTP FOR BRAIN MRI SCAN (WTP>0) 
Variable Category Obs Rank sum Z statistic p value 
PHI No 
Yes 
Total 
53 
110 
163 
3470.5 
9895.5 
13366 
-3.164 0.00 
GMS No 
Yes 
Total 
113 
50 
163 
9802 
3564 
13366 
1.968 0.05 
DPS No 
Yes 
Total 
107 
56 
163 
8234 
5132 
13366 
-1.925 0.05 
Previous MRI 
Scan 
No 
Yes 
Total 
47 
82 
129 
2556 
5829 
8385 
-2.491 0.01 
 WTP FOR A BRANDED DRUG (WTP>0) 
Variable Category Obs Rank sum Z statistic p value 
PHI No 
Yes 
Total 
22 
57 
79 
541 
2619 
3160 
-3.955 0.00 
GMS  No 
Yes 
Total 
55 
24 
79 
2478 
682 
3160 
3.161 0.00 
Age (75+ 
years) 
No 
Yes 
52 
3 
1417 
123 
-1.737 0.08 
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Table 5.10 Kruskal-Wallis Test Results 
 
WTP FOR BLOOD TESTS (WTP>0) 
Variable Category Obs Rank sum Chi2 p value 
 
Education 
Primary 
Second level 
Third level  
Other  
7 
53 
108 
3 
445.00 
4400.00 
9793.50 
67.50 
7.82 0.05 
WTP FOR BRAIN MRI SCAN (WTP>0) 
Variable Category Obs Rank sum Chi2 p value 
Education Primary 
Second level 
Third level 
Other 
6 
50 
104 
2 
309.00 
3449.00 
9286.00 
159.00 
9.242 0.03 
Income <€1,000 
€1,000 - €2,249 
€2,250 - €3,499 
€3,500 - €4,479 
€4,750 - €5,999 
€6,000+ 
Other 
33 
46 
32 
18 
9 
12 
7 
2126.5 
3445.0 
3105.0 
1671.0 
427.50 
1010.50 
617.50 
15.853 0.01 
 
5.3.12 Conclusion 
 
Following the best practice guidelines proposed by O’Brien and Gafni (1996), an 
original questionnaire was constructed to collect primary data from patients to estimate 
what patients are willing to pay for three selected healthcare services (Blood tests, MRI 
Scans and a branded over a generic prescription drug). The descriptive statistics reveal 
that patients who are willing to pay for blood tests report a median WTP value of €20, 
patients who are willing to pay for a shoulder and brain MRI scan report a median 
WTP value of €100 and €150 respectively while patients who are willing to pay for a 
branded version of a prescription drug report a median WTP value of €10. The factors 
influencing patients’ WTP for the healthcare services are predominantly socio-
economic characteristics and patients’ previous experience of the healthcare service. 
The relationships between patients’ WTP for the services and patient characteristics 
are as expected as patients’ with higher incomes are willing to pay more while patients 
with lower incomes are willing to pay less for the services. These significant 
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relationships are consistent with theoretical expectations and consequently provide 
reliability to the WTP estimates generated in this research.   
 
This research acknowledges that, as with all CVM research, this chapter measures only 
what patients claim they would be willing to pay. The estimated values may be more 
of a reflection of what they would like to pay (strategic bias) rather than an accurate 
reflection of what they would actually pay. This is recognized in the interpretation of 
the results. 
 
Section 5.4 describes the econometric methodologies that were employed to identify 
the factors which influence patients WTP for healthcare services when the choice is 
part of a time-money choice (MRI scans), a convenience choice (blood tests) and a 
preference choice (branded prescription drug) 
 
286 
 
5.4 Results 
 
5.4.1 Introduction 
  
This section presents the econometric methodologies that were employed to 
investigate the factors influencing patients’ WTP for blood tests, MRI scans and a 
branded prescription drug. Section 5.4.2 discusses the rationale as to why the particular 
method was chosen. Section 5.4.3 presents the econometric model while Section 5.4.4 
presents the model specification and model tests. The results are presented in Section 
5.4.5. 
 
5.4.2 Econometric Rationale 
 
Multivariate analysis is used to determine which independent factors influence 
patients’ WTP for the three identified healthcare services. The analysis is conducted 
using the primary data collected from patients in GP waiting rooms in Cork. While 
modelling the factors affecting patients’ WTP, the nature of the WTP question, 
underlying theoretical implications (Donaldson et al., 1998) and the consequent nature 
of the dependent variables, determined the econometric methodologies. As identified 
in Section 5.3.5, there are three dependent variables in this study which are continuous 
in nature measuring patients’ WTP for each of the three healthcare services.  
 
Identifying the factors which affect patients’ WTP is modelled as a joint process. The 
first step involves whether a patient is willing to pay for a service or not while the 
second stage includes the patients’ decision on the maximum amount they are willing 
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to pay. The dependent variable is split into two parts: ‘y > 0’ and ‘y|y > 0’. 
Consequently, a two-part model is appropriate to determine what Irish patients are 
willing to pay for the three selected services. The first part of the model is a probit 
regression which is used to estimate the patients’ decision to pay. The second part of 
the model is an OLS regression which is used to estimate what factors are associated 
with the maximum amount a patient is willing to pay for the healthcare services.  
 
As the second part of the model (OLS) estimates the factors associated with the 
maximum amount a patient is willing to pay, only the positive WTP values (WTP>0) 
are included. As the OLS regression only includes the non-zero values, there is a 
possibility of selection bias in this part of the model (Donnell et al., 2008). The 
patients’ decision to pay is not a random process as the decision is made by the patient.  
Therefore, patients who are willing to pay constitute a self-selected sample and not a 
random sample.  Consequently, selection bias needs to be controlled for. The inverse 
mills ratio (IMR) is generated using the probit coefficient and included in the OLS 
regression to control for selection bias (Heckman, 1976). If sample selection is not 
controlled for, it can result in biased estimates (Heckman, 1976).  
 
The two-part model is appropriate as the model does not aim to make inferences 
regarding parameters but simply predict the conditional means (Duan et al., 1983). The 
model predicts patients’ WTP conditional on age, health care cover, education, self-
reported health status, income level, and previous use of the service. 
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5.4.3 Econometric Model  
 
As presented in Section 5.4.2, the determinants of WTP values for the healthcare 
services are modelled as a joint decision process. First, the patient decides whether or 
not they will pay for the service (i.e. participation equation), and second, having 
decided to pay, they decide on the maximum amount they are willing to pay (i.e. 
consumption equation). The participation equation (5.1) is assumed to be a probit 
model where Z denotes a binary variable; 1 if the dependent variable is observed and 
0 otherwise. In the consumption equation (5.2) Y is a continuous variable and 
represents patients’ maximum WTP value. x and w are the matrices for the independent 
variables for the participation and consumption equations respectively. In the model, 
the error terms, ɛi and µi are assumed to be normally distributed with a mean of zero, 
variance equal to 1 and a correlation coefficient ρ. The two decisions are independent 
when ρ = 0 and the two equations can be estimated separately (Fonta et al., 2010). In 
equation 5.3, where λ(xiα) = ϕ(xiα)|Φ(xiα) is the inverse mills ratio, σ is the standard 
deviation and ϕ and Φ are the standard normal density and standard normal functions, 
respectively (Fonta et al., 2010). 
 
Z* = xiα + ɛi 
Zi = 0 if Zi ≤ 0;        (5.1) 
Zi = 1 if Zi > 0  
 
Y* = wiβ + µi 
Yi = Y
*if Zi = 1;        (5.2) 
Yi not observed if Zi = 0 
 
E (Yi|Zi  = 1, w) = wiβ + ρσλ (xiα)       (5.3) 
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The first step of the model uses a probit of 5.1 to find a consistent estimator of α. The 
α value is then used to construct the mills lambda (λ). In the second step, λ is included 
as a regressor in 5.2 allowing the parameters of the consumption equation to be 
consistently estimated using OLS.  
 
As the probit model is nonlinear, it is difficult to describe the relationship between a 
variable and its outcome probability. For ease of interpretation of the results from the 
participation equation, the marginal effects at the mean (MEM) of the significant 
categorical variables are presented. For all binary explanatory variables in the model, 
the marginal effects measure the discrete change; how the predicted probabilities 
change as the explanatory variable changes from 0 to 1 (Cameron and Trivedi, 2005).  
For a categorical variable the discrete change is computed as follows (Cameron and 
Trivedi, 2005): 
 
Xk = Pr(Y = 1|X, Xk = 1) – Pr(y=1|X, Xk = 0)    (5.4) 
 
5.4.4 Model Specification   
 
With regard to the participation equation (probit), the dependent variable is binary in 
nature. The variable was generated from the continuous variables and coded as 0 if the 
patient is not willing to pay for the service and 1 is the patient reported a WTP>0. The 
explanatory variables included in this model are based on economic theory, previous 
literature and the variables which were found to be significantly related to the 
dependent variables as described in Sections 5.3.9 and 5.3.10. If economic theory 
could not defend the inclusion of an explanatory variable it is not included in the model 
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(Kennedy, 2003). The explanatory variables included in the model are a combination 
of binary variables (GMS and PHI) and categorical variables (age, education, health 
status and income).  
 
The dependent variable used in the consumption equation (OLS regression) includes 
only the positive WTP values. This results in a variable which is right skewed and 
consequently the variable takes the logarithmic form of the continuous WTP values. 
The explanatory variables included in the consumption equation are the same as those 
included in the participation equation with the addition of the inverse mills ratio 
controlling for selection bias and the variable measuring patients’ previous use of the 
service. Patients’ previous use of a service is included in the consumption equation as 
empirical work suggests that the amount a patient is willing to pay is influenced by 
their previous experience of the service (Bergmo and Wangberg, 2007, Carrere et al., 
2008, Donfouet et al., 2011). A positive previous experience with a particular service 
is also associated with the patients’ perceived value of that service (Qin and Prybutok, 
2013). A positive previous experience is associated with a higher WTP value while a 
negative previous experience is associated with a lower WTP value.  
 
Due to the small sample size it was necessary to merge the categories of one of the 
independent variables in order to meaningfully predict WTP using regression analysis. 
The variable measuring gross monthly income level was originally measured in 7 
categories (<€1000, €1000-€2249, €2250-€3499, €3500-€4749, €4750-€5999, €6000, 
Other149). There were 9 observations in the category measuring “other” income. These 
9 observations were recoded as low income as it is assumed that students with no 
                                                          
149 See footnote 137 
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income, unemployed individuals and individuals who receive the state pension will 
have a gross monthly income level less than €1,000.  The remaining six income 
categories were then merged into three categories; low income (€<1,000 and €1,000-
€2,249) middle income (€2,250 - €3,499 and €3,500-€4,749) and high income (€4,750-
€5,999 and €6,000). The income categories are classified by CSO earnings (CSO, 
2015). CSO figures report an average weekly wage of €698 per person in Q2 2015 
(CSO, 2015). This was transformed into an average annual wage of €36,271150 and 
subsequently converted into an average monthly earning of €3,023. The merging of 
the categories is based around this average figure provided by the CSO.  
 
With regard to the consumption equation, it is also important to note that the variance 
inflation factor (VIF) was investigated after each OLS regression. The VIF quantifies 
the level of multi-collinearity in the OLS regressions (Ott and Longnecker, 2015). If 
multi-collinearity is not addressed, it results in large standard errors and consequently 
results in inaccurate estimates. A VIF of 1 means there is no collinearity but a VIF of 
10 indicates a considerable issue with collinearity (Ott and Longnecker, 2015). On 
further inspection of the variables in all OLS regressions in this research, high 
collinearity was found only amongst the self-reported health status variables (VIF > 
10). This was in particular for the variable measuring a “good” self-reported health 
status. This variable was dropped from each consumption equation and consequently 
multi-collinearity was immediately reduced. 
 
A two-part model is constructed to estimate the factors influencing patients’ decision 
to pay and their maximum WTP for each of the healthcare services; blood tests, a 
                                                          
150 €698 x 52 weeks.  
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shoulder MRI scan, a brain MRI scan and branded over a generic version of a 
cholesterol-lowering prescription drug. The independent variables, as described in the 
previous paragraphs are identical in all of the models.  
 
5.4.5 Results  
 
The following paragraphs present the WTP results for all three healthcare services. 
Each results table (Table 5.11 to 5.14) presents the independent variables, the probit 
coefficients (participation equation coefficients), the marginal effect coefficients, the 
OLS coefficients (consumption equation coefficients) and the significant p values. The 
results tables also present the probit and OLS model estimates at the end of each table. 
 
5.4.5.1 Blood Tests 
 
Table 5.11 presents the results of the two-part model that was used to identify the 
factors which influence a patient’s decision to pay for blood tests (participation 
equation) and the factors which are associated with the amount the patient is willing 
to pay (consumption equation).  
 
Interpreting the probit regression using the marginal effects at the mean, Table 5.11 
shows that if a patient is aged between 30-44 years it increases a patients WTP for 
blood tests by 14% relative to patients in the 19-24 year age category. Holding all other 
parameters at their mean, WTP for blood tests increases by 23% when patients report 
a “very good” health status and 27% if they report their health status as “good” relative 
to someone who reports their health status as “poor” (see Appendix C.8 and C.9). 
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Table 5.11 shows the results of the consumption equation in the fourth column. Once 
a patient decides to pay for a blood test, a patient with an “excellent” self-reported 
health status and a patient who has previous experience of a blood test are willing to 
pay more for the service (see Appendix C.12).  
 
The probit and OLS models are significant overall (p = 0.0278 and p = 0.0626). The 
adjusted R squared value in the OLS regression indicates that 6% of the variation of 
the dependent variable (log of WTP for blood tests) is explained by the independent 
variables. 
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Table 5.11 Two-Part Model Results for Blood Tests 
Independent Variable Probit 
(Participation 
equation) 
MEM (dy/dx) OLS 
(Consumption 
Equation) 
19-29 years base category (age) 
30-44 years   0.70* 
(0.37) 
0.14* 
(0.07) 
-0.29 
(0.21) 
45-59 years 0.44 
(0.41) 
0.09 
(0.09) 
-0.11 
(0.21) 
60-74 years 0.48 
(0.50) 
0.09 
(0.10) 
-0.05 
(0.23) 
75+ years -0.23 
(0.62) 
-0.04 
(0.12) 
0.16 
(0.31) 
GMS cover -0.16 
(0.24) 
-0.03 
(0.05) 
-0.16 
(0.13) 
PHI cover 0.37 
(0.27) 
0.07 
(0.51) 
-0.10 
(0.14) 
Primary education -0.18 
(0.54) 
-0.03 
(0.10) 
-0.16 
(0.27) 
Secondary education 0.05 
(0.28) 
0.01 
(0.013) 
-0.00 
(0.12) 
Third level education base category (education) 
Other Education151 Omitted Omitted Omitted 
Excellent health 0.62 
(0.69) 
0.12 
(0.13) 
0.43* 
(0.24) 
Very good 1.23* 
(0.65) 
0.23* 
(0.13) 
0.16 
(0.12) 
Good152 1.41** 
(0.60) 
0.27** 
(0.12) 
- 
Fair 0.43 
(0.66) 
0.08 
(0.13) 
0.36 
(0.31) 
Poor base category (health status) 
Low income (<€1,000 and 
€1,000-€2,249) 
1.20 
(0.40) 
0.04 
(0.08) 
-0.15 
(0.18) 
Mid income (€2,250-€3,499 and 
€3,500 - €4,749) 
0.26 
(044) 
0.05 
(0.09) 
0.05 
(0.18) 
High income (€4,750 - €5,999 
and €6,000)  
base category (income) 
Previous blood test           -153            -154 0.84*** 
(0.32) 
Inverse mills ratio           -155            - -0.87 
(0.71) 
cons -0.70 
(0.83) 
           - 2.40*** 
(0.48) 
Probit OLS 
No. of obs. = 188 No. of obs. = 153157 
                                                          
151 Stata automatically dropped this variable as it predicts success perfectly.  
152 I omitted this variable due to multi-collinearity as reported by the VIF (See Appendices C.10 and 
C.11).   
153 As described in Section 5.4.4., this variable was only included in the OLS (Consumption equation).  
154 See footnote 153. 
155 The IMR is created using the probit coefficients and is included only in the OLS (consumption 
equation).  
157 There is a difference in the sample size in the two models as the OLS regression only includes the 
observations whose WTP is greater than 0. Therefore, the sample size in all consumption equations 
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Wald Chi2(14) = 25.75 
Prob > chi2 = 0.0278 
Pseudo R2 = 0.1411156 
F (15, 143) = 1.68 
Prob > F = 0.0624 
R squared = 0.1551 
Adjusted R2 = 0.0626 
Root MSE = 0.60372 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
 
5.4.5.2 Shoulder MRI Scan 
 
Table 5.12 presents the results of the two-part model used to identify the factors which 
influence patients’ decision to pay for a shoulder MRI scan (participation equation) 
and which factors are associated with the amount the patient is willing to pay 
(consumption equation) to receive quicker access to a shoulder MRI scan.  
 
Interpreting the probit regression using the marginal effects at the mean, Table 5.12, 
shows that patients’ earning a low (<€1,000 and €1,000-€2,249) and middle level of 
income per month (€2,250-€3,349 and €3,250-€4,749) are 52% and 51% less likely to 
be willing to pay for quicker access to a shoulder MRI Scan in comparison to patients 
who have a higher gross monthly income level (€4,750-€5,999 and €6,000+) (see 
Appendix C.13 and C.14). Table 5.12 also shows that patients with an “other” 
education level are less likely to be willing to pay to receive faster access to a shoulder 
MRI scan.  
 
Table 5.12 also shows that once a patient decides to pay for quicker access to a 
shoulder MRI scan, a patient aged 75 years and over is willing to pay more for quicker 
access to this service. Patients with a middle income level (€2,250-€3,349 and €3,250-
                                                          
(OLS) for all healthcare services is smaller than the sample size in the participation equations (probit 
regression).  
156 The probit regression does not have an equivalent to the R squared statistic as in the OLS regression. 
The Pseudo R squared in the probit model is not interpreted in the same manner. 
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€4,749) are also willing to pay more in comparison to a patient earning a higher 
income. A possible explanation for this may be that individuals with higher incomes 
are more likely to have PHI (HIA, 2014c) and this could affect their decision to pay 
for an MRI scan as they are aware that in reality their PHI will cover the cost of this. 
Therefore, patients with higher incomes may have a lower WTP as they know PHI will 
cover the cost. A patient who has previously used the MRI service is also willing to 
pay more for quicker access (see Appendix C.17).  
  
The probit and OLS models are significant overall (p = 0.000 and p = 0.0305). The 
adjusted R squared value in the OLS regression indicates that approximately 11% of 
the variation of the dependent variable (log of WTP for a shoulder MRI scan) is 
explained by the independent variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
297 
 
Table 5.12 Two-Part Model Results for a Shoulder MRI Scan 
Independent Variable Probit MEM (dy/dx) OLS 
19-29 years  base category (age) 
30-44 years -0.07 
(0.41) 
-0.01 
(0.04) 
0.15 
(0.16) 
45-59 years 0.47 
(0.43) 
0.05 
(0.05) 
0.03 
(0.19) 
60-74 years 0.31 
(0.47) 
0.03 
(0.05) 
0.18 
(0.20) 
75+ years 0.66 
(0.67) 
0.07 
(0.07) 
0.70** 
(0.31) 
GMS cover -0.46 
(0.32) 
-0.05 
(0.03) 
0.14 
(0.16) 
PHI cover 0.37 
(0.30) 
0.04 
(0.03) 
0.16 
(0.15) 
Primary education -0.64 
(0.56) 
-0.07 
(0.06) 
-0.09 
(0.31) 
Secondary education -0.07 
(0.31) 
-0.01 
(0.03) 
-0.04 
(0.12) 
Third level education base category (education) 
Other Education  -0.84 
(0.74) 
-0.09 
(0.07) 
0.13 
(0.57) 
Excellent health 0.18 
(0.78) 
0.02 
(0.08) 
-0.07 
(0.19) 
Very good 0.55 
(0.70) 
0.06 
(0.07) 
0.11 
(0.12) 
Good  0.68 
(0.68) 
0.07 
(0.07) 
-158 
Fair 0.17 
(0.74) 
0.02 
(0.08) 
0.09 
(0.19) 
Poor base category (health status) 
Low income (<€1,000 and 
€1,000-€2,249) 
-5.09*** 
(0.43) 
-0.52*** 
(0.11) 
0.28 
(0.24) 
Mid income (€2,250-€3,499 
and €3,500 - €4,749) 
-5.00*** 
(0.53) 
-0.51*** 
(0.11) 
0.37* 
(0.22) 
High income (€4,750 - 
€5,999 and €6,000)  
base category (income) 
Previous MRI scan -159 -160 0.24** 
Inverse mills ratio -161 - -0.23 
(0.63) 
cons 5.42*** 
(0.93) 
- 4.05*** 
(0.24) 
Probit OLS 
No. of obs. = 179 
Wald Chi2(15) = 528.82 
Prob > chi2 = 0.00 
Pseudo R2 = 0.1594162 
No. of obs. = 120163 
F (15, 143) = 1.88 
Prob > F = 0.0305 
R squared = 0.2261 
Adjusted R2 = 0.1059 
                                                          
158 I omitted this variable due to multi-collinearity as reported by the VIF (See Appendices C.15 and 
C.16) 
159 As described in Section 5.4.4 this variable was only included in the OLS (Consumption equation). 
160 See footnote 159 
161 The IMR is created using the probit coefficients and is included only in the OLS (consumption 
equation).  
162 The probit regression does not have an equivalent to the R squared statistic as in the OLS regression. 
The Pseudo R squared in the probit model is not interpreted in the same manner. 
163 See footnote 157. 
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Root MSE = 0.52562 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
 
5.4.5.3 Brain MRI Scan 
 
Table 5.13 presents the results of the two-part model that was used to identify the 
factors which influence patients’ decision to pay for a brain MRI scan (participation 
equation) and which factors are associated with the amount the patient is willing to 
pay (consumption equation) to receive quicker access to a brain MRI scan.  
 
Interpreting the participation equation using the marginal effects at the mean, Table 
5.13, shows having PHI increases patients’ WTP by 5% relative to those who do not 
have PHI holding all else at the mean. Table 5.13 shows that patients’ earning a low 
(<€1,000 and €1,000-€2,249) and middle level of income per month (€2,250-€3,349 
and €3,250-€4,749) are 34% and 31% less likely to be willing to pay for quicker access 
to a brain MRI Scan in comparison to patients who have a higher gross monthly income 
level (€4,750-€5,999 and €6,000+) (see Appendix C.18 and C.19).  
 
Table 5.13 shows the results of the consumption equation in the fourth column. 
Patients with a second level education are willing to pay less for quicker access to a 
brain MRI scan than those with a third level education. Unexpectedly, a negative 
relationship is found between a low and middle income level and patients’ WTP value. 
Patients who report a low and middle income level are willing to pay more for faster 
access to a brain MRI scan 1relative to the high income base category (see Appendix 
C.22). Similar to the explanation in Section 5.4.5.2, individuals with higher incomes 
are more likely to have PHI (HIA, 2014c) and this could affect their decision to pay 
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for an MRI scan as they are aware that in reality their PHI will cover the cost of this. 
Therefore, these patients may have a lower WTP as they know PHI will cover the cost. 
 
The probit and OLS models are significant overall (p = 0.000 and p = 0.0578). The 
adjusted R squared value in the OLS regression indicates that approximately 8% of the 
variation of the dependent variable (log of WTP for a brain MRI scan) is explained by 
the independent variables. 
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Table 5.13 Two-Part Model Results for a Brain MRI Scan 
Independent Variable  Probit MEM (dy/dx) OLS 
19-29 years  base category (age) 
30-44 years 0.14 
(0.42) 
0.01 
(0.03) 
-0.15 
(0.17) 
45-59 years 0.45 
(0.42) 
0.03 
(0.03) 
-0.16 
(0.21) 
60-74 years 0.06 
(0.50) 
0.01 
(0.04) 
0.07 
(0.21) 
75+ years 0.36 
(0.71) 
0.03 
(0.05) 
0.56 
(0.38) 
GMS cover -0.18 
(0.33) 
-0.01 
(0.02) 
0.05 
(0.15) 
PHI cover 0.72** 
(0.31) 
0.05** 
(0.03) 
-0.02 
(0.21) 
Primary education -0.48 
(0.56) 
-0.04 
(0.04) 
-0.23) 
(0.34) 
Secondary education -0.05 
(0.33) 
-0.00 
(0.02) 
-0.27* 
(0.14) 
Third level education base category (education) 
Other Education164 -0.17 
(0.74) 
-0.01 
(0.05 
0.52 
(0.61) 
Excellent health 0.57 
(0.80) 
0.04 
(0.06) 
0.04 
(0.19) 
Very good 0.82 
(0.72) 
0.06 
(0.05) 
0.0. 
(0.13) 
Good165 0.84 
(0.67) 
0.06 
(0.05) 
- 
Fair 0.42 
(0.73) 
0.03 
(0.06) 
0.04 
(0.20) 
Poor base category (health status) 
Low income (<€1,000 and 
€1,000-€2,249) 
-4.70*** 
(0.45) 
-0.34*** 
(0.09) 
0.52** 
(0.26) 
Mid income (€2,250-€3,499 
and €3,500 - €4,749) 
-4.70*** 
(0.57) 
-0.31*** 
(0.10) 
0.56*** 
(0.21) 
High income (€4,750 - 
€5,999 and €6,000)  
base category (income) 
Previous MRI scan -166 -167 0.15 
(0.12) 
Inverse mills ratio -168 - -0.84 
(0.80) 
cons 4.61*** 
(9.92) 
- 4.65 
(0.29) 
Probit OLS  
No. of obs. = 179 
Wald Chi2(15) = 414.54 
Prob > chi2 = 0.0000 
No. of obs. = 123170 
F (16, 112) = 1.70 
Prob > F = 0.0578 
R squared = 0.2041 
Adjusted R2 = 0.0839 
                                                          
164 Stata automatically dropped this variable as it predicts success perfectly.  
165 I omitted this variable due to multi-collinearity as reported by the VIF (See Appendices C.20 and 
C.21).    
166 As described in Section 5.4.4 this variable was only included in the OLS (consumption equation). 
167 See footnote 166. 
168 The IMR is created using the probit coefficients and is included only in the OLS (consumption 
equation). 
170 See footnote 157.  
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Pseudo R2 = 0.2019169 Root MSE = 0.5814 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
 
5.4.5.4 Branded Over a Generic Prescription Drug 
 
Before presenting the results for Section 5.4.5.4, it is important to note that the sample 
sizes in the participation equation (n=166) and consumption equation (n=90) for this 
healthcare service are much smaller than the previous services. This is as a result of a 
large number of missing observations for this service. There are two possible reasons 
for these missing values. The first is protest non-response where respondents are 
protesting against the concept of having to pay more for a branded version of a 
prescription drug. This methodological issue is discussed in Section 5.2.4.3. The 
second reason may be due to respondents running out of time to complete the 
questionnaire. This scenario was the final one presented on the questionnaire and 
consequently may not have been completed by all respondents as they may have been 
called by the GP for their appointment.  
 
While the variables in this model remain the same as the previous models, some minor 
changes have been made due to the smaller sample size and the nature of the healthcare 
service. The reference category for the age variable is changed to 75+ years from 19-
29 years. Previous research has shown older age groups are less likely to change their 
habits (Beache and Guell, 2015).  It was assumed in this research that older patients 
would be less likely to switch to generic version of a branded drug and it was assumed 
that younger age groups would be less likely to pay for a branded version of a 
prescription drug. Therefore, the last category; 75+ years is used as the base category.  
                                                          
169 The probit regression does not have an equivalent to the R squared statistic as in the OLS regression. 
The Pseudo R squared in the probit model is not interpreted in the same manner. 
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The self-reported health status variable is merged into a dummy variable; 1 if patient 
reports “excellent” or “very good” and 0 for “good”, “fair” or “poor”. The variable is 
merged into a dummy variable due to the small sample size. Reducing the number of 
independent variables increases the degrees of freedom. The final change made to this 
model was to drop the PHI variable. PHI in Ireland does not cover the costs of 
prescription drugs. Therefore, PHI would not be an influential factor in WTP for a 
branded prescription drug.  
 
Table 5.14 presents the results of the two-part model used to identify the factors which 
influence patients’ decision to pay for a branded version of a cholesterol-lowering 
prescription drug (participation equation) and which factors are associated with the 
amount a patient is willing to pay for a branded version of the drug (consumption 
equation).  
 
Interpreting the participation equation using the marginal effects at the mean, Table 
5.14 shows patients aged between 30-44, 45-59 and 60-74 years are less willing to pay 
for a branded version of a drug, at 45%, 51% and 43% respectively compared to 
patients aged 75 and over. Patients with GMS cover are 21% less likely to pay for a 
branded version of the prescription drug. Finally, patients with an “excellent” self-
reported health status are 18% less likely to pay for a branded version of the drug (See 
Appendices C.23 and C.24) 
 
The consumption equation shows patients who are currently taking a prescribed 
cholesterol-lowering drug are willing to pay more to receive the branded version (see 
Appendix C.27).  
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The probit and OLS regression are significant overall (p = 0.05 and p = 0.02). The 
adjusted R squared value in the OLS regression indicates that approximately 14% of 
the variation of the dependent variable (log of WTP for a shoulder MRI scan) is 
explained by the independent variables. 
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Table 5.14 WTP for a Branded Over a Generic Cholesterol-Lowering 
Prescription Drug 
Independent Variable  Probit MEM (dy/dx) OLS 
19-29 years                               -0.69 
(0.58) 
-0.27 
(0.23) 
-0.32 
(0.40) 
30-44 years -1.16** 
(0.53) 
-0.46** 
(0.21) 
-0.02 
(0.38) 
45-59 years -1.30** 
(0.52) 
-0.51** 
(0.21) 
0.25 
(0.42) 
60-74 years -1.09** 
(0.53) 
-0.43** 
(0.21) 
-171 
75+ years  base category (Age) 
GMS cover -0.52** 
(0.26) 
-0.21** 
(0.10) 
-0.58 
(0.35) 
Primary education base category (Education) 
Secondary education -0.13 
(0.49) 
-0.05 
(0.19) 
-0.74 
(0.75) 
Third level education               0.03 
(0.52) 
0.01 
(0.20) 
-0.64 
(0.75) 
Other form of education -0.13 
(0.95) 
-0.05 
(0.19) 
-1.07 
(1.19) 
Excellent health -0.45** 
(0.22) 
-0.18** 
(0.09) 
0.07 
(0.27) 
Low income (<€1,000 and 
€1,000-€2,249) 
0.08 
(0.34) 
0.03 
(0.14) 
0.06 
(0.34) 
Mid income (€2,250-€3,499 
and €3,500 - €4,749) 
0.16 
(0.35) 
0.06 
(0.14) 
0.22 
(0.34) 
High income (€4,750 - 
€5,999 and €6,000)  
base category (Income) 
Taking cholesterol drug -172 -173 0.83** 
(0.33) 
Inverse mills ratio -174 - -0.27 
(0.61) 
cons 1.05 
(0.68) 
- 3.56 
(0.83) 
Probit OLS  
No. of obs. = 166 
Wald Chi2(12) = 20.98 
Prob > chi2 = 0.0506 
Pseudo R2 = 0.0991175 
No. of obs. = 90176,177 
F (12,77) = 2.20 
Prob > F = 0.0199 
R squared = 0.2550 
Adjusted R2 = 0.1389 
Root MSE = 0.91924 
Note: *** = significance at 1% level, **=significance at 5% level, *=significance at 10% level. 
 
                                                          
171 I left out age 60-74 years due to multi-collinearity as reported by the VIF (See Appendices C.25 and 
C.27). 
172 As described in Section 5.4.4 this variable was only included in the OLS (consumption equation). 
173 See footnote 172. 
174 The IMR is created using the probit coefficients and consequently is included only in the OLS 
(consumption equation). 
175 The probit regression does not have an equivalent to the R squared statistic as in the OLS regression. 
The Pseudo R squared in the probit model is not interpreted in the same manner. 
176 See footnote 157. 
177 See also the beginning of this Section (5.4.5.4) for an explanation of the small sample size in this 
model.  
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5.4.6 Discussion 
 
As discussed in Sections 1.4 and 5.2.5.1, the three healthcare service included in this 
research are a mixture of public and private primary and secondary services. Blood 
tests and prescription drugs are identified as primary services and are a mainly public 
or part-publicly financed service while MRI scans are classified as a secondary or 
referred service and are generally privately financed services. This discussion of the 
results presented in Sections 5.4.5.1 to 5.4.5.4 are discussed in this manner.  
 
The results presented in the previous sections reveal that it is mostly socio-economic 
factors; income level, PHI cover and education level178 which influence patients’ WTP 
for the more expensive secondary privately financed healthcare services; brain and 
shoulder MRI scan. This finding highlights the construct validity of the WTP values 
found in this research. Patients with a higher income level and higher healthcare cover 
are willing to pay more for MRI scans (O'Brien and Gafni, 1996). While patients with 
low and middle incomes are less willing to pay for MRI scans, the low and middle 
income patients who do decide to pay are willing to pay more than higher income 
patients (see Tables 5.12 and 5.13). A possible reason for this unexpected finding is 
that patients with higher incomes are more likely to have PHI (HIA, 2014c) and this 
could affect their decision to pay for an MRI scan as they are aware that in reality their 
PHI will cover the cost of this. Therefore, patients who have a higher income may 
report a lower WTP as they know PHI will cover the cost. This was reported on two 
questionnaires. Two respondents wrote on the questionnaire that they would be only 
                                                          
178 Education level is a proxy variable for income. The higher the education level, the higher the income 
(Day and Newburger, 2002.  
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WTP €50 for an MRI scan as they had PHI and were aware that their PHI would cover 
the cost of the scan.   
 
In contrast, patients’ WTP for the primary services included in this research; blood 
tests and branded prescription drugs, is mainly influenced by age and self-reported 
health status. While these variables influence patients’ WTP for both of these primary 
services, the effect of the variables on both models are in fact opposite. This is due to 
the different base categories used in both models (see Section 5.4.5.4). With regard to 
blood tests, patients in the 30-44 year age group are more willing to pay to receive 
blood tests in the GP surgery relative to patients in the 19-29 year age group. Patients 
in this older age category may use the GP more frequently than the younger age group 
and consequently require more blood tests. If these patients receive blood tests more 
frequently, they may be more willing to pay as it is more convenient for these patients 
rather than attending a public hospital every time they require a blood test. Another 
possible reason for this finding is that patients in the 30-44 year age group may have 
higher incomes, as they are likely to be further on in their careers. If they have higher 
incomes, they will be more willing to pay for a healthcare service.  Regarding patients’ 
WTP for a branded over a generic version of a prescription drug, patients aged between 
30 and 74 are less willing to pay for this service relative to a patient who is 75 years 
and over. These results show that the majority of the age groups included in this 
research are less willing to pay for a branded version of a prescription drug should one 
exist. This indicates that the majority of individuals are directly or indirectly 
supporting the concept of generic substitution. As discussed in Section 5.4.5.4, older 
patients are less likely to change their habits (Beache and Guell, 2015)  and as a result 
will be cautious to switch from a branded prescription drug that is on a long-term 
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prescription to a generic version of the same drug. While this research finds older age 
groups are more willing to pay for a branded prescription drug, this finding should be 
explored further by examining actual prescription drug cost-sharing in this age group 
to identify if the individuals actually do pay the difference between the reference price 
and the cost of the drug or do they simply request their GP to write “Do Not Substitute” 
on the prescription. This recommendation is discussed further in Section 6.4.  
 
The results of this research also find self-reported health status as an influential factor 
for patients’ WTP for blood tests and branded versions of prescription drugs. 
Considering WTP for blood tests first, patients with an excellent or very good health 
status are willing to pay more to receive this service in their GP surgery. Patients who 
are in excellent health are more likely to want to maintain this standard and therefore, 
are willing to pay more to receive faster access to this service. This finding is consistent 
with the theory presented in Section 2.4.1 and 2.4.2. When patients invest in health, 
this increases their stock of health which provides benefits in the future (consumption 
of health) in terms of increased time available for other activities such as work and 
leisure (Grossman, 1972). Patients with an excellent health status are willing to pay 
more to receive faster access to blood tests so they are not wasting valuable time that 
could be used for other work and leisure activities.  Excellent health status can also be 
linked to education. Patients with a higher education may have more knowledge 
regarding the maintenance of good health.  
 
In contrast, patients with an excellent (or very good) self-reported health status are less 
likely to be willing to pay for a branded version of a prescription drug. The expected 
benefit from consuming a branded version of a prescription drug is lower than the cost 
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of paying the difference between the reference price and cost of the drug, therefore, a 
patient in excellent health is less willing to pay for a branded prescription drug and 
more likely to accept the generic version for the appropriate user charge.   
  
Patients’ previous use the healthcare service is a factor which influences patients’ WTP 
for all three healthcare services included in this research. This is consistent with 
previous literature which also finds patient are more willing to pay for a service if they 
have used the service previously (Philips et al., 2010, Shearer et al., 2015). A positive 
previous experience increases the patients perceived value of a healthcare service (Qin 
and Prybutok, 2013). 
 
5.5 Conclusion 
 
This chapter identified what patients are willing to pay for three selected healthcare 
service in Ireland and also identified the factors which influence their WTP. The 
healthcare services included are blood tests, Magnetic Resonance Imaging (MRI) 
scans and a branded over a generic form of a prescription drug.  Assessing patients’ 
response to a price change is essential in the healthcare system and is particularly 
important in a healthcare system where user charges are gaining popularity as a method 
of healthcare financing.  
 
Using a specifically designed self-completion questionnaire, the research collected 
primary data from patients attending six GP surgeries in Cork. The research finds that 
some patients are willing to pay for each of these services, yet there are discrepancies 
when comparing patients’ WTP and the current market price. The descriptive statistics 
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reveal that patients who are willing to pay for blood tests report a median WTP value 
of €20 while the current price is €5 for GMS and €10 for non-GMS. Patients who are 
willing to pay for a shoulder and brain MRI scan report a median WTP value of €100 
and €150 respectively while the current price is €200 without PHI. Patients who are 
willing to pay for a branded version of a prescription drug report a median WTP values 
of €10. The current price for a GMS patient is €2.50179 while the current price for a 
non-GMS patient is €7.95.  
 
Using a two-part model to control for selection bias, the research finds socio-economic 
factors such as income, healthcare cover and education affect patients’ WTP for the 
more expensive, secondary service included in the research; MRI scans while mainly 
demographic factors such as age and self-reported health status influence patients’ 
WTP for the primary services; blood tests and a branded version of a prescription drug.  
 
These results show that patients are willing to pay to receive these healthcare services 
in Ireland. While patients are willing to pay for the services, it is important to note that 
patients with lower income are willing to pay, yet are willing to pay less then higher 
income patients.  
 
Chapters 3 and 4 of this research revealed different types of user charges may cause 
affordability and accessibility issues for low income patients when accessing services 
such as privately funded walk-in UCCs and public or part-publicly funded prescription 
                                                          
179 If a GMS wishes to purchase the branded version of the cholesterol-lowering drug, they must pay 
the difference between the reference price (€2.52) (HSE 2015) and the actual cost of the drug 
(€7.17) plus the GMS co-payment fee (€2.50). Therefore, a GMS patient would pay a user charge of 
€9.67 to receive a one-month supply of the branded version of a cholesterol-lowering prescription 
drug. 
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drugs. Despite these results, Chapter 5 finds that patients with low, middle and high 
income levels are WTP for healthcare services such as blood tests in GP surgeries, 
MRI scans and branded prescription drugs. While there are discrepancies between the 
reported WTP values and the actual market price, the results indicate that patients in 
this sample are willing to contribute towards their healthcare costs.  Chapter 5 indicates 
that patients are willing to pay for healthcare services based on their ability to pay. It 
is acknowledged that lower income individuals are willing to pay less than higher 
income individuals, however the results show that patients in this sample are willing 
to contribute towards their healthcare costs. These findings indicate that user charges 
may be a viable source of part-funding healthcare in Ireland once the user charge is 
determined from the patients’ perspective taking into account their ability to pay. 
 
The following chapter, Chapter 6 concludes this thesis by presenting the overall 
research findings, contributions and recommendations for future studies. 
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6  CONCLUSION  
 
6.1 An Overview 
 
This research assessed the impact of user charges in the context of consumer choice to 
ascertain how user charges impact on patient behaviour in Ireland. The study 
objectives, as set out in Section 1.2, were achieved by designing two specifically 
constructed questionnaires to collect primary data from patients in the Irish healthcare 
system who are subject to user charges for healthcare. This research examined three 
different topics in the Irish healthcare system and consequently, generated three 
datasets. The first topic assessed the impact of a full user charge paid OOP by the 
patient for a privately funded walk-in UCC in Ireland. The second topic collected 
primary data from patients for whom a user charge had been recently introduced or 
increased, for a mainly public or part-publicly provided service to reveal patient 
response. This topic investigated the impact of co-payments, deductibles and full user 
charges on patient behaviour for prescription drugs. The third and final topic examined 
patients’ attitudes towards the potential application of OOP user charges for both 
public and private healthcare services when the choice is part of a time-money choice 
(MRI scans), convenience choice (blood tests) and preference choice (branded 
prescription drug).  
 
In Ireland, OOP payments as a percentage of total healthcare financing has increased 
from 15% to 18.1% between 2007 and 2011 (OECD, 2013). With an extra €510 
million in additional healthcare funding required by the end of 2014 and €600 million 
supplementary funding required for public services at the end of 2015, it is evident that 
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the Irish health sector is under increasing pecuniary pressure and user charges will 
need to remain to help contribute towards healthcare financing (Hurley and Johnson, 
1991, Robinson, 2002, Usher et al., 2012, Xu et al., 2006). This research examined the 
impact of user charges on patient choice of healthcare services in Ireland in the context 
of whether user charges are a viable method of part-funding healthcare.  
 
Topic 1 in Chapter 3 used a self-completion questionnaire to collect primary data from 
patients attending three private walk-in UCCs in Ireland. This methodology was 
consistent with international empirical research studies conducted in walk-in UCCs 
across the US, UK and Canada (Bell and Szafran, 1992, Hunter et al., 2009, Rizos et 
al., 1990, Salisbury et al., 2002, Scott et al., 2009). A zero-truncated negative binomial 
(ZTNB) model was used to estimate the factors which influence patient choice of these 
clinics in Ireland. A probit regression was then used to identify the factors which 
increase the likelihood of the patient being a first-time user at the clinics. 
 
Topic 2 in Chapter 4 developed a questionnaire, based on a previous study conducted 
by Reed et al (2008), to examine the impact that prescription drug user charges have 
on patient behaviour in Ireland. This questionnaire estimated three types of patient 
behaviour that can result from an increase in user charges for prescription drugs; 
decreased adherence, financial constraints and cost-coping strategies (Reed et al., 
2008). Behavioural responses were assessed by measuring the percentage of patients 
who report any behavioural change (decreased adherence, financial burden or cost-
coping behaviours). A multinomial logit model (MNLM) was then used to measure 
the association between behavioural response and individual characteristics. 
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Finally, topic 3 in Chapter 5 is a contingent valuation method (CVM) which used a 
questionnaire-designed stated preference approach to identify what healthcare 
consumers are willing to pay for three selected healthcare services in Ireland (blood 
tests, MRI scans and a branded prescription drug).  The econometric analysis of this 
section was shaped by how the WTP question was asked and any underlying 
theoretical implications (Donaldson et al., 1998). Percentages and frequencies were 
examined to generate a response profile for WTP for the 3 identified healthcare 
services (Liu et al., 2013, Marvasti, 2006). A two-part model (probit and OLS 
regression) was used to identify the factors associated with patients’ WTP for the three 
services. 
 
6.2 Research Findings 
 
The successful completion of the specific objectives as outlined in Section 1.3 are 
described in this section. Chapter 3 aimed to identify the factors which influence 
patient choice of walk-in UCCs in Ireland in the face of user charges. The chapter 
included patients who already made the decision to pay the user charge for this private 
health service in order to identify what drives patient choice. The first objective of 
Chapter 3 was to characterize the type of patient who chooses a walk-in UCC in 
Ireland, the second objective was to identify using a ZTNB model, the factors which 
influence patients’ decision to pay a higher user charge to attend this alternative 
provider of care (compared with the cheaper traditional providers) and the final 
objective was to assess, using a Probit regression, the factors which affect the 
likelihood of the patient being a first-time user of the walk-in UCC.   
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Chapter 3 reveals that patients who use these clinics are more likely to be between 25 
to 64 years of age with a high socio-economic status indicated by a high prevalence of 
third level education and over half of the sample reporting an income level above the 
national average.180 It is mainly privately insured patients who use the clinics, as 
expected, and there are very few GMS patients who use these clinics. The ZTNB 
model found PHI, GMS, income (€70,000-€84,000), parking and travel time to the 
clinic significantly influence patient choice when choosing this alternative provider of 
urgent care. The significant socio-economic variables (PHI, GMS and income) are 
related to a patients’ ability to pay. Finally, the probit regression in Chapter 3 reveals 
that GMS patients and patients with longer travel time to the clinics are more likely to 
be first time users of the walk-in UCC. Therefore, this finding suggests that GMS 
patients and patients with a longer travel time to the clinic are less likely to be repeat 
or multiple users of private walk-in UCCs. Patients with PHI cover, an income level 
of €70,000 to €84,000 and patients who report the importance of extended opening 
hours and sufficient parking are less likely to be first-time users and consequently more 
likely to be repeat or multiple users of the clinic.  
 
In addition to the main objectives identified in Chapter 3, this chapter also found that 
66% of the sample were successfully treated at a walk-in UCC and did not require 
further treatment. If these walk-in UCCs were not available, these patients may have 
presented at a traditional provider of urgent care; a GP surgery or an A&E department. 
The high treatment success rate found in this research indicates that alternative 
providers of urgent care, such as Vhi SwiftCare Clinics, can relieve pressure on 
traditional urgent care providers in Ireland. If patients choose to attend alternative 
                                                          
180 See footnote 52. 
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providers and are successfully treated at these locations, these patients are not 
attending traditional providers, which reduces pressure for the latter providers. This 
research concludes that if it were not for these alternative providers of care, patients 
would have no choice but to attend an A&E department or GP surgery; thereby putting 
additional pressure on these services.   
 
Discussions with individuals throughout this research process at conferences181 and 
presentations182 revealed a lack of knowledge surrounding the existence of alternative 
urgent care providers such as Vhi SwiftCare Clinics. A significant number of 
individuals were either not aware of Vhi SwiftCare Clinics and if they were aware, a 
number of individuals were of the opinion these clinics were only available to Vhi 
healthcare members. This research suggests the need for a privately funded 
information campaign advocating the services that these clinics offer and emphasising 
that these clinics are available to every individual who is willing to pay the necessary 
user charge.  This would promote these clinics with a view to redirecting some patients 
away from the traditional providers of urgent care to this alternative location for some 
specific illnesses and injuries.   
 
In conclusion to Chapter 3, the high socio-economic status of the users of the clinics 
and the significant socio-economic variables (PHI cover, GMS cover and income) 
which were found to influence patient choice, indicate that ability to pay influences 
patient choice when choosing a walk-in UCC. Since these clinics do not accept GMS 
cards as a method of payment, the potentially higher user charge may act as a deterrent 
                                                          
181 Irish Society of New Economists (ISNE), NUI Galway, 5th September 2014. 
182 School of Economics, University College Cork, 25th February 2015.  
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for GMS patients who have a lower income. This raises concerns regarding 
accessibility as patients with lower income levels do not have the same access to the 
convenient care that is offered by the alternative provider of urgent care as patients 
with higher income levels. Chapter 3 reveals that patients with a higher socio-
economic status are more likely to be repeat users of these clinics in comparison to 
patients with lower income levels who are less likely to be repeat users of the clinics. 
This research concludes that the affordability of more expensive services such as 
private walk-in UCCs is not an issue for high income patients who place a higher 
preference on the convenient care offered by these clinics. 
 
Chapter 4 assesses the impact of prescription drug user charges on patient behaviour. 
The chapter examines patients for whom a user charge has been recently introduced or 
increased for this mainly public or part-publicly provided service, to reveal patient 
response. The chapter investigated the impact of the main types of user charges which 
exist for prescription drugs in Ireland; co-payments, deductibles and full OOP cost. 
The impact of the user charge focused on three types of behavioural change as a result 
of prescription drug costs; decreased adherence, financial burden and cost-coping 
strategies. A patient reported decreased adherence if they took less of a prescribed drug 
without the advice of their GP, if they stopped filling a prescription for a new 
medication or stopped filling a prescription for an old medication. Patients reported 
the cost of prescription drugs as a financial burden if they reported borrowing money 
from friends or family to pay for medication, spending less on food/heat or other basic 
needs to pay for medication or increasing credit card debt to pay for medication. A 
patient engaged in cost-coping strategies if they reported using cheaper OTC drugs 
before purchasing prescription drugs, switching to cheaper drugs such as generic 
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drugs, requesting free medication samples from the GP or purchasing drugs from an 
on-line pharmacy. 
 
The first objective of Chapter 4 was to identify the effect that different forms of 
prescription drug user charges have on patient behaviour. The second objective of 
Chapter 4 was to use a MNLM to measure the association between patient behaviour 
(decreased adherence, financial burden and cost-coping behaviours) and individual 
characteristics.  
 
Chapter 4 suggests GMS patients who pay a flat co-payment per prescription item are 
the highest reporters of decreased adherence. In other words, GMS patients reduce 
their prescription drug use and stop filling old and new prescriptions as a result of 
prescription drug costs. This finding can have both positive and negative implications. 
Firstly, this type of decreased adherence may be as a result of patient stock-piling. As 
GMS co-payments have increased since 2010, GMS patients may be becoming more 
cost-conscious of unnecessarily purchasing prescription drugs they may have stock-
piled during times when the user charge was lower and when GMS patients had no 
incentive to avoid requesting a prescription drug. Alternatively, this finding may have 
negative implications as the patient may be decreasing their use of essential drugs as a 
result of the user charge. If so, user charges can create adverse outcomes such as 
hospitalization and deteriorating health status (Goldman, 2007).  
 
Chapter 4 also finds GMS patients are the highest reporters of prescription costs 
creating a financial burden. Prescription drug user charges result in GMS patients 
borrowing money to pay for prescription drugs, spending less on food/heat or other 
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basic needs and increasing credit card debt to pay for medication. This finding raises 
affordability concerns for GMS patients.   
 
DPS patients who are subject to a monthly deductible are the highest reporters of cost-
coping strategies as a result of prescription drug costs. DPS patients are the highest 
reporters of using cheaper OTC drugs, switching to generic drugs, requesting free 
medication samples from the GP and purchasing drugs from an on-line pharmacy. 
While DPS patients are the highest reporters (35%) of switching to generic drugs, 
Chapter 4 finds that GMS and LTI patients also report this type of behaviour (28% and 
25% respectively). This finding highlights that generic substitution which was 
introduced in Ireland as part of the Health (Pricing and Supply of Medical Goods) Act 
2013 is proving to be successful. DPS, GMS and LTI patients in this sample who pay 
OOP for prescription drugs, may either accept the generic version of the prescription 
drug and pay the relevant user charge or in order to receive the branded version, they 
must pay the difference between the reference price and the cost of the drug. There is 
however, another alternative for GMS patients. Should a GP believe a GMS patient 
must be exempt from generic substitution, for medicinal reasons, the GP can write “Do 
Not Substitute” on the patients’ prescription. The pharmacist dispensing the 
prescription must then dispense the branded version of the drug to the GMS patient at 
the regular co-payment of €2.50 per item (DOH, n.d.). These results show that despite 
a percentage of the GMS patients in the sample engaging in generic substitution, there 
is still a large number of respondents (69%) who are not engaging in this type of 
behaviour.  
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The findings from the first objective of Chapter 4 reveal different types of user charges 
such as co-payments, deductibles and full OOP user charges have different impacts on 
patient choice. Supported by economic theory, the results prove that the larger the 
proportion of a patient’s income is spent on a service, the higher the degree of patient 
response. 
 
The second and final objective of Chapter 4 was to use a MNLM to measure the 
association between patient behaviour (in relation to prescription drug user charges) 
and individual characteristics. The MNLM reveals patients with GMS cover, patients 
without any form of prescription drug cover, patients with high prescription drug costs 
and patients with a low monthly income level (€1,000-€2,249) are more likely to 
engage in all three types of behavioural change; decreased adherence, financial burden 
and cost-coping strategies as a result of prescription drug user charges. These findings 
suggest that prescription drug user charges in Ireland have the largest impact on the 
most vulnerable populations; the sick and the poor.  
 
The results of Chapter 4 raise considerations in terms of patient affordability and 
accessibility for prescription drugs in Ireland. The research implies that the user 
charges for prescription drugs in Ireland may be regressive as patients with lower 
income levels (vertical affordability) and higher prescription drug costs (vertical 
accessibility) are patients who are most likely to decrease their adherence to 
prescription drugs, report a financial burden as a result of prescription drug user 
charges and engage in cost-coping strategies in an attempt to reduce their OOP 
payments. 
  
320 
 
Chapter 5 examined patients’ attitudes towards the potential application of user 
charges for both public and private healthcare services when the choice is part of a 
time-money trade-off (MRI scans), a convenience choice (blood tests) and a preference 
choice (branded drug). The chapter identified what patients are willing to pay for the 
three selected healthcare services in Ireland and also identified the factors which 
influence patients’ WTP.  The first objective of Chapter 5 was to reveal patients’ WTP 
values for three healthcare services. The second objective was to identify discrepancies 
between patients’ reported WTP values and the current market price. The third and 
final objective of Chapter 5 was to identify using a two-part model the factors that are 
associated with patients’ WTP values for the three selected healthcare services.  
 
The research reveals that patients are willing to pay €20183 to receive a blood test in a 
GP surgery. More specifically, GMS patients report they are willing to pay €12.50 to 
receive a blood test in a GP surgery while non-GMS patients are willing to pay €20. 
In the sample, patients report they are willing to pay €100 to receive faster access to a 
shoulder MRI scan and €150 to receive quicker access to a brain MRI scan. GMS 
patients are willing to pay €5 for a branded version of a cholesterol-lowering drug 
while non-GMS patients are willing to pay €10 to receive a branded version of the 
drug. 
 
When comparing the amount patients are willing to pay with the current market price 
for each service, the research found patients are willing to pay more than the market 
price for the lower costing primary care services (blood tests and a branded drug) and 
                                                          
183 Median Value. The research presents the median WTP value rather than the mean WTP value as 
the mean response is subject to bias due to outliers in WTP values (Buckland et al., 1999). The 
median value reports the WTP value that the 50th percentile are willing to pay (Heiman, 2011). All 
WTP values presented in this paragraph report he median values, unless otherwise stated.  
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patients are willing to pay less than the market price for the more expensive secondary 
care service (MRI scan). The higher cost of this secondary care service may be the 
reason patients’ WTP values are lower than the market price. This supposition is 
supported by the economic theory of Becker (1965) and Grossman (1972) as a much 
larger proportion of patients’ income is spent on an MRI scan in comparison to the 
primary care services (blood tests and a branded prescription drug).   
 
Finally, the two-part model finds socio-economic factors such as income, healthcare 
cover and education level to influence patients’ WTP for the more expensive, 
secondary service included in the research (MRI scans), while mainly demographic 
factors influence patients’ WTP for the lower costing primary care services (blood 
tests and a branded version of a prescription drug). These findings support the 
construct validity of the WTP values reported by patients in this research where 
patients with lower income are willing to pay less than patients with higher incomes. 
 
Chapter 5 indicates that patients are willing to pay for healthcare services based on 
their ability to pay. It is acknowledged that lower income individuals are willing to 
pay less than higher income individuals, however the results show that patients in this 
sample are willing to contribute towards their healthcare costs. The findings from this 
chapter indicate that user charges may be a viable source of part-funding healthcare in 
Ireland once the user charge is determined from the patients’ perspective taking into 
account their ability to pay. 
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6.3 Research Contributions 
 
Collecting primary data from a subset of the population in walk-in UCCs and GP 
surgeries, this research contributes to the literature by examining user charges in the 
context of consumer choice to determine how they impact on patient behaviour in 
Ireland. This study contributes to data as it identifies the impact of user charges on 
consumer choice from the patients’ perspective to assess whether user charges are a 
viable source to part-fund healthcare in Ireland. This contribution is important at a time 
of increasing financial pressure in the Irish healthcare system in which user charges 
are gaining popularity as a method of healthcare financing. 
 
The study found that user charges have a different impact on private, public and part-
publicly funded healthcare services.  
 
The study suggests private walk-in UCCs improve access to urgent care for patients 
who are willing and able to pay the potentially higher user charge for this service. If 
patients who can afford to pay for urgent care at alternative providers continue to do 
so, this would relieve pressure on GPs and A&E departments in Ireland. This needs to 
be recognised by the private urgent care providers who wish to increase the utilization 
of their service.  
 
This study also proves that user charges can disproportionately affect lower income 
groups and result in adverse effects such as patients decreasing their adherence to 
prescription drugs without the advice of their GP and identifying user charges as a 
financial burden. The study also indicates that patients engage in cost-coping 
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behaviours as a result of drug costs such as switching to cheaper OTC drugs, generic 
drugs, purchasing drugs from an on-line pharmacy and requesting free medication 
samples from their GP.  
 
Despite the negative impact of user charges on lower income earners as portrayed in 
Chapters 3 and 4, the results obtained from the CVM in Chapter 5 suggest that patients 
from all income backgrounds are willing to pay for healthcare services in Ireland. 
Lower income individuals are willing to pay for healthcare services, albeit at a lower 
user charge than higher income earners.  
 
The results in this thesis regarding patient response to different types of user charges 
for private, public and part-publicly funded healthcare services in Ireland generate an 
important policy contribution. At a time of increasing financial pressure in Irish 
healthcare, and with evidence provided by this study that patients are willing to pay 
for healthcare services, user charges in healthcare need to be developed based on 
patients’ ability to pay. While a standard costing approach is mandatory in the user 
charge process, the results of this study indicate that greater consideration should also 
be given to patients’ ability to pay when setting user charges for healthcare. This would 
ensure user charges are set at a level which contribute towards healthcare financing 
while also providing affordable and accessible care to patients. This could reduce the 
risk of any adverse effects associated with user charges such as; decreased adherence 
and subsequent deteriorating health.  
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6.4 Research Limitations and Future Recommendations  
 
This section presents research limitations together with a number of recommendations 
for future studies that developed throughout this research process.   
 
In Chapter 3 of this research, only users of the alternative urgent care providers are 
included. To expand knowledge in this area, future research could include both users 
and non-users of alternative urgent care providers. A full demand study of this kind 
would identify why patients choose a traditional provider of urgent care and not an 
alternative provider. This would provide insight into the urgent care system in Ireland 
in order to achieve a system where the needs of patients are met in an affordable 
manner while achieving efficiency in access as a result of shorter waiting times.   
 
Due to inaccessible Irish data, this research was unable to identify the number and type 
of prescription drugs that were subject to behavioural change as a result of prescription 
drug user charges., If possible, future studies should include the number and type of 
drugs that are analysed in the context of user charges.  This would identify whether 
patients reduce their use of high-cost drugs or all drugs, essential or non-essential drugs 
(Gibson et al., 2005a).  
 
In an Irish context, when assessing patients’ WTP for branded versus generic 
prescription drugs, more focus needs to be given to patients over 75 years of age.   
While the self-reported data in this research reveals this age group are willing to pay 
to receive the branded version of the drug, patients’ actual behaviour also needs to be 
assessed. Results would indicate whether this age cohort actually pay for the branded 
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version or whether they request that their GP  writes “Do Not Substitute” on their 
scripts in order to receive the branded version without having to pay the difference 
between the reference price and the cost of the drug? If it is the latter, then policy 
makers need to reassess this option from the prescribers’ perspective to ensure they 
only deem the patient exempt from substitution on medicinal grounds and not as result 
of the request of the patient.  
 
When conducting a contingent valuation using a WTP study, protest zeros are a 
methodological concern which need to be dealt with accordingly. Generally, protest 
zeros are explored using debriefing questions in face-to-face interviews. As this 
research used a self-completion questionnaire to collect the data, it was not possible to 
include debriefing questions in a face-to-face manner.  However, future studies that 
also use a self-completion questionnaire could investigate protest zeros by providing 
reasons on the questionnaire as to why a patient may not be willing to pay for a 
healthcare service. While this method may not be as informative as face-to-face 
interviews, it would provide additional information on protest zeros.  
 
6.5 Conclusion  
 
This research has assessed the impact of user charges in the context of consumer choice 
to ascertain how user charges impact on patient behaviour in Ireland. Using two 
specifically designed questionnaires, the research objectives were achieved by 
collecting primary data from patients in the Irish healthcare system who are subject to 
user charges. This research has provided a direct insight into the public’s response to 
326 
 
user charges in healthcare The study was conducted in the context of whether user 
charges are a viable source for part-funding healthcare in Ireland.  
 
Examining the economic theories of Becker (1965) and Grossman (1972), the research 
has assessed the impact of user charges on patient choice in terms of affordability and 
accessibility in healthcare. The research examined a number of public and private 
healthcare services in Ireland for which varying levels of user charges exist depending 
on patients’ healthcare cover. The results indicate that the impact of user charges on 
private and public healthcare services vary according to socio-economic status.  
 
Chapters 3 and 4 of this research reveal different types of user charges such as; co-
payments, deductibles and full OOP user charges, cause affordability and accessibility 
issues for low income patients when accessing services. Despite these results, Chapter 
5 suggests that patients with low, middle and high income levels are WTP for 
healthcare services. While there are discrepancies between the reported WTP values 
and the actual market price, the results of this research indicate that patients in this 
sample are willing to contribute towards their healthcare costs. Lower income patients 
are willing to pay for healthcare services, albeit, at a lower price than higher income 
earners. However, the results show that even low-income patients in this sample are 
willing to contribute towards their healthcare costs.  
 
In conclusion, this study suggests that user charges may be a feasible source of part-
financing Irish healthcare once the user charge is determined from the patients’ 
perspective, taking into account their ability to pay.  
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 It is hoped this research will inspire further studies into this evolving method of 
healthcare financing. 
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Appendix A.3 Frequently Asked Questions for Patients 
Purpose of the Study.  As a PhD student in Health Economics at University College Cork 
(UCC), it is required that I carry out a research study. The study aims to assess the factors 
that influence patient use of Vhi SwiftCare Clinics. 
 
What will the study involve? The study will involve collecting information from Vhi SwiftCare 
Clinic patients. Surveys will be used to collect this information. The survey will take 3-5 
minutes to complete.  
 
Why have you been asked to take part?  As a Vhi SwiftCare Clinic patient you have been 
asked to take part. As an alternative, you may also have attended a GP surgery or an A&E 
department. So for that reason, I am interested in what made you decide to visit the Vhi 
SwiftCare Clinic instead of a GP or A&E department for the treatment of your minor 
injury/illness. 
 
Do you have to take part? No. Participation is voluntary. There is a consent form that you 
will sign to say you agree to participate. You have the option of withdrawing from this 
research at any stage. 
 
Will your participation in the study be kept confidential? Yes. The survey does not require 
any personal details (name, address etc.). I will ensure that no clues to your identity appear 
in the thesis.  
 
What will happen to the information which you give? The data will be kept confidential for 
the duration of the study. On completion of the thesis, they will be retained for a further six 
months and then destroyed. 
 
What will happen to the results?  The results will be presented in the thesis. They will be 
seen by my supervisors, a second marker and the external examiner. The thesis may be read 
by future students on the course. The study may be published in a research journal. 
 
What are the possible disadvantages of taking part? There are no disadvantages in taking 
part in this study. 
 
Who has reviewed this study? This study has been reviewed and approved by the Social 
Research Ethical Committee and the School of Economics in UCC.  
 
Any further queries?  If you need any further information, you can contact me: Aimée Fox 
by phoning 087-7674497 or emailing me at a.fox@ucc.ie 
 
 
Thank you! 
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Appendix A.4 Codebook for Urgent Care Clinics 
Full Variable name Variable Name Coding Instruction 
Respondent resp 1 = Patient  
 2= Parent 
 3= Guardian 
 4= Friend  
. = Missing 
Gender sex 0=  Female 
1 = Male 
Age age in years 
Nationality nation 1 = Irish 
2 = Other EU 
3 = UK 
4 = Non EU citizen 
. = Missing 
Education educ 1 = No education 
2 = Primary education 
3 = Secondary education 
4 = Third level 
5 = Other 
. = Missing 
Travel time travel In minutes 
Medical card medc 0 = No 
1 = Yes 
Private health insurance phi 0 = No 
1 = Yes 
Health insurance company phicov Name 
Vhi SCC previous use sccprev 0 = No 
1 = Yes 
Times previously  scctimes Times 
Previous MIU use miuprev 0 = No 
1 = Yes 
. = Missing 
MIU name miuname Name 
Location location 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Waiting times waittime 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
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5 = Very unimportant 
. = Missing 
Treatment Setting apptreatset 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Cost cost 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Non-Appointment Service nonappserv 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
GP referral gpref 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Parking park 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Word of mouth wom 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Cleanliness cleanliness 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
350 
 
Accessibility accessibility 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Previous A&E Use preva&euse 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Cost Reimbursement costreim 1 = Very important 
2 = Important 
3 = Neither important nor 
unimportant 
4 = Unimportant 
5 = Very unimportant 
. = Missing 
Annual gross income income 1= <€25,000 
2 = €25,000 - €39,000 
3 = €40,000 - €54,000 
4 = €55,000 - €69,000 
5 = €70,000 - €84,000 
6 = €85,000+ 
. = Missing 
Minor injury/illness treated illtreat 1 = Sprain/Strain 
2 = Minor ear/eye condition 
3 = Fracture/break 
4 = Sport injury 
5 = Minor burn 
6 = Cut requiring stitches 
7 = Minor Illness 
8 = Other 
. = Missing 
Further referral  referral 1 = GP referral 
2 = A&E department 
3 = Non-referral 
4 = Other 
. = Missing 
Cost of visit visitcost In euro 
Staff Approach staffsat 1 = Very satisfied 
2 = Satisfied 
3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Treatment Quality  treatsat 1 = Very satisfied 
2 = Satisfied 
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3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Waiting Times waittimesat 1 = Very satisfied 
2 = Satisfied 
3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Privacy from others privsat 1 = Very satisfied 
2 = Satisfied 
3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Parking access (free) parksat 1 = Very satisfied 
2 = Satisfied 
3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Cleanliness cleansat 1 = Very satisfied 
2 = Satisfied 
3 = Neither satisfied nor dissatisfied 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Future use of SCC futureuse 1 = Very Likely 
2 = Likely 
3 = Neither likely nor unlikely 
4 = Dissatisfied 
5 = Very dissatisfied 
. = Missing 
Comments comments State 
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Appendix A.5 Original Urgent Care Clinic Survey 
What Factors Affect the Demand for Vhi SwiftCare Clinics?” 
Please indicate whether you are the patient or if you are a parent/guardian/relation or 
friend filling in this form on behalf of the patient. 
Any information you provide will remain anonymous and confidential. 
(  ) Patient (  ) Parent (  ) Guardian (  ) Relation (  ) Friend 
Background 
Q1. Patient’s gender? (Please tick appropriate box) 
 
 
Q2. Patient’s age? (Please State) _____________________ Years 
 
Q3. Patient’s nationality (Please tick appropriate box) 
 
 
Q4. Patient’s highest level of education achieved at this current time? (Please tick 
appropriate box) 
     
 
Q5. How long did it take the patient to travel to this Vhi SwiftCare Clinic today? (Please State) 
_____________________ Minutes 
 
Q6. Does the patient have a medical care? (Please tick appropriate box) 
 
 
Q7. (a) Does the patient have private health insurance? (Please tick appropriate box) 
 
 
Q7. (b) If yes, of which health insurance company is the patient a member of? (Please State) 
____________________ 
 
Previous Vhi SwiftCare Clinic Use 
Q8. (a) Has the patient ever attended a Vhi SwiftCare Clinic before? (Please tick appropriate 
box) 
 
Q8. (b) If yes, how many times previously? (Please State)____________________  
 
Q9. (a) Has the patient ever attended another minor injury clinic before? (E.g. Mercy Urgent 
Care Clinic or Mater Smithfield Rapid Injury Clinic) 
 
Q9. (b) If yes, which minor injury clinic has the patient previously used? (Please State) 
___________ 
Male Female
Irish Other EU UK
Non EU Citizen
Primary Education Secondary Education
Third Level Other (Please State) ____________
Yes No
Yes No
Yes No
Yes No
No Education
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Current Vhi SwiftCare Clinic Use 
Q10. Please rank in order of importance the following characteristics of the Vhi SwiftCare 
Clinic in influencing the patient’s decision to visit this clinic today.  
 (Please tick appropriate box for each characteristic) 
 
 
 
 
 
 
 
 
Characteristic Very  important     Important      Neither important      Unimportant       Very unimportant         
                                                            nor unimportant                                                                                      
            1                             2                             3                                4                                5 
Location 
(Convenient location of the                            
SwiftCare Clinic) 
          
                                                                                        
Waiting Times 
(1 hour treatment policy) 
           
                                                                                      
               
AppropriateTreatment Setting 
(Knowledge that injury  
was treatable at the                     
Vhi SwiftCare clinic) 
 
                                                                                          
Cost 
(Knowledge of possible            
cost of treatment) 
            
                                                                                                  
Non-appointment 
Service 
(No appointment                          
necessary) 
            
                                                                                                   
GP referral 
(Referred by GP)          
             
                                                                                   
                                                                                        
Parking 
(Parking access and cost)            
               
                                                                                    
                                     
Word of Mouth 
(Someone else’s 
experience)                                  
              
                                                                                                
Facilities 
(Phones, Refreshments, Toilets)  
 
                                                                                     
 
Accessibility  
(Opening hours) 
 
                                                                                     
 
Healthcare Reimbursement [For 
health insurance members only] 
(Reimbursement of                      
part of the cost) 
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Income 
Q11. Please tick the individual gross income* category which best applies to the patient. If 
the patient is a child (under 18) please choose the gross income category of the individual 
responsible for payment to the Vhi SwiftCare Clinic. 
*Gross income: your individual income level before any deductions (e.g. Tax) 
You can choose income per year, per month or per week. 
 
Previous Use of A&E Department 
Q12. (a) Has the patient ever attended an A&E department before? (Please tick appropriate 
box) 
 
If the patient has never attended an A&E department before please proceed to Q18 after 
treatment is received in this clinic today). 
 
Q12. (b) If yes, how many times previously has the patient used an A&E department? (Please 
State) 
____________________ (Times) 
 
Q12. (c) How many times has the patient used an A&E department after 2005? (Please State) 
____________________ (Times) 
 
Q13. When the patient last used an A&E department were they referred to the department 
by a GP? (Please tick appropriate box) 
 
 
Q14. Following treatment on the last visit to an A&E department, was the patient admitted 
as an in-patient to the hospital? (Please tick appropriate box) 
 
 
 
 
 
 
Yes No
Yes No
Yes No
Annually 
 
 
 
 
 
 
 
 
 
 
Monthly 
 
 
 
 
 
 
 
 
 
 
Weekly 
 
 
 
 
 
 
 
 
 
<€15,000
€15,000 - €24,999
€25,000 - €34,999
€35,000 - €44,999
€45,000 - €54,999
€55,000 - €64,999
€65,000 - €74,999
€75,000 - €84,999
€85,000 +
<€1250
€1,250 - €2,083
€2,084 - €2,916
€2,917 - €3,749
€3,750 - €4,582
€4,583 - €5,415
€5,416 - €6,249
€6250 - €7,083
€7,083 +
<€288
€288 - €479
€480 - €672
€673 - €864
€865 - €1,056
€1,057 - €1,249
€1,250 - €1,441
€1,442 - €1,634
€1,635 +
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Q15. Did the patient receive treatment for any of the following injuries during the last visit 
to an A&E department? (Please tick appropriate box/boxes) 
 
   
 
 
Q16. Please rank how satisfied the patient was with each of the following characteristics 
during their last visit to an A&E department (Please tick appropriate box for each 
characteristic) 
Characteristic      Very Satisfied      Satisfied     Neither Satisfied    Dissatisfied        Very Dissatisfied 
                                                      Nor Dissatisfied 
             1                       2                      3                      4                             5 
 Staff 
(Staff Approach) 
             
                                                                           
 
Treatment 
(Quality of 
treatment received) 
         
                                                                          
Waiting Times 
(Length of time 
spent prior to 
treatment) 
       
                                                                          
Privacy 
(From other 
patients/individuals) 
          
                                                                         
Parking 
(Parking access and 
cost)                   
            
                                                                       
Facilities 
(Phones, 
Refreshments, 
Toilets) 
             
                                                                        
Layout 
(Directions/signs to 
different areas 
within the clinic) 
         
                                                                         
 
Q17. In the future, if necessary, how likely would the patient be to return to an A&E 
department? (Please tick appropriate box) 
 
 
 
 
 
 
Sprain/Strain Minor Eye Condition Possible Break
Sport Injury Minor Burn Minor Ear Condition
Cut Requiring Stitches
Other (Please State) ______________________
Very Likely Likely Neither likely nor unlikely
Unlikely Very unlikely
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AFTER TREATMENT 
Q18. What minor injury did the patient have treated at this clinic today? (Please tick 
appropriate box) 
   
    
 
 
Q19. Has the patient been referred to..................? (Please tick appropriate box) 
 
 
Q20. How much did this visit cost in total? (Please State) 
____________________ Euro 
 
Q21. Please rank how satisfied the patient was with each of the following characteristics at 
this Vhi SwiftCare Clinic today. (Please tick appropriate box for each characteristic) 
 
 
Sprain/Strain Minor Eye Condition Possible Break
Sport Injury Minor Burn Minor Ear Condition
Cut Requiring Stitches
Other (Please State) ______________________
GP A&E department Non-referral
Other (Please State) __________ 
____________
Characteristic      Very Satisfied       Satisfied     Neither Satisfied    Dissatisfied        Very 
Dissatisfied 
                                                      Nor Dissatisfied 
             1                           2                    3                          4                              5 
 Staff 
(Staff Approach) 
             
                                                                             
 
Treatment 
(Quality of 
treatment received) 
         
                                                                            
Waiting Times 
(Length of time 
spent prior to 
treatment) 
       
                                                                            
Privacy 
(From other 
patients/individuals) 
          
                                                                           
Parking 
(Parking access and 
cost)                   
            
                                                                          
Facilities 
(Phones, 
Refreshments, 
Toilets) 
             
                                                                          
Layout 
(Directions/signs to 
different areas 
within the clinic) 
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Q22. In the future, if necessary, how likely would the patient be to return to a Vhi SwiftCare 
Clinic? 
 
 
Q23. If you wish, please provide any comments you feel necessary? 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Very Likely Likely Neither likely nor unlikely
Unlikely Very unlikely
Thank you for taking the time to complete this questionnaire. You may now either hand it back 
to the receptionist or if you prefer place in the box provided at reception. Thank you. 
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Appendix A.6 Questionnaire Brief 
“Would you mind, if you have a few minutes before you leave the clinic - to complete this 
survey. It is being conducted as part of a research study in UCC on why people use the Vhi 
SwiftCare clinics. 
It is completely anonymous and confidential and you can place the completed survey in 
the black box over there.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
359 
 
Appendix A.7 Estimating Goodness of Fit 
Bayesian Information Criteria (BIC) for the Zero-Truncated Poisson Regression Model 
 
 
Bayesian Information Criteria for the Zero-Truncated Negative Binomial Regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               Note: N=Obs used in calculating BIC; see [R] BIC note.
                                                                             
           .          263 -444.4238  -410.7296      22    865.4592   944.0466
                                                                             
       Model          Obs  ll(null)  ll(model)      df         AIC        BIC
                                                                             
               Note: N=Obs used in calculating BIC; see [R] BIC note.
                                                                             
           .          263 -417.5807  -399.1421      23    844.2842   926.4438
                                                                             
       Model          Obs  ll(null)  ll(model)      df         AIC        BIC
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Appendix A.8 Correlation between Clinic Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    293      294
                 0.0000
    cleanimp     0.2889*  1.0000 
              
                    293
              
     parkimp     1.0000 
                                
                parkimp cleanimp
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Appendix A.9 Chi 2 Tests of Independence 
Chi 2 Test of Independence between PHI and Income (€85,000) 
 
 
 
Chi 2 Test of Independence between GMS and Income (€25,000) 
 
 
 
 
 
 
 
 
 
          Pearson chi2(1) =   7.2129   Pr = 0.007
                 84.41      15.59      100.00 
                 249.0       46.0       295.0 
     Total         249         46         295 
                                             
                 82.00      18.00      100.00 
                 211.0       39.0       250.0 
       yes         205         45         250 
                                             
                 97.78       2.22      100.00 
                  38.0        7.0        45.0 
        no          44          1          45 
                                             
 insurance           0          1       Total
    health          85000+
   private  
          Pearson chi2(1) =  14.3829   Pr = 0.000
                 88.47      11.53      100.00 
                 261.0       34.0       295.0 
     Total         261         34         295 
                                             
                 63.64      36.36      100.00 
                  19.5        2.5        22.0 
       yes          14          8          22 
                                             
                 90.48       9.52      100.00 
                 241.5       31.5       273.0 
        no         247         26         273 
                                             
      card           0          1       Total
   Medical          25,000
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Appendix A.10 ZTNB with Interaction Variable (phiy17) 
 
 LR test of alpha=0: chibar2(01) = 22.80                Prob >= chibar2 = 0.000
                                                                              
       alpha     .4918313   .2050854                      .2172098    1.113661
                                                                              
    /lnalpha    -.7096196   .4169832                     -1.526892    .1076524
                                                                              
       _cons     -.463954   1.187339    -0.39   0.696    -2.791096    1.863188
     costimp    -.2932348   .1820716    -1.61   0.107    -.6500885    .0636189
     parkimp     .4278491   .1884689     2.27   0.023     .0584569    .7972414
   injuryimp     .0290469   .5449782     0.05   0.957    -1.039091    1.097185
 locationimp     -.177205   .2231029    -0.79   0.427    -.6144786    .2600687
   accessimp     .1391994   .4526723     0.31   0.758     -.748022    1.026421
    gprefimp     .1054992   .1649184     0.64   0.522     -.217735    .4287334
   nonappimp     .1535733   .3179105     0.48   0.629    -.4695199    .7766665
 waittimeimp    -.0642258   .5847545    -0.11   0.913    -1.210324    1.081872
       inc17    -16.63546   4939.963    -0.00   0.997    -9698.784    9665.513
       inc16     .4849328   .2882764     1.68   0.093    -.0800785    1.049944
       inc15    -.2853266   .2996836    -0.95   0.341    -.8726957    .3020425
       inc14    -.0379268   .2601485    -0.15   0.884    -.5478086    .4719549
       inc13     .0113132   .2489289     0.05   0.964    -.4765786    .4992049
      phiy17     16.85628   4939.963     0.00   0.997    -9665.292    9699.005
        phi1     .6096513   .2532021     2.41   0.016     .1133843    1.105918
      travel    -.0119112   .0062912    -1.89   0.058    -.0242417    .0004194
       medc1    -1.090862   .4780804    -2.28   0.023    -2.027882   -.1538413
        sex1    -.1038566   .1523232    -0.68   0.495    -.4024045    .1946913
        age4     .3346443   .7047788     0.47   0.635    -1.046697    1.715985
        age3     .5604126   .6991142     0.80   0.423    -.8098262    1.930651
        age2     .5268659   .7276918     0.72   0.469    -.8993839    1.953116
        age1     .3651128   .7099733     0.51   0.607    -1.026409    1.756635
                                                                              
clinicrecode        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -398.47042                     Pseudo R2         =     0.0458
Dispersion     = mean                           Prob > chi2       =     0.0173
Truncation point: 0                             LR chi2(22)       =      38.22
Truncated negative binomial regression          Number of obs     =        263
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Appendix A.11 Zero Truncated Negative Binomial Results 
 
 
 
  
 
 
 
 
LR test of alpha=0: chibar2(01) = 23.17                Prob >= chibar2 = 0.000
                                                                              
       alpha     .5004546   .2086041                      .2210848    1.132845
                                                                              
    /lnalpha    -.6922385   .4168293                     -1.509209     .124732
                                                                              
       _cons    -.5051317    1.19175    -0.42   0.672    -2.840919    1.830656
     costimp    -.3003669   .1828057    -1.64   0.100    -.6586595    .0579257
     parkimp     .4306522   .1893472     2.27   0.023     .0595386    .8017659
   injuryimp      .032492   .5470329     0.06   0.953    -1.039673    1.104657
 locationimp    -.1810313    .224036    -0.81   0.419    -.6201337    .2580711
   accessimp     .1365482   .4544933     0.30   0.764    -.7542422    1.027339
    gprefimp     .1099915   .1655948     0.66   0.507    -.2145683    .4345514
   nonappimp     .1604378   .3193088     0.50   0.615     -.465396    .7862716
 waittimeimp    -.0575464   .5872903    -0.10   0.922    -1.208614    1.093521
       inc17     .2010403   .2727263     0.74   0.461    -.3334934     .735574
       inc16     .4806834   .2895842     1.66   0.097    -.0868913    1.048258
       inc15    -.2942626   .3010243    -0.98   0.328    -.8842594    .2957341
       inc14    -.0425946   .2614064    -0.16   0.871    -.5549418    .4697525
       inc13     .0075757   .2500733     0.03   0.976     -.482559    .4977104
        phi1     .6462285   .2524221     2.56   0.010     .1514904    1.140967
      travel    -.0118465   .0063187    -1.87   0.061    -.0242308    .0005378
       medc1     -1.09202    .480134    -2.27   0.023    -2.033066    -.150975
        sex1    -.1106457   .1529644    -0.72   0.469    -.4104504     .189159
        age4      .338507   .7066431     0.48   0.632    -1.046488    1.723502
        age3     .5680333   .7009159     0.81   0.418    -.8057367    1.941803
        age2     .5279682   .7297379     0.72   0.469    -.9022919    1.958228
        age1     .3575222    .711868     0.50   0.616    -1.037713    1.752758
                                                                              
clinicrecode        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood =  -399.1421                     Pseudo R2         =     0.0442
Dispersion     = mean                           Prob > chi2       =     0.0174
Truncation point: 0                             LR chi2(21)       =      36.88
Truncated negative binomial regression          Number of obs     =        263
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Appendix B.1 Cover Letter from Supporting GP 
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Appendix B.2 Questionnaire for Prescription Drugs 
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Appendix B.3 Ethical Approval 
 
 
371 
 
Appendix B.4 Questionnaire Brief 
“While you are waiting for Dr. (Doctors Name), would you mind filling in a short 
questionnaire that is being conducted as part of a research project in UCC? Dr. (Doctors 
Name) is in support of this research and would be very grateful if you would complete this 
questionnaire. If you have any questions regarding the research or questionnaire, please 
see this list of FAQs. The questionnaire is completely anonymous and confidential and you 
can place the completed questionnaire in the box over there.” 
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Appendix B.5 Frequently Asked Questions for Patients 
Purpose of the Study.  As a PhD student in Health Economics at University College Cork 
(UCC), it is required that I carry out a research study. The study aims to assess the patients’ 
response to prescription drug user charges in Ireland and to estimate what Irish patients are 
willing to pay for healthcare services in Ireland.  
 
What will the study involve? The study will involve collecting information from patients as 
they wait in GP waiting areas. Surveys will be used to collect this information. The survey 
will take 3-5 minutes to complete.  
 
Why have you been asked to take part?  As a patient attending this surgery you have been 
asked to take part.  
 
Do you have to take part? No. Participation is voluntary. There is a consent form that you 
will sign to say you agree to participate. You have the option of withdrawing from this research 
at any stage. 
 
Will your participation in the study be kept confidential? Yes. The survey does not require 
any personal details (name, address etc.). I will ensure that no clues to your identity appear in 
the thesis.  
 
What will happen to the information which you give? The data will be kept confidential for 
the duration of the study. On completion of the thesis, they will be retained for a further six 
months and then destroyed. 
 
What will happen to the results?  The results will be presented in the thesis. They will be 
seen by my supervisors, a second marker and the external examiner. The thesis may be read 
by future students on the course. The study may be published in a research journal. 
 
What are the possible disadvantages of taking part? There are no disadvantages in taking 
part in this study. 
 
Who has reviewed this study? This study has been reviewed and approved by the Social 
Research Ethical Committee and the School of Economics in UCC.  
. 
Any further queries?  If you need any further information, you can contact me: Aimée Fox 
by phoning 087-7674497 or emailing me at a.fox@ucc.ie 
 
 
Thank you! 
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 Appendix B.6 Codebook  
Full Variable Name Variable Name Coding Instruction 
Number number Number (of respondent) 
Gender 
(Binary) 
sex  . = missing 
0 = male 
1 = female 
Age 
(Continuous) 
age  Number (in years) 
Nationality 
(Categorical) 
nation  . = missing 
1 = Irish 
2 = UK 
3 =Other EU 
4 = Non EU citizen 
Education Status 
(Categorical) 
educ  . = missing 
1 = Primary 
2 = Secondary 
3 = Third Level 
4 = Other  
Marital Status 
(Categorical) 
maritalstat  1 = Single 
2 = Married 
3 = Separated 
4 = Divorced 
5 = Widowed 
Medical Card  
(Binary) 
medc  0 = no 
1 = yes 
Medical Card Total 
(Continuous) 
medcno  Number (of people) 
Drugs Payment 
Scheme (Binary) 
dps  . = missing 
0 = no 
1 = yes 
Drugs Payment 
Scheme Total 
(Continuous) 
dpsno  Number (of people) 
Long Term Illness 
(Binary) 
lti  . = missing 
0 = no 
1 = yes 
No community drug 
cover  
nocomm 0 = no 
1 = yes 
Private Health 
Insurance 
(Binary) 
phi  0 = no 
1 = yes 
Private Health 
Insurance Company 
(Categorical) 
phicov  . = missing 
-8 = nophi 
1 = vhi 
2 = aviva 
3 = laya 
4 = glohealth 
5 = HSF healthplan 
6 = Other 
Other  Please state 
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Health Status 
(Categorical/Ordinal) 
healthstat  1 = excellent 
2 = very good 
3 = good  
4 = fair 
5 = poor 
Visit Reason 
(Categorical) 
visit  . = missing 
1 = consult for injury 
2 = repeat prescription 
3 = routine check-up/test 
4 = chronic illness follow-up 
5 = doctors cert for illness 
6 = to accompany a child 
7 = maternity check-up 
8 = other 
9 = more than 1 reason 
Comment  Please state 
No chronic illness chronicno1 0 = no 
1 = yes 
One chronic illness chronicno2 0 = no 
1 = yes 
Two chronic illness chronicno3 0 = no 
1 = yes 
Three or more chronic 
illnesses 
chronicno4 0 = no 
1 = yes 
Monthly Gross Income 
Level 
(Categorical/Ordinal) 
income  . = missing 
1 = <€1,000 
2 = €1,000 - €2,249 
3 = €2,250 - €3,499 
4 = €3,50 - €4,749 
5 = €4,750 - €5,999 
6 = €6,999+ 
7 = Other 
Prescription payment 
in last 12 months 
(Binary) 
rxpay  -9 = missing 
0 = no  
1 = yes 
Prescription Cost 
(Continuous) 
rxcost  Number (cost) 
   
Take less of a 
prescribed drug 
(Binary) 
rxdrugless  . = missing 
0 = no 
1 = yes 
Avoid Rx for new drug 
(Binary) 
newrx  . = missing 
 0 = no  
1 = yes 
Avoid Rx for old drug 
(Binary) 
oldrx  . = missing 
0 = no 
1 = yes 
Borrow money 
(Binary) 
borrow  . = missing 
 0 = no 
1 = yes 
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Spend Less on other 
necessities (Binary) 
spendless  . = missing 
 0 = no 
1 = yes 
Increase credit card 
debt (Binary) 
increasecred  . = missing 
 0 = no 
1 = yes 
Substitute with OTC 
(Binary) 
otcsub  . = missing 
 0 = no 
1 = yes 
Switch to generic drug 
(Binary) 
generic  . = missing 
 0 = no 
1 = yes 
Request free meds 
(Binary) 
reqfreemed  -9 = missing 
 = no 
1 = yes 
Purchase drugs from 
on-line pharmacy 
(Binary) 
onlinephar  . = missing 
 0 = no 
1 = yes 
Other measures other  State (Strategies) 
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Appendix B.7 MNLM with Perfect Prediction 
                                                                               
       _cons    -13.54234   5.566003    -2.43   0.015     -24.4515   -2.633172
  chronicno4    -.5359574    1.33391    -0.40   0.688    -3.150373    2.078458
excellhealth    -14.77126   2262.311    -0.01   0.995    -4448.819    4419.277
   incomesix    -20.16064   3249.555    -0.01   0.995    -6389.172    6348.851
  incomefour    -11.02507   3000.187    -0.00   0.997    -5891.284    5869.234
 incomethree     .7162547   2.910045     0.25   0.806    -4.987329    6.419838
   incometwo     5.223597   3.662686     1.43   0.154    -1.955136    12.40233
   incomeone     2.972745   3.411057     0.87   0.383    -3.712804    9.658295
      rxcost     .0565297   .0204759     2.76   0.006     .0163977    .0966617
      nocomm     6.303857   2.470783     2.55   0.011     1.461212     11.1465
         dps     4.758956   2.367922     2.01   0.044     .1179154    9.399997
        medc     6.739184   2.417423     2.79   0.005     2.001123    11.47725
        age5    -17.74561   4383.294    -0.00   0.997    -8608.844    8573.353
        age4    -20.23933   2249.806    -0.01   0.993    -4429.778    4389.299
        age3    -1.405312    1.57643    -0.89   0.373    -4.495059    1.684435
        age2     -.043877   1.020596    -0.04   0.966    -2.044209    1.956455
allresp       
                                                                              
       _cons    -2.114585   2.336079    -0.91   0.365    -6.693216    2.464046
  chronicno4     -.471194   1.315056    -0.36   0.720    -3.048656    2.106268
excellhealth     .2710743   .8436346     0.32   0.748    -1.382419    1.924568
   incomesix    -18.27102   4268.801    -0.00   0.997    -8384.967    8348.425
  incomefour    -1.847031   1.422352    -1.30   0.194    -4.634789    .9407278
 incomethree    -.3415691   1.061411    -0.32   0.748    -2.421896    1.738758
   incometwo    -1.479744   1.112129    -1.33   0.183    -3.659477    .6999886
   incomeone    -.0517723   1.143103    -0.05   0.964    -2.292214    2.188669
      rxcost    -.0008551   .0103275    -0.08   0.934    -.0210965    .0193864
      nocomm     .3460261   2.004874     0.17   0.863    -3.583456    4.275508
         dps    -.2160513   1.934888    -0.11   0.911    -4.008361    3.576259
        medc     .8977065   2.110348     0.43   0.671    -3.238499    5.033912
        age5     .4715207   1.613025     0.29   0.770    -2.689951    3.632993
        age4     .7726062   1.436838     0.54   0.591    -2.043544    3.588756
        age3     .5610848   1.364908     0.41   0.681    -2.114086    3.236255
        age2     1.649653   1.219585     1.35   0.176    -.7406902    4.039997
tworesp       
                                                                              
       _cons    -.8984585   1.562844    -0.57   0.565    -3.961576    2.164659
  chronicno4    -.7467906   .8737196    -0.85   0.393     -2.45925    .9656684
excellhealth     .4070477   .6079932     0.67   0.503    -.7845971    1.598693
   incomesix    -.7320625   .8428472    -0.87   0.385    -2.384013    .9198876
  incomefour    -1.165801   .8552695    -1.36   0.173    -2.842098    .5104967
 incomethree    -1.034246   .7231666    -1.43   0.153    -2.451626    .3831349
   incometwo    -1.223728   .6965974    -1.76   0.079    -2.589034    .1415776
   incomeone    -.3358564   .8149857    -0.41   0.680    -1.933199    1.261486
      rxcost      .007591   .0054198     1.40   0.161    -.0030316    .0182136
      nocomm     1.309655   1.459667     0.90   0.370     -1.55124     4.17055
         dps     1.207448    1.41151     0.86   0.392    -1.559061    3.973957
        medc     .8354276   1.507657     0.55   0.579    -2.119526    3.790382
        age5     -1.73373   1.255233    -1.38   0.167    -4.193942    .7264822
        age4    -.6010488   .8438686    -0.71   0.476    -2.255001    1.052903
        age3    -.3285884   .7479207    -0.44   0.660    -1.794486    1.137309
        age2    -.5557818   .7169456    -0.78   0.438    -1.960969    .8494056
oneresp       
                                                                              
noresponse      (base outcome)
                                                                              
  responseno        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -129.11999                     Pseudo R2         =     0.2042
                                                Prob > chi2       =     0.0211
                                                LR chi2(45)       =      66.28
Multinomial logistic regression                 Number of obs     =        143
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Appendix B.8 Multinomial Logit Model Results 
 
 
 
 
 
 
                                                                              
       _cons    -11.63209   3.489526    -3.33   0.001    -18.47144   -4.792745
  chronicno4       .43132    1.09477     0.39   0.694    -1.714389    2.577029
 incomethree     1.128678   2.250501     0.50   0.616    -3.282223    5.539578
   incometwo     4.111345   2.057843     2.00   0.046     .0780457    8.144644
   incomeone     2.027264    2.25625     0.90   0.369    -2.394904    6.449432
      rxcost     .0324496    .010794     3.01   0.003     .0112937    .0536054
      nocomm        4.945   2.062023     2.40   0.016     .9035091     8.98649
         dps     3.009208   1.850578     1.63   0.104    -.6178579    6.636274
        medc     5.435104   1.972521     2.76   0.006     1.569034    9.301174
        age3     .4136619   1.227152     0.34   0.736    -1.991512    2.818836
        age2     .9576661   .9297395     1.03   0.303    -.8645899    2.779922
allresp       
                                                                              
       _cons    -2.468528   2.146637    -1.15   0.250    -6.675859    1.738803
  chronicno4    -.1122647   1.266743    -0.09   0.929    -2.595036    2.370506
 incomethree     1.029723   .8228582     1.25   0.211     -.583049    2.642496
   incometwo    -.1312617   .8998587    -0.15   0.884    -1.894952    1.632429
   incomeone     1.252073    .967279     1.29   0.196    -.6437589    3.147905
      rxcost     .0013174   .0092396     0.14   0.887    -.0167917    .0194266
      nocomm    -.1959365   1.884283    -0.10   0.917    -3.889063     3.49719
         dps    -.7106364   1.825928    -0.39   0.697     -4.28939    2.868117
        medc     .3823745    1.93461     0.20   0.843    -3.409392    4.174141
        age3     .1477478   .9802034     0.15   0.880    -1.773416    2.068911
        age2     1.072161   .7693225     1.39   0.163    -.4356834    2.580006
tworesp       
                                                                              
       _cons    -1.327773   1.418097    -0.94   0.349    -4.107193    1.451646
  chronicno4    -.6389132   .8480021    -0.75   0.451    -2.300967     1.02314
 incomethree    -.5078814   .5673703    -0.90   0.371    -1.619907    .6041441
   incometwo    -.6368786   .5332693    -1.19   0.232    -1.682067    .4083099
   incomeone     .2033682   .6778011     0.30   0.764    -1.125098    1.531834
      rxcost     .0077382   .0050933     1.52   0.129    -.0022445    .0177209
      nocomm     .7734514    1.31463     0.59   0.556    -1.803177    3.350079
         dps     .5916306   1.269696     0.47   0.641    -1.896928    3.080189
        medc     .2975249   1.343664     0.22   0.825    -2.336009    2.931059
        age3     .1849511   .5410862     0.34   0.732    -.8755583    1.245461
        age2    -.1305576   .5116518    -0.26   0.799    -1.133377    .8722614
oneresp       
                                                                              
noresponse      (base outcome)
                                                                              
  responseno        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -140.46751                     Pseudo R2         =     0.1343
                                                Prob > chi2       =     0.0520
                                                LR chi2(30)       =      43.58
Multinomial logistic regression                 Number of obs     =        143
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Appendix B.9 Chi Square Tests of Independence 
Chi 2 Test of Independence between GMS and Income (<€1,000) 
 
 
 
Chi 2 Test of Independence between GMS and Income (€2,250-€3,499) 
 
 
  
 
 
 
          Pearson chi2(1) =  35.4221   Pr = 0.000
                 65.26      34.74      100.00 
                 139.0       74.0       213.0 
     Total         139         74         213 
                                             
                 28.26      71.74      100.00 
                  30.0       16.0        46.0 
       yes          13         33          46 
                                             
                 75.45      24.55      100.00 
                 109.0       58.0       167.0 
        no         126         41         167 
                                             
    <1,000          no        yes       Total
                  possession
                 Medical card
          Pearson chi2(1) =   7.1637   Pr = 0.007
                 65.26      34.74      100.00 
                 139.0       74.0       213.0 
     Total         139         74         213 
                                             
                 85.29      14.71      100.00 
                  22.2       11.8        34.0 
       yes          29          5          34 
                                             
                 61.45      38.55      100.00 
                 116.8       62.2       179.0 
        no         110         69         179 
                                             
     3,499          no        yes       Total
   2,250 -        possession
                 Medical card
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Appendix B.10 MNLM with Interaction Variables 
 
                                                                              
       _cons    -28.71548   2331.232    -0.01   0.990    -4597.846    4540.415
  chronicno4     1.030787   1.190093     0.87   0.386    -1.301754    3.363327
    inc1medc    -35.51826   4092.745    -0.01   0.993     -8057.15    7986.114
 incomethree    -13.44459   2331.228    -0.01   0.995    -4582.567    4555.678
   incometwo     4.829256   2.608437     1.85   0.064    -.2831871      9.9417
   incomeone     4.560237   2.636574     1.73   0.084    -.6073533    9.727828
      rxcost      .032908   .0114534     2.87   0.004     .0104598    .0553562
      nocomm     20.87425   2331.228     0.01   0.993    -4548.249    4589.998
         dps     19.13209   2331.228     0.01   0.993    -4549.991    4588.255
        medc     21.65145   2331.228     0.01   0.993    -4547.472    4590.774
        age3      1.26675   1.312539     0.97   0.334    -1.305779    3.839278
        age2      1.25712   .9882519     1.27   0.203    -.6798181    3.194058
allresp       
                                                                              
       _cons    -2.292411   2.123879    -1.08   0.280    -6.455137    1.870316
  chronicno4    -.1640124     1.2612    -0.13   0.897     -2.63592    2.307895
    inc1medc    -1.589562   1.554543    -1.02   0.307     -4.63641    1.457285
 incomethree     1.102151   .8356053     1.32   0.187    -.5356052    2.739907
   incometwo    -.2574866     .92534    -0.28   0.781     -2.07112    1.556146
   incomeone     1.994941   1.169047     1.71   0.088    -.2963489    4.286231
      rxcost     .0008951    .009352     0.10   0.924    -.0174346    .0192247
      nocomm    -.4591982   1.896379    -0.24   0.809    -4.176033    3.257637
         dps    -.9003402   1.819587    -0.49   0.621    -4.466666    2.665986
        medc     .7733783    1.94394     0.40   0.691    -3.036674     4.58343
        age3     .0550007   .9805877     0.06   0.955    -1.866916    1.976917
        age2     1.065249   .7615418     1.40   0.162    -.4273451    2.557844
tworesp       
                                                                              
       _cons    -1.275722    1.38888    -0.92   0.358    -3.997877    1.446432
  chronicno4    -.6671017   .8461788    -0.79   0.430    -2.325582    .9913782
    inc1medc      -.60709   1.357893    -0.45   0.655     -3.26851    2.054331
 incomethree    -.5091607   .5646946    -0.90   0.367    -1.615942    .5976204
   incometwo    -.6604202   .5356983    -1.23   0.218     -1.71037    .3895291
   incomeone     .5296806   .8605722     0.62   0.538     -1.15701    2.216371
      rxcost     .0078183   .0051255     1.53   0.127    -.0022274     .017864
      nocomm     .6958168    1.30042     0.54   0.593     -1.85296    3.244593
         dps     .5407156   1.247535     0.43   0.665    -1.904409     2.98584
        medc     .3806019    1.42734     0.27   0.790    -2.416933    3.178137
        age3     .1711321    .540522     0.32   0.752    -.8882715    1.230536
        age2    -.1263049   .5112173    -0.25   0.805    -1.128272    .8756626
oneresp       
                                                                              
noresponse      (base outcome)
                                                                              
  responseno        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -137.28091                     Pseudo R2         =     0.1539
                                                Prob > chi2       =     0.0295
                                                LR chi2(33)       =      49.95
Multinomial logistic regression                 Number of obs     =        143
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Appendix C.1 Cover Letter from Supporting GP 
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Appendix C.2 Questionnaire for WTP for Healthcare Services 
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Appendix C.3 Ethical Approval 
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Appendix C.4 Questionnaire Brief 
 
“While you are waiting for Dr. (Doctors Name), would you mind filling in a short 
questionnaire that is being conducted as part of a research project in UCC? Dr. (Doctors 
Name) is in support of this research and would be very grateful if you would complete this 
questionnaire. If you have any questions regarding the research or questionnaire, please 
see this list of FAQs. The questionnaire is completely anonymous and confidential and you 
can place the completed questionnaire in the box over there.” 
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Appendix C.5 Frequently Asked Questions for Patients 
Purpose of the Study.  As a PhD student in Health Economics at University College Cork 
(UCC), it is required that I carry out a research study. The study aims to assess the patients’ 
response to prescription drug user charges in Ireland and to estimate what Irish patients are 
willing to pay for healthcare services in Ireland.  
 
What will the study involve? The study will involve collecting information from patients as 
they wait in GP waiting areas. Surveys will be used to collect this information. The survey 
will take 3-5 minutes to complete.  
 
Why have you been asked to take part?  As a patient attending this surgery you have been 
asked to take part.  
 
Do you have to take part? No. Participation is voluntary. There is a consent form that you 
will sign to say you agree to participate. You have the option of withdrawing from this research 
at any stage. 
 
Will your participation in the study be kept confidential? Yes. The survey does not require 
any personal details (name, address etc.). I will ensure that no clues to your identity appear in 
the thesis.  
 
What will happen to the information which you give? The data will be kept confidential for 
the duration of the study. On completion of the thesis, they will be retained for a further six 
months and then destroyed. 
 
What will happen to the results?  The results will be presented in the thesis. They will be 
seen by my supervisors, a second marker and the external examiner. The thesis may be read 
by future students on the course. The study may be published in a research journal. 
 
What are the possible disadvantages of taking part? There are no disadvantages in taking 
part in this study. 
 
Who has reviewed this study? This study has been reviewed and approved by the Social 
Research Ethical Committee and the School of Economics in UCC.  
. 
Any further queries?  If you need any further information, you can contact me: Aimée Fox 
by phoning 087-7674497 or emailing me at a.fox@ucc.ie 
 
 
Thank you! 
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Appendix C.6 Codebook 
 
Full Variable Name Variable Name Coding Instruction 
Number number Number (of respondent) 
Gender 
(Binary) 
sex  . = missing 
0 = male 
1 = female 
Age 
(Continuous) 
age  Number (in years) 
Nationality 
(Categorical) 
nation  . = missing 
1 = Irish 
2 = UK 
3 =Other EU 
4 = Non EU citizen 
Education Status 
(Categorical) 
educ  . = missing 
1 = Primary 
2 = Secondary 
3 = Third Level 
4 = Other  
Marital Status 
(Categorical) 
maritalstat  1 = Single 
2 = Married 
3 = Separated 
4 = Divorced 
5 = Widowed 
Medical Card  
(Binary) 
medc  0 = no 
1 = yes 
Medical Card Total 
(Continuous) 
medcno  Number (of people) 
Drugs Payment 
Scheme (Binary) 
dps  . = missing 
0 = no 
1 = yes 
Drugs Payment 
Scheme Total 
(Continuous) 
dpsno  Number (of people) 
Long Term Illness 
(Binary) 
lti  . = missing 
0 = no 
1 = yes 
No community drug 
cover  
nocomm 0 = no 
1 = yes 
Private Health 
Insurance 
(Binary) 
phi  0 = no 
1 = yes 
Private Health 
Insurance Company 
(Categorical) 
phicov  . = missing 
-8 = nophi 
1 = vhi 
2 = aviva 
3 = laya 
4 = glohealth 
5 = HSF healthplan 
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6 = Other 
Other  Please state 
Health Status 
(Categorical/Ordinal) 
healthstat  1 = excellent 
2 = very good 
3 = good  
4 = fair 
5 = poor 
Visit Reason 
(Categorical) 
visit  . = missing 
1 = consult for injury 
2 = repeat prescription 
3 = routine check-up/test 
4 = chronic illness follow-up 
5 = doctors cert for illness 
6 = to accompany a child 
7 = maternity check-up 
8 = other 
9 = more than 1 reason 
Comment  Please state 
No chronic illness chronicno1 0 = no 
1 = yes 
One chronic illness chronicno2 0 = no 
1 = yes 
Two chronic illness chronicno3 0 = no 
1 = yes 
Three or more chronic 
illnesses 
chronicno4 0 = no 
1 = yes 
Monthly Gross Income 
Level 
(Categorical/Ordinal) 
income  . = missing 
1 = <€1,000 
2 = €1,000 - €2,249 
3 = €2,250 - €3,499 
4 = €3,50 - €4,749 
5 = €4,750 - €5,999 
6 = €6,999+ 
7 = Other 
WTP for blood tests plebwtp1 . = missing 
0 = no 
1 = yes 
WTP value for blood 
tests 
wtppleb . = missing 
value in € 
Previous blood test plebprev . = missing 
0 = no 
1= yes 
WTP for shoulder MRI mrishoulwtp1 . = missing 
0 = no 
1= yes 
WTP value for 
shoulder MRI 
mrishoul . = missing 
value in € 
WTP for brain MRI mribrainwtp1 . = missing 
0 = no 
1= yes 
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WTP value for brain 
MRI 
mribrain . = missing 
value in € 
Previous MRI prevmri . = missing 
0 = no 
1= yes 
WTP for a branded 
prescription drug 
wtpbrand . = missing 
0 = no 
1= yes 
GMS patients WTP for 
a branded drug 
wtpcholmedc . = missing 
-8 = nongms 
0 = no 
1 = yes 
GMS patients WTP 
value for a branded 
drug 
cholmedc . = missing 
-8 = nongms 
Value in € 
Non-GMS patient WTP wtpcholnonmed . = missing 
0 = no 
1= yes 
Non-GMS patient WTP 
for a branded drug 
cholnonmed . = missing 
-8 = nongms 
Value in € 
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Appendix C.7 Shapiro-Wilk Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
wtpcholnon~d          182    0.87185     17.615     6.569    0.00000
 wtpcholmedc          209    0.91806     12.702     5.861    0.00000
    mribrain          186    0.95249      6.654     4.345    0.00001
    mrishoul          186    0.94485      7.724     4.686    0.00000
     wtppleb          198    0.97343      3.930     3.147    0.00082
                                                                    
    Variable          Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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Appendix C.8 WTP for Blood Tests (Probit Results) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
        _cons    -.6993018    .832644    -0.84   0.401    -2.331254    .9326505
       midinc     .2594991    .441638     0.59   0.557    -.6060956    1.125094
       lowinc     .1974585   .4032121     0.49   0.624    -.5928226    .9877396
   fairhealth     .4280687   .6590372     0.65   0.516    -.8636204    1.719758
   goodhealth     1.407302   .6040583     2.33   0.020       .22337    2.591235
  vgoodhealth     1.219248   .6489362     1.88   0.060    -.0526441    2.491139
 excellhealth     .6198105   .6890073     0.90   0.368     -.730619     1.97024
    othereduc            0  (omitted)
secondaryeduc    -.0461487   .2767706    -0.17   0.868    -.5886092    .4963117
  primaryeduc    -.1757102   .5442579    -0.32   0.747    -1.242436    .8910156
          phi     .3723509   .2672555     1.39   0.164    -.1514602     .896162
         medc    -.1579655   .2400181    -0.66   0.510    -.6283923    .3124612
         age5    -.2279045   .6154711    -0.37   0.711    -1.434206    .9783967
         age4     .4849142   .5034453     0.96   0.335    -.5018204    1.471649
         age3     .4433108   .4055159     1.09   0.274    -.3514857    1.238107
         age2     .7011041   .3668781     1.91   0.056    -.0179638    1.420172
                                                                               
     plebwtp1        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                              Robust
                                                                               
Log pseudolikelihood = -66.442672               Pseudo R2         =     0.1411
                                                Prob > chi2       =     0.0278
                                                Wald chi2(14)     =      25.75
Probit regression                               Number of obs     =        188
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Appendix C.9 WTP for Blood Tests (Marginal Effects) 
 
 
 
 
 
 
 
 
 
 
                                                                               
       midinc      .050007    .085799     0.58   0.560     -.118156      .21817
       lowinc     .0380514   .0783191     0.49   0.627    -.1154513    .1915541
   fairhealth     .0824914   .1271309     0.65   0.516    -.1666806    .3316633
   goodhealth     .2711955   .1186811     2.29   0.022     .0385847    .5038062
  vgoodhealth     .2349562   .1256078     1.87   0.061    -.0112306    .4811429
 excellhealth     .1194411   .1328352     0.90   0.369    -.1409111    .3797934
    othereduc            0  (omitted)
secondaryeduc    -.0088931   .0531245    -0.17   0.867    -.1130153    .0952291
  primaryeduc    -.0338604    .104869    -0.32   0.747    -.2393998     .171679
          phi     .0717542   .0516914     1.39   0.165    -.0295591    .1730676
         medc    -.0304409   .0461916    -0.66   0.510    -.1209747     .060093
         age5    -.0439185   .1187376    -0.37   0.711    -.2766399    .1888028
         age4     .0934458   .0967851     0.97   0.334    -.0962495    .2831411
         age3     .0854286   .0787228     1.09   0.278    -.0688652    .2397225
         age2     .1351069    .071402     1.89   0.058    -.0048384    .2750522
                                                                               
                     dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval]
                           Delta-method
                                                                               
               midinc          =    .2925532 (mean)
               lowinc          =    .5744681 (mean)
               fairhealth      =    .1223404 (mean)
               goodhealth      =    .3510638 (mean)
               vgoodhealth     =    .3776596 (mean)
               excellhealth    =    .1276596 (mean)
               othereduc       =           0 (mean)
               secondarye~c    =    .3191489 (mean)
               primaryeduc     =    .0531915 (mean)
               phi             =    .6542553 (mean)
               medc            =    .3297872 (mean)
               age5            =    .0478723 (mean)
               age4            =    .1542553 (mean)
               age3            =    .2606383 (mean)
at           : age2            =    .4042553 (mean)
dy/dx w.r.t. : age2 age3 age4 age5 medc phi primaryeduc secondaryeduc othereduc excellhealth vgoodhealth goodhealth fairhealth lowinc midinc
Expression   : Pr(plebwtp1), predict()
Model VCE    : Robust
Conditional marginal effects                    Number of obs     =        188
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Appendix C.10 WTP for Blood Tests (OLS Before Controlling for 
Multicollinearity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
        _cons     .9771229   1.272403     0.77   0.444    -1.539131    3.493377
    invmills1     .3525166   1.239156     0.28   0.776     -2.09799    2.803023
     plebprev     .8275849   .3179956     2.60   0.010     .1987292    1.456441
       midinc     .1455953   .1941092     0.75   0.455    -.2382675     .529458
       lowinc    -.0610928   .1913315    -0.32   0.750    -.4394624    .3172768
   fairhealth     .8514559   .5071364     1.68   0.095    -.1514373    1.854349
   goodhealth     .9377486   .7782317     1.20   0.230    -.6012519    2.476749
  vgoodhealth     1.024103   .7301127     1.40   0.163    -.4197392    2.467945
 excellhealth      1.07844   .5856485     1.84   0.068    -.0797151    2.236596
    othereduc            0  (omitted)
secondaryeduc    -.0325055   .1277674    -0.25   0.800    -.2851734    .2201624
  primaryeduc    -.3012389   .2987992    -1.01   0.315    -.8921324    .2896547
          phi     .0478974   .1864109     0.26   0.798    -.3207414    .4165362
         medc    -.2205009   .1384566    -1.59   0.114    -.4943072    .0533053
         age5      .023238   .3343878     0.07   0.945    -.6380342    .6845101
         age4     .1746637   .2937666     0.59   0.553    -.4062775    .7556049
         age3     .0782821   .2570993     0.30   0.761    -.4301475    .5867116
         age2    -.0273034   .3052463    -0.09   0.929    -.6309466    .5763398
                                                                               
   logwtppleb        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    59.1014977       152  .388825643   Root MSE        =    .60273
                                                   Adj R-squared   =    0.0657
    Residual    49.4065931       136  .363283773   R-squared       =    0.1640
       Model    9.69490462        16  .605931539   Prob > F        =    0.0601
                                                   F(16, 136)      =      1.67
      Source         SS           df       MS      Number of obs   =       153
note: othereduc omitted because of collinearity
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Appendix C.11 Testing WTP Consumption Equation for Multicollinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Mean VIF       12.07
                                    
    plebprev        1.08    0.922250
secondarye~c        1.45    0.691760
 primaryeduc        1.64    0.609155
        medc        1.65    0.604549
        age5        1.77    0.563596
         phi        3.11    0.321064
      midinc        3.42    0.292695
      lowinc        3.81    0.262686
        age4        4.47    0.223480
        age3        5.20    0.192422
  fairhealth        9.00    0.111057
        age2        9.66    0.103529
excellhealth       14.99    0.066689
   invmills1       17.99    0.055602
 vgoodhealth       53.82    0.018580
  goodhealth       60.04    0.016656
                                    
    Variable         VIF       1/VIF  
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Appendix C.12 WTP for Blood Tests (OLS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
        _cons     2.397356   .4801754     4.99   0.000     1.447842     3.34687
    invmills1    -.8716935   .7106228    -1.23   0.222    -2.276901    .5335142
     plebprev     .8427596   .3182699     2.65   0.009     .2134029    1.472116
       midinc     .0498633   .1773978     0.28   0.779    -.3009286    .4006553
       lowinc    -.1549621   .1750424    -0.89   0.378    -.5010964    .1911721
   fairhealth     .3635743   .3058745     1.19   0.237    -.2412714      .96842
  vgoodhealth     .1565427   .1213984     1.29   0.199    -.0835144    .3965997
 excellhealth     .4323952   .2360334     1.83   0.069    -.0343446    .8991351
    othereduc            0  (omitted)
secondaryeduc     .0011011   .1248918     0.01   0.993    -.2458638     .248066
  primaryeduc    -.1581563   .2746434    -0.58   0.566    -.7012447    .3849321
          phi    -.0993702   .1409876    -0.70   0.482    -.3781635    .1794231
         medc    -.1637001   .1303997    -1.26   0.211    -.4215565    .0941563
         age5      .164751    .313602     0.53   0.600    -.4553754    .7848775
         age4     -.048105   .2286749    -0.21   0.834    -.5002939    .4040839
         age3    -.1072489   .2062349    -0.52   0.604    -.5150643    .3005665
         age2    -.2908509   .2132792    -1.36   0.175    -.7125959    .1308941
                                                                               
   logwtppleb        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    59.1014977       152  .388825643   Root MSE        =    .60372
                                                   Adj R-squared   =    0.0626
    Residual    49.9340671       137  .364482241   R-squared       =    0.1551
       Model    9.16743066        15  .611162044   Prob > F        =    0.0624
                                                   F(15, 137)      =      1.68
      Source         SS           df       MS      Number of obs   =       153
note: othereduc omitted because of collinearity
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Appendix C.13 WTP for Shoulder MRI (Probit Results) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 0 failures and 15 successes completely determined.
                                                                               
        _cons     5.418232   .9309581     5.82   0.000     3.593588    7.242877
       midinc    -5.006311   .5323943    -9.40   0.000    -6.049785   -3.962838
       lowinc    -5.090343   .4254146   -11.97   0.000    -5.924141   -4.256546
   fairhealth     .1722555   .7437852     0.23   0.817    -1.285537    1.630048
   goodhealth     .6824766   .6801554     1.00   0.316    -.6506036    2.015557
  vgoodhealth     .5469205    .701388     0.78   0.436    -.8277748    1.921616
 excellhealth     .1821657   .7830355     0.23   0.816    -1.352556    1.716887
    othereduc      -.83539   .7393224    -1.13   0.259    -2.284435    .6136553
secondaryeduc    -.0672999   .3134592    -0.21   0.830    -.6816686    .5470688
  primaryeduc    -.6439531   .5633869    -1.14   0.253    -1.748171    .4602649
          phi     .3709457   .2984841     1.24   0.214    -.2140724    .9559638
         medc    -.4551795   .3233477    -1.41   0.159    -1.088929    .1785703
         age5     .6610294   .6705493     0.99   0.324    -.6532232    1.975282
         age4     .3145349   .4710643     0.67   0.504    -.6087342    1.237804
         age3     .4686444   .4286832     1.09   0.274    -.3715593    1.308848
         age2    -.0731314   .4134194    -0.18   0.860    -.8834186    .7371558
                                                                               
 mrishoulwtp1        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                              Robust
                                                                               
Log pseudolikelihood = -66.653762               Pseudo R2         =     0.1594
                                                Prob > chi2       =     0.0000
                                                Wald chi2(15)     =     528.82
Probit regression                               Number of obs     =        179
399 
 
Appendix C.14 WTP for Shoulder MRI (Marginal Effects) 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
       midinc    -.5132223   .1133743    -4.53   0.000    -.7354319   -.2910127
       lowinc    -.5218369   .1107047    -4.71   0.000    -.7388141   -.3048597
   fairhealth     .0176588   .0768959     0.23   0.818    -.1330544    .1683719
   goodhealth     .0699641   .0717182     0.98   0.329    -.0706009    .2105292
  vgoodhealth     .0560676   .0738315     0.76   0.448    -.0886395    .2007747
 excellhealth     .0186747   .0806179     0.23   0.817    -.1393334    .1766828
    othereduc    -.0856401   .0746493    -1.15   0.251      -.23195    .0606699
secondaryeduc    -.0068992    .032033    -0.22   0.829    -.0696828    .0558843
  primaryeduc    -.0660149   .0560267    -1.18   0.239    -.1758251    .0437953
          phi     .0380275   .0312799     1.22   0.224      -.02328    .0993351
         medc    -.0466628   .0320561    -1.46   0.145    -.1094916     .016166
         age5     .0677655   .0691912     0.98   0.327    -.0678468    .2033778
         age4     .0322446   .0490408     0.66   0.511    -.0638736    .1283628
         age3     .0480431   .0454788     1.06   0.291    -.0410938      .13718
         age2    -.0074971   .0421783    -0.18   0.859     -.090165    .0751708
                                                                               
                     dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval]
                           Delta-method
                                                                               
               midinc          =    .2905028 (mean)
               lowinc          =    .5865922 (mean)
               fairhealth      =    .1340782 (mean)
               goodhealth      =    .3296089 (mean)
               vgoodhealth     =    .3798883 (mean)
               excellhealth    =    .1284916 (mean)
               othereduc       =    .0111732 (mean)
               secondarye~c    =    .3296089 (mean)
               primaryeduc     =    .0502793 (mean)
               phi             =    .6424581 (mean)
               medc            =    .3519553 (mean)
               age5            =    .0558659 (mean)
               age4            =    .1564246 (mean)
               age3            =    .2569832 (mean)
at           : age2            =    .4022346 (mean)
dy/dx w.r.t. : age2 age3 age4 age5 medc phi primaryeduc secondaryeduc othereduc excellhealth vgoodhealth goodhealth fairhealth lowinc midinc
Expression   : Pr(mrishoulwtp1), predict()
Model VCE    : Robust
Conditional marginal effects                    Number of obs     =        179
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Appendix C.15 WTP for Shoulder MRI (OLS before Controlling for 
Multicollinearity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
        _cons     3.254596   .4998931     6.51   0.000      2.26306    4.246131
    invmills2      .226942   .6697187     0.34   0.735    -1.101442    1.555326
      prevmri     .2411931   .1127907     2.14   0.035     .0174733    .4649128
       midinc     .2538392   .2282824     1.11   0.269    -.1989579    .7066364
       lowinc      .165124   .2476444     0.67   0.506    -.3260775    .6563255
   fairhealth     .7737628   .4226147     1.83   0.070    -.0644914    1.612017
   goodhealth     .7519894   .4189937     1.79   0.076    -.0790828    1.583061
  vgoodhealth     .8261045   .4166259     1.98   0.050     -.000271     1.65248
 excellhealth     .6071959   .4218358     1.44   0.153    -.2295135    1.443905
    othereduc      .021533    .563964     0.04   0.970    -1.097087    1.140153
secondaryeduc    -.0689619    .121478    -0.57   0.571    -.3099129    .1719891
  primaryeduc    -.1942464    .311446    -0.62   0.534     -.811998    .4235051
          phi     .2346733   .1586006     1.48   0.142    -.0799103    .5492569
         medc     .0917851   .1585506     0.58   0.564    -.2226993    .4062694
         age5     .7442891   .3124076     2.38   0.019       .12463    1.363948
         age4     .2565751   .2050881     1.25   0.214    -.1502162    .6633665
         age3     .1102762   .1915176     0.58   0.566    -.2695981    .4901505
         age2     .1563321   .1585637     0.99   0.327    -.1581782    .4708423
                                                                               
  logmrishoul        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    36.7706507       119  .308997065   Root MSE        =    .52004
                                                   Adj R-squared   =    0.1248
    Residual    27.5852345       102  .270443475   R-squared       =    0.2498
       Model    9.18541623        17  .540318602   Prob > F        =    0.0179
                                                   F(17, 102)      =      2.00
      Source         SS           df       MS      Number of obs   =       120
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Appendix C.16 Testing for Multicollinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Mean VIF        5.30
                                    
   othereduc        1.17    0.857449
     prevmri        1.28    0.778695
 primaryeduc        1.39    0.721065
        age5        1.40    0.716632
secondarye~c        1.40    0.716115
        age4        2.16    0.463685
         phi        2.38    0.420115
        medc        2.45    0.408670
        age2        2.71    0.368793
        age3        3.24    0.308182
      midinc        4.93    0.202784
      lowinc        6.73    0.148478
   invmills2        6.95    0.143875
  fairhealth        7.13    0.140205
excellhealth        8.14    0.122896
  goodhealth       18.26    0.054773
 vgoodhealth       18.35    0.054493
                                    
    Variable         VIF       1/VIF  
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Appendix C.17 WTP for Shoulder MRI (OLS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               
        _cons     4.046791    .237172    17.06   0.000     3.576416    4.517165
    invmills2    -.2315708   .6257162    -0.37   0.712    -1.472531     1.00939
      prevmri     .2393756   .1139957     2.10   0.038     .0132919    .4654592
       midinc     .3694148   .2213602     1.67   0.098    -.0696009    .8084305
       lowinc     .2752403   .2424968     1.14   0.259    -.2056949    .7561754
   fairhealth     .0908308   .1858483     0.49   0.626    -.2777555    .4594171
  vgoodhealth     .1092387   .1197525     0.91   0.364    -.1282621    .3467395
 excellhealth     -.067254   .1936986    -0.35   0.729    -.4514095    .3169015
    othereduc     .1256248     .56699     0.22   0.825    -.9988662    1.250116
secondaryeduc    -.0431573   .1219178    -0.35   0.724    -.2849525    .1986378
  primaryeduc    -.0915515   .3094279    -0.30   0.768    -.7052286    .5221257
          phi     .1570235   .1542218     1.02   0.311    -.1488391    .4628861
         medc     .1409425   .1578418     0.89   0.374    -.1720994    .4539844
         age5     .6981249   .3146861     2.22   0.029     .0740193     1.32223
         age4     .1780266   .2025128     0.88   0.381    -.2236097    .5796629
         age3     .0329831   .1886141     0.17   0.862    -.3410884    .4070546
         age2      .145646   .1601512     0.91   0.365    -.1719761    .4632681
                                                                               
  logmrishoul        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    36.7706507       119  .308997065   Root MSE        =    .52562
                                                   Adj R-squared   =    0.1059
    Residual    28.4563681       103  .276275419   R-squared       =    0.2261
       Model    8.31428254        16  .519642659   Prob > F        =    0.0305
                                                   F(16, 103)      =      1.88
      Source         SS           df       MS      Number of obs   =       120
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Appendix C.18 WTP for Brain MRI (Probit Results) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: 0 failures and 15 successes completely determined.
                                                                               
        _cons      4.60589   .9199962     5.01   0.000     2.802731     6.40905
       midinc    -4.277653   .5744259    -7.45   0.000    -5.403507   -3.151799
       lowinc    -4.700036   .4501375   -10.44   0.000    -5.582289   -3.817782
   fairhealth     .4169241   .7315293     0.57   0.569    -1.016847    1.850695
   goodhealth     .8359055   .6682771     1.25   0.211    -.4738936    2.145705
  vgoodhealth     .8202646   .7150506     1.15   0.251    -.5812088    2.221738
 excellhealth     .5685724   .8043746     0.71   0.480    -1.007973    2.145118
    othereduc    -.1685541   .7469391    -0.23   0.821    -1.632528     1.29542
secondaryeduc    -.0542546   .3280947    -0.17   0.869    -.6973084    .5887992
  primaryeduc    -.4778532   .5614377    -0.85   0.395    -1.578251    .6225444
          phi     .7206897   .3095604     2.33   0.020     .1139625    1.327417
         medc    -.1839949   .3305944    -0.56   0.578     -.831948    .4639582
         age5     .3606849   .7099836     0.51   0.611    -1.030857    1.752227
         age4     .0616654   .4951398     0.12   0.901    -.9087907    1.032121
         age3     .4491549   .4175275     1.08   0.282    -.3691839    1.267494
         age2     .1350279    .417022     0.32   0.746    -.6823202     .952376
                                                                               
 mribrainwtp1        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                              Robust
                                                                               
Log pseudolikelihood = -53.237035               Pseudo R2         =     0.2019
                                                Prob > chi2       =     0.0000
                                                Wald chi2(15)     =     414.54
Probit regression                               Number of obs     =        179
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Appendix C.19 WTP for Brain MRI (Marginal Effects) 
 
 
 
 
  
 
 
 
                                                                               
       midinc    -.3139037   .0958615    -3.27   0.001    -.5017888   -.1260187
       lowinc    -.3448991   .0949473    -3.63   0.000    -.5309924   -.1588058
   fairhealth     .0305948   .0555225     0.55   0.582    -.0782273    .1394169
   goodhealth     .0613406   .0512488     1.20   0.231    -.0391052    .1617864
  vgoodhealth     .0601928   .0548529     1.10   0.272    -.0473169    .1677026
 excellhealth     .0417231   .0590651     0.71   0.480    -.0740424    .1574886
    othereduc    -.0123689   .0544924    -0.23   0.820     -.119172    .0944343
secondaryeduc    -.0039813   .0238619    -0.17   0.867    -.0507497     .042787
  primaryeduc    -.0350659   .0399236    -0.88   0.380    -.1133147    .0431828
          phi     .0528858   .0251153     2.11   0.035     .0036607    .1021109
         medc     -.013502    .024191    -0.56   0.577    -.0609154    .0339115
         age5     .0264679   .0525617     0.50   0.615    -.0765512    .1294869
         age4     .0045251   .0365126     0.12   0.901    -.0670382    .0760885
         age3       .03296    .033092     1.00   0.319    -.0318991    .0978191
         age2     .0099086   .0314388     0.32   0.753    -.0517103    .0715276
                                                                               
                     dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval]
                           Delta-method
                                                                               
               midinc          =    .2905028 (mean)
               lowinc          =    .5921788 (mean)
               fairhealth      =    .1340782 (mean)
               goodhealth      =    .3296089 (mean)
               vgoodhealth     =    .3798883 (mean)
               excellhealth    =    .1284916 (mean)
               othereduc       =    .0167598 (mean)
               secondarye~c    =    .3128492 (mean)
               primaryeduc     =    .0502793 (mean)
               phi             =    .6256983 (mean)
               medc            =    .3519553 (mean)
               age5            =    .0502793 (mean)
               age4            =    .1564246 (mean)
               age3            =    .2681564 (mean)
at           : age2            =     .396648 (mean)
dy/dx w.r.t. : age2 age3 age4 age5 medc phi primaryeduc secondaryeduc othereduc excellhealth vgoodhealth goodhealth fairhealth lowinc midinc
Expression   : Pr(mribrainwtp1), predict()
Model VCE    : Robust
Conditional marginal effects                    Number of obs     =        179
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Appendix C.20 WTP for Brain MRI (OLS before Controlling for 
Multicollinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        _cons     3.576372   .6310921     5.67   0.000     2.325033    4.827711
    invmills3    -.0577903    .888936    -0.07   0.948    -1.820386    1.704806
      prevmri     .1559127   .1190733     1.31   0.193    -.0801876     .392013
       midinc     .4521105   .2111999     2.14   0.035     .0333402    .8708808
       lowinc     .3568391   .2698313     1.32   0.189    -.1781864    .8918647
   fairhealth     .8947708   .4872224     1.84   0.069    -.0713012    1.860843
   goodhealth     .9229125   .4817198     1.92   0.058     -.032249    1.878074
  vgoodhealth      .934936   .4878202     1.92   0.058    -.0323213    1.902193
 excellhealth     .9025064   .4886846     1.85   0.068     -.066465    1.871478
    othereduc     .4767988   .6015949     0.79   0.430    -.7160529     1.66965
secondaryeduc    -.2943279    .138146    -2.13   0.035    -.5682459   -.0204098
  primaryeduc     -.355334   .3428557    -1.04   0.302    -1.035153    .3244855
          phi     .1595937   .2264797     0.70   0.483    -.2894738    .6086611
         medc     .0311766   .1452742     0.21   0.830    -.2568754    .3192286
         age5     .5918157   .3787592     1.56   0.121    -.1591939    1.342825
         age4     .1315866   .2136123     0.62   0.539    -.2919671    .5551402
         age3    -.0496178   .2112361    -0.23   0.815    -.4684599    .3692244
         age2    -.0917178    .174951    -0.52   0.601    -.4386134    .2551777
                                                                               
  logmribrain        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    45.0159033       122  .368982814   Root MSE        =    .57421
                                                   Adj R-squared   =    0.1064
    Residual    34.6199234       105  .329713557   R-squared       =    0.2309
       Model    10.3959798        17  .611528225   Prob > F        =    0.0304
                                                   F(17, 105)      =      1.85
      Source         SS           df       MS      Number of obs   =       123
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Appendix C.21 Testing for Multicollinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Mean VIF        5.77
                                    
   othereduc        1.09    0.918489
     prevmri        1.24    0.807541
        age5        1.27    0.785259
 primaryeduc        1.38    0.724790
secondarye~c        1.47    0.678490
        medc        1.75    0.571567
        age4        2.03    0.493213
        age2        2.79    0.358878
        age3        3.27    0.306020
      midinc        3.55    0.281483
         phi        4.14    0.241346
      lowinc        6.69    0.149491
  fairhealth        7.80    0.128258
   invmills3        8.36    0.119603
excellhealth       10.08    0.099193
  goodhealth       19.68    0.050804
 vgoodhealth       21.42    0.046691
                                    
    Variable         VIF       1/VIF  
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Appendix C.22 WTP for Brain MRI (OLS) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
                                                                               
        _cons     4.650155   .2937229    15.83   0.000     4.067821     5.23249
    invmills3    -.8439164   .7984414    -1.06   0.293    -2.426904    .7390714
      prevmri      .152416   .1205497     1.26   0.209    -.0865855    .3914176
       midinc     .5573975   .2064776     2.70   0.008     .1480355    .9667594
       lowinc     .5172831   .2597179     1.99   0.049     .0023671    1.032199
   fairhealth      .038979   .1970057     0.20   0.844     -.351604     .429562
  vgoodhealth     .0333241     .13007     0.26   0.798    -.2245522    .2912005
 excellhealth     .0374762   .1892987     0.20   0.843    -.3378268    .4127792
    othereduc      .520495   .6086882     0.86   0.394    -.6862884    1.727278
secondaryeduc    -.2677837   .1391702    -1.92   0.057    -.5437021    .0081347
  primaryeduc    -.2279029   .3405526    -0.67   0.505    -.9030815    .4472757
          phi    -.0176107     .20932    -0.08   0.933     -.432608    .3973866
         medc     .0487795   .1467984     0.33   0.740    -.2422625    .3398216
         age5     .5550156   .3830073     1.45   0.150    -.2043337    1.314365
         age4     .0723245   .2140068     0.34   0.736    -.3519647    .4966137
         age3    -.1584674   .2059991    -0.77   0.443    -.5668806    .2499458
         age2    -.1481323   .1746141    -0.85   0.398    -.4943218    .1980572
                                                                               
  logmribrain        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                               
       Total    45.0159033       122  .368982814   Root MSE        =     .5814
                                                   Adj R-squared   =    0.0839
    Residual    35.8301558       106  .338020338   R-squared       =    0.2041
       Model    9.18574744        16  .574109215   Prob > F        =    0.0578
                                                   F(16, 106)      =      1.70
      Source         SS           df       MS      Number of obs   =       123
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Appendix C.23 WTP for a Branded Cholesterol-Lowering Drug (Probit Results) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 
          _cons     1.054718   .6806641     1.55   0.121    -.2793594    2.388795
         midinc     .1555647   .3500191     0.44   0.657    -.5304601    .8415896
         lowinc     .0832468   .3433962     0.24   0.808    -.5897973    .7562909
excellenthealth    -.4463087    .222422    -2.01   0.045    -.8822479   -.0103695
      othereduc    -.1333331   .9508871    -0.14   0.888    -1.997038    1.730371
  secondaryeduc    -.1285255   .4867682    -0.26   0.792    -1.082574    .8255228
      thirdeduc      .030068   .5164543     0.06   0.954    -.9821638      1.0423
            phi     .3323709   .2516221     1.32   0.187    -.1607994    .8255412
           medc    -.5229138   .2559841    -2.04   0.041    -1.024633   -.0211942
           age4    -1.085867   .5338345    -2.03   0.042    -2.132163   -.0395701
           age3    -1.297245   .5209679    -2.49   0.013    -2.318324   -.2761668
           age2    -1.155279   .5263684    -2.19   0.028    -2.186942   -.1236155
           age1    -.6862237   .5779998    -1.19   0.235    -1.819082     .446635
                                                                                 
       wtpbrand        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                Robust
                                                                                 
Log pseudolikelihood = -102.96639               Pseudo R2         =     0.0991
                                                Prob > chi2       =     0.0506
                                                Wald chi2(12)     =      20.98
Probit regression                               Number of obs     =        166
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Appendix C.24 WTP for a Branded Cholesterol-Lowering Drug (Marginal 
Effects) 
 
 
 
 
 
 
 
 
 
 
                                                                                 
         midinc     .0615155   .1383991     0.44   0.657    -.2097419    .3327728
         lowinc     .0329185   .1358016     0.24   0.808    -.2332476    .2990847
excellenthealth    -.1764853   .0880222    -2.01   0.045    -.3490055    -.003965
      othereduc    -.0527243    .375992    -0.14   0.888    -.7896552    .6842066
  secondaryeduc    -.0508232   .1924627    -0.26   0.792    -.4280431    .3263967
      thirdeduc     .0118899   .2042268     0.06   0.954    -.3883874    .4121671
            phi     .1314305   .0994522     1.32   0.186    -.0634923    .3263533
           medc    -.2067774   .1012988    -2.04   0.041    -.4053194   -.0082355
           age4    -.4293876   .2115695    -2.03   0.042    -.8440563    -.014719
           age3    -.5129737   .2063856    -2.49   0.013    -.9174821   -.1084653
           age2    -.4568354   .2086149    -2.19   0.029     -.865713   -.0479578
           age1    -.2713556   .2287565    -1.19   0.236    -.7197101    .1769989
                                                                                 
                       dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval]
                             Delta-method
                                                                                 
               midinc          =    .2590361 (mean)
               lowinc          =    .6204819 (mean)
               excellenth~h    =    .4879518 (mean)
               othereduc       =    .0180723 (mean)
               secondarye~c    =    .3072289 (mean)
               thirdeduc       =    .6144578 (mean)
               phi             =     .626506 (mean)
               medc            =    .3855422 (mean)
               age4            =    .1385542 (mean)
               age3            =    .2590361 (mean)
               age2            =    .3975904 (mean)
at           : age1            =    .1445783 (mean)
dy/dx w.r.t. : age1 age2 age3 age4 medc phi thirdeduc secondaryeduc othereduc excellenthealth lowinc midinc
Expression   : Pr(wtpbrand), predict()
Model VCE    : Robust
Conditional marginal effects                    Number of obs     =        166
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Appendix C.25 WTP for a Branded Cholesterol-Lowering Drug (OLS 
before Controlling for Multicollinearity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 
          _cons     3.720223   .8063639     4.61   0.000      2.11421    5.326236
      invmills4     .3259838   1.107856     0.29   0.769    -1.880502     2.53247
       choldrug     .8634667   .3388995     2.55   0.013     .1884898    1.538443
        highinc    -.0701107    .337582    -0.21   0.836    -.7424635    .6022421
         midinc     .2085548   .2562735     0.81   0.418    -.3018581    .7189677
excellenthealth    -.1067211   .3808903    -0.28   0.780    -.8653298    .6518876
      othereduc    -1.235118   1.219614    -1.01   0.314     -3.66419    1.193954
  secondaryeduc    -.8254856   .7645974    -1.08   0.284    -2.348313    .6973421
      thirdeduc    -.6781856   .7547828    -0.90   0.372    -2.181466    .8250945
           medc    -.8274429   .5210633    -1.59   0.116     -1.86523    .2103446
           age4    -.4796964   .7381434    -0.65   0.518    -1.949836    .9904436
           age3    -.2700922   .8996107    -0.30   0.765    -2.061822    1.521638
           age2    -.4623549   .7818724    -0.59   0.556    -2.019589    1.094879
           age1    -.5835595   .5716939    -1.02   0.311    -1.722187    .5550675
                                                                                 
    lnbrandamnt        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    87.3321567        89  .981260188   Root MSE        =    .92271
                                                   Adj R-squared   =    0.1323
    Residual    64.7058488        76  .851392747   R-squared       =    0.2591
       Model     22.626308        13  1.74048523   Prob > F        =    0.0279
                                                   F(13, 76)       =      2.04
      Source         SS           df       MS      Number of obs   =        90
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Appendix C.26 Testing for Multicollinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
    Mean VIF        7.05
                                    
     highinc        1.29    0.773738
      midinc        1.52    0.659534
   othereduc        1.73    0.578812
    choldrug        2.02    0.494560
excellenth~h        3.82    0.261988
        age1        4.54    0.220345
        medc        5.13    0.194770
        age4        8.00    0.125008
   invmills4        9.95    0.100474
secondarye~c       12.09    0.082747
   thirdeduc       12.65    0.079072
        age3       13.69    0.073056
        age2       15.19    0.065832
                                    
    Variable         VIF       1/VIF  
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Appendix C.27 WTP for a Branded Cholesterol-Lowering Drug (OLS) 
 
  
 
 
 
 
 
 
 
 
                                                                                 
          _cons     3.559962   .8270755     4.30   0.000     1.913044    5.206879
      invmills4    -.2726119   .6132473    -0.44   0.658    -1.493743    .9485195
       choldrug     .8266181   .3328667     2.48   0.015     .1637957     1.48944
         midinc     .2204471   .3407858     0.65   0.520    -.4581442    .8990383
         lowinc     .0606883    .336003     0.18   0.857    -.6083791    .7297557
excellenthealth     .0671551   .2700739     0.25   0.804    -.4706309     .604941
      othereduc    -1.069351    1.18816    -0.90   0.371    -3.435279    1.296577
  secondaryeduc    -.7394233   .7502114    -0.99   0.327    -2.233285    .7544384
      thirdeduc    -.6350815   .7490372    -0.85   0.399    -2.126605    .8564421
           medc    -.5759988   .3476922    -1.66   0.102    -1.268342    .1163448
           age3     .2465717   .4194046     0.59   0.558    -.5885695    1.081713
           age2    -.0195351   .3819912    -0.05   0.959    -.7801768    .7411066
           age1    -.3191237    .400064    -0.80   0.428    -1.115753    .4775055
                                                                                 
    lnbrandamnt        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    87.3321567        89  .981260188   Root MSE        =    .91924
                                                   Adj R-squared   =    0.1389
    Residual     65.065417        77  .845005416   R-squared       =    0.2550
       Model    22.2667397        12  1.85556164   Prob > F        =    0.0199
                                                   F(12, 77)       =      2.20
      Source         SS           df       MS      Number of obs   =        90
